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ABSTRACT 
 
 
This thesis investigates the ability of fermentable carbohydrates to stimulate anorectic gut 
hormones, which in turn reduce appetite and body weight. 
 
Fermentable carbohydrates have been shown to suppress food intake and body weight in rodents 
via the release of satiety hormones, glucagon-like peptide 1 (GLP-1) and peptide-YY (PYY). 
However, evidence of the effect of fermentable carbohydrates on modulating body weight in 
humans is contradictory. In this thesis, supplementing oligofructose over eight weeks has been 
shown to significantly reduce hunger and increase PYY secretion in overweight volunteers. 
However, there was no suppression on energy intake or body weight when compared with 
cellulose supplementation.  
 
Studies in rodents also suggested that reductions in food intake and body weight following intake 
of fermentable carbohydrates are associated with activation in the central nervous system. In 
contrast, oligofructose supplementation in this study had no significant effect on reducing 
activation in pre-selected brain reward regions in response to visual food cues, as measured by 
functional MRI. Surprisingly, the activation in these brain regions was reduced by cellulose 
intake.  
 
The negative findings from the oligofructose study may be due to insufficient concentrations of 
short chain fatty acids (SCFAs) in the colon. SCFAs, the fermentation end-products of ingested 
fermentable carbohydrates are thought to play a significant role in modifying energy homeostasis 
by stimulating PYY and GLP-1 from enteroendocrine L-cells in the colon. By applying a novel 
method of delivering propionate to the colon using a propionate carrier molecule (PCM), it has 
been shown that supplementation with PCM in healthy lean volunteers reduced hunger and 
energy intake in pilot studies via elevated PYY secretion. PCM also has a dose-dependent 
appetite inhibiting effect. The preliminary results in this thesis open up an interesting possibility 
of the development of the PCM as a dietary supplement to aid weight loss. 
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1 INTRODUCTION 
 
1.1 OBESITY  
Obesity is a condition in which accumulation of excessive fat in the body has reached a certain 
level that causes various health problems, leading to increased morbidity and mortality. Obesity 
is a major global health problem with more than one billion adults now classified as overweight 
(Body mass index [BMI] ≥ 25 kg/m2) and over 300 million people reported as clinically obese 
(BMI ≥ 30 kg/m2) (WHO, 2002). In England, it was reported that 24.1% of males and 24.9% of 
females were classified as obese in 2008, an increase of 10.9% for males and 8.5% for females 
since 1993 (Boyle, 2011).  
 
The cause of obesity is multifactorial, however increased consumption of palatable and energy-
dense foods containing excessive amount of sugars and saturated lipids and lack of physical 
activity are suggested the main contributors to obesity. Genetic disturbances, medications and 
physiological illness also potentially lead to obesity but to a lesser extent compared to diet and 
behavioural factors. The consequences of obesity can be severe as obesity is associated with 
devastating co-morbidities such as hypertension, diabetes, cardiovascular diseases, 
musculoskeletal disorders and certain types of cancer (Eckel et al., 2005), which increase the risk 
of morbidity and mortality. Furthermore, in countries with a high percentage of obesity cases, 
there is a significant increase in healthcare costs for treating obesity-related diseases and also a 
financial burden on the employment system due to decreased productivity. Therefore, obesity is 
not just an individual health concern, but it affects the whole community. 
 
To date, there are no known medications to cure obesity. However, reducing caloric intake and 
physical activity are the key elements in reducing body weight. Lifestyle modification 
programmes have been shown to induce body weight loss by utilising low energy diets. 
However, their effectiveness in the long term (between one to five years) is not sustained (Norris 
et al., 2004). Pharmaceutical therapies for long term treatment are limited to orlistat (Xenical®, 
Roche) after sibutramine (Reductil®, Abbott laboratories) was withdrawn as an anti-obesity 
treatment due to association with cardiovascular risk (Williams, 2010). Orlistat is suggested to 
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modestly reduce body weight by acting as a gastric and pancreatic lipase inhibitor in the 
gastrointestinal tract, which then subsequently reduces fat absorption. Although its efficacy in 
reducing body weight has been demonstrated in several studies (Hill et al., 1999; Rossner et al., 
2000; Sjostrom et al., 2007), it can cause gastrointestinal side effects such as diarrhoea, 
flatulence (Padwal et al., 2004) and malabsorption of dietary fat (Filippatos et al., 2008). 
Furthermore, in 2009, United States Food and Drug Administration reported that orlistat maybe 
closely correlated to liver injury (U.S.Food and Drug Administration, 2011). To date, bariatric 
surgery is the most effective treatment for obesity and appears the only long term solution to 
promote sustained weight loss (Sjostrom et al., 2007). However, because the procedure has high 
complication rates and involves significant financial cost, these treatments are only limited to 
individuals with minimum BMI of 40 kg/m
2
 or >35 kg/m
2
 with co-morbidities (Fajnwaks et al., 
2008). Several types of bariatric surgery have been developed since it was introduced in 1950s 
(O'Brien, 2010) including gastric banding, sleeve gastrectomy, Roux-en-Y gastric bypass 
(RYGB) and biliopancreatic diversion. However, the most common surgical operations 
performed in the UK and worldwide are gastric banding and RYGB (Buchwald and Oien, 2009; 
Flum et al., 2009). 
 
Besides triggering weight loss, bariatric surgery has also been shown to stimulate the release of 
anorectic gut hormones, therefore resulting in reduced appetite and energy intake. The anorectic 
gut hormone, peptide tyrosine-tyosine (PYY) was shown to significantly increase in post-
operative RYGB patients compared with the normal weight and obese volunteers three hours 
after the intake of a 420 kcal meal (Korner et al., 2005; Le Roux et al., 2006a). Interestingly, 
RYGB also preserved the levels of postprandial PYY in a long term period. A study showed that 
postprandial PYY levels in post-surgeries RYGB patients after 12, 18 and 24 months were 
significantly increased compared to the pre-operative patients whilst a tendency towards an 
increase glucagon-like peptide 1 (GLP-1) was also demonstrated at 18 and 24 months (Pournaras 
et al., 2010). In addition, the increased release of PYY and GLP-1 was followed with increased 
satiety and significantly decreased leptin, insulin and postprandial blood glucose levels (Le Roux 
et al., 2006a; Pournaras et al., 2010). In contrast, the role of RYGB on ghrelin secretion is still 
unclear as some studies reported a decrease in fasting and postprandial ghrelin (Leonetti et al., 
2003; Morinigo et al., 2004) but others showed no significant effect in postoperative ghrelin 
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levels (Karamanakos et al., 2008; Le Roux et al., 2007). The discrepancies of the effects of 
bariatric surgery on ghrelin secretion are needed to be further investigated. 
 
Even though gastric bypass surgery has been shown to maintain long term body weight 
management potentially by improving gut hormone release, the procedures have been related to 
various life-threatening complications such as pulmonary embolism (Podnos et al., 2003), 
leakage (Marshall et al., 2003), stomal obstruction, bleeding and nutrient malabsorption 
(Malinowski, 2006). However, it is agreed that naturally occurring anorectic gut hormones 
released following gastric bypass surgery are the potential candidates for weight loss treatment 
(Mitchell et al., 2001; Powers et al., 1999). Therefore, alternative therapies that stimulate gut 
hormone secretion are strongly needed for obesity treatment. Recently, certain dietary 
components have been suggested as potential sources for inducing the release of naturally 
occurring gut hormones and therefore receive considerable attentions to be developed as a 
treatment for obesity.  
 
 
1.2 APPETITE REGULATION 
Appetite is an eagerness feeling towards eating. It drives the consumption of food intake to 
provide adequate energy intake to maintain metabolic needs. Appetite is regulated by close 
networks between the gastrointestinal tract, adipose tissue and the brain. A loss of appetite 
regulation to balance energy intake and energy expenditure will lead to either weight loss or 
weight gain. Therefore, an energy balance is required in maintaining body weight.  
 
Appetite regulation is controlled by three linked factors creating a network of interactions. These 
factors are; 1) physiological behaviours including hunger, appetite sensations 2) signals from the 
periphery and 3) neuronal activities in the brain (Blundell, 1999). In addition to individuals’ 
internal cues, appetite regulation is also influenced by environmental factors which are social, 
economic, behavioural and cultural. Although the whole system is complex and the mechanisms 
linking these factors are currently not fully understood, it is now known that the close interaction 
between the gut signals and the brain influences human eating behaviour. Following food intake, 
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the gastrointestinal tract senses the presence of nutrients via receptors which results in the release 
of gut hormones and peptides from the periphery. This information is then signalled to the brain 
via the vagus nerve or the circulation. In the brain, these signals work together with the brain’s 
receptors and neurotransmitters to translate the information received from the gut and to decide 
either to continue or stop the eating process. Cessation of eating process is described in two 
conditions; 1-satiation (a process that brings meal intake to the end following increase of 
fullness) and 2-satiety (a process that suppresses the eagerness to eat postprandially and maintain 
the satiated feeling for a certain period of time) (Blundell, 1999).  
 
 
1.3 CENTRAL REGULATION OF APPETITE 
 
1.3.1 Homeostatic Pathway 
In the homeostatic system, there are four main sites involved, namely the hypothalamus, 
brainstem, gastrointestinal tract and abdominal viscera. These sites are linked to each other by a 
complex neuronal network with the hypothalamus and the brainstem as the centres where all the 
information is conveyed. The signals from the gastrointestinal tract and abdominal viscera are 
circulated in the blood or alternatively, conveyed to the hypothalamus and the brainstem through 
vagal nerve afferent. The information is processed by the hypothalamus and brainstem and then 
transmitted via efferent signals to influence satiety and food intake.  
 
1.3.1.1 The Brainstem 
The brainstem is located in the hindbrain and consists of the midbrain, pons and medulla oblongata. 
The dorsal vagal complex, which is situated in the medulla oblongata has been proposed to play an 
important role in the interpretation of peripheral signals via vagal afferent from the gut to the 
hypothalamus (Bailey, 2008). The dorsal vagal complex consists of the nucleus tractus solitaries 
(NTS), area postrema (AP) and dorsal motor nucleus of vagus. It is postulated that the presence of an 
incomplete blood brain barrier (BBB) in the AP facilitates the passage of peripheral satiety signals to 
the brainstem structures. Lesions in the AP have been demonstrated to cause hypophagia and 
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suppressed body weight gain, hence suggesting the role of AP in feeding behaviour (Hyde and 
Miselis, 1983).  The AP has been identified as one of the circumventricular organ, a group of organs 
which lack a complete blood brain barrier (BBB) and located at various sites in the ventricular 
system in the brain. Therefore, nuclei residing in the circumventricular organ are accessible to the 
peripheral signals especially gut hormones without the need for a specific carrier to deliver the 
signals across the BBB. Peripheral signals can also use an alternative pathway via the brainstem and 
hypothalamus (Ricardo and Koh, 1978). In this pathway, the NTS acts as a receiver for vagal afferent 
fibres to integrate satiety signals from the periphery, which are then projected to the arcuate nucleus 
(ARC), paraventricular nucleus (PVN), lateral hypothalamic area (LHA) and dorsomedial nucleus 
(DMN) in the hypothalamus (Ter Horst et al., 1984; Ter Horst et al., 1989; Thompson and Swanson, 
1998). 
 
1.3.1.2 The Hypothalamus  
The hypothalamus, a small region situated in the forebrain adjacent to the pituitary gland, plays 
an important role in regulating appetite and metabolism. It exerts its role by detecting signals 
from the periphery, such as hormones secreted from large intestine and adipose tissue and 
nutrients circulating in the blood. Furthermore, the hypothalamus also acts as an intermediary 
between the nervous and endocrine system, which are linked via the pituitary gland. Early 
investigation by Hetherington and Ranson suggested that the LHA was the ‘hunger centre’ whilst 
the ventromedial hypothalamic nucleus (VMN) functioned as the ‘satiety centre’ (Hetherington 
and Ranson, 1940). However, recent findings discovered that other hypothalamic nuclei in the 
hypothalamus are also involved in appetite regulation by having close interactions with the 
brainstem and higher cortical centres. A BBB, a barrier that separates cerebrospinal fluid from 
blood, can also be found in the hypothalamus. The existence of this barrier prevents circulating 
gut derived hormones from entering the brain, hence the delivery of gut hormones to the brain 
can only be performed using a specific carrier or in certain locations where the BBB is 
incomplete. The median eminence in the hypothalamus as well as the AP in the brainstem have 
been identified as the locations of an incomplete BBB, therefore permitting the integration of 
peripheral signals directly to the central nervous system (CNS) (Gotow and Hashimoto, 1979; 
Gross, 1992). 
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1.3.1.2.1 Arcuate Nucleus 
The ARC, which is located at the base of the hypothalamus, has been suggested to play an 
important role in appetite regulation. It detects peripheral signals due to its close proximity to the 
median eminence. The ARC is modulated by two individual sets of neuronal populations that are 
working together in appetite regulation. The anorexigenic neurons expressing pro-
opiomelanocortin (POMC) and cocaine and amphetamine regulated transcript, which can be 
found in the lateral ARC and orexigenic neurons expressing neuropeptide Y (NPY) and agouti-
related peptide (AgRP) neurones in the medial ARC (Broberger et al., 1998; Hahn et al., 1998). 
Both populations of neurons project to various hypothalamic areas that are involved in the 
central appetite centres such as the PVN, VMN, DMN and LHA.  
 
 
1.3.1.2.2 Paraventricular Nucleus  
The PVN is located parallel to the third ventricle in the anterior hypothalamus. The PVN plays a 
major role in controlling eating behaviour and energy expenditure. An ablation in the PVN 
performed in rat experiments resulted in obesity and overeating syndrome (Aravich and Sclafani, 
1983; Leibowitz et al., 1981). It also has been shown to be stimulated by peripheral and central 
peptides. Intracerebroventricular (Dakin et al., 2002) injection of NPY has been shown to stimulate 
food intake (Stanley and Leibowitz, 1984) whereas ICV infusion of GLP-1 (McMahon and Wellman, 
1998) and leptin (Satoh et al., 1997) suppressed food intake. The peripheral signals are transmitted to 
the PVN either by hypothalamic ARC and LHA or through a reciprocal linkage with brainstem 
nuclei such as the NTS. 
 
 
1.3.1.2.3 Ventromedial Nucleus 
Previously known as the ‘satiety centre’, the VMN is located on the top of the ARC in the 
hypothalamus from which it receives the periphery signals.  Recently, the VMN has been shown to 
be influenced by both anorexigenic and orexigenic neurons. Administration of NPY into the VMN by 
ICV injection or microinjection increased food intake in rats (Clark et al., 1984; Kalra et al., 1991) 
while Jacob et al. showed that injection of leptin in rats resulted in a decrease of food intake (Jacob et 
al., 1997).  
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1.3.1.2.4 Dorsomedial Nucleus 
The DMN is located above the VMN and has been suggested to play an important role as a satiety 
centre. It receives neuronal projections from the ARC and projects to the PVN. An abrasion of the 
DMN has been demonstrated to cause hyperphagia and obesity (Bellinger and Bernardis, 2002). ICV 
injection of galanin (Kuramochi et al., 2006) and orexin (Dube et al., 1999) in this region has been 
shown to increase food intake. The DMN is also reported to contain high levels of NPY/AgRP 
neurons (Broberger et al., 1998), which are suggested to be related with the development of obesity 
(Guan et al., 1998). 
 
 
1.3.1.2.5 Lateral Hypothalamic Area 
The LHA is a small region adjacent to the DMN. Early investigation by Anard and Brobeck in 1951 
showed that lesions in this area resulted in hypophagia and weight loss (Anard and Brobeck, 1951), 
which indicated the LHA as a feeding centre. The LHA is comprised of α-melanocyte stimulating 
hormone (α-MSH), orexins and orexigenic hormones and NPY/AgRP neuropeptides. The hormones 
and neuropeptides are conveyed to the LHA from the ARC. 
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The summary of the complex neuronal network of appetite regulation is illustrated in figure 1.1. 
 
Figure 1.1 The hypothalamic and brainstem regions and its interaction with peripheral signals to 
regulate appetite regulation. From (Suzuki et al., 2010).  
Abbreviations: CNS: central nervous system; ARC: arcuate nucleus; NPY/AgRP: neuropeptide Y and agouti 
related peptide; POMC/CART: pro-opiomelanocortin and cocaine- and amphetamine-regulated transcript; 
PVN: paraventricular nucleus; LHA: lateral hypothalamic area; DMN: dorsomedial nucleus; VMN: ventromedial 
hypothalamic nucleus; ME: median eminence; DVC: dorsal vagal complex; DVN: the dorsal motor nucleus of 
vagus; NTS: the nucleus of the tractus solitarius; AP: area postrema; GI tract: gastrointestinal tract; TRH: 
thyrotropin-releasing hormone; CRH: corticotrophin-releasing hormone; MCH: melanocortin-concentrating 
hormone; BDNF: brain-derivedneurotrophic factor; GLP-1: glucagon-like peptide-1; CCK: cholecystokinin; PP: 
pancreatic polypeptide; PYY: peptide YY; OXM: oxyntomodulin; BBB: blood-brain barrier. 
 
 
1.3.2 Non-Homeostatic Pathway 
It is now widely accepted that besides a homeostatic pathway, appetite regulation is also 
controlled by a hedonic or also known as ‘non-homeostatic’ pathway. However, in contrast to 
the homeostatic pathway, the role of the non-homestatic pathway has not been fully explored. 
Hedonic is characterised as a pleasant (or unpleasant) sensations that could motivate people to 
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continue or stop the provided stimulation. It seems that taste, smell and visual cues from 
palatable foods are able to influence people to override homeostatic signals. Besides sensory 
cues, cognition, emotional and reward are among the factors that modulate the hedonic 
mechanism. These factors are established in the corticolimbic and higher cortical brain regions 
(Berthoud, 2004). The brain reward regions that are studied in this work are described below 
(figure 1.2).  
 
1.3.2.1 Nucleus Accumbens  
The nucleuc accumbens (NAc) is a structure which forms part of the ventral striatum. It can be 
classified into two components, the core and the shell, which have a distinct input and output 
projections (Heimer et al., 1991; Zahm and Brog, 1992). The NAc has a close interaction with 
other brain regions by which it receives dopaminergic projection from the ventral tegmental area 
(VTA) and glutamatergic projection from the prefrontal cortex, amygdala and hippocampus 
(Carlezon, Jr. and Thomas, 2009; Kelley, 2004). It has long been known that the NAc plays a 
significant role in the reward system, notably motivational drive in seeking food (Kelley, 2004). 
Numerous human studies have shown an increase activity in the ventral striatum of fasted 
volunteers when viewing food-related images (Fuhrer et al., 2008; Goldstone et al., 2009; Schur 
et al., 2009). In rodents, lesions of the NAc decreased the reward response to drugs of addiction 
(Kelsey et al., 1989). Similar results were shown when mice-null dopamine D2-receptor was 
unable to stimulate the rewarding effect of cocaine in the NAc (Welter et al., 2007). Evidence 
from these studies showed that the NAc and neuron-related factors play a significant role in 
modulating the reward system. 
 
1.3.2.2 Amygdala 
The amygdala is an almond-sized structure located in the anterior part of the temporal lobe  and 
a part of the limbic system (Murray, 2007). It is widely known to be involved in emotion, 
reward, memory processing, motivation and attention (Murray, 2007). Bilateral ablation of the 
amygdala markedly diminishes emotional processing (Kalin et al., 2001; Meunier et al., 1999). 
In monkeys, lesions of the amygdala markedly reduce fear, impair emotional learning and 
decrease emotion awareness (Cardinal et al., 2002). The amygdala is also implicated in the 
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reward response to food. Studies show that the amygdala is highly activated when fasted 
volunteers are exposed to food-related sensory experiments (i.e. viewing food images or tasting 
food) in functional magnetic imaging resonance (fMRI) studies (Killgore et al., 2003; LaBar et 
al., 2001; Siep et al., 2009). The amygdala has a close connection with other brain nuclei. It 
receives afferent signals from the insula, fusiforum and the VTA and sends projections to the 
orbifrontal cortex (OFC), prefrontal cortex, NAc and anterior cingulate cortex (ACC) (Amaral 
and Price, 1984; Morgane et al., 2005). 
 
1.3.2.3 Cingulate Cortex 
The cingulate cortex can be divided into the anterior cingulate cortex (ACC) and the posterior 
cingulate cortex, which have a distinct function and pattern of projection. Whilst the anterior 
area is described as ‘executive’, the posterior area is evaluated as ‘evaluative’ (Vogt et al., 1992). 
The ACC mainly functions in cognition and emotional processing, which are regulated 
separately in the dorsal and ventral zones (Bush et al., 2000). The dorsal ACC exerts its effect on 
cognitive processing by regulating attention, motivation and conflict (Bush et al., 2000; 
Devinsky et al., 1995). It is connected to various nuclei including the prefrontal cortex, parietal 
cortex and motor system (Devinsky et al., 1995). On the other hand, the ventral ACC mainly 
regulates emotional responses and motivational information (Bush et al., 2000; Devinsky et al., 
1995; Passamonti et al., 2008). It is closely connected with the amygdala, NAc, hypothalamus 
and anterior insula (Devinsky et al., 1995). The ACC has also been implicated to involve in 
eating process as this area was shown to be activated when volunteers were viewing food images 
in fMRI studies  (Passamonti et al., 2009). 
 
1.3.2.4 Orbifrontal Cortex 
The orbifrontal cortex (OFC), which is a part of the limbic system has long been known to be 
involved in decision making and translational behavioural process. The OFC has been suggested 
to play a role in encoding sensory and food reward as well as in learning, decision making and 
expectation to translate emotional and reward drive into action (Gottfried et al., 2003; O'Doherty 
et al., 2000; Small et al., 2007). Numerous human neuroimaging studies showed that the OFC 
has pronounced roles in reward processing as it was shown to be activated when viewing food 
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images during fasting (Gottfried et al., 2003; Hinton et al., 2004; O'Doherty et al., 2000; Siep et 
al., 2009; Small et al., 2007; Wang et al., 2004). The OFC also has a close connection with other 
brain reward regions including the hypothalamus, amygdala, insula, dopaminergic midbrain as 
well as the ventral and dorsal striatum (Cardinal et al., 2002; Verhagen and Engelen, 2006).  
 
1.3.2.5 Insula 
The insula cortex is situated deep within the anterior part of the sylvian fissure between the 
temporal lobe and frontal lobe. The insula cortex can be divided into the smaller posterior insula 
and the large anterior insula. The insula is a primary gustatory cortex, which mainly involved in 
regulating chemical senses including taste aversion, sensory and reward-related food processing 
(James et al., 2009; Small, 2010; Small, 2012; Yaxley et al., 1990). The significant role of the 
insula on taste processing has been shown following viewing or tasting meal in several human 
fMRI studies (Siep et al., 2009; Wang et al., 2004). Nevertheless, the insula is also involved in 
regulating other sensations including pain, hunger and temperature (Craig, 2009; Damasio et al., 
2000; Paulus and Stein, 2006). The insula projects efferent signals to the anterior cingulate 
cortex, NAc and also to various striatum regions and amygdala (Chikama et al., 1997). 
 
 
Figure 1.2 Key areas in the human brain involved in the hedonic system, from (Kenny, 2011). 
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1.4 THE ROLE OF PERIPHERAL SIGNALS IN APPETITE REGULATION 
 
1.4.1 Gut Hormones 
A large group of hormones are produced and secreted from numerous part of the enteroendocrine 
cells in the gut. These hormones transmit information of nutritional and metabolic activities from 
the intestinal system to the CNS via the bloodstream or vagal afferent to various hypothalamic 
nuclei and brainstem as discussed in section 1.3. Only selected gut hormones will be discussed in 
this section.   
 
1.4.1.1 Glucagon- Like Peptide-1  
Glucagon-like peptide-1 (GLP-1), a 30 amino acid peptide is mainly produced in the L-cells 
located in the distal gut where it is co-secreted with PYY (Eissele et al., 1992). GLP-1 is a 
product of post-translational cleavage of preproglucagon from which oxyntomodulin and 
glucagon are also produced. GLP-1 exists as two biological active forms, GLP-17-37 and GLP-17-
36 amide. However, the most common circulating form is GLP-17-36 amide (Orskov et al., 1994). 
Besides being secreted in the gut, a considerable amount of GLP-1 can also be found in the 
hypothalamus and brainstem, with the highest level of GLP-1 immunoreactive neurons found in 
the DMN, PVN and NTS (Kreymann et al., 1989; Larsen et al., 1997). GLP-1 exerts its effects 
via its receptor, GLP-1R which is widely distributed throughout the CNS including the 
hypothalamic ARC, PVN and DMN and the AP and NTS in the brainstem (Merchenthaler et al., 
1999; Shughrue et al., 1996). GLP-1 is transmitted to the CNS via vagal afferent. Abbott et al. 
demonstrated that the anorectic effect of GLP-1 is abolished following bilateral vagotomy in 
rats, therefore confirming the involvement of vagal afferent in conveying circulating GLP-1 to 
the CNS (Abbott et al., 2005a). 
 
GLP-1 is secreted into the circulation in response to calorie intake (Ghatei et al., 1983; Herrmann 
et al., 1995). The anorectic effect of GLP-1 has been demonstrated in both rodents and humans. 
In rats, administration of GLP-1 either by acute intravenous infusion (Chelikani et al., 2005) or 
chronic ICV injection (Meeran et al., 1999) reduced food intake and body weight. However, 
administration of a supraphysiological dose resulted in aversive side effects which highlighted its 
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effect as an anorectic gut hormone (Thiele et al., 1997). Therefore, the potential application of 
exogenous GLP-1 as a therapeutic agent needs to be carefully interpreted. In humans, GLP-1 has 
been demonstrated to reduce food intake in both lean (Flint et al., 1998; Gutzwiller et al., 1999) 
and overweight volunteers (Verdich et al., 2001a). Overweight volunteers are reported to have 
lower GLP-1 circulation levels compared to lean volunteers. Interestingly, the levels were 
reported to increase following weight loss (Verdich et al., 2001b). De Silva et al. demonstrated 
that infusion of GLP-17-36 in healthy normal weight volunteers reduced ad libitum meal intake 
but the effects were more robust when combined with PYY3-36 (De Silva et al., 2011). 
 
Although GLP-1 has been shown to have potential effects as a therapeutic anti-obesity agent, 
rapid degradation of circulating GLP-1 by dipeptidyl-peptidase-4 (DPP-IV) resulted in GLP-1 
being inactivated with a short half-life of 1-2 minutes (Deacon, 2004; Kieffer et al., 1995; 
Mentlein et al., 1993b),  thus making it unsuitable for an obesity treatment. Nevertheless, in 
1991, Exendin-4 or exenatide, a GLP-1R agonist was developed with a longer biological half-life 
(Eng et al., 1992). Exendin-4 is synthesized from the saliva of the Gila monster lizard, 
Heloderma suspectum, and has been showed to improve glycemic control in patients with type 2 
diabetes (Buse et al., 2004; DeFronzo et al., 2005; Kendall et al., 2005). Acute and chronic 
administration of exendin-4 in type 2 diabetic mice, rats and monkeys showed to have a glucose 
lowering effect, stimulated insulin secretion and weight loss (Young et al., 1999), hence 
highlighting exendin-4 role as an anti-diabetic treatment. In humans, administration of exendin-4 
has been shown to improve glucose response, suppress energy intake in healthy volunteers 
(Edwards et al., 2001) and reduce body weight in diabetic patients (Kim et al., 2007; Zander et 
al., 2002).  
 
 
1.4.1.2 Peptide Tyrosine-Tyrosine 
Peptide tyrosine-tyrosine (PYY) is a 36 amino acid which was formerly isolated from porcine 
small intestine (Tatemoto and Mutt, 1980). It is a member of the polypeptide-fold protein family 
together with pancreatic polypeptide and NPY.  PYY is synthesised and secreted together with 
GLP-1 in the intestinal L-cells, which can be found in high numbers in the colon and rectum 
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(Adrian et al., 1985). There are two circulating forms of PYY, which are PYY1-36 and PYY3-36.  
PYY3-36 is the cleavage product of the Tyr-Pro amino terminal residues of PYY1-36 by enzymatic 
activities of DPP-IV and is distributed in the circulation (Grandt et al., 1994; Mentlein et al., 
1993a).   
 
PYY is released after ingestion of a meal and its release is proportional to calorie intake (Adrian 
et al., 1985; Batterham et al., 2003). Plasma PYY levels begin to rise in the circulation after 30 
minutes, peak at one to two hours after meal intake and remain elevated for several hours 
(Adrian et al., 1985). Meals containing high fat and protein have been recognised as the most 
potent stimulator for PYY3-36 secretion (Batterham et al., 2006; Essah et al., 2007; Helou et al., 
2008). PYY3-36 exerts its anorectic effects by reducing food intake in animals and humans. In 
rats, acute peripheral administration of PYY3-36 suppresses food intake and inhibits body weight 
gain (Batterham et al., 2002). Unexpectedly, Tschop et al. questioned this study as they were 
unable to reproduce the findings following acute and chronic PYY3-36 administration, either 
peripherally or centrally in 8 different strains of rodents (Tschop et al., 2004). This discrepancy 
is possibly due to the effect of stress  in the rodents (Halatchev et al., 2004) and lack of 
acclimatization. Indeed, Abbott et al. showed that acclimatization, habituation and careful 
handling are important for rodents which are exposed to a new environment. A failure to account 
for these factors prior to the investigation may result in an attenuation of PYY’s effect on food 
intake (Abbott et al., 2006). Clarification on this issue has helped the other groups in 
demonstrating the effect of PYY3-36 in reducing food intake as demonstrated in mice (Challis et 
al., 2004; Halatchev et al., 2004), rats (Chelikani et al., 2005; Chelikani et al., 2006) and rhesus 
monkey (Moran et al., 2005). Like PYY3-36, PYY1-36 also suppressed food intake in rats, but the 
effect is less potent compared to PYY3-36 (Chelikani et al., 2004).  
 
In humans, peripheral PYY3-36 reduces cumulative 24 hours food intake and decreases ad libitum 
meal intake in both normal and overweight volunteers (Batterham et al., 2003). Interestingly, the 
authors found that overweight volunteers have lower postprandial PYY levels compared to the 
normal weight volunteers, suggesting that a lack of PYY3-36 levels in obese volunteers results in 
reduced satiety and may therefore increase the risk of obesity (Batterham et al., 2003; Le Roux et 
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al., 2006b). The anorectic effect of PYY in humans has also been demonstrated in other studies 
(Batterham et al., 2006; Sloth et al., 2007).  
 
PYY exerts its effect via the Y family of G coupled protein receptors. There are five subtypes of 
the receptors Y1, Y2, Y4, Y5 and Y6 (Blomqvist and Herzog, 1997). PYY has been shown to 
have a high affinity for the Y2 receptor (Keire et al., 2000), which is highly expressed on NPY 
neurons in the ARC (Broberger et al., 1997). The involvement of the Y2R in exerting the 
anorectic effect of PYY has been demonstrated using the Y2 receptor antagonist. In this study, 
the inhibitory effect of PYY on food intake and body weight is attenuated due to a blockade of 
the ARC Y2 receptor by BIIE0246, a specific antagonist of Y2 receptor. Administration of this 
antagonist possibly suppressed the NPY neurons thus resulting in increased food intake in rats 
(Abbott et al., 2005b). In addition, the effect of PYY is abolished in Y2 receptor null mice 
(Batterham et al., 2002), suggesting that the Y2 receptor plays a major role in the anorectic effect 
of PYY3-36.  
 
The satiety signal of PYY is transmitted to the brain using two mechanisms; firstly, by crossing 
the BBB that is located closely to the ARC (Nonaka et al., 2003) and secondly via the vagus 
nerve to convey information to the brainstem (Koda et al., 2005). In the ARC, PYY has been 
reported to activate POMC neurons, therefore POMC neurons may be involved in regulating 
food intake (Batterham et al., 2002). Deficiency of POMC-neurons either in humans or mice is 
related to hyperphagia and obesity (Krude et al., 1998; Yaswen et al., 1999). Unexpectedly, 
acute administration of PYY3-36 in mice lacking POMC neurons significantly reduced food 
intake compared to wild type mice. However, the effect was abolished when PYY3-36 was 
administered chronically. These observations suggest that POMC neurons are required to 
maintain energy balance towards obesogenic diet in the long term period (Challis et al., 2004). α-
MSH neurons, a group of POMC derivative neurons have been shown to increase their activity 
by 20% following exogenous injection of PYY3-36 in the ARC of the control rats but not in the 
vagotomised rats (Koda et al., 2005). This suggesting that PYY3-36 exerts its anorectic effect via 
melanocortin-4 receptor system (Halatchev et al., 2004; Koda et al., 2005). Meanwhile, the 
involvement of the vagus nerve in exerting PYY3-36 effect was demonstrated by Koda et al. In 
this study, bilateral subdiaphragmatic vagotomy or bilateral midbrain transection experiments 
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performed in rats inhibited the ability of PYY3-36 to reduce food intake, highlighting the 
important role of the vagus nerve in conveying information to the hypothalamus via the NTS 
(Koda et al., 2005). 
 
1.4.1.3 Ghrelin 
Ghrelin is the only identified orexigenic gut hormone at the present time. This 28 amino acid 
peptide is produced mainly in the stomach (Kojima et al., 1999) and elsewhere in the 
gastrointestinal tract (Date et al., 2000). In the CNS, the hypothalamus is the main source of 
ghrelin with the highest levels found in the NPY/AgRP neurons in the ARC. ICV injection of 
ghrelin has been shown to increase c-fos expression (neuronal activation marker) in NPY/AgRP 
neurons (Cowley et al., 2003; Nakazato et al., 2001), whilst ghrelin effect was abolished without 
NPY/AgRP neurons (Chen et al., 2004). Other brain regions that expressed higher levels of c-fos 
following ICV injection of ghrelin were the PVN, DMN, LHA of the hypothalamus and the NTS 
and AP of the brainstem (Lawrence et al., 2002). Ghrelin levels rise prior to nutrient ingestion 
and fall postprandially upon meal intake (Tschop et al., 2001) suggesting its role as a meal 
initiator (Cummings et al., 2001). Ghrelin modulates all three macronutrients with carbohydrate 
rich- meals showing the greatest suppression of ghrelin, followed by protein and lipid rich-meals 
(Al et al., 2005; Foster-Schubert et al., 2008).  
 
ICV and intraperitoneal administration of ghrelin in rats has been shown to stimulate food intake, 
promoting weight gain and adiposity (Wren et al., 2001b) whilst in humans, intravenous infusion 
of ghrelin increased hunger and energy intake in healthy lean (Wren et al., 2001a) and in obese 
volunteers (Druce et al., 2005). High plasma ghrelin levels were demonstrated in anorexia 
nervosa patients, but the levels returned to normal after weight gain (Otto et al., 2001). 
Meanwhile, the low levels of plasma ghrelin in overweight volunteers were reported to be 
increased after weight loss (Cummings et al., 2002; Hansen et al., 2002). However, the ghrelin 
levels in patients underwent bariatric surgery are yet to be confirmed as some studies reported 
large falls following the surgery (Leonetti et al., 2003; Morinigo et al., 2004), but others showed 
no significant difference in RYGB patients compared to lean and obese volunteers 
(Karamanakos et al., 2008; Le Roux et al., 2006a).     
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1.4.1.4 Cholecystokinin 
Cholecyctokinin (CCK) is a 115-amino acid cleavage product of pro-CCK and is expressed by 
the I-cells in the duodenum and jejunum (Buffa et al., 1976). Besides the gut, it can also be 
found in the CNS, in particular in the VMN and median eminence of the hypothalamus (Beinfeld 
et al., 1981). CCK is released postprandially as a response to nutrient ingestion (Liddle et al., 
1985) and highly influenced by the presence of fat and protein (Lewis and Williams, 1990; 
Liddle et al., 1985). It exerts its anorectic effects by binding to its receptor, CCK1R and CCK2R 
which can be found in the brain, particularly in the LHA, median pons and lateral medulla 
(Schick et al., 1994). CCK starts to rise in the plasma within 15 minutes after meal ingestion and 
remains elevated up to 5 hours (Liddle et al., 1985). CCK exerts its effects in the gut by 
stimulating gallbladder contraction and pancreatic enzyme secretion (Liddle et al., 1985) as well 
as inhibiting gastric emptying (Moran and McHugh, 1982). Although CCK has been shown to 
reduce food intake in both rats and humans (Gibbs et al., 1973; Kissileff et al., 1981), its short-
term effect resulted in failing to reduce food intake when administered more than 30 minutes 
prior to a meal (Gibbs et al., 1973). Furthermore, it has also been shown to increase feeding 
frequency by more than 162% as a compensation of reduced meal size by 44% in rats study 
(West et al., 1984). High dose of CCK cause nausea and taste aversion in rodents outweighing 
the potential use of CCK as an anti-obesity treatment (Ervin et al., 1995; Swerdlow et al., 1983).  
 
 
1.4.2 Adipose Tissue Related Hormones 
 
1.4.2.1 Leptin 
Leptin, a 16 KDa peptide is an adipocyte-derived hormone and the product of the ob gene 
(Zhang et al., 1994). Leptin is released proportionally to the amount of body fat (Considine et al., 
1996). Other sites that also produce leptin are the stomach, placenta, mammary gland, ovarian 
follicles, brain and fetal organs such as heart, bone and cartilage (Masuzaki et al., 1997; 
Trayhurn et al., 1999; Trayhurn and Beattie, 2001). Leptin mediates its anorexigenic effect by 
binding to leptin specific receptors which can be found in the ARC, PVN, DMH and LHA of the 
hypothalamus. The ObRa, the short leptin receptor isoform exerts its role as a leptin transporter 
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through the BBB (Bjorbaek et al., 1998) whilst the ObRb, the long leptin receptor isoform is 
mainly produced in the hypothalamus (Fei et al., 1997).  Lack of leptin in mice (Zhang et al., 
1994) and humans (Montague et al., 1997) leads to severe obesity. Administration of leptin in 
ob/ob mice (Halaas et al., 1995) and leptin deficient humans (Farooqi et al., 1999) has been 
shown to reduce food intake and prevent body weight gain. Interestingly, obese patients have 
been shown to have high circulating levels of leptin (Considine et al., 1996; Schwartz et al., 
1996), but the levels were not related to a reduction in food intake (Considine et al., 1996). 
Meanwhile, a study showed that not all obese volunteers who underwent leptin treatment had a 
reduction in body weight (Heymsfield et al., 1999). These results suggest that the current use of 
leptin as a treatment for obesity is only applicable and effective in humans who are deficient in 
leptin. It is suggested that this could be due to the deterioration of transporting signals of leptin 
to the central of appetite regulation (Van et al., 1997).  
 
1.4.2.2 Insulin 
Insulin is secreted from the β-cells of the pancreatic islets of Langerhans. It is also known as an 
adiposity signal and involved in both short term and long term energy balance. Insulin is released 
in high levels after meal intake (Polonsky et al., 1988) and its sensitivity is highly correlated with 
the total adiposity (Kahn et al., 1993) and body fat distribution, in particularly visceral fat (Porte 
et al., 2002). Insulin levels are elevated during weight gain and reduced during weight loss. 
Insulin has been shown to cross the BBB by a saturable receptor mediated mechanism which is 
dependent on the levels of circulating insulin (Baura et al., 1993). Administration of insulin by 
ICV has been demonstrated to reduce food intake in sheep (Foster et al., 1991). Insulin exerts its 
anorectic effect by binding to its receptor which can be found in numerous sites of the 
hypothalamic regions including the ARC, VMN and PVN (Havrankova et al., 1981; Marks et al., 
1990). In the ARC, insulin has been found to co-localise with NPY and α-MSH neurons (Pardini 
et al., 2006). In addition, POMC neurons have also been reported to co-express insulin receptor 
(Benoit et al., 2002). ICV injection of an insulin mimetic compound into the third ventricle of 
fasting rats decreased POMC mRNA expression (Air et al., 2002). Besides the hypothalamus, 
insulin receptors can also be found widely in the AP, NTS and the DMV of the brainstem 
(Pardini et al., 2006). Insulin regulates energy balance via the insulin receptor substrate 2 (Burks 
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et al., 2000). An experiment using insulin receptor substrate 2 knockout mice demonstrated that 
the absence of the receptor cause an increase in food intake, body weight, fat mass (Burks et al., 
2000) and hyperphagia (Masaki et al., 2004). 
 
 
1.5 INFLUENCES OF CARBOHYDRATES ON APPETITE REGULATION  
Carbohydrate contributed the largest proportion in daily energy intake, therefore the quantity and the 
type of carbohydrate consumed are the most concern factors especially in maintaining weight 
management and controlling food intake.  Carbohydrates can be divided into four classes which are 
monosaccharides, disaccharides, oligosaccharides and polysaccharides. This classification is based 
on the chemical class and molecular size such as type of individual monomers, linkage bonds and 
degree of polymerization. The monosaccharides and disaccharides are commonly known as ‘sugars’ 
and it is basically absorbed in the small intestine for energy production. Oligosaccharides are 
characterised by having a polymerization of small numbers of simple sugars typically from two to 
ten. Unlike monosaccharides, oligosaccharides are partially digested in the small intestine and the 
undigested portion will be transported to the large intestine for bacterial fermentation. This is because 
undigestible oligosaccharides are linked by β (2-1) glycosidic bond which can only be digested by 
gut microbiota. Polysaccharides are the longest and complex structures of carbohydrates which 
contain polymerization of monomer units between 200 to 2500. Similar with olisaccharides, some 
polysaccharides (such as starches and glycogen) are also absorbed in the small intestine due to 
binding to α (1-6) linkage. Interestingly, there are some polysaccharides that are able to escape 
digestion in the small intestine and fermented by gut bacteria in the large intestine (such as cellulose 
and β-glucan) (Figure 1.3 ilustrates the classification of the carbohydrates).  
 
The following section will discuss on the effect of carbohydrates that escape digestion in the small 
intestine and transported to the large intestine for bacterial fermentation. 
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  Monosaccharide                        Disaccharide                                              Oligosaccharide 
       (Fructose)                                 (Sucrose)                                                     (Raffinose) 
 
 
Polyoligosaccharide 
(Amylose) 
 
Figure 1.3 Molecular structure of carbohydrates 
 
1.5.1 Dietary Fibre 
Dietary fibres are defined as edible constituents of plant food that are not digested in the small 
intestine and therefore reach the large bowel relatively unchanged (Trowell, 1976). It is an essential 
nutrient and has been recommended as one of the key dietary components in a healthy diet. Dietary 
fibre can be classified into four classes (EFSA, 2010), which are: 
1. Non-starch polysaccharides – cellulose, hemicelluloses, pectins, hydrocolloids (gums, 
mucilages and β-glucan). 
2. Resistant oligosaccharides – fructo-oligosaccarides, galacto-oligosaccharides and other 
resistant oligosaccharides  
3. Resistant starch – consisting of physically enclosed starch (RS1), some types of raw starch 
granules (RS2), retrograded amylose (RS3) and chemically and/or physically modified 
starches (RS4). 
4. Lignin  
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It has been reported that intake of dietary fibre has changed markedly in the recent centuries. The 
ancestral human diet has been reported to contain a greater amount of dietary fibre compared to 
the modern westernised diet (Cordain et al., 2005). During the hunter-gatherers time, fruits and 
vegetables were the main source of dietary fibre with estimation of approximately 100 g of 
dietary fibre was taken per day (Eaton, 2006). In contrast, the current westernized diet comprised 
of fibre-poor added sugars, refined grains and processed foods. Current intake of fibre in 
America and Britain was reported to be in between 12-15 g per day, less than half of the dietary 
recommendation in both countries (US Department of Agriculture recommended 28 g/day for 
women and 36 g/day for men; British Nutrition Foundation suggested intake of 24 g/day for 
adults) (United States Department of Agriculture, 2005). The change of dietary intake between 
the ancentral diet and western diet are suggested due to the agricultural and animal husbandries, 
introduction of food processing, industrialized and advance technology (Cordain et al., 2005). A 
high intake of fibre has been suggested to be beneficial in reducing many risk factors of chronic 
diseases such as cardiovascular diseases (McKeown et al., 2002; Sahyoun et al., 2006), type 2 
diabetes (Fung et al., 2002; Montonen et al., 2003; Schulze et al., 2007), certain type of cancers 
(Jacobs, Jr. et al., 1998) and mortality (Jacobs, Jr. et al., 2007).  
 
Dietary fibre have recently received much attention due to their potential effect in reducing 
appetite and energy intake, which could be use to suppress body weight gain over the long term 
(Rozan et al., 2008). In humans, a large epidemiological study that involved 159 683 volunteers 
from a multiethnic population in a period of 25 years suggested that adding one gram of fibre in 
200 kcal meals leads to 18 % and 23 % lower risk of being overweight in men and women 
respectively (Maskarinec et al., 2006). It is suggested that dietary fibres regulate body weight via 
several mechanisms. However, it is postulated that their ability to stimulate endogenous gut 
hormone secretion is the main mechanism in regulating long term body weight. The effects of 
dietary fibres however, vary from one fibre to another, possibly due to the differences in 
physicochemical properties (solubility, viscosity, fermentability and the site of fermentation in 
the gut) (Blackwood et al., 2000; Potty, 1996; Slavin and Green, 2007). The classification of 
dietary fibre based on their physicochemical properties, the source of fibres and their molecular 
structures are demonstrated in the Table 1.1 and Figure 1.4.   
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Table 1.1 Classification of dietary fibres. Adapted from (Bindelle et al., 2008; Meier, 2009; Nugent, 2005).  
Type of Dietary Fibre Solubility Fermentability  Source 
    Structural NSP    
Cellulose No 50 Whole-wheat flour, bran, vegetables 
Hemicellulose A Good 70 Bran, whole grains 
Hemicellulose B No 30 Bran, whole grains 
Beta-glucan Good  Barley, oats, rye 
    Structural non-NSP    
Lignin No 5 Mature vegetables, wheat, fruits with 
   edible seed 
    Non-structural NSP    
Pectins Very good 100 Fruits (apples, citrus) 
Gums Very good 100 Oats, barley, legumes, guar  
Mucilages Good 100 Legumes  
    
Oligosaccharides    
Inulin Good 100 Chicory, onion, artichoke, asparagus, 
Fructooligosaccharides (FOS) Good 100 Cereals, jerusalem artichoke 
    Resistant Starch    
Physically inaccessibly starch (RS1) Good ? – 100* Whole or partly milled grains and seeds, 
Crystalline resistant granules (RS2)   Raw potato, green bananas, legumes 
Retrograded starch (RS3)   Bread, cornflakes, food products treated 
   with repeated moist heat treatment 
    
* Depend to the type of resistant starch 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cellulose 
Hemicellulose 
Arabinoxylan 
β-glucan 
Pectin 
Arabinoxylan 
Inulin 
Figure 1.4 Molecular structures of dietary fibres 
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1.5.2 Dietary Fibre and Its Mechanism of Action 
Dietary fibre is proposed to influence body weight by several mechanisms involving physiological 
actions in the gastrointestinal tract including mouth, stomach, upper and lower intestines. Figure 1.3 
summarizes the proposed mechanisms of dietary fibre on modulating energy intake, satiety and 
ultimately affecting body weight.  
 
Figure 1.5 Potential mechanisms of dietary fibre in body weight regulation (Slavin, 2005). 
 
 
1.5.2.1 The Effect of Dietary Fibre on Energy Density 
Energy density is one of the major determinants in regulating food intake (Bell et al., 1998; Prentice 
and Poppitt, 1996; Rolls and Bell, 1999). In general, diet/food containing high energy density leads 
to overconsumption and ultimately, increase body weight in a long term period. Diet containing high 
fats are highly correlated with energy density (37.6 kJ/g) compared with CHO and protein (16.7 kJ/g) 
(Rolls and Bell, 1999). In contrast, diets-containing high fibres have a low energy density and 
commonly presented as a large amount of food. Adding fibre to the diet leads to an increased weight 
Dietary Fibre 
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of the diet (bulk effect), dilute energy density, induce satiation and subsequently leading to a 
reduction in energy intake (Drewnowski, 1998; Haber et al., 1977).  
 
1.5.2.2 The Effect of Dietary Fibre on Chewing 
Eating dietary fibre generally requires more time and efforts in mastication as high fibre diets 
commonly present in large quantities. It is hypothesised that this could lead to increased satiety 
because of a reduction in rate of ingestion (Howarth et al., 2001). Prolonging the time of chewing 
fibrous foods may also allow more satiety signals to be released from the gut and conveyed to the 
central appetite regulation, thus resulting in early satiety feeling and reduced amount of food intake. 
In a modified sham feeding study (a study in which specific nutrients are investigated mainly by oral 
technique such as smelling, tasting and chewing without involved swallowing process), chewing and 
tasting have been shown to increase secretion of several gut hormones such as ghrelin, CCK, 
pancreatic polypeptide, insulin and glucagon (Arosio et al., 2004; Simonian et al., 2005; Teff, 2000). 
In addition, a reduction in eating rate also has been demonstrated to influence the release GLP-1 and 
PYY (Kokkinos et al., 2010) and reduce food intake (Andrade et al., 2008; Duncan et al., 1983; 
Zijlstra et al., 2008). Moreover, eating rate can also be influenced by viscosity. A study investigated 
the effect of viscosity on energy intake demonstrated that semi-solid foods, but not liquid or semi-
liquid food have the greatest effect on reducing ad libitum meal. The authors suggested that 
prolonging viscous foods in the mouth led to increased exposure to sensory receptors located in the 
oral cavity, increased subjective satiety and subsequently reduced energy intake (Zijlstra et al., 2008; 
Zijlstra et al., 2009).  
 
1.5.2.3 The Effect of Dietary Fibre in the Stomach 
The stomach is the second site that is suggested to be influenced by dietary fibres. In the stomach, 
dietary fibres such as β-glucan, alginates, pectins, psyllium and gums exert their effects by distending 
and delaying emptying of nutrients to the small intestine as a result of increased viscosity. These 
fibres influence gastric distension and gastric emptying by absorbing high amount of water and/or 
forming gels in the stomach, therefore delaying the transport of nutrients to the small intestine 
(Cameron-Smith et al., 1994; Dikeman et al., 2006; Juvonen et al., 2009). The effect of gastric 
distension in stimulating satiety has been shown in several human studies (Bergmann et al., 1992; 
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Geliebter et al., 1988; Oesch et al., 2006; Sturm et al., 2004). To date, it is still not clear which part of 
the stomach is actively involved in stimulating subjective appetite in humans. Some studies reported 
that the proximal stomach is mainly involved in inducing fullness (Feinle et al., 1997; Hebbard et al., 
1996) while others suggested that fullness is induced from the antral site of the stomach (Hoad et al., 
2004; Hveem et al., 1996; Sturm et al., 2004). However, the effects on appetite is not only 
contributed to the gastric distension alone, but also related to the type of nutrients that are present in 
the stomach (Oesch et al., 2006). 
 
In general, high fibre foods are emptied more slowly from the stomach due to bulkiness effect. High 
viscous foods such as soluble fibres have also been suggested to influence gastric emptying (Benini 
et al., 1995; Bergmann et al., 1992; Marciani et al., 2000) due to their interaction with enzymes and 
mucosal absorption (Isaksson et al., 1982). In contrast, insoluble dietary fibres are less efficient  as 
they have minimal ability to create a viscous environment in the stomach (Bianchi and Capurso, 
2002; Vincent et al., 1995). Delay in gastric emptying has been shown to be related with increased 
release of CCK and PYY as well as decreased ghrelin levels in both rodents and humans (Li et al., 
2011; Nguyen et al., 2007).   
 
 
1.5.2.4 The Effect of Dietary Fibre on Nutrient Absorption  
Whilst the effect of fibre in the stomach relates to the mechanical action of gastric distension and 
gastric emptying, the effect of fibre in the small intestine mainly depends on the type of nutrient 
supply (Kristensen and Jensen, 2011). In the small intestine, viscous fibres are suggested to increase 
digesta viscosity (Dikeman et al., 2006; Kristensen and Jensen, 2011; Vuksan et al., 2009), which in 
turns results in prolonged absorption of nutrients and increased release of satiety-related gut hormone 
(Howarth et al., 2001). This process is also suggested to induce a phenomenon known as ‘ileal 
break’. The satiety-signals involved in relation with ileal break are CCK, GLP-1 and PYY (Blundell 
et al., 1994). Viscous fibres such as alginate, β-glucan, psyllium and guar gum have been 
demonstrated to increase satiety-related gut hormones following their effect in the small intestine 
(Beck et al., 2009a; Beck et al., 2009b; Juvonen et al., 2009).  
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1.5.2.5 The Effect of Dietary Fibre on Colonic Fermentation 
Fermentable fibres, such as inulin-type fructans or resistant starch have been shown to exert their 
effect on energy homeostasis by stimulating colonic fermentation (Cani et al., 2004; Cani et al., 
2005b; Cani et al., 2007b; Daubioul et al., 2002; Delzenne et al., 2005; Delzenne et al., 2007). 
Fermentation processes of fibre include the breakdown and hydrolysis of complex carbohydrate to 
their basic sugars by gut microbiota which can be found in the caecum and ascending colon.  
 
 
1.5.2.5.1 Gut Microbiota and its Effect on Energy Homeostasis 
The humans’ adult intestine contains between 10 trillion to 100 trillion microorganisms. These 
microorganisms can be categorised into 3 populations, bacteria, archaea and eukarya with the largest 
population belongs to bacteria. The bacterial population comprises a minimum of 10
14
 anaerobic 
bacteria from 500 to 1000 identified species (Xu and Gordon, 2003), which can be divided into the 
beneficial and the pathogenic communities. However, the most populated genera found in the human 
adults’ intestine are Bacteroidetes (gram-negative bacteria) and Firmicutes (gram-positive bacteria). 
Both of the bacteria are mainly involved in digesting carbohydrates that escaped the absorption 
process in the small intestine (Gill et al., 2006).  
 
Recently, the alteration of population levels of Bacteroidetes and Firmicutes in both rodents and 
obese people have been related to obesity.  In rodents, ob/ob mice have been shown to contain lower 
population of Bacteroidetes but higher levels of Firmicutes compared to lean mice (Ley et al., 2005). 
This proportion levels of microflora have been suggested to have high ability for energy harvesting 
compared to lean mice (Turnbaugh et al., 2006). Moreover, the population of Bacteroidetes in human 
(twin volunteers) were also found in a lower amount compared to Actinobacteria populations 
(Turnbaugh et al., 2009). Interestingly, an intervention study demonstrated that obese volunteers with 
significantly less Bacteroidetes and increased Firmicutes composition at the beginning of the study 
were shown to reverse the bacteria composition pattern by increased Bacteriodetes and decreased 
Firmicutes after one year of low-fat or low-carbohydrate diets compared to normal weight 
volunteers. In addition, alteration in the bacterial population ratio was correlated with a reduction in 
body fat (Ley et al., 2006). Indeed, Santacruz et al. demonstrated that the reduction of body weight 
following lifestyle modifications seems to be influenced by the volunteers’ gut microbiota 
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proportion. No correlation between the gut microbiota and total energy intake was reported, 
suggesting that there is possibly a link between diet, gut microbiota and the host (Santacruz et al., 
2009). 
 
Despite several studies showing that high Firmicutes / low Bacteroidetes are related to obesity, 
Duncan et al. suggested that an alteration of Bacteroidetes population is possibly not related to 
energy homeostasis. This suggestion has been made as the bacteria population was found to be in 
similar pattern in both overweight and lean volunteers. However, the authors agreed that Firmicutes 
populations were reduced after volunteers underwent a low-carbohydrate diet (Duncan et al., 2008). 
Therefore, the modification of gut microflora composition could possibly be involved in the 
regulation of energy homeostasis and could reduce the development of obesity. A number of dietary 
fibres have been suggested to alter the composition of gut microflora population. These dietary fibres 
are hypothesized to alter the gut microflora composition by selectively stimulating the growth of 
beneficial bacteria and suppressing the number of pathogenic bacteria composition. Dietary fibres 
with these physiological role are known as prebiotics (Gibson and Roberfroid, 1995). To be known 
as prebiotic, food ingredients must not be digested in the small intestine, fermented by at least one or 
more bacteria that symbiotically beneficial for gut health (e.g. bifidobacteria and lactobacilli), 
increase the composition of ‘good’ bacteria and reduce the pathogenic bacteria communities such as 
Escherichia coli and Clostridium perfringens (Kolida et al., 2002).    
 
Inulin-type fructans have been suggested to fulfil these criteria and their prebiotic role has been 
demonstrated in a few studies. Adding inulin-type fructans (i.e. fructooligosaccharides, inulin and 
oligofructose) in the human diet have been shown to stimulate the number of Bifidobacterium spp. 
and Lactobacillus spp. in humans (Bouhnik et al., 2006; Kolida et al., 2007; Kruse et al., 1999; Sghir 
et al., 1998). In addition, including oligofructose and inulin in the diet for 45 days significantly 
increased Bifidobacteria composition and at the same time reduced the number of Bacteroides, 
clostridia, Fusobacteria and gram positive cocci (Gibson et al., 1995). The bifidogenic effect of 
inulin was also demonstrated in Kleessen et al. (Kleessen et al., 1997). Recently, supplementing 
oligofructose in high fat diet has also been exhibited to reduce the pathogenic effect of endotoxemia. 
The effect was negatively correlated with an increase number of Bifidobacterium spp. compared with 
the high fat diet alone. Interestingly, the bifidogenic effect of oligofructose also results in improved 
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glucose tolerance, stimulates insulin release and suppresses endotoxemia following increased 
bifidobacteria (Cani et al., 2007c). Endotoxemia is a condition in which plasma lipopolysaccharide 
(an endotoxin produced following intake of high fat diets) is increased in high levels in the periphery 
and its abundance has been associated with increased body weight as well as a reduction in the 
number of gram positive bacteria, bifidobacteria (Cani et al., 2007a). In general, intestinal microflora 
are important to digest non-digestible fibres and resistant starch to yield short chain fatty acid 
(SCFA), gasses, heat and energy as the products of fermentation (Cummings, 1981). The main 
products of the fermentation, SCFAs have been hypothesized to play an important role in energy 
homeostasis (Delzenne et al., 2005; Reimer and McBurney, 1996). The roles of SCFAs are explained 
further in the section 1.5.3.  
 
Recently, there has been a controversy regarding the secretion of SCFA-derived intestinal 
fermentation by the gut microbiota. Evidence demonstrated that obesity is related to high energy 
harvesting of intestinal microbiota (Turnbaugh et al., 2006). In addition, SCFAs were also 
demonstrated to be significantly increased in the caecum of genetically obese mice compared to lean 
mice (Murphy et al., 2010). Schwiertz et al. showed that a high production of propionate and total 
production of SCFA were released in obese volunteers compared to lean volunteers. However, this 
observation could also possibly be due to differences in the microbe, shift in transit time or decreased 
rate of mucosal absorption (Schwiertz et al., 2010). At the same time, SCFAs-derived intestinal 
fermentation have extensively been shown to affect hosts’ health by reducing hunger, improving 
glucose tolerance and modulating body weight (Cani et al., 2005b; Cani et al., 2006b). The contradict 
effects of gut-derived SCFAs on energy homeostasis following dietary factors especially in humans 
are still unclear. Although dietary factors seem to play a role in the contrasting effect of SCFA, there 
is possibly an unknown mechanism by which colonic gut-microbiota interacts with the host in 
regulating energy homeostasis. This remains to be further clarified. 
 
 
1.5.3 Short Chain Fatty Acids  
SCFAs that arise from fibre degradation by colonic gut bacteria have been proposed to beneficially 
influence human health by modifying energy homeostasis. There are many suggestions of how their 
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physiological role can influence energy homeostasis, however their main role as anorectic gut 
hormone stimulators has attracted much attention as this could be developed as an obesity treatment.   
 
SCFAs are organic fatty acids which contain 1 - 7 carbons. Acetate (2 carbons), propionate (3 
carbons) and butyrate (4 carbons) are the main products of the bacterial degradation of dietary fibre 
apart from gasses (CO2, CH4 and H2), heat and energy. The chemical structures of acetate, propionate 
and butyrate are illustrated in figure 1.4. 
 
 
Figure 1.6 Chemical structure of acetate, propionate and butyrate produced from fermentation of fibre 
in the large intestine. Adapted from (Darzi et al., 2011). 
 
 
SCFAs can be found in herbivorous and omnivorous animals, but the highest production of 
SCFAs can be found in herbivors as SCFAs are produced from the fermentation of plant-type 
materials. Ruminants have the highest SCFA production which provides approximately 60 – 80 
% of metabolised energy (Bergman, 1990). In contrast to ruminants, SCFAs in humans are 
produced typically from western diet which contains less plant-based materials. Therefore, this 
produces comparably low amounts of metabolised energy (5 – 10%) (Mortensen and Clausen, 
1996). 
 
There are several factors that influence the production of SCFAs, such as the population and 
amount of bacteria present in the gut, the bowel transit time and the type of substrate or fibre 
ingested (Cook and Sellin, 1998). Evidence suggested that the fermentation of dietary fibre and 
malabsorbed carbohydrate contributed between 220 – 760 mmol SCFAs daily (Freeland and 
Wolever, 2010). Protein is also a potential fermentation substrate. It is digested into branched 
amino acid such as valine, leucine and isoleucine by a group of bacteria called proteolytic. 
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However, the amount of SCFAs produced by protein digestion is much lower than carbohydrate 
digestion (Macfarlane and Macfarlane, 1995; Macfarlane and Macfarlane, 2003).  
 
The overall SCFAs intestinal production is in the order of acetate > propionate > butyrate, which 
comprise 90-95 % of the total colonic SCFA production (Cummings, 1981). The SCFAs production 
and the type of SCFAs are determined by the location and availability of the substrate. The caecum 
and proximal colon contain the highest concentration of SCFAs because of higher bacterial 
fermentation activities and high amounts of substrate availability compared to other parts of the 
colon. The SCFAs concentrations are slowly reduced towards the distal colon as the levels of 
available substrate declined (Bach Knudsen et al., 1991; Govers et al., 1999; Marsono et al., 1993; 
Topping et al., 1993). It is estimated that the caecum and proximal colon contain between 100 – 140 
mmol/l of total colonic SCFAs whilst the distal colon contains 40 – 80 mmol/l (Bach Knudsen et al., 
1991). From the colon, SCFAs are rapidly absorbed and transported to the liver and the periphery via 
portal blood. Investigation of SCFA concentrations in sudden death victims revealed that the portal 
blood contained the highest amount of the SCFAs (375 ± 70 µmol/l) compared to the hepatic 
circulation (148 ± 42 µmol/l) and the peripheral (79 ± 22 µmol/l). Nevertheless, the SCFAs levels 
reported in the portal blood was 1/1000
th
 less than the amount produced in the colon (Cummings and 
Englyst, 1987). SCFAs play their role at different sites in the body. The three most important sites 
where SCFAs exert their roles are the colon for butyrate, the liver for acetate and propionate, whilst 
muscle cells are predominantly fuelled by acetate. The individual SCFA productions in the large 
intestine and blood are summarised in Table 1.2. 
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Table 1.2 Individual SCFA levels in the large intestine and blood circulations in humans. Adapted from 
(Cummings et al., 1987). 
SCFA  Blood (µmol/l)  Large intestine (mmol/kg) 
  Portal Hepatic Peripheral  Ascending Transverse Descending Sigmoid 
       
Acetate  258 ± 40 115 ± 28 70 ± 18  63.4 ± 6.8 57.9 ± 5.4 43.5 ± 11.1 50.1 ± 16.2 
       
Propionate  88 ± 28 21 ± 10 5 ± 2  26.7 ± 4.0 23.1 ± 2.8 14.2 ± 3.1 19.5 ± 6.7 
       
Butyrate  29 ± 8 12 ± 4 4 ± 2  24.5 ± 4.2 24.4 ± 2.2 14.7 ± 2.9 17.9 ± 5.6 
       
Total  375 ± 70 148 ± 42 79 ± 22  114.6 ± 15.0 105.4 ± 10.4 72.4 ± 17.1 87.5 ± 28.5 
       
Results are expressed as mean ± SEM (n=6) 
 
1.5.3.1 Acetate 
Acetate is the most abundant SCFA produced in the gut. Once produced, it is absorbed and 
transported to the liver. In the liver, acetate is the main substrate for cholesterol synthesis. Rectal 
infusion of 90 mmol of acetate (+ 30 mmol propionate) and 180 mmol of acetate (+ 60 mmol 
propionate) positively correlated with elevated levels of cholesterol and triglycerides, which strongly 
suggested the role of acetate in lipogenesis (Wolever et al., 1989; Wolever et al., 1989). Theoretically, 
acetate stimulates lipid synthesis by converting into acetyl-CoA with the help from acetyl-CoA 
synthetase, an enzyme that can be found mainly in the adipocytes and mammary glands (Wong et al., 
2006).  
 
Lactulose has been suggested as a good source of acetate as it has been shown to increase acetate 
levels compared to a control group (Fernandes et al., 2000; Pomare et al., 1985; Pouteau et al., 1998). 
Intake of lactulose has been shown to increase fasting serum cholesterol in humans. The authors 
suggested that this effect could potentially be due to increased acetate, which is a substrate for 
cholesterol synthesis (Jenkins et al., 1991). In addition, lactulose might have produced insufficient 
levels of propionate (Fernandes et al., 2000) to suppress cholesterol synthesis (Wolever et al., 1991; 
Wolever et al., 1995). Indeed, Wolever et al. also highlighted the role of propionate in suppressing 
cholesterol synthesis after they demonstrated that adding propionate into acetate infusion leads to a 
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decrease in serum cholesterol but the effect was diminished when infusing acetate alone. In addition, 
these observations also suggested that the effect of acetate and propionate on lipogenesis is not solely 
depend on individual SCFAs production, but also depends on acetate and propionate ratio (Wolever 
et al., 1991).   
 
1.5.3.2 Propionate 
The role of propionate on human health will be discussed in Chapter 5 
 
1.5.3.3 Butyrate 
Butyrate is the main energy regulator for colonocytes (Roediger, 1980). It is reported that about 70 – 
90 % of butyrate is metabolised by the colonocytes (Cook and Sellin, 1998). Indeed, the importance 
of butyrate as the energy provider in the colonocytes when compared to propionate and acetate is 
estimated in the ratio of 90:30:50 (Cook and Sellin, 1998). As a regulator in the colon, butyrate has 
been shown to influence colonic cell proliferation and differentiation (Li and Elsasser, 2005; Topping 
and Clifton, 2001) and inflammatory response (Topping and Clifton, 2001). Nilsson & Nyman 
demonstrated that butyrate concentration is higher in the distal colon compared to the caecum, 
whereas butyrate proportion was found to be elevated both in the caecum and the distal colon 
(Nilsson and Nyman, 2005). Oligofructose, Plantago ovate, guar gum, butyrylated starch, lactulose, 
cornstarch and barley kernels are the plants and food components that produce high amount of 
butyrate (Bajka et al., 2006; Fernandes et al., 2000; Morrison et al., 2006; Nordgaard et al., 1996; 
Stewart and Slavin, 2006). 
 
 
1.5.3.4 Short Chain Fatty Acids Receptor 
Although many studies suggest that SCFAs may have numerous physiological effects on intestinal 
health and improving the host health, the exact mechanisms of how they regulated these effects 
remains unclear. It was not until 2003, Brown et al., Nilsson et al. and Le Poul et al. identified the 
presence of two receptors, free fatty acid receptor 2 (FFAR2) and free fatty acid receptor 3 (FFAR3) 
were activated by SCFAs (Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003). The 
discoveries of these two SCFAs receptors have opened a new perspective in appetite research and 
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hopefully this could lead to a better understanding of how SCFAs mediate their effect on energy 
homeostasis. 
 
Interestingly, FFAR2 and FFAR3 have a different affinity towards the SCFAs. In FFAR3, the 
potential orders of SCFA binding are propionate ≥ butyrate > acetate whilst in FFAR2, each SCFA 
has equal affinity for the receptor (Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003). 
FFAR2 and FFAR3 are expressed in various types of tissues. FFAR3 is highly expressed in the 
adipose tissue, pancreas, spleen and bone marrow (Brown et al., 2003; Le Poul et al., 2003; Xiong et 
al., 2004)  and FFAR2 has been reported to be expressed in the immune cells, particularly monocytes 
and neutrophils (Brown et al., 2003; Le Poul et al., 2003), adipocytes, spleen, skeletal muscle and 
heart (Ge et al., 2008; Hong et al., 2005; Nilsson et al., 2003; Xiong et al., 2004; Zaibi et al., 2010). 
In the intestine, mRNA and protein of both receptors can be found in the whole wall and mucosa 
extracts (Karaki et al., 2008; Tazoe et al., 2008). It has also been demonstrated that FFAR2 and 
FFAR3 were bound to Gi/o-proteins that can be found in the adipose tissue (Brown et al., 2003; Le 
Poul et al., 2003). G-proteins is a group of signalling protein that exert their effects by binding to the 
cytoplasmic of the receptors and help in sensing and aid in their coupling downstream process. 
Binding of G-protein with SCFAs receptors in the adipose tissue highlighted the important of adipose 
tissue as the target for SCFA. The localization of both of the receptors in various types of tissues have 
suggested that the receptors functions may not just be limited to the stimulation of gut hormones 
secretion but possibly involved in the regulating of various immune and inflammatory responses 
(Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003). 
 
 
1.5.3.4.1 The Role of Short Chain Fatty Acids Receptors 
Recently, studies demonstrated that PYY containing enteroendocrine cells, the L-cells also expressed 
FFAR2 and FFAR3 which suggests that the cells possibly sense SCFAs directly via both receptors in 
rats and human (Karaki et al., 2006; Karaki et al., 2008; Tazoe et al., 2008) to release PYY. However, 
it is still not fully understood how the cells respond to this stimulus. In addition to this finding, 
activation of SCFA on FFAR2 may also stimulate the expression of 5-hydroxytryptophan, also 
known as serotonin. This hypothesis has been made following the recent finding of co-localisation of 
FFAR2-IR cell with serotinin in the mucosal mast cells (Karaki et al., 2006). However, this 
observation has only been demonstrated in rat, but not in human colonic mucosa (Karaki et al., 
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2008). Serotinin is a neurotransmitter, which is secreted primarily in the gastrointestinal tract and also 
in the CNS. It is mainly involved in regulating energy homeostasis and food intake, mood and 
gastrointestinal motility (Berger et al., 2009).  The importance of FFAR3 in releasing PYY levels has 
been investigated in a mice null FFAR3 study. In this study, Samuel et al. reported that the lack of 
FFAR3 in mice resulted in reduced PYY levels and body weight compared to the wild type mice, 
potentially due to the lack of PYY expression (Samuel et al., 2008). The L-cell, the enteroendocrine 
cell located in the intestine has been postulated as an important site in regulating appetite. This is due 
to its physiological role in the synthesis and secretion of anorectic gut hormones such as GLP-1 and 
PYY, which have been shown as an important inhibitor of food intake and body weight in both 
rodents and human (Batterham et al., 2002; Batterham et al., 2003; Cani et al., 2005b; Cani et al., 
2007b).  
 
Besides stimulating gut hormone secretion, SCFAs receptors are also postulated to play significant 
roles in the adipose tissue. Hong et al. and Zaibi et al. demonstrated that acetate and propionate 
stimulated adipogenesis and reduced expression of leptin,  which was activated via FFAR2 (Hong et 
al., 2005; Zaibi et al., 2010). Activation of FFAR2 by both of the SCFAs, acetate and propionate in 
the adipocytes resulted in reducing lipolysis while acetate has been shown to suppress plasma free 
fatty acid levels in vivo in both male and female mice (Ge et al., 2008). Surprisingly, it seems that 
FFAR3 is not involved in this process (Hong et al., 2005).   
 
 
1.5.3.5 Short Chain Fatty Acids and Gut Hormones Release 
Numerous evidences demonstrated that SCFAs-derived from colonic fermentation potentially 
modulate energy homeostasis by stimulating the release of anorectic gut hormones such as PYY, and 
GLP-1, GLP-2 and reducing the amounts of orexigenic hormone, ghrelin (Cani et al., 2004; Cani et 
al., 2005b; Cani et al., 2009; Parnell and Reimer, 2009) possibly via their receptors, FFAR2 and 
FFAR3. Nevertheless, although all three main SCFAs can be generated endogenously via fat 
oxidation and gluconeogenesis metabolism, the amounts of SCFAs produced seem insufficient to 
stimulate the production of gut hormones. It was reported that the average colonic production was 
100 mM whilst the stimulation of PYY occurred at 300 mM (Cherbut et al., 1998). Therefore, 
increased intake of other source of SCFAs such as dietary fibre are highly encouraged in order to 
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increase colonic pools of SCFAs needed to stimulate gut hormone release. Based on this objective, 
appetite research has now focusing on finding ways to increase endogenous production of SCFAs 
either by finding new plant source or approaches that could induce SCFAs production. 
 
 
1.5.4 The Effect of Dietary Fibre on Appetite Regulation 
 
1.5.4.1 The Effect of Dietary Fibres in Rodents 
Dietary fibres with viscous and fermentable properties have been shown to reduce food intake and 
body weight compared to low fermentable non-viscous fibres. Adding β-glucan in the obese mice for 
six weeks reduced food intake and suppressed weight gain possibly due to increased postprandial 
plasma PYY3-36 concentration (Huang et al., 2011). In other study, Hara et al. suggested that 
fermentable viscous fibre was more effective in reducing food intake and weight gain compared to 
other tested fibres. In this study, the effect of 10 % guar gum, psyllium, sugar-beet fibre, cellulose or 
diet without fibre were investigated in three weeks. Guar gum, a high fermentable viscous fibre 
showed the highest effect in attenuate weight gain compared to psyllium, sugar-beet fibre, cellulose 
and fibre-free diet (138 ± 8.9 g, 142 ± 3.7 g, 143 ± 5.2 g, 148 ± 7.0 g and 149 ± 5.2 g respectively) 
(Hara et al., 1996). The effect of guar gum on food intake and body weight is also reported elsewhere 
(Henningsson et al., 2002; Johnson and Gee, 1986; Lu et al., 2000; Vachon et al., 1988). A study 
showed that although guar gum significantly reduced food intake compared to cellulose, bran or  
fibre-free diet in a short term (six weeks), the effect was not sustained to reduce weight gain in the 
long term (67 weeks) (Track et al., 1985). The same observation was also reported in other studies 
(Davies et al., 1991; Isken et al., 2010). Isken et al. suggested that the energy produced from high 
SCFA levels of fermented soluble fibre in the gut may have influenced the overall endogenous 
energy production therefore outweighed the known acute effect of fermentable carbohydrates on 
food intake and body weight (Isken et al., 2010). 
 
Diet supplementing with 5 % pectin, 5 % cellulose and combination of 2.5 % pectin and 2.5 % 
cellulose for six weeks showed no significant effect on food intake or body weight although there 
was a significant modulation on plasma cholesterol and HDL-cholestrol levels in rats fed pectin-
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enriched diet (Krzysik et al., 2011). It is possible that 5 % of fibres used in this study were too low to 
attenuate food intake and body weight. This is because the effect of dietary fibre on reducing food 
intake and body weight in rodents were usually reported following intake of 10 % fibre per total 
dietary intake (Cani et al., 2004; Cani et al., 2005b; Cani et al., 2006b). Surprisingly, adding 500 g 
mixed fibre diet of oat based products consists of resistant starch, β-glucan and dietary fibre in Wistar 
rats for six weeks also showed no significant effect on food intake and body weight although the 
treatment did increased caecal and colon walls weight, increased the genus bifidobacterium and 
reduced coliform numbers upon the treatment (Drzikova et al., 2005). The pronounced effects of the 
treatment on gut architecture could possibly be due to the presence of resistant starch, which mainly 
modulated its effect on appetite and body weight via colonic fermentation (Keenan et al., 2006; Zhou 
et al., 2008; Zhou et al., 2009). The effect however, diminished in this study. 
 
Resistant starch, via its colonic fermentation effect has been shown to suppress body weight gain, 
deposition of fat mass and increased release PYY and GLP-1 gene expression (Charrier et al., 2011; 
McCutcheon et al., 2009; Shen et al., 2009; So et al., 2007; Zhou et al., 2008). However, Keenan et 
al. did not find the same observation in their study. They demonstrated that supplementing the same 
amount of either resistant starch or methylcellulose diet to rats resulted in no significant effect on 
food intake and body weight. The reason behind this observation is possibly due to increased food 
intake in order to compensate for low energy density from the fibre-enriched diet. Oligofructose, 
another fermentable carbohydrate also has been suggested to alter food intake and body weight 
through colonic fermentation (Cani et al., 2004; Cani et al., 2005b; Cani et al., 2007b; Daubioul et 
al., 2002; Delzenne et al., 2005). The effect of oligofructose treatment on body weight is potentially 
due to the increased release of GLP-1 and PYY (Cani et al., 2004; Cani et al., 2005b; Delzenne et al., 
2005). The role of oligofructose is discussed in more detail in Chapter 2.  
 
 
1.5.4.2 The Effect of Dietary Fibres in Suppressing Appetite in Humans 
A systematic review comparing the effect of different physico-chemical properties of dietary fibres 
on subjective appetite, energy intake and body weight suggested that fibres with viscous property 
suppressed appetite and acute energy intake to a greater extent compared with other type of fibres 
(Wanders et al., 2011). β-glucan, one of the viscous fibres, has been demonstrated to modulate 
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subjective appetite and gut hormones when added to different type of foods such as beverages 
(Barone et al., 2012; Lyly et al., 2009; Lyly et al., 2010), breakfast cereals (Beck et al., 2009a) and 
bread (Vitaglione et al., 2009). Surprisingly, although it has been shown to affect subjective appetite, 
it does not always reduce food intake (Juvonen et al., 2009; Vitaglione et al., 2010). Peters et al. also 
demonstrated that β-glucan when taken as cereal bars had no significant effect on both appetite and 
energy intake, although it increased in vitro digesta viscosity (Peters et al., 2009).  
 
Nevertheless, a study comparing the effect of different viscosities on satiety demonstrated that guar 
gum, the highest viscous fibre investigated in this study, increased subjective satiety and decreased 
desire to eat compared to other low viscous fibre and wheat bran (Lyly et al., 2009). French and Read 
demonstrated that supplementing 3 % of guar gam to low and high fat soup hindered the return of 
hunger sensations in young men, due to delayed gastric emptying (French and Read, 1994). In 
contrast, Lavin et al. suggested that reduced glycaemic and insulinemic response following three 
hours intake of 2% of guar gum added in a 250ml glucose beverage was not related to delayed 
gastric emptying, but possibly due to increased circulating plasma GLP-1, insulin and gastric 
inhibitory polypeptide levels (Lavin and Read, 1995). 
 
The role of alginate in modulating subjective appetite and food intake has been demonstrated in 
healthy normal weight and obese volunteers (Georg et al., 2011; Hoad et al., 2004; Peters et al., 2011; 
Solah et al., 2010) either in controlled clinical studies (Georg et al., 2011; Pelkman et al., 2007) or in 
free living volunteers (Paxman et al., 2008). It is suggested that alginate exerts its effect by forming 
gelling particles either in the acidic environment (pH less than 3.5) in the stomach or by the 
interaction with divalent ions such as Ca
+ 
(Hoad et al., 2004). However, some studies cannot 
replicated the same effect (Mattes, 2007; Odunsi et al., 2010). Inconsistencies in showing the effect 
of alginate on subjective appetite and food intake may be due to several factors; such as differences 
in study design and the levels of alginate investigated, the carriers (whether solid or liquid) and type 
of biopolymer used in alginate (guluronate or mannuronate). Different types of biopolymer can 
influence the viscosity and strength of gel mass production during the reaction in the stomach, due to 
different gelling abilities and molecular weight (Georg et al., 2011).   
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Adding psyllium in the diet has been shown to reduce hunger and increase satiety in twelve healthy 
lean volunteers following six hours intake of the test meal. It was suggested that psyllium exerts it 
effects by delaying gastric emptying, which was demonstrated to be started three hours after meal 
intake in this study (Bergmann et al., 1992). In contrast, Rigaud et al. reported that the effect of 7.4 g 
psyllium on suppressing hunger and energy intake was not related to a delay in gastric emptying, but 
primarily due to high viscous environment, which subsequently leads to slow intestinal absorption of 
nutrients. The effect of psyllium in reducing energy intake was also reported by other studies 
(Cybulski et al., 1992; Rigaud et al., 1998; Turnbull and Thomas, 1995). Surprisingly, adding 
psyllium in breads has resulted in no significant effect on appetite although postprandial glucose and 
insulin, plasma ghrelin, GLP-1 and PYY were modulated by psyllium treatment (Karhunen et al., 
2010). The authors suggested that the unaffected subjective appetite found in this study was related to 
solid foods (bread) as the carriers. Furthermore, because subjective appetite has a large inter-
individual variation, the number of volunteers involved in the study (sixteen volunteers) maybe 
insufficient to detect small differences on subjective appetite (Karhunen et al., 2010).      
 
A non-viscous, fermentable carbohydrate is another group of fibre which has been postulated to have 
a major impact on appetite regulation. Fermentable carbohydrates control appetite and energy intake 
by acting in the distal gut and therefore little or no modulation of its effect on the small intestine is 
expected. There are a few type of fibres categorised in this group, which are methylcellulose, 
resistant starch, fructans, xylans and mannans families. The role of non-viscous fermentable 
carbohydrates on the short term effect of appetite has been investigated in several studies (Archer et 
al., 2004; Bodinham et al., 2010; Cani et al., 2006a; Cani et al., 2009; Delargy et al., 1997; Isaksson 
et al., 2009; Peters et al., 2009; Raben et al., 1994; Weickert et al., 2006; Willis et al., 2009). A study 
comparing the effect of different fibres supplemented in muffins; β-glucan (viscous fibre), corn bran 
(insoluble fibre), resistant starch (fermentable carbohydrate) and low fibre on appetite sensations 
exhibited that resistant starch consistently affects appetite by reducing hunger-related scores and 
increased satiety-related ratings (Raben et al., 1994; Willis et al., 2009). However, assessment on 
energy intake was not performed in this study. Meanwhile, inclusion of 30 g resistant starch, high-
amylose corn starch (RS2) and retrograded high-amylose corn starch (RS3) had little effect on 
subjective appetite and energy intake (de Roos et al., 1995)  
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Interestingly, although increased resistant starch to 48 g taken twice per day during breakfast and 
lunch in 20 healthy BMI volunteers had no significant effect on subjective appetite, the supplement 
reduced energy intake 4 hours after meals and in 24 hours thereafter (Bodinham et al., 2010). Late 
effect on energy intake was also demonstrated in Archer et al. In their study, inclusion of inulin (24 g) 
in a fat-reduced sausage patty reduced energy intake compared to the full fat sausage patty during 
breakfast, although no significant effect on subjective appetite was observed. This observation 
suggests that the effects of resistant starch on appetite did not necessarily appear at the meal time but 
could be affected later in the day (Archer et al., 2004). Besides resistant starch, inulin has also been 
suggested to modulated satiety and energy intake following intake of 16 g oligofructose for two 
weeks (Cani et al., 2009). The effect of oligofructose on appetite and energy intake potentially 
modulated via increased circulating plasma gut hormones after fibre fermentation by gut bacteria. 
The effect of inulin-type fructans on appetite will be discussed in detail in Chapter 2.  
 
1.5.4.3 The Effect of Dietary Fibres on Reducing Body Weight in Humans 
Based on the evidence discussed in the previous paragraphs, dietary fibres have a great potential to 
affect acute subjective appetite and energy intake. However, whether the modulations of subjective 
appetite and energy intake in the short term could be translated to weight loss or prevention of weight 
gain are remain controversial. Nevertheless, until now, large epidemiological, cross-sectional and 
intervention studies consistently showed that high fibre diet or fibre-related products in a long term 
have a negative correlation with body weight, weight gain, WC and adiposity (Du et al., 2010; Koh-
Banerjee et al., 2004; Liu et al., 2003; Ludwig et al., 1999; Maskarinec et al., 2006; Miller et al., 
1994; Nelson and Tucker, 1996; van, V et al., 2009).  
 
Alginate, a viscous fibre is proposed to reduce energy intake (Georg et al., 2011; Paxman et al., 2008; 
Pelkman et al., 2007) by forming gels with the presence of ionic cations (Ohta et al., 1997). The 
gelling property of alginate is the main feature that differentiates its mechanism of action with other 
viscous fibres such as guar gum and psyllium. A study showed that intake of hypocaloric diet 
containing 15 g alginate three times per day for two weeks reduced body weight (-1.42 ± 0.38 kg). 
However, the effect was less pronounced than the effect showed by the control group (-1.56 ± 0.21 
kg) (Georg et al., 2011). It was postulated that two weeks was insufficient to affect body weight. In 
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addition, the authors suggest that body weight reduction can be induced if the supplement is 
continuously taken in a long term period. Indeed, recent findings showed that a 15 g alginate-
containing hypocaloric diet significantly suppressed body weight by 6.78 ± 3.67 kg after 12 weeks 
treatment in 80 obese volunteers compared to 5.04 ± 3.40 kg in the placebo group.  However, no 
significant difference was demonstrated in intention-to-treat analysis (Georg et al., 2012). 
 
Guar gum has been suggested to exert its effect on appetite and energy intake by delaying gastric 
emptying (Todd et al., 1990).  Investigations into the effects of guar gum on controlling body weight 
has been studied in several populations, hypercholesterolemic patients (Blake et al., 1997; 
Tuomilehto et al., 1980; Uusitupa et al., 1984), dyslipidemic patients (Tuomilehto et al., 1983), 
overweight or obese volunteers (Heini et al., 1998; Kovacs et al., 2001; Kovacs et al., 2002) and 
post-menopausal women (Makkonen et al., 1993; Pasman et al., 1997b). Supplementing 2.5 g guar 
gum to a semi-solid meal of a low energy diet showed a tendency to alter subjective appetite 
compared to meals without guar gum and solid meals in 28 overweight healthy volunteers. However, 
no significant effect on weight loss was demonstrated (Kovacs et al., 2001). In contrast, adding 20 g 
guar gum in orange juice twice daily for a week in 17 obese women three months after weight loss 
significantly reduced energy intake by 1.3 ± 0.2 MJ compared with the control group (Pasman et al., 
1997a). Meanwhile, supplementing 20 g partially hydrolysed guar gum in a low calorie diet in 25 
obese women increased postprandial CCK levels, but showed no significant effect in reducing 
appetite or weight loss during the treatment course (Heini et al., 1998). Similarly, no significant body 
weight loss was also reported in 20 weight-reduced women who received 20 g/day of guar gum 
supplementation for 14 months (Pasman et al., 1997b) and in 15 menopausal women supplemented 
with 15 g/day guar gum for six months (Makkonen et al., 1993). Indeed, a meta-analysis on eleven 
randomized guar gum studies concluded that guar gum is not effective as a weight loss treatment. 
Furthermore, a high number of side effects (constipation, diarrhoea, flatulence) reported by 
volunteers may have masked the beneficial effect of this fibre (Pittler and Ernst, 2001).     
 
Intake of two capsules of 500 mg glucomannan three times per day in 20 obese women induced 
weight loss by 2.5 kg and reduced serum related-cholesterol after eight weeks supplementation 
period (Walsh et al., 1984). Furthermore, addition of 4 g/day of glucomannan in a low caloric diet in 
25 severely obese volunteers for three months significantly reduced body weight compared to a 
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hypocaloric diet without the supplement (Vita et al., 1992). Meanwhile, combination of glucomannan 
and other fibres (inulin, psyllium and pectin) in a dose of 7 g/day suppressed an increase in BMI 
(26.3 ± 1.7 to 25.0 ± 1.41 kg/m
2
) in ten volunteers over four weeks (Bortolotti et al., 2008). Indeed, 
Birketvedt et al. also showed that adding glucomannan alone or in a combination with other fibres 
(guar gum or alginate) in hypocaloric diet significantly increased weight loss (3.8 – 4.4 kg) compared 
to a low caloric diet alone or placebo after five weeks treatment in 176 volunteers (Birketvedt et al., 
2005). A similar observation was demonstrated when Salas-Salvado et al. investigated the effect of 
delivering mixed fibre (3 g Plantago ovata and 1 g glucomannan) in a large scale, parallel, double-
blinded, randomised and placebo-controlled study. In this study, 4 g of mixed fibres taken either 
twice or three times per day induced weight loss (-4.52 ± 0.55 and -4.60 ± 0.56 kg respectively) 
compared with the control group (-0.79 ± 0.59 kg) in 200 overweight or obese volunteers for 16 
weeks, but no significant difference was found between the treatments (Salas-Salvado et al., 2008). 
However, no effect on body weight loss was also demonstrated by Hylander et al. and Rodriguez-
Moran et al. (Hylander and Rossner, 1983; Rodriguez-Moran et al., 1998).  
 
β-glucan has been proposed to alter subjective appetite and energy intake in the short term by 
increased viscosity in the stomach (Beck et al., 2009a; Lyly et al., 2009; Lyly et al., 2010; 
Vitaglione et al., 2009). However, there is currently a controversy whether continuous 
consumption of β-glucan for a longer period can aid weight loss. This is either because the data 
on the role of β-glucan on weight loss is insufficient or the findings from the previous studies are 
not supporting its role in weight management. Saltzman et al. demonstrated that consumption of 
a hypocaloric diet containing oats (45g/1000 kcal) in 41 adults did not affect body weight 
compared to the control, although there was a tendency towards a reduction of hunger. The 
authors suggested that this observation was possibly due to the lower amount of supplementation 
or the number of volunteers in this study were insufficient to effect body weight change 
(Saltzman et al., 2001).  No significant effect on reducing body weight was also observed when 
Maki et al. supplemented 3 g/day oat β-glucan-enriched hypocaloric diet in 144 overweight 
women for 12 weeks (Maki et al., 2010).  
 
Although non-viscous fermentable carbohydrates have been shown to reduce subjective appetite 
and acute energy intake, evidence on the effect of long term studies on maintaining body weight 
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is inconsistent. Numerous evidence have demonstrated that resistant starch reduced energy 
intake and body weight in rodents (de Deckere et al., 1995; Keenan et al., 2006; Shen et al., 
2009; Zhou et al., 2009). However, evidence in humans is currently insufficient to support the 
role of resistant starch in reducing body weight. Supplementing resistant starch (40 g/day) for 12 
weeks in 20 insulin resistance volunteers did not affect body weight and fat deposition although 
it significantly improved insulin response. These results suggest that modulation on insulin is not 
directly mediated via change in body fat but possibly other mechanisms that need further 
investigation (Johnston et al., 2010). Supplementing 24 g/day resistant starch in healthy 
overweight volunteers for 21 days also had no significant effect on body weight although it 
reduced postprandial glucose and cholesterol levels (Park et al., 2004). However, none of the 
effect was demonstrated by Heijnen et al. following supplementing 30 g of either high-amylose 
cornstarch (RS2) or retrograded high-amylose cornstarch (RS3) for three weeks. It is thought 
that a lack of statistical study power, low doses and short study period had caused no clear 
effects of resistant starch on glycaemic and lipidemic responses (Heijnen et al., 1996). 
Interestingly, de Roos et al. managed to show a little effect in reducing body weight in 24 
healthy male volunteers after intake of 30 g resistant starch for four weeks (de Roos et al., 1995). 
Based on this study, resistant starch might have a potential to be developed as a weight 
suppressant if the study is extended to a longer period. Investigations are needed to support this 
hypothesis.  
 
Administration of a non-viscous fibre in a conjunction with a low calorie diet (1200 kJ) showed 
mixed findings. Supplementing 6 g/day of non-viscous fibre (cereal, citrus, insoluble fibre) for 
eight weeks and followed with intake of 4 g/day for 16 weeks in 53 healthy overweight females 
showed to reduce body weight by 8.0 kg compared to only 5.8 kg in the placebo group 
(Birketvedt et al., 2000). However, Astrup et al. showed that after adding 30 g/day cellulose in a 
very low calorie diet (women: 388 kcal/day, men: 466 kcal/day) in 21 obese volunteers had no 
significant effect in reducing body weight although the treatment reduced subjective hunger 
(Astrup et al., 1990). Interestingly, Fragala et al. demonstrated that supplementing cellulose and 
cetylated fatty acids in combination with a caloric restricted diet and exercise significantly 
reduced body weight and body fat. Moreover, the authors also showed that the treatment 
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significantly decreased adipose-related hormones, leptin, insulin as well as increased adiponectin 
levels after the treatment (Fragala et al., 2009).  
 
In contrast, a randomised crossover study comparing the effect of 27 ± 0.6 g/day fermentable 
carbohydrates (pectin, β-glucan) and non-fermentable carbohydrate (methylcellulose) for three 
weeks in healthy adults showed no significant effect on energy intake and body weight. 
Nevertheless, the non-fermentable carbohydrate group showed an increased satiety compared to 
the fermentable carbohydrate group (Howarth et al., 2003). Inulin-type fructans have been shown 
to consistently reduce body weight in rodents through its colonic fermentation effect (Cani et al., 
2004; Cani et al., 2005b; Cani et al., 2006b). However, data in humans is currently insufficient to 
support this observation. However, Parnell and Reimer have shown a promising result as 
supplementing 21 g/d oligofructose for 12 weeks significantly reduced body weight in healthy 
overweight volunteers (Parnell and Reimer, 2009). The role of inulin-type fructans in weight 
maintenance will be discussed in more detail in Chapter 3. 
 
In conclusion, there is evidence that dietary fibres have the potential to be developed as a weight loss 
agent. Beneficial effects of fermentable carbohydrates in rodents have been used as guidance in 
human studies, however, to date, data regarding dietary fibre in human studies is inconsistent and 
needs further investigation. The contradict effects of dietary fibre on weight loss may be due to 
different methodologies used, type and dose of fibres investigated as well as different type of carriers. 
Whilst this warrants further investigations, it is worthwhile to explore a new approach to increase the 
efficacy of dietary fibre on suppressing appetite and body weight. 
 
 
 
1.6 THE EVALUATION OF BODY FAT AND WEIGHT MANAGEMENT 
Since 1972, BMI has been used as a classification system to determine human body size. The BMI is 
determined by dividing an individual’s body weight (in kg) by the squared height (m2). The WHO 
has classified BMI into categories, which are 18.5 to 25 kg/m
2
 as healthy individuals, 25 to 30 kg/m
2
 
as overweight individuals and BMI from 30 kg/m
2
 or more are known as obese people. As BMI has 
been used to describe body size, the same index also can be used to predict body fat (Deurenberg and 
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Yap, 1999). Individuals with a high BMI are predicted to have high body fat compared to individuals 
with lower index numbers. However, because BMI estimates body size and fat composition by 
correcting weight for height, it can be unsuitable to use as an assessment tool for some specific 
populations such as pregnant women and body builders. 
 
Furthermore, BMI is not a precise method to assess adiposity as it cannot differentiate between fat 
mass or fat-free mass (Kontogianni et al., 2005; Wellens et al., 1996). Anthropometric measurements 
such as skinfold thickness and body circumferences seem to be more efficient in estimating body fat 
composition. In this method, total body adiposity is estimated based on the thickness of the 
subcutaneous fat measured by a special calliper designed to assess skinfold thickness. This is based 
on the assumption that total adiposity has a constant relationship with subcutaneous fat (Deurenberg 
and Yap, 1999). The skinfold thickness can be measured in any part of the body, but the most 
common areas are the upper arm (biceps and triceps), scapula (subscapular) and upper area of iliac 
crest (suprailiac). Although anthropometric measurements are not able to provide a precise 
estimation of total body fat, it is a common method used in estimating body adiposity due to its 
practicality, availability, non-invasive and relatively inexpensive method. Therefore, it is suitable to 
use in large scale and field studies. However, the reliability of these studies relies on the skills of the 
observers (Wang et al., 2000) as large errors in body fat estimations could arise from untrained 
observers. In addition, skinfold measurements are also influenced by age, sex, race and body fat 
contents (Wang et al., 2000).  
 
Recently, many studies have shown that the metabolic consequences of obesity are not 
determined by the total amount of adiposity, but the effects are highly associated with body fat 
specific regions (Kelley et al., 2000; Pi-Sunyer, 2004). Therefore, in contrast to skinfold 
thickness which estimates general total adiposity, WC and waist to hip ratio (WHR) are 
suggested to be more accurate in predicting abdominal fat (Prentice and Jebb, 2001). Indeed, WC 
has been shown to have a strong correlation with abdominal fat compared to WHR or BMI (Han 
et al., 1995; Lean et al., 1995; Pouliot et al., 1994). However, all of these techniques (skinfold 
thickness, WC and WHR) are based on assumption and therefore inaccurate in quantifying the 
actual in vivo levels of abdominal fat and other non-adipose tissue depot such as ectopic areas. 
This is important as numerous studies have shown that these regions are associated with 
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metabolic consequences such as insulin resistance, hyperinsulinemia, hypertension and 
cardiovascular diseases (Boyko et al., 2000; Mathieu et al., 2008; Patel et al., 1999; Vega et al., 
2005; Consitt et al., 2009; Thomas et al., 2005). Therefore, precise and effective assessment 
tools which can measure and distinguish body fat compartments are needed in order to identify 
individuals that are at high risk of metabolic diseases. Advances in the development of modern 
equipment have lead to improve body fat measurement techniques. In these techniques, body fat 
is no more estimated based on assumption but is directly measured from individuals and 
conveyed to computerised devices for quantification. Interestingly, some of the devices are able 
to distinguish different tissues of body composition including regional body fat and visualized it 
as segmental of human body compositions.  
 
Bioeletrical impedance (BIA) quantifies body composition by measuring the resistance or 
impedance of human tissues to an electric current. In this method, a small electric current is 
emitted by the machine through the body and the impedance measurement is performed as the 
current travels via the body’s water pool. BIA is used to measure many types of human body 
composition including total body water, fat-free mass, body cell mass and body fat. Although it 
is among the attractive methods used in clinical and research studies (due to its practicality, 
portability and low cost), the accuracy of BIA depends on many variables such as body fluid, 
hydration, food intake, skin temperature water in the tissues. In addition, the precision of BIA 
also can be influences by technician skills and instrumentation (Deurenberg and Yap, 1999). 
Other technique, dual-energy X-ray absorptiometry (DEXA) uses X-ray beams to measure fat 
storage and body composition. In measuring fat content, DEXA can also be used to determine 
both total and regional (e.g. trunk, arms or legs) fat and fat-free tissues. However, DEXA 
measures adiposity as a total amount as it is unable to distinguish between subcutaneous and 
visceral adipose tissue. Moreover, DEXA measures fat mass through tissue thickness, which 
could led to increase errors in measurement as the tissues thickness increased. Apart from these 
limitations, DEXA is a preferable method to use in assessing body composition studies due to its 
practical, non-invasive approach, its availability and its low-radiation exposure as well as 
suitable to use in all ages.  
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Computed tomoghraphy (CT) measures body fat or muscles by creating cross-sectional images 
or ‘slices’ based on its different attenuation towards the X-ray source. This X-ray beam rotates 
around the volunteers by producing a pencil or fan-shaped beam that penetrates the body. The 
rotation of the X-ray produces three-dimensional images which are known as tomograms. These 
images are then conveyed to a computer for image reconstruction. Although CT seems able to 
give accurate information of specific and regional muscles, adipose tissue and organs compared 
to the other aforementioned body composition methods (Thibault et al., 2012), CT uses ionizing 
radiation which limited its application for repeated measurements especially in vulnerable 
populations such as children and pregnant women.      
 
1.6.1 Magnetic Resonance Imaging  
Among of all the methods used to measure body composition, MRI has been recognised as a 
gold standard mainly because it is a non-invasive technique, without exposure to ionizing 
radiation, allowing for repeated measures in longitudinal studies (Fowler et al., 1991; Ross et al., 
1993) in all age-groups and clinical settings. Most importantly, MRI produces good contrast 
images of body fat tissues, and provides great structural detail about complex organs such as the 
brain, heart and muscle. This feature is particularly important in assessing total, regional and 
ectopic fat distribution which cannot be performed with other techniques (Hu et al., 2011; 
Thomas et al., 1998; Thomas et al., 2012). The accuracy of structural MRI for body fat 
assessment has been validated against dissection in human cadavers (Abate et al., 1994; 
Mitsiopoulos et al., 1998). 
 
Since the 1990s, another application of functional MRI – fMRI – has been introduced in the field of 
neuro-obesity research. fMRI is able to provide functional data about regional neuronal activation 
within the brain, and has effectively been used to identify and map specific brain regions that 
involved in modulating appetite regulation. In fMRI neuroimaging studies, brain activity has been 
measured following stimulation with food images (Goldstone et al., 2009), infusion of gut hormones 
(De Silva et al., 2011; Rosenbaum et al., 2008) which have been performed in obese and lean 
volunteers (Martin et al., 2010) in both the fed and fasted state (Batterham et al., 2007; De Silva et al., 
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2011), to provide information about which brain regions play a significant role in mediating satiety 
and hunger. The application of fMRI in neuro-appetite studies will be discussed in detail in Chapter 4.  
 
 
1.6.1.1 Principles of Magnetic Resonance Imaging 
Clinical MRI machines primarily image protons (or hydrogen nuclei) within the body. Each 
proton has its own magnetic property known as a magnetic dipole moment (MDM), by virtue of 
the fact that it is essentially a spinning positive charge, and each proton can therefore be thought 
of as a tiny bar magnet.  In the absence of an external magnetic field, the protons have randomly 
oriented magnetic moments, but when an external magnetic field (B0) is applied, they try to align 
with it.  The combined effect of the aligned MDMs is known as the magnetization vector (Mz). 
MRI signal is produced by the application of another magnetic field, in the form of a short 
electromagnetic wave, which is the radio frequency (RF) pulse.  This second magnetic field flips 
the Mz by 90
0
.  The longitudinal magnetization is now known as transversal magnetization (Mxy). 
Alignment of Mz to Mxy is important as this step produces signal needed for generating MRI 
images (Huettel et al., 2009) (see figure 1.6).  
 
Once the RF pulse is finished, Mxy always tries to return to the stable ground, z axis. This happens 
because the MR signals losses its strength due to two independent phenomenons known as spin-
lattice relaxation and spin-spin relaxation. Spin-lattice relaxation occurs when the transverse (xy) 
magnetization is slowly attenuated by releasing the absorbed energy obtained from the RF pulse to 
the surroundings and at the same time slowly increasing the longitudinal magnetization in the z axis. 
This phenomenon is called T1 longitudinal relaxation. At the same time, spin-spin relaxation or T2 
transverse relaxation process occurs when the orbicular rotations of transverse magnetization slowly 
losses its spin affinity and subsequently decays after some period, but, unlike the spin-lattice 
relaxation that gives away its energy to the surrounding, the spin-spin relaxation exchanges its energy 
with other nuclei. Both T1 and T2 are measured in milliseconds. Body tissues have longer T1 
compared to T2; Fluid has 1500-2000 ms T1 compared to 700 – 1200 ms T2, water-based tissues 
have 400 – 1200 ms T1 compared to 40 – 200 ms T2 and fat tissues have 100 – 150 ms T1 compared 
to 40 – 200 ms T2.   
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However, an RF pulse is not a single process. It is a serial process that occurs in several time periods. 
In between repetitions of the RF pulses, there are two periods occur; repetition time (TR) and echo 
time (TE). These periods are important factors in creating the image contrast of MRI. TR is the 
relaxation time from one RF pulse to the next RF of the same slice and mainly influences T1 as it 
quantifies the magnitude of longitudinal relaxation after the end of one RF pulse to the next. In 
comparison to TR, TE is a time length from the RF pulse to the signal peak stimulated in the coil and 
it is used to determine T2 images.   
 
 
 
  
 
 
 
 
 
 
 
 
1.6.1.2 Image contrast 
In generating image contrast, body tissues are discriminated from each other by using signal 
intensities. A typical MRI image appears as bright for tissue with high signal property whilst a tissue 
with low signal property is viewed as dark. The signal intensities of human tissue are influenced by 
the combination of the intrinsic (proton density, T1 and T2) and extrinsic factors (TR and TE). 
Intrinsic factors describe the features of body tissues and therefore cannot be changed but extrinsic 
factors can be altered as T1-weighted images or T2-weighted images. In T1-weighted images, a 
bright tissue image is produced due to high longitudinal magnetization. Meanwhile, in T2-weighted 
image, a bright tissue image is created for a tissue containing large transverse magnetization. The 
brightness is due to the increased amount of MR signal transmitted to the receiver. In contrast, a dark 
X 
The concept of MRI. 
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Figure 1.7 The concept of magnetic resonance imaging. 
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image is exhibited for a tissue with low transverse magnetization which therefore results in low 
signal transmission to the receiver coil (Westbrook et al., 2011). 
 
 
1.6.1.3 Limitations 
MRI is costly, since both the use and maintenance of the machinery is expensive.  It is estimated 
that a one hour scanning session requires approximately £300. Subsequently, the images 
produced need to be analysed with specific software by trained staff. MRI studies typically 
produce several hundred images which are time intensive to analyse.  Furthermore, this method 
is also limited in claustrophobic and severely obese volunteers with BMI of > 40 kg/m
2
. This 
disadvantage becomes extremely important especially in assessing body fat distribution in 
patients who will undergo gastric bypass, which usually involves the morbidly obese. Despite of 
these limitations, MRI is the only applicable method to quantify regional and ectopic body fat 
distribution.    
 
 
1.7 SUMMARY 
Gut hormone secretion has been suggested as a potential mechanism to modulate appetite 
regulation in rodents and humans. Although it can be stimulated via gastric bypass surgery, this 
approach is associated with life-threatening complications, adverse side effects and high costs 
which make this approach the last option in obesity treatment. Furthermore, gastric bypass is 
only limited to severely obese patients, thus limiting treatment options at a population level. 
Interestingly, some dietary sources are able to increase the production of naturally occurring gut 
hormones. One of the suggested dietary sources is dietary fibre. Fermentable carbohydrate, a 
dietary fibre-derivative, via its end products, SCFAs, has been suggested to modulate appetite 
regulation via gut hormone secretion. This thesis investigates the role of dietary fibres on 
stimulating gut hormone production and its effect on appetite, body weight and change in brain 
activation following food image stimulation in healthy individuals.     
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1.8 AIMS 
 
To investigate my hypotheses, It is aimed to: 
 
 
1) Investigate the effects of supplementing oligofructose on plasma PYY and GLP-1 levels, 
subjective appetite and energy intake in overweight/obese volunteers.   
 
2) Investigate the effects of supplementing oligofructose on body weight, total, regional, ectopic 
body fat and insulin sensitivity in healthy overweight/obese volunteers following an eight 
week supplementation period. 
 
3) Assess the effect of oligofructose intake on reducing brain activation in NAc, amygdala, 
OFC, hippocampus, insula and vACC. 
 
4) Investigate the effects of supplementing propionate carrier molecule directly to the colon on 
plasma PYY and GLP-1 levels, subjective appetite and energy intake in healthy normal and 
overweight volunteers. 
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1.9 Hypothesis 
Fermentable carbohydrate, through increase of PYY and GLP-1 may have an important role in 
regulating appetite and maintenance body weight following release from entero-endocrine L-cells in 
the gut. In this thesis, two types of fibre components are investigated, which are oligofructose and 
propionate carrier molecule.  
 
 
General hypothesis 
It is hypothesised that intake of fermentable carbohydrate and its product, propionate increases 
plasma PYY and GLP-1 levels, decreases subjective appetite and energy intake thus leads to a 
reduction of body weight in humans. 
 
 
Oligofructose study 
It is hypothesised that oligofructose supplementation increases circulating PYY and GLP-1 levels, 
decreases subjective appetite, energy intake and decreases neuronal activation and leads to a 
reduction of body weight and body adiposity in overweight volunteers following eight weeks 
supplementation period. 
 
 
Propionate carrier molecule study 
It is hypothesised that intake of propionate carrier molecule, a novel dietary substance, delivers 
propionate directly to the large intestine, increases plasma PYY and GLP-1 secretion, reduces hunger 
and therefore decreases energy intake in healthy normal and overweight volunteers. 
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Chapter 2 
 
 
The Effect of Oligofructose on 
Appetite and Gut Hormones 
in Healthy Overweight 
Volunteers: A Randomised, 
Controlled, Single-blind 
Study 
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2 BACKGROUND 
 
2.1 INTRODUCTION 
 
2.1.1 Inulin-type fructans 
Inulin-type fructans are a group of linear fructose polymers or oligomers bound β (2-1) linkages and 
its first monomer of the structure is either β-D-glucopyranosyl or β-D-fructofuranosyl residue (figure 
2.1). Inulin is a plant storage carbohydrate which can be found in wheat, bananas, onion, garlic and 
leek. Besides inulin, also categorized in this group are oligofructose and fructooligosaccharides, 
which are produced from partial enzymatic hydrolysis of inulin. In the food industry, the main source 
for inulin and oligofructose are either chicory roots or Jerusalem artichoke (Bach Knudsen and 
Hessov, 1995). Inulin and oligofructose are estimated to have a caloric value of 1.5 kcal / g (6.3 kJ/g) 
(Roberfroid, 1999). Although containing similar caloric contents, inulin and oligofructose have 
different amounts of monomeric sugars, or also known as the degree of polymerization. Inulin has 
been reported to contain a degree of polymerization between 2 – 60 units, whilst oligofructose 
contains a degree of polymerization between 3 – 8 units, which also determined their physical 
characteristics. Inulin, which is a longer chain of fructan has lower solubility level than oligofructose 
and capable to crystallise when dissolved in a liquid, whilst oligofructose, a shorter form of inulin is a 
soluble component and completely dissolves in a liquid. Because of their natural sweet taste, 
oligofructose has been used as a sugar replacer while inulin is used for fat replacement in the food 
manufacturing industry (Niness, 1999). 
 
 
 
Figure 2.1 The chemical structure of inulin-type fructans. Inulin-type fructans are series of fructose units 
linked to each other by β-(2-1) linkage. The first monomer of the structure is either β-D-glucopyranoside or β-
D-fructofuranoside. From (Darzi et al., 2011). 
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2.1.1.1 Consumption of Inulin-Type Fructans 
It is reported that Americans consume between 1 - 4 g inulin-type fructans daily, with wheat as the 
most common food source (Moshfegh et al., 1999). In Europe, it was reported that daily intake of 
inulin-type fructans is between 3 – 11 g/day (van et al., 1995d). Recently, Dunn et al. studied the 
reliability of food frequency questionnaires in quantifying intake of inulin and oligofructose in 
comparison with seven day food diaries in the UK population and reported intakes of 3.8 to 4.0 g/day 
of oligofructose and inulin. However, it is most likely that this level is not applicable to describe the 
actual intake of the UK population, as the majority of the volunteers involved in this study were 
young female (49 females out of 66 subjects in total) with limited age group and high academic 
background (Dunn et al., 2011). 
 
 
2.1.1.2 Fermentation of Inulin-Type Fructans 
Inulin-type fructans are classified as fermentable carbohydrate due to its capability to escape 
enzymatic digestion in the small intestine (Bach Knudsen and Hessov, 1995) and therefore, delivers 
intact to the large intestine. In the large intestine, inulin-type fructans undergo bacterial fermentation 
(Roberfroid et al., 1998) in which the process will produce short chain fatty acids (SCFAs) (acetate, 
propionate and butyrate), gasses (H2, CH2 and CO2) and energy. Inulin-type fructans are fermented at 
different location depending on the degree of polymerization of each substrate. Oligofructose, which 
has an average degree of polymerization of 4.5 is fermented predominantly in the caecum and in the 
upper part of the colon, whereas inulin with an average degree of polymerization of 25, is fermented 
in the lower part of the colon (van et al., 1995c). Inulin-type fructans are fermentation agents. It has 
been reported that no residues of fructans were found in the stools or urine upon fructo-
oligosaccharides supplementation in healthy men. Indeed, fructo-oligosaccharides also increased 
breath hydrogen release, a surrogate marker of colonic fermentation (Alles et al., 1996). High breath 
hydrogen excretion following intake of inulin-type fructans has also been demonstrated in other 
studies (Cani et al., 2009; Gibson et al., 1995; Hess et al., 2011; Oku and Nakamura, 2003; Piche et 
al., 2003).  
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2.1.1.3 The Role of Inulin-Type Fructans on Colonic Fermentation 
Recently, inulin-type fructans have attracted much attention because of their role in reducing food 
intake, body weight and fat mass in rodent.  It is postulated that inulin-type fructans modulated these 
effects by stimulating anorectic gut hormones into the circulation following colonic fermentation 
(Cani et al., 2005b; Cani et al., 2007b; Cani et al., 2009; Delzenne et al., 2005; Parnell and Reimer, 
2012; Verhoef et al., 2011). Supplementing fructans with different degree of polymerization: 
oligofructose, inulin and oligofructose-enriched inulin in the diet of rodents reduced energy intake in 
all groups. However, the shorter chain of fructans, oligofructose and oligofructose-enriched inulin 
were more efficient in reducing epidydimal fat mass, inducing caecum enlargement, increasing levels 
of GLP-17-36 amide and proglucagon mRNA in the proximal colon as well as GLP-17-36 amide levels 
in the portal vein and suppressing active ghrelin levels (Cani et al., 2004).   
 
In addition, supplementing 10 % (w/w) oligofructose with a high fat diet has been shown to suppress 
weight gain and accumulation of body fat in Wistar rats (Cani et al., 2004; Cani et al., 2007b). In this 
study, the effect of oligofructose on body weight was correlated with two fold increases in release of 
GLP-17-36 in the proximal and medial colon, increased portal GLP-17-36 amide and GLP-2 levels 
(Cani et al., 2004). The latter effect of oligofructose has been related to the increase of proglucagon 
mRNA in the proximal colon, caecal and colonic pools of GLP-17-36 amide due to the enlargement of 
caecal and colonic tissues (Cani et al., 2004; Cani et al., 2005b; Cani et al., 2007b; Delzenne et al., 
2005; Kok et al., 1998). Furthermore, oligofructose also reduced DPP-IV activity by 30% which 
could have contributed to the increase in portal vein GLP-17-36 amide levels (Cani et al., 2005b). The 
increased in GLP-1 secretion might be related to oligofructose’s capability to stimulate differentiation 
of the L-cells in the proximal colon and therefore increase the number of GLP-1-expressing cells 
(Cani et al., 2007b). In addition, Lippl et al. showed that increased portal GLP-1 levels might also be 
related to the reduced plasma ghrelin levels (Lippl et al., 2004). However, the effect of oligofructose 
on reducing plasma ghrelin levels can only be seen when it was added to normal chow as no effect 
was demonstrated after consumption of high fat-enriched oligofructose diet (Cani et al., 2004; Cani 
et al., 2005b; Delzenne et al., 2005; Parnell and Reimer, 2012). Besides GLP-1, plasma PYY levels 
were also found in the high levels in the caecum and portal vein after intake of oligofructose, 
possibly due to caecal tissue hypertrophy and gene expression in the L-cells (Cani et al., 2005b; 
Delzenne et al., 2005). 
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The effects of fructans on gut hormone secretion and peptide gene expression are suggested to be 
mediated via a release of SCFAs. Addition of oligofructose / inulin to the diet of rats led to an 
increase of caecal butyrate production and butyrate pools (Campbell et al., 1997; Le et al., 1999) 
which subsequently modulated proglucagon gene expression in L-cells (Tappenden et al., 1998). 
Besides butyrate, treatment with oligofructose also increased caecal propionate and acetate pools 
(Campbell et al., 1997; Le et al., 1999). It was reported that oligofructose yielded 65:20:15 (Gibson 
et al., 1995), whilst inulin provided 60:26:14 (Kleessen et al., 1997) (acetate:propionate:butyrate) of 
SCFA profile detected in the human faeces. However, faecal SCFA ratios may not be a reliable 
indicator to evaluate colonic fermentation activity, as small amount of SCFAs has been found to be 
excreted in the faeces. However, as human colon is inaccessible for direct SCFAs measurement, 
human SCFAs colonic production can only be evaluated using stool sampling (Campbell et al., 
1997). Meanwhile, it was reported that several studies experienced difficulties in developing suitable 
methods for measuring SCFA in humans’ faecal sample (Brighenti et al., 1999; Costabile et al., 2010; 
Kleessen et al., 1997; Kruse et al., 1999; Nyman, 2002; Ramnani et al., 2010). 
 
Interestingly, Tarini et al. clearly demonstrated the effect of inulin in postprandial SCFA plasma 
profiles four hours after ingestion of inulin (Tarini and Wolever, 2010). To date, this is the only study 
which has shown an increase in all of the three major SCFAs after intake of fermentable 
carbohydrate. Other studies reported that β-glucan, resistant starch and L-rhamnose increased serum 
propionate (Nilsson et al., 2008; Robertson et al., 2005; Vogt et al., 2004b; Vogt et al., 2004a) whilst 
wheat and low fibre increased acetate and butyrate levels in a long term study (Freeland and Wolever, 
2010; Wolever et al., 2002). The discrepancies in SCFA patterns in different type of fibres depended 
on the type of basic monomeric content of the carbohydrates, the complexity and combination of 
substrates, type of linkages that binds the carbohydrate monomers as well as the degree of 
polymerisation and the site for carbohydrate fermentation (Henningsson et al., 2002; Nilsson and 
Nyman, 2005).  
 
2.1.1.4 The Role of Inulin-Type Fructans on Appetite Regulation 
Recently, Rozan et al. showed that adding oligofructose-enriched inulin in the diet has increased the 
longevity of rats by 33.3% compared to a control group. This is the first study to demonstrate the 
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lifelong effect of inulin and the authors suggested that the prolonged life of rats fed oligofructose-
enriched inulin is potentially due to its effects on maintaining body weight, thus preventing the 
deposition of fat mass and obesity as well as reduced obesity-related diseases such as cardiovascular 
disease and diabetes (Rozan et al., 2008). Whilst fructans have shown promising effects on food 
intake and fat mass in rodents, the effects in humans are still inconclusive. Initial investigation of 
fructans’ role in human appetite regulation began when Piche et al. investigated the effect of fructo-
oligosaccharides in patients with gastroesophageal reflux disease. Although appetite assessment was 
not one of their outcome measures, they showed that including 19.8 g fructo-oligosaccharides (6.6 g 
taken three times per day) in volunteers’ diet for seven days increased postprandial plasma GLP-1. In 
addition, they also found an increase in breath hydrogen levels (fermentation marker) which 
suggested that increase in plasma GLP-1 levels is closely related to a modulation on colonic 
fermentation (Piche et al., 2003). Following that, Cani et al. showed that supplementing 16 g/day 
oligofructose for two weeks increased satiety, reduced hunger and energy intake in normal BMI 
subjects (Cani et al., 2006a).  
 
In contrast, Hess et al. showed that intake of five grams and eight grams of fructo-oligosaccharides 
increased breath hydrogen levels in 240 minutes but no significant effect on reducing appetite was 
found (Hess et al., 2011). However, the lack of effects of fructo-oligosaccharides on appetite in this 
study could be due to acute study period (240 minutes). Furthermore, in comparison to Cani et al., 
Hess et al. provide volunteers with half of the amount of oligofructose used by Cani et al. Therefore, 
the dose might be insufficient to suppress appetite (Cani et al., 2006a; Hess et al., 2011). 
Interestingly, Archer et al. showed that although inulin-enriched sausages had no significant effect on 
appetite in 33 overweight volunteers, the dose reduced fat intake and 24 hours energy intake 
compared to a full-fat sausage patty (Archer et al., 2004). Similarly, Hess et al. also demonstrated 
that addition of fructo-oligosaccharides in the diet had no significant effect on energy intake during 
ad libitum meal, but the dose reduced 24 hour energy intake. Surprisingly, this observation was only 
demonstrated in female volunteers as no change in energy intake was found in male volunteers, 
suggesting that there might be gender variations in satiety response to oligofructose (Hess et al., 
2011).  
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Recently, Cani et al. investigated the effect of supplementing the diet with 16 g oligofructose-
enriched inulin for two weeks. They showed that intake of oligofructose-enriched inulin reduced 
subjective hunger and total energy intake assessed at the end of the supplementation period. 
Interestingly, these effects were associated with a significant decrease in area under the curve (AUC) 
of postprandial plasma glucose levels and increase in circulating PYY and GLP-1 levels. Therefore, 
it is possible that modulation of gut hormones and glucose response were among the factors that 
contributed to the alteration in hunger and energy intake demonstrated in this study (Cani et al., 
2009). Findings from this study have lead to a speculation whether 16 g/ day is the minimum dosage 
of oligofructose to alter appetite profiles. Verhoef et al. compared the effect of supplementing 10 
g/day and 16 g/day for 13 days and found that 16 g/day is more efficient than 10 g/day in increasing 
circulating plasma GLP-1 and PYY levels as well as reducing energy intake. This study suggests that 
16 g/d is the least amount of oligofructose to induce an effect on energy intake (Verhoef et al., 2011). 
Based on these studies, it might be possible that inulin-type fructans have a beneficial role to 
modulate body weight following long term supplementation. This will be investigated in more detail 
in Chapter 3. 
 
2.1.1.5 The Role of Inulin-Type Fructans on Lipid, Glucose and Insulin Levels 
Effects of inulin-type fructans on modulating appetite and energy intake might also associate with 
improve postprandial lipid, glucose and insulin levels. Inulin-type fructans have been suggested to 
modulate lipid metabolism by lowering triacylglycerol levels (Delzenne and Kok, 1999; Fiordaliso et 
al., 1995; Kok et al., 1996) possibly due to increased levels of propionate released in the portal vein. 
During the process, propionate exerts its effect by preventing the conversion of acetate into lipid 
(Brighenti et al., 1999; Daubioul et al., 2000; Grysman et al., 2008; Tarini and Wolever, 2010; 
Fiordaliso et al., 1995; Kok et al., 1996; Rozan et al., 2008). In humans, a meta-analysis of 15 
randomised, controlled studies showed that inulin-type fructans also significantly reduced serum 
triacylglycerol (Brighenti, 2007).  In contrast, the role of inulin-type fructans on modulating human 
blood glucose levels is equivocal. Whilst some studies demonstrated the hypoglycaemic effect of 
inulin-type fructans (Daubioul et al., 2005; Jackson et al., 1999; van Dokkum et al., 1999; Yamashita 
et al., 1984), others found that inulin-type fructans had no role in reducing blood glucose levels 
(Alles et al., 1996; Causey et al., 2000; Giacco et al., 2004). 
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However, rodent studies showed contrast effect from human studies. Supplementing inulin-type 
fructans in rodents’ diet were shown to reduce glycaemic response potentially due to increased 
release of GLP-1 (Cani et al., 2006b; Cani et al., 2009; Kok et al., 1998) and associated with an 
increase release of insulin (Daubioul et al., 2000). In diabetic rats, supplementing oligofructose in 
combination with streptozocin has increased pancreatic and portal insulin levels (Cani et al., 2005a). 
Kok et al. showed that there was a significant decrease in serum insulin after oligofructose treatment, 
which potentially related to improved glucose disposal following increased of circulating serum 
GLP-1 from L-cells (Kok et al., 1998).  
 
 
2.1.2 Rationale of Supplementing 30 g Oligofructose in This Study 
This study is established from a preliminary work performed by Pedersen and Frost (Pedersen, 
2010). In this study, a dose escalation study was developed in order to characterise the optimum dose 
needed to modulate appetite, gut hormone and energy intake. This is because there is no consensus of 
the oligofructose dose to modulate appetite sensations and energy intake in the literature. In this 
study, a dose of 15 g, 25 g, 35 g, 45 g and 55 g were supplemented in 12 healthy volunteers (4 men 
and 7 women), aged 25.0 ± 3.9 years and BMI 21.6 ± 2.2 kg/m
2
 for five weeks. The outcome 
parameters were assessed on the appetite study days (subjective appetite ratings, energy intake, gut 
hormones, glucose and insulin) and also during free-living supplementation (appetite assessment, 
energy intake, BMI and body fat).  
 
The result from this study suggested that high doses of oligofructose (van et al., 1995b) induced the 
most pronounce effects on energy intake and plasma PYY release. However, intake of doses more 
than 30 g/day may potentially caused gastrointestinal discomforts, therefore it is not encouraged to be 
used in humans (Kaur and Gupta, 2002). Due to these reasons, a dose of 30 g/day oligofructose was 
chosen as the potential dose to be developed as an appetite suppressor in this study. Furthermore, 
USDA 2005 recommended that 28 g dietary fibre in 2000 kcal/day for women and 36 g in 2600 
kcal/day for men should be consumed to achieve adequate intake requirement. In UK, British 
Nutrition Foundation recommended to take 24 g fibre daily in both men and women. Therefore, 
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supplementing 30 g/day oligofructose in this study would fulfil the dietary guidance recommendation 
suggested in both countries. To date, 30 g oligofructose supplemented in this study is the highest dose 
that has been supplemented in human appetite studies. Apart from my study, Kleessen et al. also have 
supplemented 40 g/day inulin in their study (Kleessen et al., 1997). However, this dose was used to 
investigate the role of inulin on constipation in older volunteers (mean age 76.4 years old). Other 
human studies; Antal et al., Cani et al., Verhoef et al. and Parnell and Reimer used 14g, 16g and 21g  
respectively (Antal et al., 2008; Cani et al., 2006a; Cani et al., 2009; Parnell and Reimer, 2009; 
Verhoef et al., 2011).   
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2.2 AIMS AND HYPOTHESIS  
 
2.2.1 Aims 
The main aim for this study was to investigate the change in gut hormone response, appetite and 
energy intake following intake of 30 g/day oligofructose for six weeks (following two weeks run-in 
period) in contrast to cellulose supplementation in healthy overweight and obese volunteers. To 
achieve this objective, the below parameters were measured: 
 
 Plasma glucose and insulin levels and gut hormones, GLP-1 and PYY levels 
 
 Breath hydrogen levels as a marker for colonic fermentation  
 
 Visual analogue scales to access subjective appetite  
 
 Energy intake during supplementation period and ad libitum meal assessment.   
 
 
 
 
 
2.2.2 Hypothesis 
It was hypothesized that supplementing 30 g/day oligofructose for six weeks (following two weeks 
run-in period) would suppress subjective appetite, reduce food intake and body weight to a greater 
extent compared with a non-fermentable carbohydrate, cellulose. 
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2.3 MATERIALS AND METHODS 
 
2.3.1 Materials 
 
2.3.1.1 Supplements 
Oligofructose, Beneo
TM
 P95 and cellulose were kindly provided by ORAFTI, (van et al., 1995a). 
Both of these supplements were provided in sachets. Each sachet contained 10 g of white, powdery 
form and has a similar appearance. Oligofructose has a slight sweet taste whilst cellulose is a 
supplement without any taste. However, volunteers were not aware of the taste differences as they 
only took one treatment during the study. The caloric content of oligofructose is approximately 15.8 
kcal/ 66.2 kJ (per sachet or 10 g). As cellulose does not contain any calories, 13 g of maltodextrin 
was added to the 30 g cellulose in order to provide the same amount of energy as the oligofructose 
supplement. Therefore, both of the supplements provided approximately 47.4 kcal/ 198.6 kJ per 30 g 
supplement.     
 
2.3.1.2 Randomization 
Volunteers were randomly allocated to the treatment prior the start of the study using enveloped 
system based on gender by a member of the laboratory who was not directly involved in the day-to-
day execution of this study.   
 
2.3.1.3 Power Calculation 
The study sample size was based on power calculations that used plasma PYY results from a 
pilot dose finding study as a primary outcome (Pedersen, 2010).  With the estimation of 
AUC480min of 5234 ± 3638 ρmol*min based on 0.8 power to detect a significant difference of P = 
0.05, two sided, a minimum of 18 participants were needed. To allow for dropouts, 22 volunteers 
were recruited for this study.  
 
2.3.1.4 Volunteers 
Healthy overweight male and female volunteers were recruited to take part in this randomised, 
controlled, single blinded and parallel study (subject characteristics are described in Section 2.4.1).  
Volunteers were recruited by advertisement either from posters at the Imperial College London 
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campus sites (Hammersmith Hospital, St. Mary’s and Charing Cross), Metro and Evening Standard 
newspapers or by search engine website, Gumtree. They were also recruited from Sir John 
McMichael Centre’s Healthy Panel clinic and by word of mouth. Volunteers were excluded if they 
had any of serious illnesses including gastrointestinal diseases, physiological problems such as 
depression and anorexia nervosa, gastrointestinal surgeries, metallic or electronic implants such as 
pacemaker and fixed dental braces, claustrophobic, regular user of prebiotics, probiotics or laxatives, 
lactose-intolerance, vegan or vegetarians, were pregnant or breastfeeding and excessive exercise 
more than five hours per week, donated blood, used antibiotics or had unstable body weight within 
three months before the study started. Before they could participate in the study, volunteers had to 
attend the screening study day.  During the screening visit, they were screened for abnormal eating 
behaviour using Sick Control One Fat Food (SCOFF) (Morgan et al., 1999) (appendix 4), Dutch 
Eating Behaviour Questionnaire (DEBQ) (van Strien et al., 1986) (appendix 5) and Eating Attitude 
Test (Garner et al., 1982) (appendix 6). They also had a meal testing for a meal which will be served 
during the buffet meal on the three appetite study days. A three day food diary (appendix 8) was also 
assessed for abnormal food and fibre intake prior the study. Written informed consent was obtained 
from each volunteer during the screening visit. Ethical approval was obtained from the Hounslow 
and Hillingdon Research Ethics Committee (Project registration number: 09/H0709/18) and the 
study was performed in accordance with the Declaration of Helsinki. 
 
 
2.3.2 Methods 
 
2.3.2.1 Study design 
Volunteers were required to attend seven baseline and post-supplementation visit for appetite, 
whole body MRI and brain fMRI scanning days. Supplementation period was started on day 1 
until day 56, which comprised of two weeks run-in period and six weeks full supplementation 
period. This chapter will discuss the appetite study days and the supplementation period. MRI 
body composition and fMRI brain scanning will be discussed in the Chapter 3 and Chapter 4 
respectively. The protocol design is summarized in Figure 2.2.  
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Figure 2.2 A schematic diagram of the study design. Volunteers are instructed to attend 7 visits in the period of 10 weeks. Before volunteers started their 
supplementation, they have to attend a baseline study visits which are MRI fat scanning study day which they had a full body fat scan, fMRI brain scanning study day 
on visit 2 and an acclimatization appetite study day on visit 3. A week before they started their study, they were asked to fill in 7 days food dietary records and appetite 
assessment. On day 0, they attended an appetite study day (visit 4) which they were assessed for subjective appetite ratings, meal intake, breath hydrogen 
production and blood were withdrawn for gut hormones measurement. On the next day (day 1), they started their oligofructose or cellulose supplementation depended 
to the randomisation procedure which had been done prior of the study. The first and the second weeks of the supplementation were the run-in supplementation 
period which 10 g/d need to be taken in the first week and followed with 20 g/d in the second week. They were instructed to start their actual dose (30 g/d) of 
supplementation on day 15 and the dosage is remained to be taken until week 8. In week 6 (between day 32-42), they were asked to come to the hospital for post-
supplementation fMRI brain scan study day. 7 days post-supplementation dietary record and appetite assessment were obtained at week 7 which was a week before 
the end of the supplementation period. On day 56, subjects attended a visit 6, a post-supplementation appetite study day assessment. In this visit, the same 
observation as visit 4 has been done. Lastly, subjects attended their final visit on visit 7 which they had a post-supplementation MRI total body fat. 
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2.3.2.2 Appetite study day 
The appetite study protocol is summarized in Figure 2.3. The study was performed in the Sir 
John McMichael Centre, Hammersmith Hospital. Volunteers were instructed to arrive at 0845 on 
each study day. There were three appetite study days, acclimatization day (Visit 3), pre 
supplementation (Visit 4), which was performed on day 0 and post supplementation visit (visit 6) 
performed on day 56.  The study days started at 0900 and finished at 1700. Participants arrived 
fasted overnight for at least 12 hours. During the fasting, only water was allowed. During the 
appetite study day, visual analogue scales (VAS), breath hydrogen and blood were obtained from 
the volunteers. Blood pressure was also measured once at the start of the study. Breakfast was 
served at 0 minute and lunch was provided at 240 minutes. At this meal time, they were 
instructed to finish their meal in 20 minutes. For energy intake assessment, an ad libitum meal 
based on their choice determined at the screening visit was served at 420 minutes. Volunteers 
were given 30 minutes to eat the meal. During this time, no reading materials, TV or electronic 
devices were allowed. Before they had the meal, they were instructed to eat until comfortably 
full. The final assessment was performed at 450 minutes.  
 
 
 
 
 
Figure 2.3 Oligofructose appetite study day protocol. Subjects attended appetite study days on visit 3 
(acclimatization visit), visit 4 and visit 6. VAS, breath hydrogen levels and blood for gut hormones analyses 
were assessed on these study days. Breakfast, lunch and ad libitum meal were provided at 0, 240 and 420 
minutes. 30g oligofructose / cellulose supplementation was provided on post-supplementation visit (day 56). 
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2.3.2.2.1 Meals 
Volunteers were provided 500 kcal breakfast which comprised of a cereal (a choice of cornflakes or 
rice crispies), semi-skimmed milk, orange juice and croissant or bread roll. At lunch, volunteers had 
sandwiches (a choice of a piece of ham, chicken and/or a piece of cheese), water, orange juice, a 
choice to have two foods of either: a bag of crisp, a pot of yogurt or mini kit kat, which containing 
550 kcal. On visit 6 only (the last appetite study), supplements were provided by mixing it with 
orange juice during breakfast and lunch. At 420 minutes, a preweighted ad libitum meal was served 
to the volunteers. Volunteers were given a choice between macaroni cheese, bolognaise bake or 
chicken tikka masala which was served in excess. A jug of water was also served with the meal. The 
weight of both the meal and water were recorded at the end of the study session. 
 
 
2.3.2.2.2 Subjective Appetite Scores 
Subjective appetite scores were measured using 100 mm VAS (Appendix 7) at the same time 
breath hydrogen was accessed. The VAS questionnaires assessed motivation to eat, palatability, 
fullness, hunger and satiety sensation using questions such as “how hungry do you feel now?”, 
“how full do you feel now?” which were assessed between the extremes of “not at all” to 
“extremely”  at either end of the scale (Flint et al., 2000). Volunteers were asked to mark a small 
vertical line on the VAS to indicate their feelings at every 20 - 30 minutes during the study 
period. Besides of subjective appetite, we also used VAS to monitor gastrointestinal side effects; 
stomach discomfort, bloating, nausea, flatulence, diarrhoea and flatulence which were accessed 
at hourly until the end of the study day.  
 
 
2.3.2.2.3 Breath Hydrogen Assessment 
Hydrogen gas is one of the end products produced by bacterial fermentation of dietary fibre in 
lower intestine and was therefore use in the study as an indicator for bacterial fermentation 
activity. The assessment was performed using a portable hand-held breath hydrogen monitor 
(Gastrolyzer, Bedfont Scientific Ltd. Kent, UK). Breath samples were taken twice before 
breakfast (-10 and 0 minutes) and at 60, 120, 150, 180, 240, 280, 300, 330, 360, 390, 420 and 
450 minutes post supplementation during breakfast.  The hydrogen levels was measured in parts 
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per million (ppm). Monitors were calibrated before use with the calibration gas (200 ppm 
hydrogen). Volunteers were asked to inhale as deeply as possible, hold their breath for 15 
seconds before exhaled it directly into a mouthpiece attached to the apparatus. The peak H2 
levels in the expired air were then recorded.   
 
 
2.3.2.2.4 Blood Sampling 
A cannula was inserted in the forearm for blood sampling throughout the day. Blood for gut 
hormones, glucose and insulin were withdrawn at -15, 0, 20, 40, 60, 90, 120, 180, 240, 260, 280, 
300, 360, 420 and 450 minutes. 160 ml of blood were collected during visit 4 and visit 6 whilst 
only 15 ml were withdrawn on the acclimatization study day. Collecting blood on the 
acclimatization study day is a necessary step so that volunteers could get the idea of the real 
situation on the study day. Blood for gut hormones was transferred to EDTA containing tubes 
(Teklab) containing aprotinin (Bayer trasylol 500.000 KIU; 200 µL/7.5 ml blood), a protease 
inhibitor to prevent the degradation of gut hormones. Blood for glucose analysis was transferred 
to fluoride oxalate tubes. Blood for insulin analysis was transferred to yellow gel separator tubes 
and allowed the blood to clot before centrifugation. Blood was centrifuged at 3000 g at 4
○
C for 
10 minutes. The separated plasma was then aliquoted into eppendorf tubes and was stored in the 
-20
○
C freezer until assaying process.     
 
 
2.3.2.2.5 Gut Hormones Analysis (Radioimmunoassay) 
‘In house’ radioimmunoassay using iodine-125 experiment has been used to analyse the gut 
hormones PYY and GLP-1. The objective of this analysis was to measure the levels of 
unlabelled antigen bound to the antibody. In this analysis, antibody site of binding was competed 
between a radioactively labelled and unlabelled radioactive ligand. A standard curve was plotted 
from a known level of labelled ligand and the antibody used. This could be achieved by setting 
up a series of standards of known levels. This allows determination of known levels of 
unlabelled peptide from the samples by interpolation from the standard curve. As the level is 
increased, the binding percentage will decrease. The antibody-bound and free-ligands are able to 
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separate from each other before the radioactively-labelled was measured by counting the 
radioactivity.    
 
*Ag + Ab + Ag          *AgAb + AgAb 
 
*Ag = Radiolabelled antigen 
Ag = Unlabelled antigen 
Ab = Antibody 
 
 
2.3.2.2.5.1 Methodology  
Prior the radioimmunoassay experiment, gut hormones plasma samples, which had been stored 
at -20
○
C, were thawed and vortexed for 1 minute to homogenise the sample. All samples were 
analysed in one batch to prevent inter-assay variation and were run in duplicate after being 
thawed once. In this experiment, there were a series of reagents were involved; buffer, label, 
antibody, standards and samples per se. A few days before the assay experiment, tubes were 
numbered and arranged in duplicate in racks. The first 30 tubes have been designated with the 
assay specific order. The first 2 tubes were designated for non specific binding and contained no 
antibody. Tubes 3-6 were used for iodinated peptide containing 50 µl for 1/2x label and 200 µl 
for 2x label. This step is needed in order to measure specific activity of the label. “Zero” tubes 
were followed in quadruplicate after that, which start from tubes 7 to 10. These tubes were used 
to detect any intra-assay drift and usually included approximately in every 100 tubes in an assay. 
Tubes 11 to 30 were designated for standards which arranged in gradual increased from 1, 2, 3, 
5, 10, 15, 20, 30, 50 and 100 µl. In this assay, three sets of standards were included and were 
located at the beginning of the assay (usually rack 1), middle and the end of the assay. Similar to 
the ‘zero’ function, a number of standards were needed to detect any intra-assay drift. These 
standard curves were then used to determine the levels of the antigen contained in the samples. 
The next tubes were allocated for the samples. 100 µl was added in each assay tube for PYY and 
GLP-1 gut hormones.  
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The assay was performed in 0.06 M phosphate buffer containing 0.3% bovine serum albumin. 
Then, standards or samples were added to the allocated tubes as described in the previous 
paragraph. After that, each assay was added 100 µl of label with inclusion of 1/2x label which 
contained 50 µl (tube 3 and 4) and 2x which contained 200 µl (tube 5 and 6). Finally, 100 µl of 
antibody was added in each tube with the exception of non-specific binding tubes. Total volume 
in each tube was therefore 700 µl. At the end of the assay, excess antibody was added in order to 
determine the maximal binding of the antibody to labelled peptide. At the end of day 1, the assay 
racks were covered in aluminium foil and incubated at 4ºC for 3-5 days before separation of 
antibody-antigen complex from the free antigen were performed later.  
 
There are various methods of separating the antigen-antibody complexes from the supernatant 
including charcoal adsorption and secondary antibody separation. For the GLP-1 assay, 250 µl 
dextran-coated charcoal in 0.06 M phosphate buffer with gelatine was added to each tube and the 
tubes were subsequently vortexed gently to mix the contents and centrifuged at 4ºC at 2500 rpm 
or 748 g for 20 minutes. In GLP-1 assay, the free antigen is trapped in the porous charcoal 
whereas the antigen-antibody complex was left in the supernatant. For the PYY assay, a 
secondary antibody (sheep anti-rabbit antibody) separation technique was used. Upon addition of 
secondary antibody, the assay was then left at room temperature for one hour before 500 µl of 
0.01% Triton-X-100 (Sigma, Poole, UK) was added to each tube.  Each assay was then 
centrifuged at 4ºC at 2500 rpm or 748 g for 20 minutes. Addition of second antibody into the 
PYY assay induced the antigen-antibody complex to form a pellet whilst the free antigen 
remained in the supernatant. Aspiration of the supernatant into empty tube was performed using 
pipetting. Tubes were the sealed using heated paraffin wax.   
 
The radioactivity of each PYY and GLP-1 supernatant and pellet were counted in a gamma 
counter (NE 1600, Thermo Electron Corporation).  Counting time was set at 179 seconds.  The 
peptide levels were then determined using a non-linear plot (Radioimmunoassay software, 
Thermo Eletron Corporation) and results calculated in terms of the standard. The results for the 
peptide levels in the unknown samples were interpolated from the standard curve.            
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2.3.2.2.5.2 PYY Immunoassay 
A specific and sensitive radioimmunoassay was used to measure plasma PYY, as previously 
described (Adrian et al., 1985). This technique allowed for total PYY to be measured, which 
comprised of the truncated fragment PYY3-36 and the full-length hormone PYY1-36 which are both 
biologically active. The antiserum Y21 used in the assay was produced in a rabbit against 
synthetic porcine PYY (Bachem, St. Helen’s, UK) coupled to bovine serum albumin by 
gluteraldehyde and used at a final dilution of 1:50000. The antibody also has full cross reactivity 
with the biological active circulating forms of PYY but not with pancreatic polypeptide, 
neuropeptide Y or other known gut hormones.  Label was prepared on the assay day with the 
required volume of buffer so the specific activity of the iodine-125 labelled PYY was 25-30 
Bq/100 µl. The 
125
I PYY was prepared by the iodogen method and purified by HPLC. The 
detection limit of PYY assay was 2.5 pmol/l with an intra-assay coefficient of variation of 5.8% 
and interassay variation below 10%. 
 
 
2.3.2.2.5.3 GLP-1 Immunoassay 
Plasma GLP-1 like immunoreactivity was measured with a specific and sensitive 
radioimmunoassay as described in Kreymann et al. (Kreymann et al., 1987). The antibody was 
produced in rabbits against GLP-1 coupled to bovine serum albumin. Antibody was used at a 
final dilution of 1:190 000. The antibody cross-reacted 100% with all amidated forms of GLP-1 
but did not cross react with glycine extended form (GLP-11-37 and GLP-17-37) or any other known 
pancreatic or gastrointestinal peptide. Like 
125
I PYY, 
125
I-labelled GLP-1 was also prepared by 
iodogen method and purified by HPLC. The specific activity of the 
125
I-labelled GLP-1 was 48 
Bq/fmol. The detection limit of GLP-1 assay was 7.5 pmol/l with an intra-assay variation of 
5.4% and interassay variation below 10%. 
 
 
2.3.2.2.6 Insulin Assay 
Insulin levels at -15, 0, 20, 40, 60, 90, 120, 180, 240, 260, 280, 300, 360, 420 and 450 minutes 
were performed by using iodine-125 RIA kits (Millipore, Missouri, USA). In the beginning of 
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the experiment, samples were thawed and vortexed for 1 minute to remove any fibrin clots. To 
avoid any inter-assay variation, samples were analysed in one assay and in duplicate.  
 
Each tube in the assay needs to be numbered and arranged according to the assay protocol. Tube 
1 and 2 were allocated for total count, tube 3-4 were for non-specific binding, tube 5-6 were for 
‘zero’, tube 7-20 were allocated for standards, tube 21-24 was specified for quality controls the 
rest of the assay were continued with study samples. Tube 1 and 2 only contained the 
125
I-insulin 
therefore this would allow 100 counts. The blank tube 3-4 contained all assay reagents except of 
antibody and it serves to assess non-specific binding of the label to other plasma fractions. The 
principle of Millipore RIA kit and ‘in house’ assay is similar except of the kits provided all the 
reagents and solution whilst in ‘in house’ RIA, the reagents and solutions such as buffer, label 
and antibody need to be prepared before performing the assay experiment. 
 
The assay was performed in a total volume of 50 µl of 0.05 M phosphosaline buffer pH 7.4 
containing 0.025 M EDTA, 0.08% sodium azide and 1% RIA grade bovine serum albumin with 
the exception of total count tube (tube 1-2) which only contained 
125
I-insulin. The next step was 
the addition of 50 µl of standards or sample to the allocated tubes (tube 7-20). In this assay, the 
standard levels were set in the gradual increase. Standards contained 3.125 µU/mL, 6.25 µU/mL, 
12.5 µU/mL, 25 µU/mL, 50 µU/mL, 100 µU/mL and 200 µU/mL purified recombinant human 
insulin. Followed after that was 50 µl of the 
125
I-insulin. The tracer was prepared by the iodogen 
method and purified by HPLC.  Next, 50 µl of antibody was added after that. The antibody was 
produced in guinea pig against purified human insulin. The antibody was cross reacted with 
human proinsulin but did not cross react with any other known gastrointestinal hormones. As the 
step 5 (addition of antibody) completed, each tube was vortexed and covered with foil and 
incubated for 20-24 hours in the room temperature.  
 
The next day, the experiment was continued with the addition of 500 µl precipitating reagent. 
The precipitate reagent is raised in goat against guinea pig lgG and contained 3% PEG and 
0.05% triton X-100 in 0.05M phosphosaline, 0.025 M EDTA and 0.08% sodium azide.  The 
assay was then vortexed and incubated for 20 minutes at 4
○
C and centrifuged for 20 minutes at 
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3000 g at 4
○
C.  The limit of detection was 1.3575 µU/mL for 50 µl sample size with an intra-
assay variation of 4.4%.          
 
 
2.3.2.2.7 Glucose Assay 
Plasma glucose levels collected at -15, 0, 20, 40, 60, 90, 120, 180, 240, 260, 280, 300, 360, 420 
and 450 minutes were analysed in the Department of Clinical Biochemistry, Hammersmith 
Hospital. Analyses of the glucose were performed using an Abbott Architect ci8200 analyser 
(Abbott Diagnostics, Maidenhead, UK). Glucose assay sensitivity was 0.3 mmol/L with an intra-
assay coefficients of variation of 1.0% . 
 
 
2.3.2.3 Free-Living Supplementation Period 
On the day following the baseline appetite study day (Visit 4), volunteers were instructed to start 
their supplementation for 8 weeks. During this period, they lived at their own accommodation 
and prepared their own meals but supplemented oligofructose or cellulose at the same time. The 
first and second week was the gut adaptation weeks. 10 g/day need to be taken in the first week 
and increased to 20 g/day in the latter week. This is important for gut to adapt with the fibre and 
also to reduce potential gastrointestinal side effects (Parnell and Reimer, 2009). On day 15, the 
actual supplementation period (30 g/day) began and continued until day 55. They were asked to 
take three sachets per day. Each sachet provided 10 g fibre. Volunteers were asked to take the 
supplement with main meals. They were given the choices of whether to mix it with drinks, 
sprinkle or mix it into food. The supplement must not be cooked or exposed to high 
temperatures. During these 6 weeks supplementation period, volunteers were contacted by 
investigators by phone to ensure that instructions were followed and for gastrointestinal side 
effect assessment.   
 
 
2.3.2.3.1 Compliance 
Compliance of supplementation was monitored by counting of unused sachets returned by 
volunteers after the supplementation period.    
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2.3.2.3.2 Energy intake Assessment 
Assessment of energy intake was performed using the seven day food diaries obtained at baseline 
(day -8 until day -1), whilst the post supplementation energy intake assessment was measured on day 
49 until day 55. Subjects were advised to keep their intake of prebiotic or probiotic products to a 
minimum (they were given a list of food that have high prebiotic, probiotic and synbiotic food 
products to avoid) (appendix 11), not to start any diet regime and not to gain or lose weight 
consciously during the supplementation period. The seven day food diaries were analysed using a 
standard dietary calculator, Dietplan6 (Forestfield Software Ltd, West Sussex, UK). Whenever 
portion sizes were not provided by the volunteers, standard portion sizes provided with this 
programme were used. 
 
 
2.3.2.4 Statistical Analysis  
Data are presented as mean ± standard error means (SEM). Prior the analyses, data were checked 
for Gaussian distribution using D'Agostino & Pearson omnibus normality test. An analysis of 
covariance (ANCOVA) with baseline data (day 0), age, gender and BMI as covariates were used 
to determine the effect between treatments for the hydrogen breath test, subjective appetite, 
gastrointestinal side effects assessment, gut hormones GLP-1, PYY, insulin and glucose levels. 
In addition, a two-tailed paired t-test was also used to compare the mean total area under the 
curve (tAUC) value within group analysis (baseline visit [day 0] vs. post-supplementation [day 
56] group effect). Gastrointestinal side effect data were not normally distributed, thus data 
analysis for this parameter only, was performed on log10-transformed variables prior the 
ANCOVA and t-test analyses. Statistical significance is defined by a P value of 0.05 or less and 
all statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, San Diego 
CA, USA). ANCOVA was performed using SPSS 20.0 (SPSS Inc. Chicago, IL, USA). 
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2.4 RESULTS 
 
 
2.4.1 Appetite Study day  
Appetite study days were performed on baseline study day (day 0) (visit 2) and post-supplementation 
study day (day 56) (visit 6). On appetite study day, breath hydrogen test, visual analogue scales 
(VAS) and blood for gut hormones, PYY and GLP-1 were obtained from each volunteer. The result 
of the appetite study days are described below. 
 
2.4.1.1 Volunteers Characteristics 
Twenty two, [oligofructose = 12 (male=4, female=8) and cellulose = 10 (male=2, female=8)] healthy 
overweight and obese volunteers were participated in this study. The mean ages were 36.5 ± 2.2 
years (range 21 – 49 years) in the oligofructose group and 28.7 ± 2.3 years (range 20 – 47 years) in 
the cellulose group. The mean BMI were 29.7 ± 1.0 kg/m
2
 (range 25.0 – 34.6 kg/m2) for 
oligofructose group and 31.1 ± 1.1 kg/m
2 
(range 26.0 – 35.0 kg/m2) for cellulose group. 
 
 
2.4.1.2 Compliance 
Adherence to the supplementation was calculated based on the return of unused sachets at the end of 
the supplementation period (day 55). Four of 22 volunteers involved in this study were reported to 
experience mild side effects such as bloated, flatulence or stomach discomfort between week three 
and week four and therefore they were allowed to continue taking two sachets per day (20 g) during 
this time. They were on 30 g of oligofructose or cellulose treatment on week five and week six. The 
reduced intake of supplement resulted in reduced compliance in the range of 60 – 77 % whilst the 
rest of the volunteers had high compliance rates between 86 – 100 %. Nevertheless, the reduced 
compliance rate demonstrated in four volunteers in the oligofructose group did not affect mean group 
compliance rate, oligofrucose (89.8 ± 13.1 %) (n=12). Cellulose group had a compliance rate of 
(89.7 ± 12.8 %) (n=10).   
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2.4.1.3 Energy Intake Assessment 
Figure 2.4 demonstrates energy intake assessed during ad libitum meal assessment. There was no 
significant difference between oligofructose and cellulose group (P=0.739). Nevertheless, intake 
of oligofructose significantly reduced ad libitum energy intake (P=0.007) (760.2 ± 51.6 kcal) 
compared to baseline visit (873.2 ± 54.1 kcal) whilst cellulose supplementation has a tendency to 
reduce energy intake (P=0.066) (725.3 ± 117.4 kcal [day 56] and 867.6 ± 159.5 kcal [day 0]).  
 
 
 
 
Figure 2.4 Postprandial energy intake assessment (kcal) in oligofructose and cellulose groups. The 
doses were supplemented into the meal during breakfast (0 min) and lunch (240 minutes) in the post-
supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is expressed as mean 
± SEM. oligofructose (n=12), cellulose (n=10). **P<0.01 oligofructose vs. baseline 
 
 
 
2.4.1.4 Subjective Appetite Ratings 
Subjective appetite ratings for hunger, fullness, motivation to eat and side effects were assessed at 0, 
20, 40, 60, 90, 120, 180, 240, 260, 280, 300, 330, 360, 390, 420 and 450 minutes on both pre-
supplementation (day 0) and post-supplementation study day (day 56). The results are shown in 
Figures 2.5 – 2.11.  
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2.4.1.4.1 Appetite Assessment 
 
 
2.4.1.4.1.1 Hunger 
Figure 2.5 shows subjective hunger scores (i) and tAUC450min hunger scores (ii). Intake of 
oligofructose significantly reduced tAUC450min hunger scores (P=0.034) compared to cellulose 
treatment. In addition, oligofructose also significantly reduced tAUC450min within the group (P=0.001) 
(1387.3 ± 263.2 cm*min [day 56] and 2053.7 ± 308.7 cm*min [day 0]). No significant effect on 
tAUC450min hunger scores was demonstrated in the cellulose group (P=0.964) (1838.6 ± 315.9 
cm*min [day 56] and 1850.6 ± 395.3 cm*min [day 0]).  
 
(i)                                       
 
 
 
 
 
 
 
 
 
 
 
ii)  
 
 
 
 
 
 
 
 
 
 
 
* 
Figure 2.5 Subjective hunger scores (cm) (i) and tAUC450min (ii) in oligofructose and cellulose groups. 
The doses were supplemented into the meal during breakfast (0 min) and lunch (240 minutes) in the post-
supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is expressed as mean 
± SEM. Oligofructose (n=12), cellulose (n=10). *P<0.05 oligofructose vs. other treatments, ***P<0.001 
oligofructose vs. baseline, 
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2.4.1.4.1.2 Fullness 
Figure 2.6 exhibits subjective fullness scores (i) and tAUC450min fullness scores (ii). 
Oligofructose supplementation had no significant effect on tAUC450min fullness scores (P=0.493) 
compared with cellulose treatment. Nevertheless, oligofructose was shown to significantly 
increase (P=0.029) tAUC450min fullness scores (2095.3 ± 249.3 cm*min [day 56] compared to 
baseline 1790.8 ± 243.7 cm*min [day 0]). No significant effect (P=0.431) was demonstrated in 
the cellulose group (1805.3 ± 254.7 cm*min [day 56] and 1615.1 ± 314.5 cm*min [day 0]).  
 
 
(i)         ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              
                                      ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Subjective fullness scores (cm) (i) and tAUC450min (ii) in oligofructose and cellulose groups. 
The doses were supplemented into the meal during breakfast (0 min) and lunch (240 minutes) in the post-
supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is expressed as mean 
± SEM. Oligofructose (n=12), cellulose (n=10). *P<0.05 oligofructose vs. baseline. 
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2.4.1.4.1.3 Motivation to Eat 
Figure 2.7 shows subjective motivation to eat scores (i) and tAUC450mins motivation to eat scores 
(ii). Oligofructose supplementation significantly reduced tAUC450min motivation to eat scores 
(P=0.013) compared with cellulose treatment. In addition, oligofructose also significantly 
reduced tAUC450min motivation to eat scores within the group (P=0.004) (1412.5 ± 229.2 cm*min 
[day 56] and 2059.6 ± 294.5 cm*min [day 0]) whereas no significant modulation on tAUC450min 
scores was demonstrated in the cellulose group (P=0.635) (1847.4 ± 313.4 cm*min [day 56] and 
1946.4 ± 367.6 cm*min [day 0]).  
 
 
(i)                     ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
 
Figure 2.7 Subjective motivation to eat scores (cm) (i) and tAUC450min (ii) in oligofructose and cellulose 
groups. The doses were supplemented into the meal during breakfast (0 min) and lunch (240 minutes) in the 
post-supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is expressed as 
mean ± SEM. Oligofructose (n=12), cellulose (n=10). *P<0.05 oligofructose vs. baseline. 
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2.4.1.4.1.4 Desire to Eat Sweet Food  
Figure 2.8 demonstrates subjective desire to eat sweet food scores (i) and tAUC450min desire to 
eat sweet food scores (ii). Oligofructose supplementation had no significant effect on tAUC450min 
desire to eat scores compared with cellulose (P=0.342). Nevertheless, oligofructose significantly 
reduced the tAUC450min scores (1232.8 ± 361.3 cm*min) compared to baseline (day 0) (1759.5 ± 
372.2 cm*min) (P=0.022), but no significant effect was demonstrated in the cellulose treatment 
(P=0.353) (1904.3 ± 364.1 cm*min [day 56] and 2022.8 ± 444.9 cm*min [day 0]).  
 
          i)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Subjective desire for sweet food scores (cm) (i) and tAUC450min (ii) in oligofructose and 
cellulose groups. The doses were supplemented into the meal during breakfast (0 min) and lunch (240 
minutes) in the post-supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is 
expressed as mean ± SEM. Oligofructose (n=12), cellulose (n=10). *P<0.05 oligofructose vs. baseline. 
  
103 
 
2.4.1.4.1.5 Desire to Eat Savoury Food 
Figure 2.9 depicts subjective desire towards savoury food scores (i) and tAUC450min desire 
towards savoury food scores (ii). Oligofructose supplementation significantly reduced 
tAUC450min desire for savoury food scores (P=0.003) compared to other treatments. In addition, 
oligofructose also significantly reduced within group tAUC450min scores (P=0.004) (1090.6 ± 
251.1 cm*min [day 56] and 1658.0 ± 365.3 [day 0]). However, no significant effect on savoury 
tAUC450min scores in the cellulose group (P=0.203) (cellulose: 1757.7 ± 420.0 cm*min [day 56] 
and baseline: 1534.7 ± 445.3 cm*min [day 0]). 
 
           (i) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                         ii) 
 
 
 
 
 
 
 
 
Figure 2.9 Subjective desire for savoury food scores (cm) (i) and tAUC450min (ii) in oligofructose and 
cellulose groups. The doses were supplemented into the meal during breakfast (0 min) and lunch (240 
minutes) in the post-supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is 
expressed as mean ± SEM. Oligofructose (n=12), cellulose (n=10). **P<0.01 oligofructose vs. baseline, 
*P<0.05 oligofructose vs. other treatments. 
* 
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2.4.1.4.1.6 Desire to Eat Fatty Food 
Figure 2.10 exhibits subjective desire to eat fatty food scores (i) and tAUC450min desire to eat 
fatty food scores (ii). Inclusion of oligofructose in the diet significantly reduced tAUC450min fatty 
scores compared to other treatments (P=0.013) and tAUC450min within oligofructose group 
(P=0.001) (566.3 ± 191.2 cm*min [day 56] and 1401.9 ± 324.8 cm*min [day 0]). No significant 
effect was found in tAUC450min desire to eat fatty scores in the cellulose group (P=0.408) (1095.5 
± 320.9 cm*min [day 56] and 1022.4 ± 380.8 cm*min [day 0]).  
 
(i)                                                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                    ii) 
 
 
 
 
 
 
 
 
 
Figure 2.10 Subjective desire for fatty food scores (cm) (i) and tAUC450min (ii) in oligofructose and 
cellulose groups. The doses were supplemented into the meal during breakfast (0 min) and lunch (240 
minutes) in the post-supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is 
expressed as mean ± SEM. Oligofructose (n=12), cellulose (n=10). **P<0.01 oligofructose vs. baseline, 
*P<0.05 oligofructose vs. cellulose. 
* 
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2.4.1.4.1.7 Desire for Salty Food 
Figure 2.11 depicts subjective desire for salty food scores (i) and tAUC450mins desire for salty 
food scores (ii). There was a significant reduction in reducing tAUC450mins desire for salty food in 
the oligofructose group compared to other groups (P=0.009). tAUC450mins for desire salty food at 
450 minutes in the oligofructose group (880.8 ± 238.8 cm*min) was significantly reduced 
compared to baseline (day 0) (1617.4 ± 369.6 cm*min) (P=0.002). No significant effect was 
demonstrated in the cellulose group (1322.0 ± 341.4 cm*min) compared to baseline (day 0) 
(P=0.190) 1035.7 ± 350.6 cm*min [day 0]).  
 
(i)                                                                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                     ii) 
 
 
 
 
 
 
 
 
Figure 2.11 Subjective desire for salty food scores (cm) (i) and tAUC450min (ii) in oligofructose and 
cellulose groups. The doses were supplemented into the meal during breakfast (0 min) and lunch (240 
minutes) in the post-supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is 
expressed as mean ± SEM. Oligofructose (n=12), cellulose (n=10).**P<0.01 oligofructose vs. baseline, 
**P<0.01 oligofructose vs. cellulose 
* 
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2.4.1.4.2 Gastrointestinal Side Effect Assessment 
Gastrointestinal side effect data were not normally distributed, thus data analysis was performed 
on log10-transformed variables. The geometric means (95% confident interval) are presented in 
Table 2.1. Oligofructose supplementation significantly increased tAUC450mins bloating and 
flatulence scores compared to cellulose supplementation (P=0.007 and P=0.005 respectively) and 
a tendency to increase both of bloating and flatulence when compared to baseline study day (day 
0) (P=0.097 and P=0.077 respectively). No significant effect was demonstrated in the cellulose 
group (P=0.629 and P=0.496 respectively). 
 
 
 
Table 2.1 Gastrointestinal side effects at baseline (day 0) and following intake of 30 g/day oligofructose 
and cellulose supplementation on post-supplementation (day 56) of appetite study day. 
Appetite 
sensation 
Oligofructose (n=12)  Cellulose (n=10) P
c
 
Value Day 0 Day 56  Day 0 Day 56 
       
Bloated (cm*min)
b
 15.1 (1.0 – 218.6) 51.6 (2.7 – 985.8)a  105.2 (21.6 – 512.8) 14.1 (0.6 – 363.4) 0.007 
Stomach discomfort 
(cm*min)
b
 
72.6 (19.4 – 271.5) 4.0 (0.2 – 75.4)  43.3 (11.6 – 161.0) 10.6 (1.1 – 106.1) 0.011 
Flatulence (cm*min)
b
 11.1 (0.9 – 132.4) 57.6 (7.0 – 470.5)a  32.8 (3.8 – 280.5) 5.9 (0.4 – 99.1) 0.005 
Diarrhoea (cm*min)
b
 1.2 (0.1 – 9.8) 0.5 (0.1 – 3.9)  5.1 (1.1 – 24.0) 0.5 (0.1 – 5.1)a 0.896 
Sick (cm*min)
 b
 14.4 (2.5 – 81.8) 1.9 (0.2 – 20.9)  19.4 (5.6 – 67.8) 2.4 (0.2 – 37.9) 0.613 
       
 
a
significantly different compared to baseline (day 0) study day. 
 
b
Data are presented as geometric mean (95% confidence interval) 
 
c
Statistical analysis was performed by ANCOVA 
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2.4.1.5 Breath Hydrogen Analysis 
Figure 2.12 demonstrates breath hydrogen levels (i) and tAUC450mins breath hydrogen levels (inset). 
Both of the supplementation showed no significant effect on fasting breath hydrogen levels when 
compared to baseline (oligofructose: P=0.431 and cellulose: P=0.871). Intake of oligofructose 
significantly increased breath hydrogen levels and tAUC450min (P< 0.0001 and P=0.001 respectively) 
compared to cellulose treatment. Breath hydrogen levels following ingestion of oligofructose 
supplementation started to increase from 180 minutes and peaked around 260 to 300 minutes. One 
participant showed a late peak at 420 minutes with hydrogen levels of 88 ppm. After 300 minutes, 
hydrogen levels remained stable at 15 – 20 ppm until 450 minutes. This means that fermentation was 
still increased when the ad libitum meal intake was administered at 420 minutes. In contrast, no 
significant effect was demonstrated in the cellulose group, with the levels being consistently below 
than 10 ppm throughout the study day. Please refer to Section 2.4.1.3 for ad libitum meal assessment. 
 
 
Figure 2.12 Breath hydrogen levels (ppm) and tAUC450min (inset) in oligofructose and cellulose groups. 
The doses were supplemented into the meal during breakfast (0 min) and lunch (240 minutes) in the post-
supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is expressed as mean 
± SEM. Oligofructose (n=12), cellulose (n=10). **P<0.01 oligofructose vs. cellulose and **P<0.01 oligofructose 
vs. control oligofructose tAUC450mins). ***P<0.001 oligofructose vs. other treatments (time course). 
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2.4.1.6 Gut Hormones, Glucose and Insulin Analyses 
 
2.4.1.6.1 Peptide Tyrosine-Tyrosine 
Figure 2.13 illustrates plasma PYY levels (i) and tAUC420min plasma PYY levels (ii). 
Supplementing oligofructose in volunteers’ diets had no significant difference compared with 
cellulose (P=0.219) No significant effect on fasting plasma PYY levels was also demonstrated 
(P=0.941). However, PYY levels were shown to be increased after two hour ingestion of 
oligofructose supplement and remained elevated throughout the study day compared to cellulose 
treatment. In addition, the plasma PYY levels peaked at 260 minutes and significantly increased 
tAUC420min plasma PYY levels (13876.2 ± 1078.3 pmol/L*min) compared to baseline (P=0.037) 
(12377.5 ± 794.5 pmol/L*min) whilst no effect was shown in the cellulose group (P=0.432).  
 
(i)                                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
                                    ii) 
 
 
 
 
 
 
 
 
 
Figure 2.13 Postprandial plasma PYY levels (pmol/L) (i) and tAUC420min (ii) in oligofructose and 
cellulose groups. The doses were supplemented into the meal during breakfast (0 min) and lunch (240 
minutes) in the post-supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. 
Data is expressed as mean ± SEM.  Oligofructose (n=12), cellulose (n=10).*P<0.05 oligofructose vs. 
baseline.   
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2.4.1.6.2 Glucagon-like Peptide 1 
Figure 2.14 exhibits plasma levels of GLP-1 (i) and tAUC420min of plasma GLP-1 (ii). Cellulose 
supplementation significantly increased (P=0.006) tAUC420min postprandial plasma GLP-1 
compared to baseline but no significant effect when compared to oligofructose group (P=0.327). 
No significant effect was also demonstrated in the oligofructose group (P=0.412). 
 
(i)                                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                 ii) 
 
 
 
 
 
 
 
 
 
Figure 2.14 Postprandial plasma GLP-1 levels (pmol/L) (i) and tAUC420min (ii) in oligofructose and 
cellulose groups. The doses were supplemented into the meal during breakfast (0 min) and lunch (240 
minutes) in the post-supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is 
expressed as mean ± SEM. Oligofructose (n=12), cellulose (n=10).*P<0.05 cellulose vs. baseline 
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2.4.1.6.3 Insulin  
Figure 2.15 depicts plasma levels of insulin (i) and tAUC450min of insulin levels (ii). 
Oligofructose had no significant effect when compared to cellulose treatment (P=0.750). No 
significant effect also demonstrated in tAUC450min plasma insulin in both oligofructose and 
cellulose group (P=0.413 and P=0.895).  
 
(i)                                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              ii) 
 
 
 
 
 
 
 
 
 
 
Figure 2.15 Postprandial plasma insulin levels (uU/mL) (i) and tAUC450min (ii) in oligofructose and 
cellulose groups. The doses were supplemented into the meal during breakfast (0 min) and lunch (240 
minutes) in the post-supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is 
expressed as mean ± SEM. Oligofructose (n=12), cellulose (n=10). 
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2.4.1.6.4 Glucose  
Figure 2.16 demonstrates plasma levels of glucose (i) and tAUC450min (ii). Inclusion of 
oligofructose in meals significantly increased glucose response when compared to the baseline 
(P=0.040) whilst cellulose had no significant effect on plasma glucose levels (P=0.846) 
compared to the baseline. No significant difference between the oligofructose and cellulose 
treatments was also demonstrated (P=0.643).    
 
(i)                                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                    ii) 
 
 
 
 
 
 
 
 
 
 
Figure 2.16 Postprandial plasma glucose levels (mmol/L) and tAUC450min (ii) in oligofructose and 
cellulose groups. The doses were supplemented into the meal during breakfast (0 min) and lunch (240 
minutes) in the post-supplementation visit (day 56). The ad libitum meal was assessed at 420 minutes. Data is 
expressed as mean ± SEM. Oligofructose (n=12), cellulose (n=10).*P<0.05 oligofructose vs. baseline. 
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2.4.2 Free-living Supplementation Period 
Assessment was performed at prior to the supplementation period (Day -8 to -1) (baseline) and 
during the last week of supplementation (day 49 to 55) (post-supplementation), VAS and energy 
intake were assessed.  
 
 
2.4.2.1 Energy intake Assessment 
Figure 2.17 shows energy intake assessment. There was no effect of treatment in reducing 
energy intake at home in the oligofructose and cellulose group when compared to the baseline; 
oligofructose (P=0.522) and cellulose (P=0.652). Oligofructose group also showed no significant 
difference when compared to cellulose supplementation (P=0.821). For this analysis, the result 
represents the mean value for 21 volunteers as one volunteer in the cellulose group lost the food 
diary (oligofructose = 12 and cellulose = 9 volunteers). 
 
 
                                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17 Seven days energy intake assessment (kcal) in oligofructose and cellulose groups.  The 
supplementation were taken thrice daily during meal intake (10 g each time) for six weeks following two weeks 
run-in supplementation period. Assessment was performed at baseline (day -8 to day -1) and post-
supplementation period (day 49 to day 55). Data is expressed as mean ± SEM. oligofructose (n=12), cellulose 
(n=9). 
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2.4.2.2 Subjective appetite ratings 
 
2.4.2.2.1 Hunger 
Figure 2.18 shows subjective hunger scores. There was a tendency in the oligofructose group to 
reduce hunger scores (3.9 ± 0.6 cm) compared to baseline (day 0) (P=0.054) (5.4 ± 0.7 cm) 
whilst no significant effect was demonstrated within cellulose group (P=0.711) (5.1 ± 0.3 cm 
[day 56] and 4.7 ± 0.9 cm [day 0]). No significant effect was also demonstrated between the 
supplementations (P=0.219). 
 
                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18 Subjective hunger scores (cm) in oligofructose and cellulose groups.  The supplementation 
were taken thrice daily during meal intake (10 g each time) for six weeks following two weeks run-in 
supplementation period. Assessment was performed at baseline (day -8 to day -1) and post-supplementation 
period (day 49 to day 55). Data is expressed as mean ± SEM. oligofructose (n=12), cellulose (n=10). 
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2.4.2.2.2 Fullness  
Figure 2.19 demonstrates the subjective fullness scores. There was no significant effect of 
treatment on increasing fullness score (4.7 ± 0.4 cm) compared to baseline (5.1 ± 0.4 cm) in both 
oligofructose group (P=0.210) and cellulose group (P=0.688) (4.3 ± 0.6 cm [day 56] and 4.4 ± 
0.8 cm [day 0]). No significant effect was also seen when comparing between oligofructose and 
cellulose treatment (P=0.634). 
 
 
                                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19 Subjective fullness scores (cm) in oligofructose and cellulose groups.  The supplementation 
were taken thrice daily during meal intake (10 g each time) for six weeks following two weeks run-in 
supplementation period. Assessment was performed at baseline (day -8 to day -1) and post-supplementation 
period (day 49 to day 55). Data is expressed as mean ± SEM. oligofructose (n=12), cellulose (n=10). 
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2.4.2.2.3 Gastrointestinal Side effects 
Table 2.2 demonstrates the geometric mean and 95% confidence interval of gastrointestinal side 
effect assessed during free-living supplementation period. No significant effect was showed 
between oligofructose and cellulose supplementation.  
 
 
 
Table 2.2 Gastrointestinal Side effects following intake of 30 g/day oligofructose or cellulose during 
free-living supplementation period, baseline (day -8 to -1) and post-supplementation (day 49 to 55) appetite 
study day.  
*
Data are presented as geometric mean (95% confidence interval) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Side 
effects 
(cm) 
Oligofructose (n=12)  Cellulose (n=10) P Value 
Baseline Post- 
supplementation 
 Baseline Post- 
supplementation 
       
Bloating 0.9 (0.2 – 1.5) 2.3 (0.6 – 3.9)  0.4 (0.1 – 1.2) 0.4 (0.1 – 1.2) 0.9737 
Stomach 
discomfort 
0.5 (0.2 – 1.2) 0.4 (0.1 – 1.2)  0.2 (0.1 – 0.8) 0.2 (0.1 – 0.8) 0.8682 
Flatulence 0.9 (0.4 – 1.5) 1.7 (0.3 – 3.2)  0.3 (0.1 – 1.1) 0.3 (0.1 – 1.3) 0.224 
Diarrhoea 0.1 (0.04 – 0.2) 0.1 (0.04 – 0.5)  0.01 (0.03 – 0.3) 0.1 (0.04 – 0.4) 0.837 
Sickness 0.1 (0.05 – 0.3) 0.1 (0.05 – 0.4)  0.1 (0.04 – 0.4) 0.2 (0.04 – 0.6) 0.760 
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2.5 Discussion 
 
2.5.1 Appetite Study Day Assessment 
The result of this study is consistent with the hypothesis that intake of oligofructose for eight weeks 
significantly increased breath hydrogen secretion and reduced several subjective appetite scores 
(hunger, motivation to eat, desire to eat savoury, fatty and salty) compared to cellulose group. 
However, oligofructose supplementation had no significant effect on energy intake, fullness scores 
and plasma PYY levels compared to cellulose although the effects were significant within the group.  
 
Data in the literature suggests that intake of fermentable carbohydrates, oligofructose (Cani et al., 
2009), inulin (Fernandes et al., 2011) and fructo-oligosaccharides (Piche et al., 2003) increased 
colonic fermentation (Cani et al., 2004; Delzenne et al., 2005). Indeed, the present study showed that 
colonic fermentation activity assessed by breath hydrogen test was significantly increased two hours 
after oligofructose intake and the levels were maintained throughout the study day. Similar to our 
study, Gee et al. reported that intake of 10 g lactitol also resulted in peaked breath hydrogen levels 
after 3-5 hours ingestion (Gee and Johnson, 2005). Nevertheless, it is surprising that oligofructose 
has no significant effect on fasting breath hydrogen levels as demonstrated in Cani et al. and Piche et 
al. (Cani et al., 2009; Piche et al., 2003). Hydrogen breath test is a non invasive, simple and common 
test used in clinical studies to test for the malabsorption of carbohydrates (Simren and Stotzer, 2006), 
therefore it is also suitable to be used as a surrogate marker for fermentability of fibre. However, 
there are some limitations to hydrogen breath test analysis. Some people do not have bacteria that 
produce bydrogen and this make the breath hydrogen measurement impossible in these people. 
Therefore, it is important to identify volunteers that able to produce breath hydrogen before the start 
of the study. In addition, hydrogen can also be metabolised to other metabolites such as ethanol and 
methane. Instead of hydrogen, some people have bacteria that produce a different gas, such as 
methane or produce both methane and hydrogen concurrently. Although methane can also be 
measured in the breath just like hydrogen, the production of methane is more complex and its 
analysis is less experience in carbohydrate malabsorption studies.    
 
It is widely known that stimulation of colonic fermentation by fermentable carbohydrates produced 
SCFAs. Although SCFAs were not measured in this study, other studies have suggested that intake of 
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fermentable carbohydrates elevated SCFAs, which is associated with increase expression of 
proglucagon genes in the gut (Delzenne et al., 2005; Tappenden et al., 1998). In addition, the 
relationship between SCFAs and L-cells derived hormones has been demonstrated in both human 
and rodent studies. In humans, rectal infusion of acetate has been shown to significantly increase 
plasma PYY and GLP-1 levels (Freeland and Wolever, 2010). In rodents, intracolonic infusion of 
SCFA has been shown to trigger the release of PYY in the circulation (Cherbut et al., 1998). 
Interestingly, Zhou et al. showed that SCFAs directly induced release of proglucagon and PYY 
mRNA expression in vitro study (Zhou et al., 2008). In the present study, the peak levels of hydrogen 
release following oligofructose intake was detected between 260 to 300 minutes and this is well-
correlated with the peak levels of plasma PYY showed at 260 minutes. Moreover, oligofructose 
significantly increased tAUC420mins plasma PYY secretion compared to the baseline study day (day 
0).  To date, the mechanism of how SCFAs modulated the release of PYY is still unclear. However, 
SCFAs might modulate their effects on stimulating gut hormone release by binding to their receptors, 
FFAR2 and FFAR3. FFAR2 and FFAR3 are co-localised with cell producing GLP-1 and PYY in the 
colonic L-cells, therefore activation of these receptors by SCFAs could potentially triggers GLP-1 
and PYY secretion (Brown et al., 2003; Karaki et al., 2008; Le Poul et al., 2003; Xiong et al., 2004; 
Zaibi et al., 2010). 
 
Despite of a significant increase tAUC420mins PYY levels in the oligofructose group, the levels were 
not significantly different when compared with the cellulose group. The result of this study is in 
agreement with Parnell and Reimer’s result. In Parnell and Reimer study, oligofructose was shown to 
significantly increase tAUC360mins plasma PYY levels after 12 weeks oligofructose intake, but the 
effect was not different with the control, maltodextrin (Parnell and Reimer, 2009). Contrary to our 
observation, Cani et al. and Verhoef et al. showed that intake of 16 g oligofructose for 14 and 13 days 
significantly increased plasma PYY levels compared to the control treatment. However, the results of 
these studies are debateable. In Cani et al., a significant increase in plasma PYY levels in the 
oligofructose group was demonstrated only at 10 minutes after ingestion whilst no clear effects were 
demonstrated at other timepoints. Furthermore, this effect was compared with the control at 
individual timepoints whilst no measurement of tAUC was performed (Cani et al., 2009). On the 
other hand, Verhoef et al. showed a significant increase of AUC 0 – 230 mins (morning until lunch) 
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following intake of oligofructose, but the effect was not maintained until the end of the study day, 
thus resulting in no significant different in the tAUC420mins (Verhoef et al., 2011).  
 
Evidence suggests that fermentable carbohydrates suppress food intake via increased in plasma PYY 
secretion (Delzenne et al., 2005). However, the present study showed that the tAUC420mins plasma 
PYY levels were not related to subjective hunger scores. The lack of relationship between hormonal 
changes and subjective appetite was reported to be common in human studies (Cani et al., 2009; 
Parnell and Reimer, 2009; Weickert et al., 2006; Weickert and Pfeiffer, 2008). Nonetheless, intake of 
oligofructose in this study significantly reduced tAUC450mins subjective appetite scores. Similarly, 
associations between oligofructose supplementation and modulation of subjective appetite scores 
have been previously demonstrated (Cani et al., 2006a; Cani et al., 2009). In contrast, Archer et al. 
explained in their study that appetite suppression following intake of fermentable carbohydrates does 
not necessarily happen during the meal testing time but the effect can be delayed until later in the 
day. This is due to the extra time needed for colonic fermentation and subsequently increases SCFAs 
secretion (Archer et al., 2004). The same observation was found by Verhoef et al. (Verhoef et al., 
2011). On the other hand, other studies showed that neither reduction of energy intake nor 
modulation of subjective appetite scores were demonstrated after addition of oligofructose in meal 
replacement bars and beverages (Hess et al., 2011; Karalus et al., 2012; Peters et al., 2009). However, 
it is suggested that this might be due to the lower oligofructose dose provided in the study (10 g or 
less per day) compared to 30 g of oligofructose provided in this study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 
Consistent with the change in appetite scores, oligofructose was also showed to significantly reduce 
energy intake at ad libitum meal and the effect is possibly resulted from an increase postprandial 
tAUC420mins plasma PYY levels. The same result was observed in Parnell and Reimer study (Parnell 
and Reimer, 2009). Unexpectedly, intake of cellulose in the current study also reduced ad libitum 
meal intake (cellulose: 142.27 ± 67.89 kcal; oligofructose: 112.98 ± 33.80 kcal). However, no 
different between the treatments was found. In contrast, Howarth et al. suggested that intake of 27 ± 
0.6 g/day cellulose in 11 healthy volunteers with BMI 20.0-34.4 kg/m
2
 for 3 weeks had no significant 
effect on appetite and energy intake (Howarth et al., 2003). The mechanisms of how cellulose 
reduced energy intake are unclear, but it might be related to an increase in plasma GLP-1 levels. In 
this study, plasma GLP-1 levels in the cellulose group were significantly increased compared to after 
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intake of oligofructose. However, this observation was not really unexpected as cellulose is an 
insoluble fibre, thus it could have its own effect on stimulating GLP-1 secretion. Insoluble fibres in 
humans act as a bulking agent and help to slow down the transit time (Jenkins et al., 1978), which 
leads to a decrease in starch absorption (Lewis and Heaton, 1997). In addition, polongation of time 
for carbohydrate to reach the distal small intestine also resulted in secretion of GLP-1 (Qualmann et 
al., 1995; Seifarth et al., 1998). Moreover, results from other fermentable carbohydrates human trials 
also showed conflicting results. Whilst some studies demonstrated a high release of GLP-1 after 
oligofructose supplementation (Cani et al., 2009; Piche et al., 2003; Verhoef et al., 2011), some 
oligofructose (Parnell and Reimer, 2009; Pedersen, 2010), inulin (Tarini and Wolever, 2010) and 
resistant starch (Gee and Johnson, 2005; Weickert and Pfeiffer, 2008) studies showed no significant 
effect on plasma GLP-1 levels. 
 
In contrast, evidence from rodents’ studies showed that the levels of plasma GLP-1 and PYY were 
significantly increased following fermentable carbohydrates intake (Cani et al., 2004; Cani et al., 
2005b; Cani et al., 2006b; Cani et al., 2007b; Gee and Johnson, 2005; Kok et al., 1998). The possible 
explanation of the discrepancy in findings between human and rodents’ plasma GLP-1 and PYY 
levels might be due to several reasons. Firstly, humans have a low tolerability towards high fibre 
intake as this could leads to gastrointestinal adverse effects (Kaur and Gupta, 2002). In contrast, 
rodents are able to tolerate fibre doses up to 10 % of their body weight without any gastrointestinal 
side effects (Cani et al., 2005b; Peters, 2010). Secondly, plasma GLP-1 and PYY levels in rodents 
were obtained mostly from portal blood, where these gut hormones are expected to be released in 
high amounts. However, in humans, this location is not accessible for direct measurement; hence 
both of the plasma satiety hormones can only be quantified from the periphery, where the lowest 
amount of gut hormone levels is found. Thirdly, having a large caecum might have been an 
advantage to rodents to increase fermentation activity. The caecum is an organ in the gastrointestinal 
tract that involved in microbial fermentation activities in mammals (DeSesso and Jacobson, 2001).  
 
In this study, oligofructose supplementation significantly increased postprandial glucose, but had no 
significant effect on insulin levels compared to cellulose. This observation is contrary to rodent 
studies which have consistently shown to reduce postprandial glucose and insulin levels (Cani et al., 
2005a; Cani et al., 2006b; Kok et al., 1998; Urias-Silvas et al., 2008). Although there were evidence 
  
120 
 
to show that inulin-type fructans significantly reduced glucose and insulin levels in humans (Cani et 
al., 2009; Daubioul et al., 2005; Jackson et al., 1999; Russo et al., 2008), several groups showed no 
significant effect of inulin-type fructans on both postprandial glucose and insulin levels  (Giacco et 
al., 2004; Parnell and Reimer, 2009; Tarini and Wolever, 2010; van Dokkum et al., 1999). The role of 
inulin-type fructans on modulating blood glucose levels has been disscused in more details in a 
systematic review. The authors demonstrated that out of the thirteen studies they have reviewed, only 
four studies have shown a decrease in serum glucose levels after inulin-type fructans intake and only 
one of these studies were statistically significant. The nine other studies showed no significant effect 
on serum glucose levels. This review reveals that the effect of inulin-type fructans on reducing blood 
glucose in humans remains unclear and needs further investigation (Bonsu et al., 2011).     
 
2.5.2 Self-living Supplementation Period 
During the 8-week supplementation period, four volunteers in the oligofructose group showed a 
mean compliance of 72.9%. However, this does not affected the overall group compliance as 
oligofructose group was shown to have compliance rate of 89.8 ± 13.1 % whilst 89.7 ± 12.8 % was 
demonstrated in the cellulose group. Furthermore, assessment of gastrointestinal side effects using 
VAS questionnaires suggested that both oligofructose and cellulose were well-tolerated. No 
significant effect was reported with the dosage except for a significant increase in delta change of 
nausea scores in the oligofructose group when compared to cellulose group. However, the mean 
scores was less than 1.0 cm (0.45 ± 0.22 cm) and that the increase scores were actually obtained from 
one volunteer who scored 3.1 cm in the baseline study day and 5.4 cm in the post-supplementation 
study day. The rest of the volunteers scored nausea below 1.5 cm on both of the study days. Some 
volunteers also complained of the occurrence of flatulence and bloating, however these were reported 
as mild and no significant effect was reported.  
 
Generally, dosage of less than 30 g of fibre per day is related to fewer gastrointestinal side effect 
(Kaur and Gupta, 2002) whilst dosage of 40-50 g/day has been shown to correlate with rumbling 
stomach and diarrhoea (Briet et al., 1995; Carabin and Flamm, 1999; Marteau and Flourie, 
2001). Serious gastrointestinal side effects could discourage the consumption of fibre, which 
therefore could affect the study’s compliance. As a precaution, studies using a dosage of more 
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than 20 g/day may need to introduce a gut adaptation period, including a lower starting dose of 
fibre and a stepwise increase to the actual fibre dose investigated. Thus, this would help to 
reduce gastrointestinal symptoms during the investigation and allow for higher dosages of fibre 
to be consumed.  
 
Home-supplementation VAS scores showed that hunger was decreased in the oligofructose 
group compared with cellulose group, but this was not significant. Fullness scores were also not 
affected by the treatment in both groups. During the supplementation period, volunteers were 
asked to rate VAS once a day for seven days at baseline and during the supplementation period 
as a summary of their subjective appetite feeling. Using VAS for measuring subjective appetite 
has been related to increased variability (Flint et al., 2000; Stubbs et al., 2000) which possibly 
resulted from methodological and biological day-to-day differences in individuals (Raben et al., 
1995). Moreover, differences in the setting of the study might also influence the VAS scores. 
Appetite scores which were rated during study days in a clinical setting are possibly more robust 
as volunteers were supervised and in controlled conditions compared to during free-living. 
Therefore, performing studies in clinical settings is more sensitive to detect and reduce any 
confounding variables that may influence the result (Livingstone et al., 2000) (e.g. during the 
appetite study day, meals were provided at a fixed time whilst volunteers might have their meals 
at their convenience during free-living supplementation period). 
 
Although subjective hunger score was reduced in the oligofructose group, no significant effect 
on energy intake was demonstrated when assessed using the food diaries. The results showed 
that energy intake in the oligofructose group was slightly increased (101.92 ± 154.04 kcal) from 
the baseline whilst there was a reduction in the cellulose group (-46.82 ± 172.57 kcal), but this 
was not significant. However, as mean energy intake was low for both groups, this indicated that 
subjects underreported their energy intake. Evidence from the literature suggests that under-
reporting is very common in overweight/obese individuals (Briefel et al., 1997; Johansson et al., 
1998; Kretsch et al., 1999; Lafay et al., 1997). So it is not a surprise that volunteers in this study 
underreported their energy intake. Moreover, diet diary data are also not that reliable / accurate 
in reporting energy intake (Hoidrup et al., 2002; Trabulsi and Schoeller, 2001; Westerterp and 
Goris, 2002). However, in this study, the lack of change in energy intake is supported by the fact 
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that body weight did not change either (the effect of oligofructose on body weight is discussed in 
chapter 3). Adding oligofructose in the diet also might have increased the caloric content on the 
post-supplementation assessment compared to the baseline assessment. However, cellulose also 
contained the same amount of calories as oligofructose. Therefore, an increase in calorie intake 
following supplementation if any, can be found in both groups.  
 
As a conclusion, supplementation of oligofructose in the volunteers’ diet significantly increased 
colonic fermentation which subsequently elevated PYY, but not GLP-1 secretion. It is suggested 
that PYY suppressed appetite scores and energy intake in the oligofructose group. However, the 
amount of postprandial plasma PYY levels was insufficient to suppress energy intake when 
compared to cellulose. Oligofructose also had no significant effect on postprandial glucose and 
insulin levels. Based on the result of this study, it can be concluded that oligofructose when 
compared to cellulose has temporal effect on appetite during acute clinical investigation, but the 
dose levels were insufficient to alter appetite and energy intake over eight weeks free-living 
supplementation period. 
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On Adiposity & Insulin 
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3 Background 
 
3.1 Introduction 
 
3.1.1 Magnetic Resonance Imaging and Metabolic Disorders 
Over the past 10 years, large numbers of studies have used MRI to investigate the relationship 
between regional body fat distribution and its related metabolic disorders. Indeed, via MRI, it is now 
known that metabolic disturbances are primarily related to regional body fat, particularly intra-
abdominal adipose tissue (IAAT) or visceral fat. IAAT has been shown as the major contributor in 
the development of insulin resistance, hyperinsulinemia, hypertension, cardiovascular disease and 
mortality (Carey et al., 1996; Goodpaster et al., 2005; Hayashi et al., 2004; Nicklas et al., 2003; 
Pouliot et al., 1992; Yamashita et al., 1996). Another related region, abdominal subcutaneous adipose 
tissue (ASAT) also associates with these diseases, but to a lesser extent compared to IAAT (Demerath 
et al., 2008; Fox et al., 2007; Goldstone et al., 2001; Kelley et al., 2000; Kuk et al., 2006). This is 
because IAAT is more metabolically active in secreting hormones and inflammation markers 
compared to ASAT (Bjorntop, 1996). IAAT is hypothesised to influence hepatic insulin resistance 
(Cnop et al., 2002; Kelley et al., 2000) by releasing its lipolysis product, free fatty acids. These free-
fatty acids are transported to the portal circulation which results in increasing hepatic glucose 
production, reducing insulin secretion and leads to the development of insulin resistance. In contrast 
to IAAT, free fatty acids from subcutaneous fat are delivered to the systemic circulation (Gastaldelli 
et al., 2007; Kershaw and Flier, 2004).   
 
Besides IAAT and ASAT, evidence reveals that saturation of adipose tissue (AT) due to excessive 
accumulation of fat from energy intake causes the fat to accumulate in other non-adipose tissue 
organs. This group of fat is known as ectopic fat and it can affect important organs such as liver, 
pancreas, skeletal muscle, heart and kidneys (Heilbronn et al., 2004). As a consequence, ectopic fat 
also associated with pathogenesis of various metabolic diseases such as insulin resistance, type 2 
diabetes and cardiovascular disease (Lettner and Roden, 2008; Montani et al., 2004; Rasouli et al., 
2007; Szendroedi and Roden, 2009).  
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Looking at the patho-physiological effects of regional and ectopic fat on generating metabolic 
disturbances, a reduction of body fat distribution is now considered as the main focus in obesity 
research. Recent evidence demonstrated that a reduction of IAAT repository either via surgical 
removal (Barzilai et al., 1999; Gabriely et al., 2002) or lifestyle modifications; including exercise 
(Johnson et al., 2009; Thomas et al., 2000), dietary changes (Gasteyger et al., 2009) or combination 
of exercise and dietary changes (Idoate et al., 2011) have led to improved insulin sensitivity (Larson-
Meyer et al., 2006; Ross et al., 2004). Therefore, increase insulin sensitivity may be used as a 
predictive tool for regional and ectopic fat reduction following weight loss-related treatments. 
 
Although surgical removal is an effective approach in reducing body fat, it can relate to many 
adverse side effects. Besides, it is also an expensive procedure compared to a lifestyle modification 
approach. Therefore, lifestyle modifications are potentially a better option in reducing body fat 
distribution (Carr et al., 2005; Laaksonen et al., 2003; Slentz et al., 2004; Slentz et al., 2011). A 5 
year intervention Insulin Resistance and Atherosclerosis study (IRAS) among 1114 African and 
Hispanic Americans showed that lifestyle modifications of consistent physical activity and 
consumption of soluble fibre led to a reduction of visceral fat accumulation. Interestingly, this study 
also highlights the role of fibres in controlling body fat by suggesting that every 10 g increase of 
soluble fibres resulted in a 3.7 % reduction of visceral AT (Hairston et al., 2012). This observation is 
also supported by Davis et al. which have shown that increased intake of insoluble fibres in 85 
overweight Latino adolescents in a 2-year longitudinal study significantly decreased visceral AT. In 
addition, they also reported that a slight reduction of 3 g insoluble fibre / 1000 kcal per day resulted 
in a 21 % increase of visceral fat (Davis et al., 2009).  
 
These studies suggest that dietary fibres have a potential role in modulating body fat distribution and 
in stimulating insulin sensitivity. On the other hand, the role of isolated dietary fibres on AT 
metabolism has not been fully explored yet. Interestingly, recent evidence suggests that fermentable 
carbohydrates may have a significant role in modulating insulin sensitivity (Robertson et al., 2003; 
Robertson et al., 2005; Robertson et al., 2012) and therefore raising a possibility to be developed as 
anti-obesity treatment.  
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3.1.2 Fermentable Carbohydrates, Adipose Tissue Metabolism and Insulin Sensitivity 
Evidence suggests that the role of fermentable carbohydrates in regulating adiposity maybe related to 
its end fermentation products, SCFAs. SCFAs’ receptors, FFAR2 and FFAR3 have been shown to be 
expressed in the AT (Ge et al., 2008; Hong et al., 2005; Le Poul et al., 2003). In addition, acetate and 
propionate have also been demonstrated to inhibit lipolysis of adipocytes in vitro which potentially 
leads to suppression of plasma non-esterified fatty acid levels in the circulation (Ge et al., 2008). 
Indeed, intraperitoneal infusion of sodium acetate into wild-type mice significantly decreased non-
esterified fatty acid levels as a result of increased circulating plasma acetate levels. This effect has 
been shown to be abolished in FFAR2-null mice, suggesting that acetate exerts this effect via 
activation of FFAR2 (Ge et al., 2008). Besides lipolysis, acetate and propionate also have been 
shown to mediate its effect on adipogenesis via FFAR2. This result highlights the role of FFAR2 in 
adipocytes development and differentiation (Hong et al., 2005).  
 
Evidence reported that adipocyte size has a negative association with insulin sensitivity, in which the 
larger the adipocytes, the more they become less-insulin sensitive (Salans et al., 1968; Unger, 2003). 
Obese / overweight individuals have been shown to have large adipocytes (Salans et al., 1973). 
Therefore, adipocytes of obese/overweight individuals are more likely to become less-insulin 
sensitive. It has also been shown that increased size of abdominal adipocyte is strongly associated 
with whole body insulin resistance and tissue inflammation (Lundgren et al., 2007; Maffeis et al., 
2007; Weisberg et al., 2003). Nevertheless, the cell will restore its sensitivity following weight loss 
(Lofgren et al., 2005; Shadid and Jensen, 2003) via a reduction in adipocyte size.  
 
Therefore, it is proposed that increased circulating SCFAs following intake of high amount of 
fermentable carbohydrates in the diet could influence AT metabolism by improving insulin 
sensitivity.  Evidence from a mouse study showed that eight weeks of high resistant starch diet lead 
to significant reduction of total body fat, subcutaneous, visceral and intrahepatocellular. It is 
suggested that the effect of resistant starch on body adiposity is due to significant reduction of 
adipocyte size as no change in body weight was demonstrated compared to the control group. 
Moreover, insulin secretion was also reduced in the treatment group compared to the control group, 
suggesting that mice-fed high resistant starch are insulin-sensitive compared to the control group (So 
et al., 2007). 
  
127 
 
In humans, supplementing 30 g/day resistant starch in ten obese volunteers for four weeks 
significantly increased insulin sensitivity compared to the control group. This could be explained 
by reduced non-esterified fatty acid secretion from visceral adipocytes and increased levels of 
circulating plasma acetate and propionate (Robertson et al., 2005). In another study, intake of 40 
g/day resistant starch for twelve weeks in 20 insulin-resistance volunteers led to improved 
insulin sensitivity, which was positively correlated with a reduction of WC and tibialis fat depot 
(Johnston et al., 2010). Robertson et al. suggested that resistant starch improved insulin 
sensitivity via peripheral muscle and adipocytes, but not via hepatic metabolism (Robertson et 
al., 2012). 
  
In contrast to resistant starch, the role of inulin-type fructans on AT metabolism, specifically in 
humans, is not fully explored. Nevertheless, as inulin-type fructans are also fermentable 
carbohydrates, it might be possible that both of these fibres have similar mechanisms in regulating 
body adiposity. Moreover, recent evident showed that adding oligofructose in mice-fed high fat diet 
for four weeks has been shown to suppress overexpression of FFAR2, derived from accumulation of 
adipocyte cells following obesogenic diet (Dewulf et al., 2011). This finding highlighted the role of 
inulin-type fructans in modulating AT metabolism. Studies in rodents showed that supplementing 5% 
fructooligosaccharides for five weeks significantly reduced visceral fat mass although no significant 
difference on body weight or food intake were demonstrated when compared to control group. In 
addition, the beneficial effect of fructooligosaccharides on suppression abdominal fat also lead to 
improved insulin sensitivity (Shinoki and Hara, 2011). The effect of inulin-type fructans on AT 
suppression has been demonstrated by other group. Anastasovska et al. showed that supplementing 
oligofructose-enriched inulin in high fat diet in mice led to significantly reduce total, subcutaneous, 
internal and intrahepatocellular fat depot (Anastasovska et al., 2012).  
 
In humans, Abrams et al. showed that 8 g of oligofructose-enriched inulin supplemented for a 
year as an adjunct supplementation with calcium for pubertal growth in young adolescents 
reduced BMI, BMI z-score and fat mass compared to individuals who were on calcium treatment 
alone (Abrams et al., 2007). However, as the body weight change was not the main study 
outcome, no plasma-related AT and gut hormones were investigated in this study. In another 
study, the authors showed that the effect of 14 g/day oligofructose on reducing body fat and body 
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weight in 16 obese school children and 17 obese women for 12 weeks possibly related to  
significant decreased resistin levels (an adipokine) (Antal et al., 2008). However, no 
investigation on gut hormone release was performed. Interestingly, Parnell and Reimer showed 
that the effect of 21 g/day oligofructose for 12 weeks on reducing body weight was related to 
significant increased AUC plasma PYY, lowered insulin and ghrelin levels. The treatment 
however, did not affect plasma GLP-1 levels and subjective appetite (Parnell and Reimer, 2009). 
 
To our knowledge, Parnell and Reimer is the only study which closely investigated the effect of 
supplementing high dose of fructans on body composition in adults over a long term period (Parnell 
and Reimer, 2009). Moreover, no studies have investigated the role of oligofructose or inulin-type 
fructans on regional and ectopic body fat distribution. Insufficient data on the effects of 
supplementing high dose of oligofructose in human adult has therefore encouraged us to investigate 
the effect of supplementing 30 g/day oligofructose in 22 overweight volunteers for eight weeks 
(including two weeks run-in supplementation period).  
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3.2 Aims and Hypothesis  
 
 
3.2.1 Aims 
The aims of this study were to investigate the role of oligofructose supplementation on body weight, 
total body fat, regional body fat, ectopic fat as well as insulin sensitivity and compare these effects 
with cellulose supplementation. To achieve these objectives, the following parameters were 
measured: 
 Changes in body weight, waist circumference and waist hip ratio (WHR) 
 
 Change in total and regional body fat distribution 
 
 Change in intrahepatocellular and intramyocellular muscle (soleus and tibialis) fat 
 
 Plasma glucose, insulin, lipid, Homeostatic model assessment – Insulin resistance (HOMA-
IR) levels. 
 
 
 
3.2.2 Hypothesis 
It was hypothesized that supplementing 30 g per day oligofructose for six weeks (following two 
weeks run-in period) would reduce body weight, total, regional body fat as well as ectopic adiposity, 
leading to a reduction in insulin and glucose levels, and subsequently decreased insulin resistance. 
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3.3 Material and Methods 
 
 
3.3.1 Materials 
 
3.3.1.1 Volunteers 
Healthy male and female overweight/obese volunteers that participated in this study were the 
same volunteers that involved in the appetite study days, described in Chapter 2. The inclusion 
and exclusion criteria for this study were described in Section 2.3.1.4. 
 
 
3.3.2 Methods 
 
3.3.2.1 Study Design 
This study is a part of a randomised, single-blinded, placebo-controlled study on the effects of 
oligofructose on appetite, gut hormones, body composition and brain activity. The day before 
attending the study day, volunteers were asked to avoid any strenuous physical activity and 
alcohol. They were also required to eat standardized evening meal before the start of fasting at 9 
pm for 12 hours until the study day. On the study day, volunteers attended MRC Clinical 
Sciences Imaging Unit, Hammersmith Hospital at 9 am for whole body composition MRI scans. 
These were acquired on the baseline (day 0) and post-supplementation study day. Each study 
visit lasted three hours. The scanning procedures and images analysis were performed by the 
Metabolic and Molecular Imaging Research group; Prof. Jimmy Bell, Dr. Louise Thomas and 
Mrs. Julie Filtzpatrick. 
 
Upon arrival, volunteers were asked to complete a metal check form to ensure they were free 
from any metal prior to the scanning procedure. They were required to change into scrubs before 
anthropometric measurements were recorded. Volunteers then had their whole body MRI 
scanning for total and regional fat quantification whilst liver and muscle fat were measured using 
MR spectroscopy performed on a 1.5 Tesla Philips Achieva MR scanner (Phillips Medical 
Systems, Best, the Netherlands) in a period of one hour. All of these measurements are described 
in the next sections. 
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Upon scanning completion, 30 ml fasting blood samples for glucose, insulin and lipid profile, 
were withdrawn from volunteers. VAS and blood pressure were assessed at 20 minute before 
scanning and at 20 minutes post scanning. Volunteers were discharged from the unit at 11 am.  
 
 
 
 
 
 
   
 
 
 
 
 
 
3.3.2.2 Anthropometric Measurements 
Body weight, waist and hip circumference were measured prior to the scanning. Body weight 
was measured in volunteers lightly clothed in scrubs and barefoot, to the nearest 0.1 kg whilst 
height was measured to the nearest 0.1 cm with a Harpenden stadiometer (Holtain Ltd, 
Crosswell, UK) only on the first visit. Waist and hip circumference were quantified using a tape 
measure based on the WHO recommendation in which the measurement was performed at 
midpoint between the distal border of the lower rib and the superior border of the iliac crest 
(Lean et al., 1996). Hip circumference was measured at the level of the largest circumference 
around the hip. From these measurements, BMI and WHR were calculated. 
 
 
3.3.2.3 Body Fat Distribution Measurements 
 
3.3.2.3.1 Magnetic Resonance Body Fat Measurements 
Total body and regional fat masses were quantified using 1.5 Tesla Philips Achiva MRI scanner 
(Phillips, Best, The Netherlands) by using a rapid T1-weighted spin-echo sequence imaging as 
described elsewhere (Thomas et al., 2012). Volunteers were asked to lie in a prone position on 
the scanning table with arms straight above their head before they were moved into the magnet 
for the scanning. Volunteers were scanned from fingertips to toes by, acquiring 10-mm thick 
Figure 3.1 Schematic diagram for MRI total body fat scan study day. 
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transverse images with 10 mm gaps between slices. The total and regional fat masses were 
quantified in litres (Lean et al., 1996) and the images were analyzed using SliceOmatic 
(Tomovision, Montreal, Quebec, Canada).  
 
In measuring body fat distribution (Thomas et al., 1998; Thomas et al., 2012), the following AT 
depots were quantified: 
 
1- Total adipose tissue = Subcutaneous adipose tissue (SAT) + total internal adipose tissue (IAT) 
2- Subcutaneous adipose tissue = Abdominal subcutaneous adipose tissue (ASAT) + non-
abdominal subcutaneous adipose tissue (non-ASAT) 
3- Total internal adipose tissue = intra-abdominal adipose tissue (IAAT) + non-intra-abdominal 
adipose tissue (non-IAAT)  
4- Total trunk 
5- Abdominal subcutaneous adipose tissue (ASAT) 
6- Intra-abdominal adipose tissue (IAAT) 
 
3.3.2.3.2 Magnetic Resonance Spectroscopy (MRS) of the Liver  
Following whole body fat measurement, 
1
H MR spectra for liver was obtained from the right 
lobe of the liver using a PRESS sequence without water saturation (repetition time 1,500 ms, 
echo time 135 ms) and with 128 signal averages. Transverse images were used in order to ensure 
accurate positioning of the (20 x 20 x 20 mm) voxel in an area in the liver avoiding blood 
vessels, the gall bladder and fatty tissue. Spectra were analysed using AMARES (Naressi et al., 
2001; Vanhamme et al., 1997). Peak areas for all resonances were obtained and intra-
hepatocellular lipid resonances measured relative to water resonance after correcting for T1 and 
T2 (Thomas et al., 2005). 
 
 
3.3.2.3.3 Magnetic Resonance Spectroscopy (MRS) of the Muscle 
Subsequently after intrahepatocellular lipid measurement, spectra of intramyocellular lipid were 
obtained from the soleus and tibialis muscles using 
1
H MR as previously described (Thomas et 
al., 2005). Spectra were obtained from 20 x 20 x 20 mm voxels were placed in the soleus and 
tibialis muscles of the left calf and avoiding apparent streaky fat and main blood vessels using a 
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PRESS sequence (repetition time 1,500 ms, echo time 135 ms) and with 128 signal averages. 
Following the acquisition, intramyocellular were measured with reference to total muscle 
creatine signals after correcting for T1 and T2 as previously described (Rico-Sanz et al., 1999). 
 
 
3.3.2.4 Biochemical Analysis 
 
3.3.2.4.1 Fasting Glucose, Insulin and Lipid Profile Analysis 
Blood samples for glucose, lipid profile and insulin levels were collected at 120 minutes after the 
scanning. The samples were analysed in the Department of Clinical Biochemistry, Hammersmith 
Hospital using either an Abbott Architect ci8200 analyser (Abbott Diagnostics, Maidenhead, 
UK) or an Axsym analyser (Abbott Diagnostics, Maidenhead, UK) respectively. The intra-assay 
coefficients of variation of these analyses were between 1.0 -5.0% . 
 
 
3.3.2.5 HOMA-Insulin Resistance Assessment 
 
The level of insulin resistance was calculated based on the HOMA model (Matthews et al., 
1985): 
 
HOMA-IR = Fasting insulin levels (µU/L) x fasting glucose levels (mmol/L) 
            22.5 
 
 
3.3.2.6 HOMA-Pancreatic B-cell Function Assessment 
 
HOMA-B =         20  x   fasting insulin levels (µU/L) 
        Fasting glucose levels (mmol/L) - 3.5 
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3.3.2.7 Statistical Analysis 
Data are presented as mean ± SEM. Data were checked for Gaussian distribution using the 
D'Agostino & Pearson omnibus normality test prior the analysis. Non-normally distributed 
variables were logarithmically transformed, and non parametric tests were used if normality was 
not obtained. An ANCOVA with baseline data (day 0), age and gender as covariates were used 
to determine the effect between oligofructose and cellulose treatments. Effects of treatment 
within the groups (baseline visit [day 0] vs. post-supplementation [day 56]) were compared using 
two-tailed paired t-test if normally distributed and Wilcoxon signed-ranks test if the data is not 
normally distributed. A P value of < 0.05 was considered significant. Statistical analysis was 
performed on Graph Prism 5 (GraphPad Software, Inc., La Jolla, USA) and ANCOVA analysis 
was performed using SPSS 20.0 (SPSS Inc. Chicago, IL, USA). 
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3.4 Results 
 
3.4.1 Volunteers Characteristics 
Twenty two, [oligofructose=12 (male=4, female=8) and cellulose=10 (male=2, female=8)] healthy 
overweight and obese volunteers participated in this study. The mean ages were 36.5 ± 2.2 years 
(range 21 – 49 years) in the oligofructose group and 28.7 ± 2.3 years (range 20 – 47 years) in the 
cellulose group. The mean BMI were 29.7 ± 1.0 kg/m
2
 (range 25.0 – 34.6 kg/m2) in the oligofructose 
group and  31.1 ± 1.1 kg/m
2 
(range 26.0 – 35.0 kg/m2) in the cellulose group. 
 
 
3.4.2 Anthropometric Measurements 
 
 
3.4.2.1 Body Weight and Body Mass Index 
Supplementing oligofructose and cellulose into volunteers’ diet for eight weeks had no 
significant difference on body weight (P=0.743) and BMI (P=0.637) between the groups. No 
significant difference was also found within the groups, body weight (oligofructose: P=0.392 and 
cellulose:P=0.474) [Figure 3.2 (i)] and BMI (oligofructose:P=0.321 and cellulose:P=0.505) 
[Figure 3.2 (ii)].  
 
i)      ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Body weight (i) and BMI (kg/m
2
) (ii) in oligofructose and cellulose groups. The 
supplementations were taken thrice daily during meal intake (10 g each time) for six weeks following two weeks 
run-in supplementation period. Assessment was performed at baseline and 8 weeks post-supplementation 
period. Data is expressed as mean ± SEM. oligofructose (n=12), cellulose (n=10). 
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3.4.2.2 Waist Circumference (WC) and Waist Hip Ratio 
Adding oligofructose and cellulose into volunteers’ diet showed no significant difference on WC 
(P=0.920) and WHR (P=0.257) between the groups and also within each groups, WC 
(oligofructose:P=0.281 and cellulose:P=0.254) [Figure 3.3 (i)] and WHR (oligofructose:P=0.065 
and cellulose:P=0.177) [Figure 3.3 (ii)].  
 
i)       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Waist circumference (cm) (i) and WHR (ii) in oligofructose and cellulose groups. The 
supplementations were taken thrice daily during meal intake (10 g each time) for six weeks following two 
weeks run-in supplementation period. Assessment was performed at baseline and 8 weeks post-
supplementation period. Data is expressed as mean ± SEM. oligofructose (n=12), cellulose (n=10). 
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3.4.3 Body Composition Measurements 
 
3.4.3.1 Total Body Fat Distribution 
Supplementing the diet with oligofructose or cellulose for eight weeks showed no significant 
effect between oligofructose and cellulose group in reducing total AT (P=0.858) and 
subcutaneous AT (P=0.914) contents. Similarly, within group analysis demonstrated that both 
oligofructose and cellulose had no significant trend in reducing total AT (oligofructose:P=0.178 
and cellulose:P=0.700) and subcutaneous AT (oligofructose:P=0.566 and cellulose:P=0.592) 
[Figure 3.4 (i) - (ii)]. Total AT distribution demonstrates that male volunteers in the 
oligofructose group have high internal AT levels compared with female volunteers (Figure 3.4 
(iii) and (iv). Clear separation between male and female volunteers in both groups can also be 
seen in IAT:SAT ratio. Male volunteers were shown to have high IAT:SAT ratio compared with 
female volunteers (Figure 3.4 (v) and (vi)). 
 
 
 
(i)                                                                       (ii) 
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(iii)                                                                           (iv) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v)                                                                             vi) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Subcutaneous AT (I) (i), total AT (I) (ii), internal AT of oligofructose (I) (iii), internal AT of 
cellulose (l) (iv), IAT:SAT oligofructose (v) and  IAT:SAT cellulose (vi) in oligofructose and cellulose 
groups. The supplementations were taken thrice daily during meal intake (10 g each time) for six weeks 
following two weeks run-in supplementation period. Assessment was performed at baseline and 8 weeks post-
supplementation period. Data is expressed as mean ± SEM. oligofructose (n=12), cellulose (n=10). 
Abbreviations: AT = adipose tissue, SAT = Subcutaneous adipose tissue, IAT = Internal adipose tissue. 
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3.4.3.2 Abdominal Body Fat Distribution 
Both of the supplements had no significant effect in reducing ASAT within the groups 
(oligofructose:P=0.923 and cellulose:P=0.114) or between the treatments  (P=0.194). Similarly, 
no significant effect in total trunk was demonstrated (P=0.717) [Figure 3.5 (i) – (ii)]. 
Oligofructose was shown to significantly increase IAAT when compared to baseline (P=0.043). 
This significant effect might be influenced by increased IAAT in two male volunteers in this 
group. No significant effect was demonstrated in the cellulose group (P=0.869) (Figure (iii) and 
(iv)). Surprisingly, both groups showed that male volunteers (oligofructose = 4 and cellulose = 2) 
have high IAAT: ASAT ratio compared with female volunteers [Figure 3.5 (v) and (vi)].    
 
(i)                                                                    (ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii)                                                                                 vi) 
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v)                                                                              vi) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Total trunk (I) (i), ASAT (I) (ii), individual IAAT oligofructose (I) (iii) individual IAAT cellulose 
(iv) IAAT:SAAT oligofructose (v) and IAAT:SAAT cellulose (vi) in oligofructose and cellulose groups. 
The supplementations were taken thrice daily during meal intake (10 g each time) for six weeks following two 
weeks run-in supplementation period. Assessment was performed at baseline and 8 weeks post-
supplementation period. Data is expressed as mean ± SEM. oligofructose (n=12), cellulose (n=10). *P=0.043 
oligofructose vs. baseline. Abbreviations: SAAT = Abdominal subcutaneous adipose tissue, IAAT = intra-
abdominal adipose tissue. 
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3.4.3.3 Intrahepatocellular Lipids  
Intrahepatocellular levels between volunteers demonstrated a large inter-variation, ranging from 
0 to 43.18 litres. Three volunteers in the oligofructose group had high intrahepatocellular lipid 
levels compared to other volunteers [Figure 3.6 (i) and (ii)]. This high inter-individual variation 
potentially may have influenced the mean value in the oligofructose group and resulted in no 
significant change in log transformed intrahepatocellular oligofructose compared to cellulose 
(P=0.814). There was no significant effect demonstrated in the oligofructose group (P=0.176) 
and cellulose treatment (P=0.343) although the mean levels of post supplementation in the 
oligofructose group were reduced compared to baseline, mean ± SEM (baseline:7.2 ± 3.4 and 
oligofructose:6.4 ± 3.9) and (baseline:0.9 ± 0.3 and cellulose:0.9 ± 0.3) [Figure 3.6 (i) and (ii)]. 
 
(i)                                                                  (ii) 
 
 
 
 
 
 
 
 
 
 
 
(iii)                                                                             (iv) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Intrahepatocellular fat oligofructose (i), cellulose (ii), mean (iii) and delta change 
intrahepatocellular (iv) in oligofructose and cellulose groups. The supplementations were taken thrice 
daily during meal intake (10 g each time) for six weeks following two weeks run-in supplementation period. 
Assessment was performed at baseline and 8 weeks post-supplementation period. Data is expressed as 
mean ± SEM. oligofructose (n=12), cellulose (n=10). 
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3.4.3.4 Soleus and Tibialis Intramyocellular lipids  
Including oligofructose or cellulose supplementation in the diet for eight weeks showed no 
significant difference on log transformed soleus intramyocellular compared to baseline 
(oligofructose:P=0.340 and cellulose:P=0.667) [Figure 3.7 (i)]. No significant effect was also 
demonstrated between oligofructose and cellulose group (P=0.883). However, some volunteers in the 
cellulose group were demonstrated to have high variation of soleus lipid. Therefore, this may have 
influenced the lowering mean values of soleus intramyocellular in post-supplementation data of 
cellulose group, mean ± SEM; 19.3 ± 8.9 (baseline) and 15.5 ± 4.9 (post-supplementation) compared 
to mean values in the oligofructose group, mean ± SEM; 14.1 ± 3.6 (baseline) and 14. 9 ± 3.3 (post-
supplementation) No significant difference was demonstrated in tibialis intramyocellular analysis 
between the groups (P=0.366) [Figure 3.7 (ii)].  
 
 
(i)                                                                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 Soleus intramyocellular (i) and tibialis intramyocellular (ii) lipid levels in oligofructose and 
cellulose groups. The supplementations were taken thrice daily during meal intake (10 g each time) for six 
weeks following two weeks run-in supplementation period. Assessment was performed at baseline and 8 
weeks post-supplementation period. Data is expressed as mean ± SEM. oligofructose (n=12), cellulose 
(n=10). 
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3.4.4 Biochemical Analysis 
 
3.4.4.1 Fasting Plasma Glucose and Insulin Levels 
Figure 3.8 demonstrates fasting plasma glucose (i) and plasma insulin (ii) levels. Intake of 
oligofructose supplementation showed no significant effect on both fasting plasma glucose levels 
(P=0.986) and fasting plasma insulin levels (P=0.770) between the groups. Only 11 volunteers 
from the oligofructose group were involved in this analysis as data from one volunteer in the 
oligofructose was excluded due to a haemolysed sample.    
i)                                                                      
 
 
 
 
 
 
 
 
 
 
 
                              ii) 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Plasma glucose (mmol/l) (i) and plasma insulin levels (mU/L) (ii) in oligofructose and 
cellulose groups. The supplementations were taken thrice daily during meal intake (10 g each time) for six 
weeks following two weeks run-in supplementation period. Assessment was performed at baseline and 8 
weeks post-supplementation period. Data is expressed as mean ± SEM. oligofructose (n=12), cellulose 
(n=10). 
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3.4.4.2 HOMA-IR and HOMA-B 
Figure 3.9 demonstrates HOMA-IR (i) and HOMA-B (ii) levels. Adding oligofructose into 
volunteers’ diet showed a trend toward higher HOMA-IR (P=0.058) but no significant effect on 
HOMA-B (P=0.992) levels [Figure 3.10 (i) and (ii)] was found. However, cellulose 
supplementation significantly increased HOMA-IR levels compared to baseline (P=0.049) 
[Figure 3.10 (i)]. However, the effect was not significant between these groups, (P=0.880). No 
significant effect was found in HOMA-B levels, (P=0.861) [Figure 3.9 (ii)].  
 
i)        
 
 
 
 
 
 
 
 
 
 
 
 
                              ii) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 HOMA-IR (i) and HOMA-B (ii) levels in oligofructose and cellulose groups. The 
supplementations were taken thrice daily during meal intake (10 g each time) for six weeks following two 
weeks run-in supplementation period. Assessment was performed at baseline and 8 weeks post-
supplementation period. Data is expressed as mean ± SEM. oligofructose (n=12), cellulose (n=10). *P=0.049 
cellulose vs. baseline. *P<0.05 cellulose vs. control. 
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3.4.4.3 Lipid Profile 
Figure 3.10 demonstrates plasma lipid profile levels in delta change. No significant difference 
was demonstrated in cholesterol levels between oligofructose and cellulose group (P=0.746) 
(0.02 ± 0.12 mmol/L and 4.65 ± 0.89 mmol/L respectively). In contrast, intake of oligofructose 
appeared to reduce triglycerides, HDL and LDL compared to the cellulose group. However, the 
effect was not significant (P=0.391, P=0.847 and P=0.671 respectively). 
 
 
 
 
Figure 3.10 Delta change plasma lipid profile levels in oligofructose and cellulose groups. The 
supplementations were taken thrice daily during meal intake (10 g each time) for six weeks following two 
weeks run-in supplementation period. Assessment was performed at baseline and 8 weeks post-
supplementation period. Data is expressed as mean ± SEM. oligofructose (n=12), cellulose (n=10). 
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3.5 Discussion 
This chapter discusses the effect of supplementing 30 g/day oligofructose into 22 volunteers’ diet 
for six weeks following two weeks run-in supplementation period on body fat distribution (total, 
abdominal and ectopic body fat distribution), insulin resistance and its related plasma 
metabolites compared to cellulose supplementation in a randomised, single-blinded, placebo-
controlled study. The results of this study did not support the hypothesis that oligofructose would 
have beneficial effects on body weight, body adiposity and plasma metabolites. In this study, no 
significant effect on reducing body weight, BMI, WC, WHR, total body fat (total AT, 
subcutaneous AT, internal AT), regional body fat (ASAT and IAAT) and ectopic fat 
(intrahepatocellular, soleus and tibialis intramyocellular lipid) were demonstrated. This was 
surprising as evidence from rodent studies showed positive effects of fermentable carbohydrates 
on reducing total, intra-abdominal, subcutaneous, and intrahepatocellular AT (Shinoki and Hara, 
2011; Anastasovska et al., 2012). 
 
However, rodent studies typically used high dose that humans are unable to tolerate. Therefore, it 
is unlikely to replicate these findings in humans. The effect on suppressing body weight in 
rodents usually demonstrated following addition of 10% of their total dietary intake with 
fermentable carbohydrates (Cani et al., 2005b; Johnson and Gee, 1986; Peters et al., 2011). 
However, this effect was only demonstrated when fermentable carbohydrates are added to high 
fat diets (Anastasovska et al., 2012; Cani et al., 2005b; Delzenne et al., 2007) as the effect was 
abolished when fermentable carbohydrates are included in a normal diet (Anastasovska et al., 
2012; Cani et al., 2005b). In contrast, 30 g/day oligofructose supplemented in the volunteers’ 
diet in this study corresponds to ≈ 5% of rodents’ total dietary intake (Jenkins et al., 1999), half 
the dose used in rodent studies. There is evidence to suggest that humans are only able to tolerate 
a maximum dose of 30 g/day. Beyond than that amount, intake of fermentable carbohydrates are 
highly correlated with gastrointestinal side effects (Briet et al., 1995; Carabin and Flamm, 1999; 
Marteau and Flourie, 2001). Therefore, it is not possible to implement the same dose from 
rodents study to humans’ diet. 
 
In humans, current evidence is insufficient to support the role of oligofructose on body weight 
maintenance. Until now, only a few publications have shown that oligofructose significantly 
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reduces body weight (Abrams et al., 2007; Antal et al., 2008; Parnell and Reimer, 2009). Parnell 
and Reimer showed that 21 g/day oligofructose for 12 weeks significantly reduced 1.03 ± 0.43 
kg body weight in 48 healthy overweight and obese volunteers. In another study, Antal et al. 
demonstrated that 14 g/day oligofructose in combination with a hypocaloric diet of 33 obese 
young adolescents and women also significantly decreased BMI and percentage of body fat.  
 
There are a number of factors that have resulted in discrepancy between the current study and 
these studies. Whilst these studies comparing the effect of oligofructose with maltodextrin as 
their study control, this study comparing intake of oligofructose with cellulose, a non-
fermentable fibre. However, 13g maltodextrin was also added to 30 g cellulose in order to 
provide equal caloric content with oligofructose. Maltodextrin is a digestible carbohydrate with 
α-1-4 linkages and a glycaemic index of 110 (Foster-Powell et al., 2002). Meanwhile, 
oligofructose is a fermentable carbohydrate and not digested in the small intestine due to the lack 
of α- linkages, which subsequently transported to the large bowel for colonic fermentation. 
Unlike maltodextrin, cellulose has similar digestive properties with oligofructose. As a fibre, it is 
also able to escape small intestinal digestion and transported to the large intestine for stool 
bulking. Furthermore, cellulose is also fermented in the large intestine (Topping and Clifton, 
2001), but to a lesser extent compared to oligofructose. Therefore, physiological properties of 
both treatments in the large intestine able to promote satiety signals at different part of the gut, 
thus this potentially the reason why there was no significant effect on body weight and body fat 
between the treatments. However, this hypothesis was not proven as the post-supplementation 
body weight and body fat were not significantly different compared to baseline (day 0) 
measurement.  
 
Currently, studies comparing the effect of oligofructose with non-fermentable carbohydrates are 
lacking. Apart from this study, Howarth et al. was the only study in humans which has 
investigated the role of fermentable carbohydrate on body weight with a non-fermentable 
carbohydrate. Similarly, the authors also demonstrated no significant difference between 
fermentable carbohydrates, pectin and β-glucan with a non-fermentable carbohydrate, cellulose 
on appetite, energy intake and body weight in 11 healthy adults with BMI 20.0 – 34.4 kg/m2 for 
three weeks. The lack of effect of fermentable carbohydrate in this study could possibly be due 
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to short term period (three weeks). Thus, the findings of this study cannot be used to evaluate the 
role of fermentable carbohydrate on promoting body weight loss (Howarth et al., 2001).   
 
However, increasing the study period from three weeks to eight weeks in the present study also 
showed no significant effect on modulating body weight and body fat. It seemed that eight weeks 
supplementation period may not long enough for oligofructose to exert its effect on body weight 
loss. To date, there is still no consensus to suggest the minimum duration needed for fermentable 
carbohydrates to exert its effect on reducing body weight. Nevertheless, Parnell and Reimer and 
Antal et al. showed that body weight can be suppressed after 12 weeks supplementation (Antal et 
al., 2008; Parnell and Reimer, 2009). In contrast, 12 weeks supplementation of 40 g/day resistant 
starch showed no significant effect on reducing body weight, abdominal, liver and muscle fat 
after for in insulin resistance volunteers. However, the study found a correlation between 
reduced WC as well as tibialis muscle fat with insulin sensitivity following the intervention 
(Johnston et al., 2010). However, volunteers in Johnston et al. were patients with metabolic 
syndrome whilst the volunteers in this study were relatively young healthy overweight 
volunteers, thus this might have different effect between the groups. Interestingly, a year 
supplementation with 8 g/day oligofructose with calcium in 97 young school children was also 
showed to suppress body weight gain during their pubertal growth although the study was not 
initially designed to evaluate body weight change (Abrams et al., 2007). Based on the findings 
from these studies, it is postulated that fermentable carbohydrates require more than 12 weeks to 
modulate body weight and AT metabolism.  
  
Additionally, it is also possible that the lack of effect of oligofructose on body weight in the 
present study is attributed to the small sample size. Whilst the effect of oligofructose on body 
weight in the current study were performed in 22 volunteers, the effect of oligofructose on body 
weight in the previous studies were demonstrated in 33 volunteers (Antal et al., 2008), 48 
volunteers (Parnell and Reimer, 2009) and 97 volunteers (Abrams et al., 2007). Therefore, it is 
not impossible that the current study may have low statistical power to detect a significant 
difference between the treatments.  
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Despite of the study showed no significant change in body weight and body adiposity, the result 
reveals that using MRI for assessing body adiposity showed large inter-individual variations, 
particularly in male volunteers in the intrahepatocellular fat, internal AT, IAAT, IAT:SAT and 
IAAT:ASAT ratio although there were known as healthy volunteers. It is widely known that men 
and women have different body fat distribution, with men normally have fat deposition around 
mid and upper body (central adiposity) and women are more associated with high fat distribution 
in the lower body area, particularly in the hip and thigh areas. Based on the different fat 
composition between gender, therefore, it is wisely to separate the analysis. However, because of 
limited number of male volunteers in this study (oligofructose = 4 and cellulose = 2), it is 
impossible to show gender effects on body adiposity on separate analysis. Nevertheless, 
separation between the genders within each group could still be seen in the aforementioned 
regions, particularly in IAT:SAT and IAAT:ASAT ratio (Figure 3.4 (v) - (vi) and Figure 3.5 (v) 
– (vi)), i.e. all males in the oligofructose and cellulose group have relatively high body fat 
distribution compared to female volunteers. It might be possible that the gender effect could be 
the confounding factor in determining the effect of oligofructose on body adiposity. Perhaps the 
effect of oligofructose in reducing body fat would be better explained if the volunteers are 
divided into each gender. The role of gender in modulating intra-abdominal fat storage has been 
discussed more details in (Thomas et al., 2012). 
 
In dietary intervention studies, low compliance also can reduce the efficacy of 
supplement/treatment. In the current study, although four volunteers in the oligofructose group 
reduced compliance to 60 – 77% due to mild gastrointestinal side effects in the first two weeks 
following increased supplementation from 20 g/day to 30 g/day, this does not affect group mean 
compliance (Section 2.4.1.2). Both treatment groups in the current study were demonstrated to 
have compliance with ≈ 90% (oligofructose = 89.8 ± 13.1% and cellulose 89.7 ± 12.8%). 
Therefore, the non-significant effect of oligofructose on body adiposity is not related to low 
compliance. Another possible explanation for no effect on body weight can be related to changes 
in energy expenditure. In this study, volunteers were advised to maintain their usual physical 
activity levels throughout the study period and avoided any extreme physical activities 
programme in order to prevent any bias outcome. As the physical activities were not measured 
during the intervention period, hence it is unconfirmed whether this has changed. However, as 
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body weight and adiposity were not changed during the intervention period, it is most likely that 
no significant modification on physical activities have been made.  
 
Evidence from previous studies showed that intake of inulin-type fructans led to improved lipid 
profile, reduced glucose and insulin levels as well as insulin sensitivity in both rodent and human 
studies (Beylot, 2005; Daubioul et al., 2005; Robertson et al., 2003; Robertson et al., 2005). 
Interestingly, a recent investigation by Johnston et al. demonstrated improved insulin sensitivity 
following intake of 40 g/day resistant starch in 12 weeks of metabolic syndrome volunteers and 
associated with change in WC, tibialis fat depot as well as IAAT:ASAT ratio (Johnston et al., 
2010). Contrary to these results, adding oligofructose into volunteers’ diet in this study did not 
have any significant effect on lipid profile, plasma glucose and insulin levels as well as insulin 
resistance markers, HOMA-IR and HOMA-B. However, these results were predictable as no 
significant modulation on body weight and body adiposity were found in this study.  
 
Although the exact mechanism is still unclear, it is suggested that fermentable carbohydrates 
improved insulin sensitivity via its end products, SCFAs (Robertson et al., 2003; Robertson et 
al., 2005). SCFAs, which have been delivered to the periphery following colonic fermentation 
have been shown to reduce lipolysis (Crouse et al., 1968; Robertson et al., 2005) in adipose 
tissue thus result in decrease circulating non-esterified fatty acid levels in the periphery (Venter 
and Vorster, 1989; Wolever et al., 1989). Interestingly, Robertson et al. in their very recent study 
demonstrated that intake of 40 g/day resistant starch for 8 weeks in insulin resistance volunteers 
significantly reduced HOMA-IR, which is a marker for insulin sensitivity. The authors suggested 
that resistant starch improved insulin sensitivity by modulating adipose tissue and muscle fat 
depot but not through hepatic metabolism. This suggestion is made due to the significant 
elevation of the genes expression of lipase, lipoprotein lipase and perilipin, enzymes that 
involved in regulating adipose tissue differentiation (Robertson et al., 2012).  
 
In conclusion, the results of this study showed that supplementing 30 g/day oligofructose for six 
weeks following two weeks run-in supplementation period, had no significant effect on 
modulating AT metabolism, glucose, insulin and lipid profile levels in healthy, overweight and 
obese volunteers when compared with cellulose supplementation. Based on the promising result 
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demonstrated by other fermentable carbohydrates studies which showed that 12 weeks are 
needed to modulate AT metabolism, therefore it might be possible that duration of > 12 weeks 
are needed to alter adiposity. Further work is required to ascertain whether these findings can be 
achieved using oligofructose supplementation.  
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Chapter 4 
 
 
 
The Effect of Oligofructose 
on Brain Reward Regions 
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4 Background 
 
4.1 INTRODUCTION 
It is generally accepted that appetite and feeding behaviour are controlled by two complex 
systems which are the homeostatic and hedonic networks. The homeostatic system is centred 
around the hypothalamus, where peripheral signals about the body’s energy status are assembled 
and subsequently regulated appetite and energy expenditure. On the other hand, hedonic network 
is a higher network of mesolimbic structures, where the rewarding properties of food are 
encoded. Hedonic or ‘non-homeostatic’ pathways are influenced by external factors such as food 
cues (sensory properties and palatability), emotional, learning, cognitive and environmental 
influences (Berthoud, 2011). Although traditionally it has been thought that obesity is caused by 
the disruption of the homeostatic network per se, modern functional MRI has led to a re-
evaluation of hedonic network that also plays a significant role in causing obesity. In addition, 
fMRI also has highlighted the importance of the mesolimbic reward system in humans. The 
latest evidence now suggests that these homeostatic and non-homeostatic processes do not work 
in isolation, but have a concerted role in the control of feeding (Taghva et al., 2012). 
 
In functional neuroimaging studies, positron emission tomography (PET), single photon 
emission computed tomography (SPECT), fMRI and manganese-enhanced MRI (MEMRI) have 
been used to investigate changes in brain activation with factors that modulate feeding 
behaviour. However, PET, SPECT and MEMRI pose several disadvantages that limit its 
application as an assessment tool in humans. Firstly, PET and SPECT require the intravenous 
use of radioactive biological tracers. Secondly, these tracers have to be produced in a specific 
device known as a cyclotron, an expensive and high maintenance machine. MEMRI uses Mn
2+
 
ions as a contrast medium (manganese ions are preferentially taken up into activated neurones), 
so its use is strictly limited in humans because of toxicity. fMRI has been known as the best 
technique for performing repeated measures of brain activity because of its lack of invasiveness 
and no exposure to ionising radiation.  
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4.1.1 functional Magnetic Resonance Imaging 
fMRI is an adaptation of the structural MRI scanning technique, to create images of brain 
regions related to localised neuronal activities following stimulation of cognitive, sensory and 
motor tasks (Huettel et al., 2009) (principle of MRI is discussed in section 1.8.1.3). fMRI and 
MRI share the same technique, nuclear magnetic resonance to image nuclei of atoms in the body. 
However, although both of the techniques were built on the same principle, MRI is mainly used 
to image tissue structures whilst fMRI is used to evaluate the function of localised brain areas. 
The major fMRI paradigm in use today localises neuronal activity in response to a stimulus, by 
measuring the change in blood flow to that region (Huettel et al., 2009; Kristensen et al., 2009).  
 
 
4.1.1.1 Blood-Oxygenation-Level-Dependent fMRI 
In recent years, BOLD-fMRI has been widely used as an assessment tool in evaluating brain 
activity in appetite-related neuroimaging studies. BOLD fMRI applies an imaging paradigm 
which detects changes in localised blood flow. It is based on the fact that oxygenated and 
deoxygenated bloods have differential effects on the localised magnetic field. When brain tissue 
(collections of neurones) is activated or stimulated with sensory, motor or cognitive stimulation, 
it requires more oxygen supply than normal, which consequently increases blood flows to that 
area. However, the physiological response always provides a greater increase in blood flow than 
is actually required. As a result, there is an increase in the ratio between oxygenated and 
deoxygenated blood in the activated region. Deoxyhaemoglobin is paramagnetic. It creates local 
field inhomogeneities which result in a quicker decay of the T2 signal. Thus, in activated brain 
areas, where the level of deoxyhaemoglobin is relatively lower (because of the physiological 
overshoot in blood supply greater than the local metabolic demand), there is greater MRI signal 
on a T2-weighted protocol (Huettel et al., 2009).  
 
 
4.1.2 fMRI Studies and Appetite Control 
The main objective in fMRI appetite research is to investigate brain activity that is associated 
with cognition, motivation and behaviour to stimulate or terminate the eating process. This can 
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be achieved via several methods including whole brain exploration, resting state scans or 
investigation in pre-selected regions of interest (ROI) brain region analysis, which is the most 
common method used in fMRI appetite-related experiments. ROI analysis is an approach in 
which the signals are extracted from specific brain regions that is pre-determined prior the 
analysis. It is preferably chosen for fMRI studies potentially due to its high chances to detect 
statistically different result in comparison with whole-brain analysis. Nevertheless, choosing 
ROI analysis also can increase chances of missing significant signals from other excited brain 
areas that were excluded from view (De Silva et al., 2012). 
 
In fMRI, stimulations including olfactory, gustatory or visual images of food are typically 
studied either via block designs or event-related designs. In block designs, two or more 
alternating sets of stimuli are presented to volunteers in separate runs whilst event-related 
designs presents stimuli as individual events in a mixed, pseudo-randomised order, hence 
individual evaluation on each single stimuli can be performed. In appetite studies, the most 
common paradigm used are visual food cues. It is usually presented in groups such as high 
calorie and low calorie, or high palatability and low palatability, and the effect/changes in brain 
activation are typically investigated in two different nutritional states (i.e. fasted vs. fed) or 
intervention (i.e. before vs. after intake of tested meals or gut hormone infusion).  
 
By using visual food images in BOLD-fMRI experiments, it is now known that activation of 
brain regions within reward systems (i.e. NAc, amygdala, insula, OFC and etc.) is highly related 
to the nutritional state, most notably in the fasting state. LaBar et al. was among the earliest 
group to investigate the effect of viewing food pictures vs. non-food pictures on amygdala and 
corticolimbic system during fasted and fed conditions. They found that the amygdala, 
parahippocampal gyrus and fusiform gyrus were highly activated during the hunger state (LaBar 
et al., 2001). Since then, other brain areas have also been shown to be activated during hunger 
condition, such as the ACC, superior temporal gyrus, insula, OFC, striatum, and the dorsolateral 
prefrontal cortex (Schur et al., 2009; Goldstone et al., 2009; Fuhrer et al., 2008; St-Onge et al., 
2005). Interestingly, increased activation in the amygdala, ventrial striatum, insula and medial 
OFC during the fasting state was shown to be blunted when the experiments were repeated in the 
fed state/satiety condition (Goldstone et al., 2009; Fuhrer et al., 2008; LaBar et al., 2001; Farooqi 
et al., 2007).  
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Most notably, viewing high calorie food images during fasted state was shown to induce greater 
activation in several brain regions including the insula, ventral striatum, amygdala, medial OFC, 
medial prefrontal cortex and the dorsolateral prefrontal cortex compared to when viewing low 
calorie food images (Goldstone et al., 2009; Killgore et al., 2003; Siep et al., 2009). In contrast, 
viewing low calorie foods has been shown to attenuate activation in the aforementioned ROI 
areas (even in the fasted state), but it is also suggested to induce greater activation in the 
somatosensory areas possibly due to lesser cephalic phase signals by classical conditioning to 
less appealing food images (Killgore et al., 2003). 
 
However, these observations were performed in healthy lean volunteers. Therefore, it is also of 
interest to investigate the neuronal responses in obese/overweight subjects and whether these 
subjects respond differently to normal lean individuals in response to food cues. Rothemund et 
al. investigated the effect of exposing obese women (BMI>31) and lean women (BMI 19-24) to 
food images (high calorie and low calorie food pictures) and non-food images. They found that 
obese women had augmented activation in the caudate/putamen, anterior insula, claustrum, 
posterior cingulate, hippocampus and lateral OFC following viewing high calorie food pictures 
vs. non-food pictures (Rothemund et al., 2007) during the fasted state. In agreement with this, 
heightened activation of the NAc / ventral striatum, medial and lateral OFC, insula, amygdala 
and arterior cingulate cortex following viewing of high calorie foods vs. non-food images were 
also demonstrated in 12 fasted obese and 12 lean women (Stoeckel et al., 2008). Based on these 
studies, it has been suggested that a hyper-reactive reward system in response to high calorie 
food cues contributes to the pathogenesis of obesity. 
 
Unexpectedly, evidence suggests that brain activation in obese volunteers’ does not just increase 
during fasting/premeal condition, but also during satiety/postmeal. Martin et al. showed that 
when viewing food images, obese volunteers had augmented activation in the ACC (premeal) 
and medial prefrontal cortex before and after intake of 500 kcal meal compared with healthy lean 
volunteers (Martin et al., 2010). This observation was also supported by Dimitropoulos et al. In 
this study, increased activation was demonstrated in the anterior prefrontal area following 
viewing food stimuli when fasted. In contrast, eating has led to heightened activation in frontal, 
temporal and limbic areas (Dimitropoulos et al., 2012).  
  
157 
 
An interesting study of women who had increased body weight over a six month period showed 
an attenuate postprandial striatal BOLD fMRI signal when BMI had gone up. The authors 
suggested that weight gain potentially reduced striatal activation as a consequence of down-
regulation of dopamine D2 receptors (Stice et al., 2010). Lack of dopamine expression D2 
receptors in obese subjects also has been shown in PET studies (Wang et al., 2001). Therefore, 
decreased levels of dopamine D2 in obese subjects may be another mechanism that causes 
overeating syndrome in humans (De Silva et al., 2012).  
 
Evidence suggests that gut and adipose tissue-derived hormones have a significant role in the 
initiation and termination of energy intake. Whilst there are many studies have shown their role 
in systemic regulation, the role of these hormones on regulating neuronal activity remains 
unclear. The orexigenic hormone, ghrelin and anorectic hormones, leptin, insulin, PYY and 
GLP-1 have been postulated to influence neuronal response towards appetite-related stimuli. 
Evidence suggests that intravenous infusion of ghrelin increases activation in the amygdala, 
OFC, insula, prefrontal cortex and striatum after viewing food images vs. non-food images, 
alongside an increase in subjective hunger scores (Malik et al., 2008). On the other hand, 
viewing food pictures following leptin treatment not just decreased activation in the accumbens-
caudate and putamen-globus pallidus areas (Farooqi et al., 2007), it also reduced activation in the 
insula, parietal and temporal cortex in leptin-deficient patients (Baicy et al., 2007). In another 
study, administration of intranasal insulin in nine healthy lean volunteers has been shown to 
reduce activation in the fusiforum gyrus, hippocampus, temporal superior cortex and frontal 
middle cortex (Guthoff et al., 2010). Based on these studies, it is suggested that circulating leptin 
and insulin reduce the subjective reward value of food and also motivation to eat (Palmiter, 
2007). 
 
It is widely known that PYY and GLP-1 are co-secreted together from the gut’s L-cells. 
Recently, infusion of PYY3-36 has been shown to significantly alter activation in the 
hypothalamus and OFC following resting BOLD-signals study. The authors showed that the 
positive correlation between energy intake and BOLD hypothalamic activation was transformed 
into negative correlation when PYY3-36 was administered. The result of this study suggested that 
the existence of PYY3-36 in the system has shifted the regulation of energy intake from a 
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homeostasis (hypothalamus) to a hedonic region (OFC) (Batterham et al., 2007). Very recently, 
De Silva et al. showed that viewing food-related stimuli following infusion of combination 
PYY3-36 and GLP-17-36 amide infusion in healthy normal weight volunteers reduced BOLD 
activation mainly in the insula and to a lesser extent in the OFC and NAc when compared to 
saline infusion. Interestingly, this effect was also associated with a reduction of ad libitum 
energy intake provided at the end of the study day (De Silva et al., 2011). These encouraging 
findings of the role of gut and adipose tissue-related hormones on neuronal responses may help 
to emphasis the regions that involved in controlling motivation and reward, thus regulating 
energy intake. 
 
Fermentable carbohydrates are suggested to modulate food intake and body weight via 
stimulation of the release of PYY and GLP-1 as a result of increased release of SCFAs (Cani et 
al., 2004; Delzenne et al., 2005; Delzenne et al., 2007). Interestingly, in 2009, Shen et al. showed 
that resistant starch potentially exerts its effect on food intake and body weight by increasing the 
hypothalamic POMC expression (Shen et al., 2009). Starting from this finding, a few studies also 
investigated the effect of fermentable carbohydrates on hypothalamic regions. So et al. showed 
that adding resistant starch in the diet of mice not only resulted in reducing energy intake and 
body fat, but the effect was also related to increased uptake of Mn
2+
 in the hypothalamic VMH 
and PVN (So et al., 2007). Very recently, the effect of resistant starch in hypothalamic regions 
was also supported by another fermentable carbohydrate, oligofructose-enriched inulin (synergy 
1). In this study, including synergy1 in high fat diet of mice decreased energy intake and body 
weight alongside of significant increased activation of ARC (Anastasovska et al., 2012). 
Moreover, evidence also demonstrated that acetate, a 2-carbon SCFA also has been shown to 
transport to the brain (Song et al., 2009). Therefore, these results highlighted the potential role of 
fermentable carbohydrates on central appetite regulation. In contrast to rodent studies, no known 
human studies have investigated the role of fermentable carbohydrates on neuronal response. 
This has therefore encouraged us to investigate the role of fermentable carbohydrates on 
neuronal responses and its effect on satiety in humans. 
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4.2 Aims and Hypothesis  
 
4.2.1 Aims 
The aim of this study was to investigate the effect of oligofructose supplementation on brain 
activation and subjective appetite when viewing food images. To achieve this objective, the below 
parameters were measured: 
 
 Change in fMRI signals in pre-selected ROIs pertaining to mesolimbic reward structures.  
 
 Food appeal ratings 
 
 Subjective appetite scores 
 
 Circulating levels of gut hormones, PYY and GLP-1. 
 
 
 
4.2.2 Hypothesis 
It was hypothesized that intake of 30 g per day oligofructose for six weeks (following two weeks 
run-in period) would reduce brain activation in six pre-selected ROI regions, reduce appetite ratings 
and food appeal scores following viewing of food images. 
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4.3 Materials and Methods 
 
4.3.1 Study Visit Protocol  
This study is a part of The effect of oligofructose on appetite, gut hormones, body 
composition and brain activity in healthy overweight subjects. Volunteers were asked to 
attend two fMRI brain scan study days (Visit 2 and Visit 5), the baseline and supplementation 
study day which were held at the Robert Steiner MRI unit, MRC Clinical Sciences Centre, 
Hammersmith Hospital after 10 – 12 hours overnight fasting. Upon arrival, they were asked to 
remove any metal from their body before changing into hospital scrubs and filling in a metal 
checklist form as a confirmation that no metal was attached to their body. A mood/depression 
assessment questionnaire was also obtained from volunteers. This questionnaire enabled 
confirmation of the volunteers’ mental state and that they were free from depression on the 
scanning day (Appendix 7). Female volunteers were also confirmed not to be pregnant prior to 
scanning using a urine HCG dipstick testing. In addition, to avoid any hormone induced changes 
that influence food selection and brain activation that might have occurred due to variable stage 
of menstrual cycle during the scanning (Dreher et al., 2007; Frank et al., 2010), study visits for 
female volunteers were only arranged during the follicular phase of their menstrual cycle 
(preferably between 2-10 days). Due to technical problems with the scanner during the study 
period, only 10 out of 22 volunteers managed to complete the scanning section (pre and post 
brain scans).  
 
Prior to scanning, a cannula was inserted into the antecubital vein preferably on their left arm as 
a hand keypad for picture rating will be placed on the right arm during the scanning. On the 
study day, the first blood withdrawal was performed at 35 minutes prior to the scanning, 
followed with second assessment at 0 minute and lastly at 1 hour and 30 minutes after the 
scanning session started. VAS and blood pressure were also obtained concurrently with the 
blood withdrawal. They were also required to fill in three-day food diaries started from the day 
before the scanning and ending a day after the scanning day. The food diary was performed to 
assess for differentiation of nutritional intake before and after taking the supplementation (the 
food diary data has not been analysed for this thesis).  
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The study visits took 3-4 hours to complete. On the supplementation visit only (Visit 5), 
volunteers took the supplement at 7 am prior attending the study visit in order to allow for 
colonic fermentation activities to be maximal when volunteers had their brain scans later in the 
afternoon. It is estimated that approximately five hours is needed for the supplement to be fully 
fermented by the gut bacteria, therefore, the scanning session was started at noon (please refer to 
Section 4.3.2 for fMRI scanning protocol). Volunteers were discharged at 3 pm after final blood 
and VAS assessment (Figure 4.1).  
 
 
 
 
 
  
 
 
 
 
 
Figure 4.1 Schematic diagram for fMRI study day. Volunteers attended 2 fMRI study days at baseline (visit 
2) and supplementation (visit 5). After cannulation, VAS, BP and blood were obtained from volunteers at 35 
and 70 minutes. After that, volunteers had fMRI scan for 60 minutes and post-scanning VAS, BP and blood 
withdrawal were obtained at 150 minutes. On the supplementation study day only, volunteers took the 
supplementation at 7 am before attending the study session. In addition, they were also asked to rate the liking 
and frequency of consumption of the food pictures seen during the fMRI scanning. Three-day food diaries 
were completed from a day prior the study day and finished a day after each fMRI study day.    
 
 
4.3.1.1 Randomization 
Prior to the baseline fMRI study day, volunteers were randomised to view four different preudo-
randomised food picture orders known as AB, CD, EF and GH using a computerised excel sheet 
by a member of the department which was not directly involved in the study. These picture 
orders were then randomly selected for the fMRI picture paradigm on the study days.  
 
Cannulated VAS, BP  
& blood 
    Arrived VAS, BP  
& blood 
VAS, BP & blood. 
Food picture ratings accessed on 
the last visit only 
0 35 -30 70 120 150 
Day 1 
 
Food diaries 
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Food diaries  
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Day 2 
 
Food diaries   
 
 
fMRI scan 
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4.3.1.2 Visual Analogue Scales 
VAS for hunger, fullness and motivation to eat were obtained from each volunteers at 35, 70 and 150 
minutes in the same way as described in the previous Section 2.4.1.2. However, there are some 
additional subjective appetite questionnaires related to the scanning procedure such as anxiety, 
sleepiness and pleasantness to eat which were also assessed. Volunteers were also asked to rate 
hunger three times during the scanning (Figure 4.3).  
 
 
4.3.1.3 Picture Ratings 
On the fMRI supplementation visit only (visit 5), volunteers were asked to name each of the food 
pictures that they viewed during the scanning. This task was performed in order to monitor 
whether volunteers could recognised the pictures (expressed in percentage correct recognition). 
In addition, they were also asked to rate their liking and frequency of eating of each picture seen 
by rating questions of how much do you usually like to eat this food: hate a lot (score -3) to like a 
lot (score +3) and a question of; On average how often do you actually eat this food: never (score 
0) to once per day or more (score 8) (Figure 4.2). The scores were summed separately based on 
high calorie and low calorie foods so that high calorie vs. low calorie intake can be accessed.  
 
 
How much do you usually LIKE to eat this food (please circle)? 
 
Hate  
a lot  
Hate 
somewhat 
Hate  
a little 
Neither  
like nor 
hate 
Like  
a little 
Like 
somewhat 
Like  
a lot 
 
On average how OFTEN do you actually eat this food (please circle)? 
 
Figure 4.2 Preference and frequency questionnaires asked during food ratings pictures.  
 
Never 
3 times 
or less 
per 
year  
6 times 
or less  
per 
year 
Once 
per 
month 
or less 
2-3 
times 
per 
month 
Once 
per 
week 
2-3 
times 
per 
week 
4-6 
times 
per 
week 
Once 
per day 
or more 
  
163 
 
4.3.1.4 Plasma Gut Hormones Analysis 
Blood for total PYY and GLP-1 measurement were drawn at 35, 70 and 150 minutes and were 
collected into lithium heparin tubes containing aprotinin (40 µl/10 ml bloods). Each sample was 
then spun at 4000g at 4
o
C for 10 minutes and the plasma separated and divided into aliquots 
before immediate storage at -80
o
C. PYY and GLP-1 were analysed by radioimmunoassay using 
the in-house RIA as described in Section 2.3.2.2.5.  
 
4.3.2 fMRI Scanning Protocol 
Each fMRI scanning experiment took approximately an hour to complete. In the MRI scanner, 
volunteers were asked to lie in the supine position. They were provided with ear plugs to wear and 
headphone to reduce noise from the MRI scanner. Then, a padded head coil was placed around their 
head for supports. An alarm buzzer was also given to hold in their left arm, in case they needed to 
stop or were uncomfortable with the scanning. On the right hand, a keypad was placed for the picture 
appeal button scores task. Volunteers were advised to stay still and not to move their head as this 
would disturb the scanning process. Seven tasks were performed during the scan. These tasks were 
test run, resting scans, the visual images run 1 and run 2, field maps, an audio-motor-visual task 
(AMV) and DTI scans (Figure 4.3). During the scanning, volunteers were also asked to rate hunger 
ratings three times (after test run, resting scans and field maps) on a scale from 1 to 5 from not at all 
(little finger), not really (ring finger), neutral (middle finger), a little stimulation (index fingers) and a 
lot (thumbs) (Figure 4.4) 
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   5 mins           10 mins           10 mins            10 mins          5 mins         6 mins         5-10 mins 
 
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 A hand-held keypad used for accessing hunger and picture appeal scores during the fMRI 
scanning. 
 
 
 
 
 
 
Test 
Run 
Resting 
scans 
Picture 
run 1 
Picture 
run 2 
Field 
maps 
AMV 
scans 
TI/ 
DTI 
Hunger 
rating 
Hunger 
rating 
Hunger 
rating 
Figure 4.3 Schematic diagram of fMRI protocol. The scanning procedure was performed in a fixed order for 
60 minutes, 1) Test run consisting of animal pictures as a practice and for volunteers to familiarize themselves 
with the keypad pressing to rate pictures, 2) Resting state fMRI scan to assess brain activity without the 
presence of any stimulation 3) fMRI picture run 1 and 4) run 2 using evaluation of food and non-food pictures 
5) Field maps to correct for signal distortion, 6) Audio-Motor-Visual (AMV) control fMRI task, 7) TI and DTI 
anatomical scans to look for brain abnormalities and allow image registration. Each volunteer were also asked 
to rate hunger ratings three times during the scanning. 
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4.3.2.1 Visual Stimuli Images 
A total of 372 coloured photographs were presented during the brain scans. These photographs 
were presented in a block design and divided into 4 different groups: 1) 60 high-calorie foods, 2) 
60 low-calorie foods, 3) 60 pictures of non-food-related household objects and 4) 192 Gaussian 
blurred images of high-calorie foods (e.g. chocolate and cakes), low-calorie foods (e.g. salads, 
fish-based dishes) and objects (e.g. keys, chairs, clothes) pictures (example of the stimuli are 
displays in figure 4.5). These photographs were acquired from the internet and the International 
Affective Picture System (IAPS, NIMH Centre for the study of Emotion and Attention, 
University of Florida, Gainesville, FL, USA).  All of these images were arranged to be of similar 
luminosity and resolution. Food pictures, high and low calorie food images were the tested tasks 
whilst non-food and Gaussian blurred images were used as low level baseline images and to 
allow study of the effect of dietary intervention (before and after intake of supplementation) on 
control stimuli. Only foods that are consumed in the Western diet were used in the study. The 
nutritional contents of both high calorie and low calorie foods were analysed using DietPlan6 
(Forestfield Software Ltd, West Sussex, UK) (Table 4.1).  
 
Table 4.1 The total caloric load, caloric density and macronutrients composition of the high calorie 
and low calorie foods. 
Type of foods  Total caloric 
(kCal) 
 Caloric density 
(kCal/100g) 
 Macronutrient composition (%)  
CHO Protein Fat 
High calorie  834 ± 100  321 ± 13  48 ± 1 10 ± 1 48 ± 1 
Low calorie  157 ± 18  64 ± 5  35 ± 3 29 ± 3 35 ± 3 
High calorie vs. low calorie   P<0.001  P<0.001  P<0.001 P<0.001 P=0.03 
 
 
In each scanning session, two runs of stimuli images were shown to the volunteers for 18 
minutes. Stimuli were presented in a block design experiment. In total, five blocks of pictures 
from the categories were showed in one of two pseudo-randomised block orders containing 
randomised pictures in each block. Each block has six different pictures either from the high-
calorie food, low-calorie food or objects categories. Each of these pictures were presented for 2.5 
seconds and followed by a 0.5 seconds fixation cross image in between the images. Therefore, 
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each block category was shown in 18 seconds. Each block of high-calorie foods contained two 
pictures of chocolate, non-chocolate sweet and savoury non-sweet food pictures. Each stimuli 
block was followed by a block of six blurred images with the same duration as food and object 
images in each block. This step was performed in order to allow the BOLD signal to return back 
to baseline after complete viewing each block of stimuli. Images were viewed via a mirror 
mounted above an 8 channel RF head coil which displayed images from a projector using the 
IFIS image presentation system (In Vivo, Wurzburg, Germany) using ePrime 2.0 software 
(Psychology Software Tools Inc, Pittsburgh,PA, USA).  
 
In this task, volunteers were also asked to immediately rate each picture as soon as the images 
were shown in the scanner by pressing the keypad button on their right hand (1 = not at all, 2 = 
not really, 3 = neutral, 4 = a little, 5 = a lot).  
 
 
4.3.2.2 Auditory-Motor-Visual (AMV) Task 
An AMV task was used as a control task to rule out non-specific changes of fMRI BOLD 
activation between pre-supplementation and supplementation visits in both oligofructose and 
cellulose groups (the schematic diagram for this process is described in Figure 4.5). This six 
minute task was performed at the end of the scanning session. In this paradigm, two tasks were 
performed at the same time from: 
 
1. Watching a 4Hz colour flashing checkerboard and listening to a story or 
2. Watching a 4Hz colour flashing checkerboard and pressing the right index finger once 
every second, or 
3. Listening to a story and pressing the right index finger once every second.   
 
The single run consisted of nine 33 second blocks, with each task performed in six blocks, and 
instructions about whether to start or stop the motor task displayed for three seconds prior each 
block. 
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High calorie  
Sweet  
non-chocolate 
Sweet chocolate  
Savoury  
Low calorie  Objects Blurred  
2.5 sec / picture 
0.5 sec / stimulus interval  
6 pictures / category/ block 
5 blocks / category 
2 runs 
Visual Stimuli 
Picture appeal ratings 
Figure 4.5 Schematic diagram for fMRI visual stimulation tasks. Visual stimuli are presented in blocks and comprised of four types of stimuli: 
high calorie foods (sweet chocolate, sweet non-chocolate and savoury), low calorie foods, objects and blurred images (i). During the fMRI 
scanning, these pictures are shown in a pseudo-randomised block design. Each picture was shown for 2.5 seconds and six pictures were 
presented in a block. Each category (high-calorie foood, low calorie food and objects) has 5 blocks per run which were shown in 2 pre-
randomised picture runs (AB, CD, EF and GH). Volunteers were asked to rate the appeal of each pictures that they saw during the scanning on a 
1-5 scale from not at all (little finger), not really (ring finger), neutral (middle finger), a little (index finger) and a lot (thumb).        
Pseudo-randomised block design 
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4.3.2.3 fMRI Imaging Acquisition  
T2*-weighted gradient-echo planar images were acquired with BOLD contrast using a 3T 
Philips Intera whole body scanner using a -30º tilted acquisition angle from anterior and 
posterior commissure plane to decrease signal dropout in orbifrontal regions resulting from air 
sinuses. Image parameters were echo time (TE) = 30 ms; repetition time (TR) = 3000 ms; flip 
angle = 90º, 44 slices ascending contiguous; slice thickness = 3.25mm, 2 x 2 mm voxels, matrix 
size =112x112, field of view 190 x 219 mm
2
. B0 fieldmaps were collected to correct for 
geometric distortions caused by inhomogenities in the magnetic field as follows: TR 29 ms; TE 
3.6 ms, 30º flip angle; field of view 190 x 219, 44 ascending contiguous 3.25mm thick slices, 2 x 
2 mm voxels, ∂TE 0 and 2.5. A high resolution T1-weighted structural scan was also collected at 
each visit for fMRI image co-registration and mapping the ROIs (TE = 4.6 ms; TR = 9.7 ms; flip 
angle = 8°; field of view = 240 mm; voxel dimensions = 0.94 x 0.94 x 1.2 mm).  
 
 
4.3.2.4 Pre-processing and Analysis of fMRI Images 
FMRI data processing was carried out using FEAT (FMRI Expert Analysis Tool) version 5.98, 
part of FSL (FMRIB’s Software Library, www.fmrib.ox.ac.uk/fsl). No subjects had excess head 
movement (average relative motion across both food runs >0.5mm/TR). The following 
preprocessing was applied: motion correction using MCFLIRT (Jenkinson et al., 2002); 
fieldmap-based EPI unwrapping using PRELUDE+FUGUE (Jenkinson, 2003; Jenkinson, 2004); 
non-brain removal using BET (Smith, 2002); spatial smoothing using a Gaussian kernel of 
FWHM 6.0mm; grand-mean intensity normalization of the entire 4D dataset by a single 
multiplicative factor and high pass temporal filtering (Gaussian-weighted least-squares straight 
line fitting, with sigma=100.0s). 
 
Time-series statistical analysis was carried out using FILM with local autocorrelation correction 
including picture onsets (high-calorie and low-calorie food and objects) integrated with the 
gamma HRF, with temporal derivative and motion parameters as co-variates (Woolrich et al., 
2001). Registration to high resolution T1 structural images was carried out using FLIRT  
(Jenkinson and Smith, 2001; Jenkinson et al., 2002). Registration from high resolution structural 
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to standard space was then further refined using FNIRT nonlinear registration (Andersson et al., 
2007b; Andersson et al., 2007a). For the food pictures, higher level analysis was carried out 
using a fixed effect model to combine the 2 runs, by forcing the random effects variance to zero 
in FLAME (FMRIB’s Local Analysis of Mixed Effects) (Beckmann et al., 2003; Woolrich et al., 
2004) to determine activation for the following contrasts: high-calorie or low-calorie food > 
object, high-calorie food > object and low-calorie food > object. Similar time-series statistical 
analysis was performed for the single run AMV paradigm including the onsets of each task 
(auditory, motor and visual) to contrast activation during performance of each task with that 
when the other tasks were being performed. All higher-level analysis was carried out using 
FLAME (FMRIB's Local Analysis of Mixed Effects) stage 1 (Beckmann et al., 2003; Woolrich 
et al., 2004).Hi 
 
 
4.3.2.4.1 Generation of functional ROIs 
The first stage in fMRI analysis was to create group activation maps in order to locate voxels of 
brain regions that were activated by the food image paradigm (any food [high-calorie or low-
calorie] vs. object) in order to generate functional ROIs. This was performed using an identical 
paradigm and analysis with fMRI scans from another study. An activations were thresholded at 
false discovery rate (FDR) P<0.05 for correction of multiple comparisons. In this analysis, scans 
were used from an initial baseline fasted scanning visit from 22 healthy overweight volunteers 
before undergoing another dietary intervention, omega-3 polyunsaturated fatty acid (PUFA) 
study. This cohort had no-significant difference in BMI, age and weight with the volunteers 
involved in this study (Table 4.2). The group activation is illustrated in Figure 4.6. Similar 
localizers were made from this group analysis for the control auditory, motor and visual tasks 
(Figure 4.8). 
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Table 4.2 Demographic profiles for PUFA and oligofructose study 
Profiles  PUFA  Oligofructose / cellulose study  P value 
n  22  10  - 
Age (years)  33.4 ± 1.7  34.8 ± 3.0  P = 0.719 
Body weight (kg/m
2
)   80.6 ± 3.3  85.4 ± 4.0  P = 0.366 
BMI  28.7 ± 0.7  29.9 ± 1.0  P = 0.308 
% fat   35.1 ± 1.5  36.2 ± 2.5  P = 0.455 
Gender  18 females, 4 males  6 females, 4 males  - 
    
 
The functional ROIs were obtained by masking these group activation maps with a priori 
anatomical ROI. For the food picture task these were the nucleus accumbens (NAc), amygdala, 
anterior OFC, hippocampus, insula and ventral ACC (Figure 4.7). For the AMV task these were 
bilateral primary visual cortex (lingual gyrus), bilateral secondary auditory cortex (superior 
temporal gyrus), and left supplementary motor area (Figure 4.8). These were defined by the 
relevant bilateral ROIs from the cortical and subcortical structural Harvard FSL atlas thresholded 
at 10% probability. The OFC functional ROI included regions in the OFC and frontal pole with y 
> 22 and z < -6, since analysis of functional activation in this region demonstrated distinct 
bilateral clusters overlapping the anatomical Harvard atlas regions. 
 
4.3.2.4.2 Comparison of group Activation for Oligofructose and Cellulose  
The average (median) magnitude of bilateral BOLD activation within each a priori fROI was 
then extracted for each individual subject for each of the visits (pre- and post-supplementation 
visits) in each oligofructose and cellulose group for the following contrasts: (i) any food (high-
calorie or low-calorie food) > objects, (ii) high-calorie food > objects, (iii) low-calorie food > 
object and (iv) objects > blurred pictures, using featquery in FSL, to measure the differences in 
activation between visits and groups for the different picture categories. Similar analysis was 
performed to compare auditory, motor and visual activation in the relevant fROIs between visits 
and groups. Average change in BOLD activation for each of these contrasts within each ROI was 
then compared between visits and groups outside FSL. 
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Figure 4.6 Group brain activation to food pictures used to generate functional ROIs.  Group activation 
map for any food (high-calorie or low-calorie) minus object picture contrast at the pre-supplementation visit 
(red yellow). Colour bar indicates z value. Activations are thresholded at FDR P<0.05, overlaid onto the 
average T1 scan for all subjects (n=22 subjects from PUFA study). Co-ordinates are given in standard MNI 
space. Abbreviations; Amy: amygdala, BSTEM: brainstem, Hipp: hippocampus, Ins: insula, MFG: medial 
frontal gyrus, NAc: nucleus accumbens, PAL: pallidum, Thal: Thalamus, vACC: ventral anterior cingulate 
cortex, Colour bar gives Z statistic. 
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Figure 4.7 Funtional ROIs used in analysis for food picture task. Activation is thresholded at FDR P<0.05, 
overlaid onto the average T1 scan for all subjects (n=21). A priori functional regions of interest (ROI) are 
indicated: OFC (OFC, light blue), amygdala (Amy, green), NAc (NAc, yellow), insula (Ins, magenta), 
hippocampus (Hipp, dark blue) and ventral anterior cingulate cortex (vACC, light brown). Coordinates are 
given in standard MNI space. 
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Figure 4.8 Functional regions of interest for control Auditory-Motor-Visual task: Group activation maps 
thresholded at FDR P<0.05 are overlaid with functional ROIs on background image of average T1 scan for all 
subjects (n=22 subjects from PUFA study): auditory (red:listening to story) with bilateral posterior division of 
superior temporal gyrus (overlaid in yellow), motor task (green: button press) with left pre-central gyrus 
(overlaid in magenta), visual (dark blue: flashing checkerboard) with lingual gyrus (overlaid in light blue). Co-
ordinates are given in standard MNI space. 
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4.3.2.5 Statistical Analysis 
Results are presented as mean ± SEM. As this study has a small sample size (oligofructose=4, 
cellulose=6), Gaussian distribution cannot be used to assess normality of the data distribution. 
Therefore, statistical analyses were performed using parametric tests. Changes in ROI activation 
on viewing and rating food vs. objects, high calorie foods vs. objects, low calorie foods vs. 
objects and objects vs. blurred pictures, and during auditory, motor and visual control tasks 
between oligofructose and cellulose groups were calculated by substracting BOLD activation at 
post-supplementation fMRI scans from baseline visit and the result was compared using two-
tailed unpaired t-test. Within groups effects were examined using two-tailed paired t-test 
(oligofructose and cellulose vs. baseline) to compare effect on picture appeal rating scores. The 
change in activation was then compared between oligofructose and cellulose using two-tailed 
unpaired t-test. An ANCOVA analysis with baseline value, BMI and gender as co-variates was 
used to compare the differences between the treatments for subjective appetite VAS (tAUC), 
picture appeal ratings, plasma GLP-1 and plasma PYY levels and the end of study food picture 
ratings. Statistical significance is defined by a P value of 0.05 or less. Statistical analysis for 
within group student t-test was performed using GraphPad Prism 5 (GraphPad Software, San 
Diego CA, USA) whilst ANCOVA analysis was performed using SPSS version 20.0 (SPSS Inc, 
Chicago, IL, USA). 
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4.4 Results 
 
4.4.1 Volunteers Characteristics 
10 healthy overweight/obese right-handed volunteers participated in this study. Four volunteers 
were from the oligofructose group (2 male, 2 female, mean age 39.3 ± 4.1 years, range 31 – 49 
years, mean BMI 27.5 ± 0.9 kg/m2, range 25.4 kg/m
2
 – 29.7 kg/m2) and 6 volunteers were from 
the cellulose group (2 male, 4 female, mean age 27.3 ± 1.6 years, range 22 – 47 years, mean BMI 
31.7 ± 0.5 kg/m
2
, range 27.0 – 35.7 kg/m2).   
 
 
4.4.2 Activation to Food Pictures in ROI analysis 
Figure 4.9 – Figure 4.11 demonstrates changes in BOLD signal in the NAc, amygdala, OFC, 
insula, hippocampus and vACC on viewing food vs. objects (i), high calorie vs. objects (ii) and 
low calorie vs. objects (iii) after intake of oligofructose and cellulose supplementations.  
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4.4.2.1 Food vs. Object Pictures 
There was no significant difference in the change in activation on viewing food vs. object 
pictures after oligofructose vs. cellulose supplementation though there was a suggestion that 
OFC and insula activation was reduced more by cellulose than oligofructose (NAc: P=0.479, 
amygdala: P=0.633, OFC: 0.273, insula: P=0.261, hippocampus: P=0.441 and vACC: P=0.733) 
(Figure 4.9) 
 
         i) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          ii) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9 BOLD signal (i) and change in BOLD signal (ii) in NAc, amygdala, OFC, insula, 
hippocampus and vACC on viewing of food vs. objects pictures in oligofructose and cellulose groups. 
Change in BOLD signal is expressed as supplementation – baseline study day. Post-supplementation brain 
scans (between day 36-42 supplementation period) were performed after 5 hours ingestion of oligofructose or 
cellulose. Data is expressed as mean ± SEM. Oligofructose (n=4), cellulose (n=6). 
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4.4.2.2 High-calorie Food vs. Object Pictures 
Figure 4.10 shows the change in ROI activation on viewing high calorie food vs. object pictures 
in the oligofructose and cellulose group. Intake of cellulose reduced activation significantly more 
than oligofructose in the OFC (P=0.018) with a trend for a reduction in NAc and insula, but not 
in other regions (NAc: P=0.146, amygdala: P=0.599, OFC: P=0.273, insula: P=0.111, 
hippocampus: P=0.396 and vACC: P=0.985). 
 
         i) 
 
 
 
 
 
 
 
 
 
 
 
 
 
          ii) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10 BOLD signal (i) and change in BOLD signal (ii) in NAc, amygdala, OFC, insula, 
hippocampus and vACC on viewing of high calorie food vs. object pictures in oligofructose and 
cellulose groups. Change in BOLD signal is expressed as supplementation – baseline study day. Post-
supplementation brain scans (between day 36-42 supplementation period) were performed after 5 hours 
ingestion of oligofructose or cellulose. Data is expressed as mean ± SEM. Oligofructose (n=4), cellulose (n=6). 
P<0.05 cellulose vs. oligofructose group. 
  
178 
 
4.4.2.3 Low-calorie Food vs. Object Pictures 
No significant difference or trend in change of activation on viewing low-calorie food vs. object 
pictures was demonstrated between supplementation with oligofructose and cellulose in any 
ROI, NAc: P=0.872, amygdala: P=0.646, OFC: P=0.663, insula: P=0.573, hippocampus: 
P=0.801 and vACC: P=0.624 (Figure 4.11).   
 
            i) 
 
 
 
 
 
 
 
 
 
             ii) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 BOLD signal (i) and change in BOLD signal (ii) in NAc, amygdala, OFC, insula, 
hippocampus and vACC on viewing of low calorie food vs. object pictures in oligofructose and 
cellulose groups. Change in BOLD signal is expressed as supplementation – baseline study day. Post-
supplementation brain scans (between day 36-42 supplementation period) were performed after 5 hours 
ingestion of oligofructose or cellulose. Data is expressed as mean ± SEM. Oligofructose (n=4), cellulose (n=6). 
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4.4.2.4 Control Activation 
In this study, blurred vs. objects picture contrast and auditory, motor, visual task activation were 
used as control tests for any non-specific changes in BOLD activation following intake of 
oligofructose or cellulose. 
 
 
4.4.2.4.1 Object vs. Blurred Pictures 
There was no significant difference in the effects of oligofructose vs.cellulose supplementation 
on ROIs activation to viewing object vs. blurred pictures though there was a trend for insula 
activation to increase more with cellulose, NAc: P=0.437, amygdala: P=0.659, OFC: P=0.969, 
insula: P=0.123, hippocampus: P=0.538 and vACC: P=0.847 (Figure 4.12).   
 
 
 
 
Figure 4.12 Change in BOLD signal change in NAc, amygdala, OFC, insula, hippocampus and vACC 
on viewing of objects vs. blurred pictures in oligofructose or cellulose groups. Results are expressed as 
supplementation – baseline study day. Post-supplementation brain scans (between day 36-42 
supplementation period) were performed after 5 hours ingestion of oligofructose or cellulose. Data is 
expressed as mean ± SEM. Oligofructose (n=4), cellulose (n=6). 
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4.4.2.4.2 Visual Checkerboard 
There was no significant difference or trend in change of activation in superior temporal gyrus, 
precentral gyrus and lingual gyrus during the control auditory-motor-visual task between 
oligofructose and cellulose supplementation: superior temporal gyrus (P=0.917), precentral gyrus 
(P=0.347) and lingual gyrus (P=0.523) (Figure 4.13). 
 
 
 
 
Figure 4.13 Change in BOLD signal change in superior temporal gyrus, precentral gyrus and lingual 
gyrus during auditory-motor-visual control task in oligofructose or cellulose groups. Results are 
expressed as supplementation – baseline study day. Post-supplementation brain scans (between day 36-42 
supplementation period) were performed after 5 hours ingestion of oligofructose or cellulose. Data is 
expressed as mean ± SEM. Oligofructose (n=4), cellulose (n=6). 
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4.4.3 Picture Appeal Rating 
Table 4.3 demonstrates the appeal rating scores in mean ± SEM. High calorie food pictures were 
rated as more appealing compared to other visual stimuli in both groups. However, no significant 
difference was found between before and after supplementation in both oligofructose and 
cellulose groups, oligofructose [blurred (P=0.639), high calorie foods (P=0.396), low calorie 
foods (P=0.598) and objects (P=0.260) pictures] and cellulose [blurred (P=0.994), high calorie 
foods (P=0.336), low calorie foods (P=1.00) and objects (P=0.708) pictures] and also between 
the treatment, blurred (P=0.396), high calorie foods (P=0.056), low calorie foods (P=0.766) and 
objects (P=0.284).  
 
 
Table 4.3 Picture appeal rating scores 
Tasks Oligofructose (n=4)  Cellulose (n=6) 
 Pre Post Change  Pre Post Change 
Blurred 1.42 ± 0.27 1.25 ± 0.20 -0.17 ± 0.32  1.43 ± 0.13 1.38 ± 0.15 -0.05 ± 0.13 
High calorie foods 3.74 ± 0.16 3.89 ± 0.19 0.15 ± 0.16  4.08 ± 0.29 3.98 ± 0.49 -0.10 ± 0.21 
Low calorie foods 3.30 ± 0.40 3.24 ± 0.49 -0.07 ± 0.11  3.70 ± 0.25 3.71 ± 0.18 0.02 ± 0.15 
Objects 2.28 ± 0.49 1.91 ± 0.47 -0.36 ± 0.26  2.21 ± 0.37 2.28 ± 0.32 0.07 ± 0.21 
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4.4.4 End of Study Food Picture Ratings 
Figure 4.14 demonstrates the recognition (i), liking (ii) and frequency of eating (iii) of food 
pictures. In this assessment, 98.2 ± 0.5 % high calorie food pictures and 96.5 ± 0.9 % low calorie 
food pictures (P=0.205) were correctly recognised by the volunteers [Figure 4.14 (i)]. The result 
also showed that volunteers have a tendency to significantly like (P=0.055) high calorie foods 
more than low calorie foods However, volunteers rated that they consumed low calorie foods 
more compared to high calorie foods, but this was not significant (P=0.306). 
 
(i)                                                                              
 
 
 
 
 
 
 
 
 
i)                                                                iii) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Recognition (i) liking (ii) frequency of eating of food pictures in oligofructose or cellulose 
groups. Results are expressed as supplementation – baseline study day. Post-supplementation brain scans 
(between day 36-42 supplementation period) were performed after 5 hours ingestion of oligofructose or 
cellulose. Data is expressed as mean ± SEM. Oligofructose (n=4), cellulose (n=6). 
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4.4.5 Subjective Appetite Scores 
 
Hunger Score 
Figure 4.15 describes the hunger scores in tAUC150mins. Cellulose had a tendency to reduce 
hunger score within the group (P=0.081) and compared with oligofructose (P=0.054). No 
significant effect was demonstrated in the oligofructose group (P=0.670), oligofructose 
(baseline: 838.2 ± 96.6 cm*min and post: 804.1 ± 108.2 cm*min) and cellulose (baseline; 697.8 
± 145.3 cm*min and post: 471.1 ± 47.8 cm*min).  
 
Pleasant Score 
Oligofructose supplementation had no significant effect on reducing subjective pleasant score 
compared to baseline (P=0.875) (baseline; 636.4 ± 138.6 cm*min and post: 658.4 ± 189.1 
cm*min) whilst intake of cellulose showed a trend to reduce pleasant scores compared to 
baseline (P=0.082) (baseline; 734.0 ± 136.5 cm*min and post: 478.9 ± 59.3 cm*min). However, 
no significant difference between the treatment was demonstrated (P=0.183) (Figure 4.15). 
 
Volume Intake Score 
Intake of cellulose has been shown to have a tendency to reduce volume food intake compared to 
oligofructose (P=0.063). In addition, it was also shown to significantly reduce volume intake 
scores when compared to baseline (P=0.029) (baseline; 696.5 ± 132.9 cm*min and post: 425.2 ± 
61.3 cm*min) [figure 4.6] but no significant effect was demonstrated in the oligofructose group 
(P=0.437), (baseline; 847.2 ± 78.7 cm*min and post: 778.6 ± 116.1 cm*min) (Figure 4.15).  
 
Fullness Score 
Intake of oligofructose has been shown to increase fullness score compared to baseline, but this 
did not reach statistical significance (P=0.402) (baseline; 51.9 ± 25.1 cm*min and post: 92.4 ± 
57.8 cm*min). No significant difference was also demonstrated in the cellulose group (P=0.563) 
(baseline; 51.8 ± 28.5 cm*min and 38.2 ± 13.6 cm*min). No significant difference between the 
group was also found (P=0.268) (Figure 4.15). 
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ii)              ii) 
 
 
 
 
 
 
 
 
 
 
iii)                               iv) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Subjective hunger, pleasant, volume intake and fullness scores in oligofructose or cellulose groups (tAUC150mins). Results are 
expressed as supplementation – baseline study day. Post-supplementation brain scans (between day 36-42 supplementation period) were performed 
after 5 hours ingestion of oligofructose or cellulose. Data is expressed as mean ± SEM. Oligofructose (n=4), cellulose (n=6). 
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4.4.5.1 Side Effects 
Figure 4.16 demonstrates the subjective scores of sickness, anxiety, stress and sleepiness. 
Inclusion of oligofructose in the diet had no significant effect on sickness, anxiety, stress and 
sleepiness scores compared to cellulose supplementation (P=0.095, P=0.114, P=0.352 and 
P=0.424 respectively).  
 
 
Figure 4.16 Change in subjective sickness, anxiety, stress and sleepiness scores in oligofructose or 
cellulose groups. Results are expressed as supplementation – baseline study day. Post-supplementation 
brain scans (between day 36-42 supplementation period) were performed after 5 hours ingestion of 
oligofructose or cellulose. Data is expressed as mean ± SEM. Oligofructose (n=4), cellulose (n=6). 
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4.4.6 Gut Hormones 
In this section, two types of gut hormones were assessed, GLP-1 and PYY which was obtained at 
40, 55, 70 and 150 minutes at baseline (visit 2) and supplementation (visit 5). Two volunteers in 
the cellulose group had a problem with cannulation which resulted in haemolysed samples, 
therefore only eight volunteers were involved in this group analysis (oligofructose=4, 
cellulose=4).  
 
4.4.6.1 Plasma GLP-1 Concentrations 
Figure 4.17 demonstrates plasma GLP-1 (i) and tAUC150mins plasma GLP-1 (ii). The result 
showed that intake of oligofructose and cellulose had no significant effect on increasing plasma 
GLP-1 within each group (oligofructose: P=0.342 and cellulose: P=0.283). No significant effect 
was also demonstrated between the groups (P=0.198). 
 
(i)                                                                ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17 Fasting plasma GLP-1 levels in time course (pmol/l) (i) and tAUC150mins (ii) in oligofructose or 
cellulose groups. Results are expressed as supplementation – baseline study day. Post-supplementation brain 
scans (between day 36-42 supplementation period) were performed after 5 hours ingestion of oligofructose or 
cellulose. Data is expressed as mean ± SEM. Oligofructose (n=4), cellulose (n=6). 
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4.4.6.2 Plasma PYY Concentrations 
Figure 4.18 shows circulating plasma PYY levels in time course (i) and tAUC150mins. Intake of 
oligofructose had no significant effect on increasing tAUC150mins PYY levels compared to 
baseline (P=0.730). The same observation was demonstrated within cellulose supplementation 
(P=0.683), mean ± SEM oligofructose [baseline; 2213.9 ± 117.5 and post: 3365.6 ± 456.0 
pmol/l*min) and cellulose (baseline: 2143.2 ± 496.3 and post: 1925.1 ± 118.3 pmol/l*min]. No 
significant effect was also found between these groups (P=0.762). 
 
(i)                                                                   (ii) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Fasting plasma PYY levels in time course (pmol/L) (i) and tAUC150mins (ii) in oligofructose or 
cellulose groups. Results are expressed as supplementation – baseline study day. Post-supplementation 
brain scans (between day 36-42 supplementation period) were performed after 5 hours ingestion of 
oligofructose or cellulose. Data is expressed as mean ± SEM. Oligofructose (n=4), cellulose (n=6). 
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4.5 Discussion 
This preliminary study performed in humans is the first to investigate the effect of 
supplementing fermentable carbohydrate on BOLD fMRI activation. It was hypothesised that 
oligofructose supplementation would increase circulating plasma PYY and GLP-1 levels, leads 
to a reduction in BOLD signals in reward ROIs following viewing visual food stimuli, reduce 
food appeal rating and suppress subjective appetite scores. However, the results of this study did 
not support this hypothesis. Oligofructose supplementation showed no significant effect in pre-
selected a priori ROIs (NAc, amygdala, OFC, hippocampus, insula and vACC) following 
viewing of visual food cues, PYY and GLP-1 levels, appeal ratings or VAS scores.  
 
This is surprising as adding oligofructose to the diet has previously been shown to significantly 
increase plasma PYY and GLP-1 circulating levels, reduce energy intake and body weight in 
both rodents (Cani et al., 2004; Cani et al., 2005b; Cani et al., 2007b; Delzenne et al., 2005; Kok 
et al., 1998) and human studies (Cani et al., 2009; Parnell and Reimer, 2009; Verhoef et al., 
2011). In addition, reductions in energy intake, body weight and body fat in rodents fed resistant 
starch and oligofructose-enriched inulin have also been shown to associate with increased 
hypothalamic activation signals particularly in the VMN and PVN (So et al., 2007) as well as in 
the ARC in MEMRI experiments (Anastasovska et al., 2012) . 
 
In contrast, adding cellulose in the diet reduced BOLD activation in the ROIs: NAc, amygdala, 
hippocampus and insula. A significant reduction was also demonstrated in the OFC when 
viewing high calorie foods vs. object images. Additionally, reduced activations in OFC, 
amygdala and insula were also demonstrated after viewing food vs. objects images. The effect on 
reducing BOLD signals activation in cellulose group also maybe related with reduced hunger 
and volume food intake of VAS scores. However, no significant modulation on food appeal 
rating as well as circulating PYY and GLP-1 levels were found in both groups.  
 
The lack of oligofructose effects on increasing circulating plasma PYY and GLP-1 levels could 
be because this study was conducted in the fasted state. In this study, measurements of plasma 
PYY and GLP-1 were performed following a 12 hour fast. Hence, it might be possible that 
oligofructose requires interaction with nutrients to modulate its effect on gut hormone release. 
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This suggestion is supported by the result obtained from the appetite study visit (figure 2.13, 
Chapter 2). The result showed that the effect of oligofructose on fasting plasma PYY and GLP-1 
levels in the baseline visit (day 0) was no different compared with plasma fasting PYY and GLP-
1 on post-supplementation visit (day 56). Similarly, Parnell and Reimer also showed no 
significant modulation on fasting plasma gut hormones after oligofructose supplementation 
(Parnell and Reimer, 2009). In contrast, intake of oligofructose with meal during breakfast leads 
to rise of postprandial plasma PYY levels at 120 minutes and subsequently peaked at 260 
minutes compared with cellulose supplementation.  
 
In this study, volunteers were scanned approximately six hours (12.30 hours) following 
oligofructose/cellulose intake in order to allow for the supplements to reach large intestine and 
subsequently be fermented by the gut bacteria (Molis et al., 1996; Rumessen et al., 1990). It was 
hypothesised that this time frame would allow oligofructose to increase released of circulating 
plasma gut hormones and in turn reduce BOLD activation following exposure to food stimuli 
and reduce hunger rating. However, it seems that this hypothesis was not proven. Based on these 
results, it is postulated that intake of 10 g (15.8 kcal) oligofructose (with water), without meals 
stimulation at seven am prior to scanning led to insufficient production of gut hormone secretion. 
This might be the reason why oligofructose failed to reduce BOLD activation in ROIs. Perhaps, 
the effect of oligofructose on reducing BOLD reward ROIs can be clearly demonstrated if the 
effect was compared between fasted versus postprandial supplementation visits. This is based on 
the result from the appetite study that intake of oligofructose with meal during breakfast 
significantly reduced energy intake at four hours thereafter (Section 2.4.1.3, Chapter 2).  
 
It is still not entirely clear what caused the reduced BOLD activation in the reward ROIs in the 
cellulose group. Nevertheless, cellulose has been suggested to exert its role on satiation via three 
mechanisms, namely colonic fermentation, decrease transit time and bulking effects (Eastwood 
et al., 1973; Topping and Clifton, 2001; Wrick et al., 1983). However, It is unlikely that cellulose 
exerts it effect on BOLD activations via colonic fermentation as cellulose is mainly known as a 
low fermentation agent (Sunvold et al., 1995) compared to oligofructose. The distinct effect on 
increasing postprandial colonic fermentation between these two fibres has been shown very 
clearly using the breath hydrogen test performed on the appetite study day (Figure 2.12, Chapter 
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2). Instead of being a fermentation agent, cellulose has been shown to have a pronounced effect 
on shortening transit time (Cummings, 1984; Hillman et al., 1983; Wrick et al., 1983). Cellulose 
is the main structural component in plant cell walls. Adding cellulose in the diet reduces transit 
time as it escapes nutrient and absorption process, absorbs water from the colonic contents 
leading to increase faecal bulking. Therefore, it is suggested that cellulose, via its transit time and 
bulking effects, reduced BOLD reward in ROIs by activating intestinal vagal afferent to the 
hypothalamus and brainstem, which can then subsequently signals to the limbic regions, 
including the reward ROIs.  
 
To date, no known study has investigated the effect of isolated dietary fibres on brain reward 
regions to study appetite control. Therefore, it is not possible to compare the findings with other 
studies. However, our observation that intake of cellulose reduces BOLD activation in brain 
reward regions is similarly demonstrated by other gut hormone infusion studies. Administration 
of anorectic hormones, PYY3-36 (Batterham et al., 2007) and PYY3-36  + GLP-17-36amide (De Silva 
et al., 2011) have been shown to reduce activation in the hypothalamus (Batterham et al., 2007), 
OFC (Batterham et al., 2007; De Silva et al., 2011) and insula (De Silva et al., 2011) following 
viewing food cues stimulation and resting state experiment. Interestingly, both of these studies 
showed that the reduced activation in reward ROIs associated with a reduction of ad libitum 
energy intake. In this study, energy intake was not measured. Therefore, it is remains unknown 
whether the effect of cellulose on ROIs would lead to reduced energy intake. Nevetheless, 
cellulose supplementation showed a tendency to reduce hunger and volume scores compared to 
oligofructose. However, as the effect of cellulose on reducing BOLD activation and subjective 
appetite were demonstrated in a small study, this observation needs to be further clarified in a 
larger cohort.  
 
Despite the promising findings demonstrated in the cellulose group, there are a number of 
limitations that should be taken into consideration before firm conclusions on the role of fibres 
on brain responses to food cues can be made. Firstly, this study was designed as a substudy of 
oligofructose intervention study which mainly looked into appetite, energy intake, and body 
weight. Therefore, the initial sample size (n=22) was not powered to fMRI signal change effects 
but it was determined based on the postprandial circulating plasma PYY levels. In addition, 
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powering this type of study based on expected changes in fMRI signal is difficult mainly because 
not many studies has been done in obese volunteers to investigate the effect of ROI BOLD signal 
changes in combination with other investigation (e.g. investigate the effect of oligofructose on 
brain activation and body weight at the same time).  
 
Unfortunately, as the study developed, technical problems with the scanner were encountered, 
which resulted in only 10 out of 22 volunteers (oligofructose=4, cellulose=6) completing both of 
the baseline and supplementation brain scanning sessions. In contrast to other fMRI studies 
(Batterham et al., 2007; De Silva et al., 2011; Rothemund et al., 2007), the sample size of this 
study was comparatively low. Therefore, until the result of this study can be confirmed and re-
investigated using a large sample size, the effect of cellulose on neuronal activity demonstrated 
in this study remains as a preliminary finding. However, the result of this study can be evaluated 
as a pilot study and used to power future investigation. 
 
In this study, instead of whole-brain analysis, only several priori ROI regions were selected for 
the analysis. It might be possible that this has resulted in potentially overlooking activation in 
other regions. The primary reason for this was to limit the statistical tests to a few ROIs in order 
to control type I error during the analysis as this is only a small study of oligofructose on brain 
activity. In this study, the six pre-selected priori ROI regions; NAc, amygdala, OFC, 
hippocampus, insula and Acc were determined based on the activation map produced from food 
vs. object contrast which has been used to map with signal activation in another fMRI nutritional 
intervention study (section 4.6.2.4.1). 
 
In order to assess whether the effect of dietary supplementation on ROIs activation was related to 
non-specific changes, control tasks such as object vs. blurred pictures contrast and an audio-
motor-visual task were exposed to volunteers. An audio-motor-visual task mainly looked for 
non-specific changes in lingual gyrus, temporal gyrus and precentral gyrus. The result suggested 
that the effect of supplementation on ROI activation was not related to non-specific 
modifications as no significant difference was demonstrated when viewing blurred vs. object 
images as well as in the temporal gyrus, precentral gyrus and lingual gyrus regios following the 
AMV task. Including a control task in fMRI studies is important as it has been showed that 
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certain dietary components have the ability to alter fMRI BOLD signal activations (Laurienti et 
al., 2003). 
 
In conclusion, supplementing oligofructose had no significant effect on reducing BOLD fMRI 
signal change following visual food-cues stimulation. In contrast, cellulose significantly reduced 
activation in the OFC and to a lesser extent reduced activation in other ROIs. These effects are 
also possibly leads to a trend towards reducing subjective hunger and volume intake scores 
demonstrated in the cellulose group. However, modulation in ROIs did not associate with 
circulating PYY and GLP-1 levels. The lack of effect of oligofructose on reducing fMRI BOLD 
signals possibly because it requires interaction with nutrients to exert its effect on inducing gut 
hormones secretion, thus reducing neuronal activation. This is because oligofructose has been 
shown to augment post-prandial PYY levels following intake with food/meal. Therefore, it might 
be possible that lack of effect on BOLD signals is related to the absence of gut hormone 
secretion. However, as this is only a small study with limitations including a relatively small 
number of volunteers, it is not possible to make a firm conclusion of the effect of dietary fibre on 
brain responses to food images. Therefore, confirmation of these findings needs to be performed 
in a larger cohort. 
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The Development of 
Propionate Carrier Molecule 
as a Method of Understanding 
the Role of Propionate in 
Energy Homeostasis 
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5 Background 
 
5.1 INTRODUCTION 
The results from Chapter 2 to Chapter 4 suggest that fermentable carbohydrate, oligofructose has 
no significant effect in promoting weight loss in overweight / obese volunteers consuming high 
dose supplementation. Here, the effect of supplementing the end product of fermentable 
carbohydrate, SCFA on appetite and energy intake is explored.  
   
It has been hypothesised that SCFAs, the main products generated from colonic fermentation of 
dietary fibres may have a significant role in modulating appetite and body weight. SCFAs are 
postulated to alter energy homeostasis by stimulating the release of anorectic gut hormones from 
the enteroendocrine L-cells possibly by binding to its receptors, FFAR2 and FFAR3 (Karaki et 
al., 2008). Therefore, increasing colonic production of SCFAs may have beneficial metabolic 
effects. Among the SCFAs, propionate is of interest due to its potential effect in modulating 
body composition (Berggren et al., 1996) and adipose tissue metabolism (Ge et al., 2008; Hong 
et al., 2005). Furthermore, recent evidence showed that propionate potentially involved in the 
stimulation of leptin secretion in adipocytes (Al-Lahham et al., 2010b; Xiong et al., 2004), 
therefore raising its potential as an anti-obesity treatment. This chapter will explore the role of 
propionate on gut hormone release and its effect on appetite.  
 
 
5.1.1 Propionate 
Propionate is a SCFA with three carbons and is the second most abundance colonic SCFA produced 
after acetate. Following its production in the colon, propionate is absorbed by the colonyctes and 
rapidly transported to the liver and the periphery. It was reported that 90% of the total propionate 
production is metabolised in the liver and the remaining 10% is circulated to the periphery (Wong et 
al., 2006). Propionate is predominantly produced from bacterial fermentation of dietary fibres in the 
colon. Besides endogenously produced by colonic microbial fermentation, certain foods also contain 
small amounts of propionate. Nevertheless, these foods are also produced from microbial 
fermentation, particularly propionibacteria (Fernandez-Garcia and McGregor, 1994) such as cheese, 
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yogurt, soured cream, sourdough bread and milk. Propionate has also been used as a preservative 
(E280) due to its role as fungal and bacterial growth suppressor (Levison, 1973).  
 
Interestingly, studies have shown that L-rhamnose, a hexose sugar also able to increase serum 
propionate levels by four times compared with lactulose and glucose in both acute and long term 
studies (Vogt et al., 2004a; Vogt et al., 2004b). This suggested that L-rhamnose is potentially a 
propionate producer. In addition of natural food source, some studies also supplemented propionate 
directly to food products, such as  breads (Dakin et al., 2004; Darzi et al., 2012; Liljeberg et al., 1995; 
Liljeberg and Bjorck, 1996; Todesco et al., 1991), pasta (Frost et al., 2003) and also beverage 
(Ruijschop et al., 2008) in order to increase endogenous propionate production. In addition, this 
method also allow for a known amount of propionate to be delivered for metabolic activity. However, 
unlike propionate-derived colonic fermentation, propionate produced as part of the food products or 
added as a fermentative agent is likely to be absorbed in the small intestine, therefore may have 
different metabolic effects compared with propionate generated from colonic bacterial fermentation. 
To date, no known oral ingestion method has been shown to successfully increase propionate-derived 
colonic fermentation. 
 
 
5.1.1.1 The Production of Propionate 
During the colonic fermentation, gut microbiota degrade fermentable carbohydrates such as inulin-
type fructans and resistant starch to propionate mainly via two distinct pathways. Substrates that 
contain pentoses undergo pentose phosphate pathway whilst substance with hexoses configuration 
are metabolised via Embden-Myerhoff-Parnas glycolytic pathway or alternatively, they can also be 
converted to 6-phospho-gluconate before entering pentose phosphate pathway for degradation. Both 
of these pathways generate pyruvate, a primary intermediary for propionate production. Pyruvate is 
then rapidly converted to propionate either via succinate decarboxylase pathway or the acrylate cycle 
(Cummings, 1981; Miller and Wolin, 1996; Prins, 1977; Wong et al., 2006) (figure 5.1). 
  
196 
 
 
 
 
 
 
 
 
5.1.2 Metabolic Effects of Propionate 
 
5.1.2.1 Propionate and Glucose Metabolism 
From the large intestine, propionate is transported to the liver for glucose and lipid metabolism. In 
ruminants, propionate is known as the main gluconeogenic substrate (Leng et al., 1967; Wiltrout and 
Satter, 1972) whilst in humans, it is the only SCFA that is able to generate glucose (Al-Lahham et al., 
2010a). In gluconeogenesis, propionate has two distinct roles; a substrate and also an inhibitor. As a 
substrate for gluconeogenesis, propionate enters kreb cycle through succinyl-CoA, which is then 
converts to oxaloacetate to produce glucose. The gluconeogenic effect of propionate in humans has 
been demonstrated in Wolever et al. (Wolever et al., 1991). In contrast to stimulate glucose 
production, propionate exerts its role as a gluconeogenesis inhibitor by inhibiting activation of 
pyruvate carboxylase, an enzyme that stimulates the conversion of pyruvate to oxaloacetate, 
 Figure 5.1 Colonic production of propionate by gut microbiota. Hexoses and pentoses derived from 
bacterial colonic fermentation of complex carbohydrates, protein or lipids are subsequently metabolised into 
pyruvate which is then either undergo succinate decarboxylation pathway or involved in the acrylate pathways. 
Diagram is adapted from (Al-Lahham et al., 2010a). 
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therefore reducing glucose production. In addition, methyl malonyl-CoA and propionyl-CoA, 
propionate’s metabolites are also involved in gluconeogenesis by decreasing the activation of 
pyruvate carboxylase, hence inhibiting glucose production (Chan and Freedland, 1972; Wong et al., 
2006) (figure 5.2). However, the effect of propionate in regulating blood glucose levels in humans is 
still unclear as data in the literature is inconsistent (Laurent et al., 1995; Todesco et al., 1991). 
 
 
 
Figure 5.2 The role of propionate in gluconeogenesis, from (Verbrugghe et al., 2011). Propionate 
stimulates glucose production by entering citric acid cycle at the level of succinyl-CoA whilst it suppresses 
glucose production via its intermediates, methylmalonyl CoA and succinyl-CoA which inhibit the release of 
pyruvate carboxylase, the enzyme that modulate the conversion of pyruvate to glucose.  
 
 
5.1.2.2 Propionate and Lipid Metabolism 
Evidence from hepatocyte studies suggest that propionate may have a significant role in reducing 
fatty acid synthesis (Demigne et al., 1995; Lin et al., 1995; Nishina and Freedland, 1990). 
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Furthermore, several studies also showed that propionate has a hypocholestrolemic effect (Chen et 
al., 1984; Illman et al., 1988). The direct mechanism of how propionate reduces cholesterol is still 
not fully understood, but it is suggested that addition of propionate suppresses the release of 3-
hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, an enzyme that involved in hepatic 
cholesterol synthesis (Bush and Milligan, 1971; Topping and Pant, 1995). Nevertheless, the role of 
propionate on lowering postprandial lipid levels in humans is controversial as studies showed no 
significant effect on plasma lipid levels after intake of 103 mmol/day and 78 mmol/day propionate 
for one week and seven weeks (Todesco et al., 1991; Venter et al., 1990). Nevertheless, Wolever et 
al. demonstrated that combination infusion of propionate and acetate was able to suppress the 
conversion of acetate to acetyl-CoA, a precursor for cholesterol synthesis (Wolever et al., 1991) and 
therefore reduced serum free fatty acid levels (Wolever et al., 1989). Indeed, addition of propionate 
into radiolabeled acetate infusion significantly reduced the conversion of acetate into triglycerides 
and lowered blood cholesterol levels compared when acetate was infused alone (Wolever et al., 
1995). This finding showed that propionate has a promising role in modulating lipid metabolism. 
However, further investigations are required to confirm this observation. 
 
 
5.1.2.3 Propionate and Insulin Sensitivity 
The role of propionate on reducing free fatty acid and cholesterol levels mentioned in section 
5.1.2.2, leads to a suggestion that propionate is a potential candidate for improving insulin 
sensitivity. Indeed, improved insulin sensitivity following lowering free fatty acid levels has 
been discussed in other studies (Boden, 2002; Boden and Shulman, 2002). Free fatty acids are 
generated from lipolysis in visceral adipose tissue and its secretion have been related with insulin 
resistance (Kennedy et al., 2009; Micha and Mozaffarian, 2009; Sharma and Chetty, 2005). 
Furthermore, the effect of propionate on insulin sensitivity might also relate with the role of 
SCFA receptors, FFAR2 and FFAR3 in stimulating adipogenesis and lipogenesis and 
suppressing lipolysis in adipocyte (section 5.1.2.4). Supplementing propionate in rodents 
(Ximenes et al., 2007) and human diets’ (Darwiche et al., 2001; Liljeberg et al., 1995; Liljeberg 
and Bjorck, 1996) also showed to reduce circulating insulin levels. 
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5.1.2.4 Propionate and Adiposity 
SCFAs have been suggested to have a potential role in regulating adiposity after evidence showed 
that their receptors, FFAR2 and FFAR3 are found in adipocytes cells (Al-Lahham et al., 2010b; 
Brown et al., 2003; Ge et al., 2008; Hong et al., 2005; Le Poul et al., 2003; Xiong et al., 2004) 
(Please refer to Chapter 1 for the characteristic and physiological role of these receptors). Studies 
using 3T3 cell lines and primary mouse adipocytes cell cultures showed that acetate and propionate 
modulated adiposity by suppressing lipolysis and stimulating adipogenesis via FFAR2. Interestingly, 
PPARγ2, a pre-adipocyte differentiation marker was also shown to be stimulated following SCFAs’ 
treatment (Ge et al., 2008; Hong et al., 2005). Although propionate has been shown to have a 
promising role in modulating adiposity, there is a disagreement of the availability of FFAR3 in the 
adipocytes in the literature. This is because after Xiong et al. confirmed the presence of FFAR3 
mRNA expression in human and mouse adipose tissue in 2004, Hong et al. failed to show the same 
effect as Xiong et al. although the same techniques were applied (Hong et al., 2005; Xiong et al., 
2004). Therefore, the availability of FFAR3 in adipocyte tissues is yet to be fully established. 
 
5.1.2.5 Propionate and Leptin Expression   
Recent evidence also showed that SCFAs, particularly propionate potentially plays a role in 
stimulating leptin secretion in rodents, bovine and human adipocytes (Al-Lahham et al., 2010b; 
Hong et al., 2005; Lee and Hossner, 2002; Soliman et al., 2007; Xiong et al., 2004). However, Al-
Lahham et al. demonstrated that the levels of propionate needed to induce leptin secretion in in vitro 
human adipocytes explants are relatively high compared to the levels produced endogenously by the 
colonic fermentation, therefore questioning whether this is achievable in vivo (Al-Lahham et al., 
2010b). In another experiment, Xiong et al. showed that propionate stimulated leptin production 
(increased by 2 fold) potentially via its receptor, FFAR3 in mice which were orally feed by gavage. 
However, the stimulated leptin levels were insufficient to reduce food intake. Nevertheless, it is 
interesting to note that the propionate supplemented in this study was in the physiological range 
therefore raising a possibility to be applied endogenously (Xiong et al., 2004). Taken together, these 
findings suggest that propionate may have a pronounced role in stimulating leptin expression, 
however the actual mechanism of how propionate regulates this process is yet to be determined.  
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5.1.3 Effects of Supplementing Propionate on Gut Hormones Released, Satiety and 
Food Intake 
Studies have suggested that adding propionate in the diet leads to increased satiety sensation 
(Liljeberg et al., 1995; Liljeberg and Bjorck, 1996; Ruijschop et al., 2008), which is suggested to  
be due to a delay of gastric emptying (Liljeberg and Bjorck, 1996). In addition, Frost et al. 
agreed that adding 3 g of sodium propionate (31 mmol) into pasta not only delayed gastric 
emptying, but also increased plasma GLP-1 release and lowered postprandial glucose levels. 
Surprisingly, inclusion of propionate into sourdough bread administered to 12 healthy volunteers 
did not alter either appetite or energy intake in an acute test meal study (Darzi et al., 2012) 
possibly due to lower amount of propionate supplemented (2.3 mg/g propionic acid and 2.98 
mg/g calcium propionate). In contrast to other studies (Darwiche et al., 2001; Liljeberg et al., 
1995; Liljeberg and Bjorck, 1996; Todesco et al., 1991), this study supplemented low amount of 
propionate in order to investigate the effect of palatable propionate bread as it has been 
suggested that high supplementation of propionate could caused nausea (Frost et al., 2003), 
which could be a confounding factor in reducing energy intake and appetite. Therefore, Darzi et 
al. suggested that the effect of propionate on energy intake and appetite scores demonstrated in 
these studies (Darwiche et al., 2001; Frost et al., 2003; Liljeberg et al., 1995; Liljeberg and 
Bjorck, 1996; Todesco et al., 1991) were influenced by the unpalatable propionate taste, not a 
metabolic effect. 
 
Recently, infusion of 20 mmol (peripheral) and 60 mmol (rectal) acetate in six hyperinsulinemic 
female patients has been shown to increase PYY and GLP-1 secretion. However, no effects on 
adiponectin and ghrelin secretion were demonstrated (Freeland and Wolever, 2010). In contrast, 
rectal infusion of 54 or 90 mmol of mixed SCFA (37.8 and 63 mmol acetate respectively) 
showed no effect on stimulating GLP-1, PYY and oxyntomodulin release (Ropert et al., 1996). 
These discrepancies might be due to different rates of infusion administered, which subsequently 
influenced the gut hormones secretion. In these studies, Freeland et al. infused 300 ml in 8 mins 
(37.5 ml/min) whilst Ropert et al. administered 180 ml in 60 mins (3 ml/min) (Freeland and 
Wolever, 2010; Ropert et al., 1996).  
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Despite SCFAs supplementation being shown to modulate appetite and gut hormones secretion, 
there are not many studies that have investigated SCFAs role on body weight. There is currently 
only one human study to investigate the role of SCFA on body weight. In this study, a low dose 
(15 ml or equivalent to 12.5 mmol acetate) or high dose (30 ml or equivalent to 25 mmol acetate) 
apple cider were supplemented in 105 obese Japanese volunteers for 12 weeks. The result 
showed that including acetate in a diet significantly reduced body weight, BMI, body fat and 
waist-hip ratio compared to the control (Kondo et al., 2009). In animals, supplementing 
propionate (4.3 % w/w) and butyrate (5 % w/w) in mice diet have been shown to suppress body 
weight gain in four weeks study (Lin et al., 2012). These encouraging results highlight the 
potential role of SCFAs supplementation as an anti-obesity treatment. However, this effect needs 
to be strengthened with extensive investigations to support this observation.  
 
 
5.1.3.1 Challenges in delivering SCFAs to the large intestine 
Although including SCFAs into diet have been shown to positively affect energy homeostasis, 
there are some drawbacks that might limit potential use as a food supplement. As previously 
mentioned, current available methods in delivering SCFAs to the gut are either via oral feeding 
and rectal infusion. Rectal infusion, although successfully able to deliver a high amount of 
SCFAs to the colon, is not a practical method to use both in clinical and free-living individual 
monitoring. Therefore, oral feeding is the only practical and suitable method to deliver the 
SCFAs to the gut (Bonnema et al., 2010; Karalus et al., 2012). However, oral supplementation 
with high fibre diets, although potentially demonstrated to suppress appetite and improve body 
composition, is related to gastrointestinal side effects, which can discourage food intake, thus 
this can confound the effect on appetite and energy intake. Inclusion of SCFAs per se in oral 
supplementation showed to potentially suppress appetite and body weight, the main challenge is 
the side effect (nausea), poor organoleptic issues and its short circulating plasma half-life (Darzi 
et al., 2011; Frost et al., 2003; Liljeberg et al., 1995; Liljeberg and Bjorck, 1996). 
 
The challenge is how to modulate energy homeostasis with SCFA without generating the adverse 
side effect. Therefore, a new route is needed to ensure increased colonic SCFA production 
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without the negative side effects associated with high fibre diets or oral supplementation of 
SCFAs. In order to achieve this goal, a collaboration with Dr Douglas Morrison and his 
colleagues from Scottish Universities Environmental Research Centre (SUERC), Glasgow, 
Scotland UK), we have created a novel delivering system whereby, propionate is bound to a 
carrier molecule (i.e. fermentable carbohydrate, inulin). This bound propionate can only be 
cleaved by colonic enzymes, which ensures that the conjugated propionate is released only after 
it arrives in the colon and the carrier is then digested by the gut microbiota. It is therefore 
proposed that by supplementing food with this novel propionate carrier molecule (PCM) will 
generate high colonic levels of propionate to stimulate FFAR2/FFAR3 receptors on L-cells to 
release gut hormones PYY and GLP-1 and increase satiety. The propionate carrier molecule 
could therefore be used as an effective treatment for obesity and its associated co-morbidities. 
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5.2 AIMS & HYPOTHESIS  
 
 
5.2.1 AIMS 
To develop an effective method of increasing colonic propionate levels in order to stimulate PYY and 
GLP-1 production leading to suppressed appetite and body weight. To achieve this objective, the 
following parameters were measured: 
 
 Breath hydrogen release as a surrogate marker of colonic fermentation  
 
 Plasma anorectic gut hormones, GLP-1 and PYY  
 
 Subjective appetite scores using VAS 
 
 Energy intake during ad libitum meal.   
 
 
 
5.2.2 HYPOTHESIS 
Delivering propionate, to the colon using a novel carrier molecule would stimulate the release of 
postprandial GLP-1 and PYY levels, affect appetite and decrease energy intake at an ad libitum meal. 
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These sections onwards will discuss four different propionate carrier molecule pilot studies 
which are the first investigations performed in humans.  
 
5.3 STUDY 1: A first-in-man study to evaluate the safety, tolerability, colonic 
fermentation and gut hormones of Propionate Carrier Molecule: A single-
blinded, pilot study. 
 
 
Aim: To investigate the tolerability of 10 g propionate carrier molecule and its effect on colonic 
fermentation, GLP-1 and PYY levels and energy intake. 
 
Hypothesis: Supplementing the diet with 10 g propionate carrier molecule would be well-
tolerated in humans, increases colonic fermentation and trigger the release of anorectic gut 
hormones. 
 
 
 
5.3.1 Materials  
 
 
5.3.1.1 Propionate Carrier Molecule 
The propionate carrier molecule (PCM) supplemented in this study was formulated and 
synthesized by Dr. Douglas Morrison from SUERC, Scotland, UK. This molecule is synthesized 
by chemically joining propionate to some of the carboxyl groups of fructose units via a novel 
conjugating system. In this conjugated molecule, PCM with a degree of esterification (DE) 0.25 
was used in this study. This would allow 10% propionate to be bound to inulin. This means that 
in 10g PCM supplemented into a diet, one gram of propionate was added to nine grams inulin. 
Following supplementation, PCM is brought to the colon intact where the conjugated linkage is 
digested by the colonic enzymes. Inulin is then fermented by the gut microbiota. The exact 
methodology for the production of the PCM is currently in the process of getting intellectual 
property pattern. Hence, the exact method of this product is protected.  
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5.3.1.2 Dietary Treatments 
PCM was added to wholemeal bread rolls which each roll contained ten grams PCM. The study 
control was also made from wholemeal bread, but without addition of PCM. The bread rolls 
weighted 110 g and were provided by Premier Foods, Holgran-Hovis division (Lichfield, 
Staffordshire, UK). The rolls were formulated to have the same taste and energy content of 320 
kcal or 1339 kJ/100g and were stored at -20ºC before distributed to volunteers for home 
supplementation. The ingredient of the bread rolls are described below in Table 5.1. 
 
Table 5.1 Ingredient of the control and propionate carrier molecule bread rolls  
Ingredient Weight (g) / bread roll %  
   
Bakers pride (flour) 57.6 52.3 
Zippy + 0.6 0.5 
Water 39.4 35.9 
Block yeast 1.7 1.6 
Salt 0.9 0.8 
PCM (Treatment visit only)  9.8 8.9 
Total 110 100 
   
 
 
5.3.1.3 Volunteers 
As this is the first time that PCM is investigated in human, a small pilot study was performed in 
six volunteers (four men and two women), aged between 21 to 65 years old and BMI in the range 
of 25 to 35 kg/m
2
 following approval from Hammersmith, Queen Charlotte’s and Chelsea 
Research Ethic Committee (08/H0707/99) (Registration No: NCT00750438). Written informed 
consent was obtained from each volunteer before the study began. Volunteers were recruited 
through poster advertisements at Hammersmith Hospital, St. Mary’s Hospital, Charing Cross 
Hospital and the South Kensington campus of Imperial College London. Volunteers had a stable 
weight (not gain or loss weight more than three kg prior the start of the study), were free from 
any chronic diseases and were not on any prescription medication.  
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5.3.2 Methods 
 
5.3.2.1 Study Design 
 
5.3.2.1.1 Screening Session 
Potential volunteers were first asked to attend a screening session in which their weight and 
height were measured, blood pressure was monitored, heart checked using an ECG and a small 
amount of blood for full blood count, urea and electrolytes, liver function tests, thyroid function 
tests and blood glucose levels were obtained. In order to access their dietary intake, volunteers 
were asked to complete DEBQ (van Strien et al., 1986) and SCOFF questionnaires (Morgan et 
al., 1999). Volunteers who were identified as restrained dieters from the questionnaires were not 
enrolled into the study. The study was performed in accordance with the declaration of Helsinki.  
 
5.3.2.1.2 Before the Study Day 
Volunteers were given verbal and written instruction to refrain from drinking alcohol, 
undertaking strenuous physical activity or abnormal energy intake for 24 hours before the study 
sessions. They were asked to eat a standardised evening meal and commencing a 10-12 hour fast 
before attending appetite study day the next morning. Only water was allowed to be consumed 
during this time. They were asked to complete a food diary 24 hours before each study day to 
ensure the standardised meal was consumed. The food diaries were analysed using Dietplan6 
(Forestfield Software Ltd, West Sussex, UK). 
 
5.3.2.1.3 Assessment Day 
Volunteers were asked to attend two feeding study sessions at Sir John McMichael Centre, 
Hammersmith Hospital at 0845 after been fasted for 10 – 12 hours. The study days commenced 
at 0900 and finished at approximately 1500. An intravenous cannula was inserted into 
antecubital vein for blood sampling throughout the study day. Meals, hydrogen breath tests and 
serial blood samples were administered at defined time points (the parameters are described in 
the section 5.3.2.1.3.1, 5.3.2.1.3.2 and 5.3.2.1.3.3). Volunteers were asked to remain seated 
during the study with minimal physical activity. Study day one was the control study day where 
no supplement was given. Before volunteers were discharged home, they were given five bread 
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rolls containing ten grams of PCM for home consumption. They were advised to consume one 
roll per day by dividing it into three equal portions to eat with their breakfast, lunch and dinner. 
Five days PCM supplementation was performed in order for the gut to adapt with the new diet 
and reduce any potential gastrointestinal side effects. On day seven (study day 2), ten grams 
PCM was supplemented in the bread rolls and served during breakfast. The rest of the study 
protocol was similar to the study day one. Compliance was checked by counting the uneaten 
bread rolls returned on the second study day. An overview of the study is depicted in figure 5.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.2.1.3.1 Study Meals 
Standardised breakfast and lunch were served at 0 and 180 minutes respectively. Meals supplied 
during the study days were based on choices made during the screening visit and these were 
applied for both of the study days (table 5.2). During the meal intake, volunteers were instructed 
to finish both of their breakfast and lunch within 10 and 30 minutes respectively.  
  
Supplemented with 10 g/d 
PCM  
 
10 g/d home 
supplementation 
 
Day -1 
 
 
Feeding study day 1 
 
Feeding study day 2 
0900 
(0 min) 
Breakfast 
 
1130 
(180 mins) 
Lunch 
 
1430 
(360 mins) 
 
0900 
(0 min) 
Breakfast 
 
1130 
(180 mins) 
Lunch 
 
1430 
(360 mins) 
Day 1 to day 5 
 
                       = Fasting 
     = Blood & Breath test 
     = Breath hydrogen test 
Figure 5.3 The schematic diagram of propionate carrier molecule pilot study. Volunteers were asked to 
attend two appetite study days; the control study day and 10 g PCM supplementation study day. A day after 
attending the control study day, volunteers started their 10 g/day PCM supplementation at home for 5 days. 
They completed their study by attending the supplementation study day on day 7 in which 10 g of PCM was 
administered.  On each appetite study day, blood and breath hydrogen test were obtained throughout of the 
study period. The time course of the study were the baseline -10 and 0 mins whilst 30, 60, 120, 180, 210, 240, 
270, 300, 330 and 360 mins for postprandial measurement. 
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Table 5.2 Meals options and macronutrients composition on the study days. 
 Carbohydrate Protein Fat Energy (kcal) 
Breakfast      
150 ml semi-skimmed milk 7.05 5.10 2.55 69.00 
250 ml Tropicana orange juice 22.50 1.75 - 107.50 
110 g propionate ester / control roll 62.90 15.30 2.70 352.00 
6.5 g butter 
 
0.01 0.03 5.31 47.91 
Cereals (chosen by volunteers)     
 30 g Nestle Cookie crisp 24.03 1.92 1.02 113.10 
 30 g Nestle Nesquick 23.73 2.19 1.14 113.70 
 30 g Nestle golden nugget 25.20 2.10 0.45 113.40 
     
10 g PCM bread rolls    320 kcal 
     
Lunch (One of the ready meal below)     
     
Ready meals (Sainsbury’s)     
 Spaghetti Bolognese 64.70 28.90 21.10 141.0 
 Tomato & mozzarella pasta bake 72.00 20.20 12.80 120.0 
 Chilli con carne 50.00 34.70 11.30 98.00 
     
 
 
5.3.2.1.3.2 Breath Hydrogen Assessment 
Breath hydrogen was assessed in the same method applied in the previous oligofructose study 
(section 2.3.2.2.3). The timepoints were -10, 0, 30, 60, 120, 180, 210, 240, 270, 300, 330 and 
360 minutes.   
 
 
5.3.2.1.3.3 Gut Hormones Analysis 
Blood sampling for gut hormones PYY and GLP-1 were drawn and collected into lithium 
heparin tubes containing aprotinin (200 µl/7.5 ml blood). Each sample was then spun at 4000g at 
4
o
C for 10 minutes and the plasma separated and divided into aliquots before immediate storage 
at -80
o
C. Gut hormones, PYY and GLP-1 were analysed using radioimmunoassay. Please refer 
to section 2.3.2.2.5 for the RIA methodology.   
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5.3.2.1.3.4 Gastrointestinal side effect assessment 
In order to assess tolerability of the supplement, gastrointestinal side effects of stomach 
discomfort, nauseous, bloating, flatulence, heartburn, belching and diarrhoea scores were 
measured at 120 minutes using VAS (section 2.3.2.2.2). 
 
 
5.3.2.1.4 Statistical Analysis 
Data are presented as means ± SEM.  Before statistical analyses were performed, data was 
checked for Gaussian distribution using the Kolmogorov-Smirnov test. All the data involved in 
this study are normally distributed. The area under the curve for breath hydrogen, plasma GLP-1 
and PYY were calculated using the trapezoid rule. Differences between PCM and the control 
treatment for tAUC360mins breath hydrogen levels, tAUC120min postprandial GLP-1 and PYY 
levels as well as side effects assessment were assessed using a student two-tailed paired t-test. 
Statistical significance is defined by a P value of 0.05 or less and all statistical analysis was 
performed using GraphPad Prism 5 (GraphPad Software, San Diego CA, USA).   
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5.3.3 Result 
 
5.3.3.1 Volunteers Characteristics 
Six participants (male=4 and female= 2) with mean age 36.8 ± 5.8 years (age range: 21 – 55 
years) and BMI 30.5 ± 1.4 kg/m
2
 were enrolled into this study, all of which completed both of 
the study days.  
 
5.3.3.2 PYY and GLP-1 Analysis 
Figure 5.4 shows tAUC120min plasma PYY (i) and GLP-1 levels (ii). Consumption of PCM 
supplementation on day seven showed a trend towards higher tAUC120mins PYY levels (P=0.059) 
(5884.4 ± 534.7 pmol/l*min) compared to the control group (4873.0 ± 494.3 pmol/L*min). In 
contrast, no significant effect of treatment (P=0.218) on plasma GLP-1 levels was demonstrated.   
 
i)      ii) 
 
 
Figure 5.4 tAUC120min postprandial plasma PYY (i) and tAUC120min GLP-1 (ii) levels following intake of 10 
g of PCM and control supplementations. The doses were supplemented to volunteers at 0 min. 
Standardised breakfastand lunch were provided at 0 and 180 mins respectively. Data is expressed as mean ± 
SEM, (n = 6).  
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5.3.3.3 Breath Hydrogen Analysis 
Figure 5.5 demonstrates the breath hydrogen levels and tAUC360mins following intake of PCM 
and the control treatments. Intake of PCM significantly increased tAUC360minsbreath hydrogen 
excretion (P=0.048) compared to the control treatment. Fasting breath hydrogen levels were 
increased with PCM (PCM: 8.9 ± 4.5 ppm) but this was not significant (P=0.270) when 
compared with the control treatment (control: 2.4 ± 1.6 ppm). Intake of PCM consumption also 
led the breath hydrogen to peak at 270 minutes and remained in the higher levels until the end of 
the assessment timepoint. Contradictory, breath hydrogen following intake of control treatment 
resulted the levels remained under 15 ppm throughout the study period, mean ± SEM (36.7 ± 
10.6 ppm and 12.2 ± 6.6 ppm (PCM and control respectively). 
 
 
Figure 5.5 Breath hydrogen excretion (ppm) and tAUC360mins (inset) following intake of 10 g of PCM 
and control supplementations. The doses were supplemented to volunteers at 0 min. Standardised 
breakfast and lunch were provided at 0 and 180 mins respectively. Data is expressed as mean ± SEM, (n = 6). 
*P=0.048 PCM vs. control.  
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5.3.3.4 Side Effects Assessment 
PCM supplementation was well-tolerated when rated at 120 mins with low cases of 
gastrointestinal side effects were reported. Ratings of stomach discomfort (P=0.625), nauseous 
(P=0.289), bloated (P=0.708), flatulence (P=1.000), heartburn (P=0.500), belching (P=0.177) 
and diarrhoea (P=0.500) were not significantly difference between the treatments (Figure 5.6).  
 
 
 
 
Figure 5.6 Assessment of GI side effects; stomach discomfort, nausea, bloating, flatulence, heartburn, 
belching, diarrhoea and bowel habits following 2 hours intake of 10 g PCM and control. The doses were 
supplemented to volunteers at 0 min. Standardised breakfastand lunch were provided at 0 and 180 mins 
respectively.  Data is expressed as mean ± SEM, (n = 6) 
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5.3.4 Discussion 
Propionate carrier molecule (PCM) is a novel SCFA colonic delivery method and its effect in humans 
has not yet been investigated. Therefore, the aim of this study was to investigate tolerability and its 
ability to deliver propionate directly to the human gut. In addition, its effect on postprandial gut 
hormones levels was also explored. The findings from this study will then be used in an investigation 
looking at the effect of PCM on appetite and energy intake in overweight and obese volunteers 
(Study 2).  
 
The result of this study is consistent with the hypothesis that supplementing 10 g PCM for five days 
in six overweight volunteers was generally well-tolerated with no significant gastrointestinal side 
effect. Only one volunteer scored moderate on bloating scores. Evidence showed that increasing fibre 
intake in the diet could be associated with bloating and flatulence (Bonnema et al., 2010; Cani et al., 
2006a; Karalus et al., 2012). However, these side effects were usually reported following high fibre 
intakes (>20 g), whilst less effects were demonstrated with fibre dose less than 15 g/day (Kaur and 
Gupta, 2002). Another issue was that some volunteers reported that intake of PCM bread rolls 
associated with bitter taste. It is speculated that the bitter taste could be attributed to the unbound 
propionate which was released during the binding of propionate to inulin. The palatability of the 
PCM will be improved in the next study. 
 
Breath hydrogen analysis showed that adding PCM to the diet of volunteers significantly increased 
tAUC360min breath hydrogen levels compared to the control. In addition, the levels peaked at 270 
minutes with mean value of 37 ppm, suggesting that PCM took approximately five hours to reach the 
colon to be fermented by the gut microbiota. Interestingly, after peaking at 270 minutes, breath 
hydrogen excretion levels seemed to be maintained at that level until the end of the study period. 
Hence, it might be possible that the fermentation activities were still occurring after six hours PCM 
ingestion. In contrast to PCM treatment, hydrogen excretion remained at a low level (≤ 10 ppm) 
throughout the experiment in the control group. Piche et al. suggested that the elevation of breath 
hydrogen levels of more than 10 ppm from the baseline as an indicator of fermentable carbohydrate 
reaching the cecum thus activating the colonic bacterial fermentation (Piche et al., 2003). This 
observation highlights the potential of SCFA-carrier complex system to be used as a mediator to 
deliver specific SCFA to the colon. However, this observation remains to be investigated. 
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Evidence suggests that increased hydrogen excretion following fibre intake is associated with an 
increase in PYY and GLP-1 released (Cani et al., 2009; Frost et al., 2003; Gee and Johnson, 
2005; Piche et al., 2003; Verhoef et al., 2011). In the present study, diet containing PCM showed 
a trend towards increasing tAUC120mins plasma PYY levels, but no significant effect on plasma 
GLP-1 was observed. It might be possible that the SCFA-carrier complex provided in this study 
is insufficient to increase colonic SCFA levels to a level that would increase gut hormone 
release. Nevertheless, it is might be possible that five days intake of PCM is not long enough to 
elevate plasma GLP-1 release compared to plasma PYY secretion. In contrast to our study, Cani 
et al. and Verhoef et al. showed an increase of plasma GLP-1 levels after 13 and 16 days of 
fermentable carbohydrates supplementation (Cani et al., 2009; Verhoef et al., 2011). Also, the 
fact that this study involved a small number of volunteers (n=6) might have resulted in 
insufficient power to detect changes in gut hormone release.  
 
As a conclusion, this acute pilot study suggested that diet containing PCM was well-tolerated by 
volunteers, increased colonic fermentation activities and increased plasma PYY secretion. 
Further investigation is warranted to determine the possible effect of the PCM on appetite 
control.  
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5.4 STUDY 2: The Effects of Propionate Carrier Molecule on Colonic 
Fermentation, Gut Hormones Release and Appetite: A Controlled, 
Randomised, Double-Blind, 5 weeks study. 
 
Aim: To investigate the effect of supplementing 10 g propionate carrier molecule on colonic 
fermentation, postprandial GLP-1 and PYY levels, appetite and energy intake.   
 
Hypothesis: Diet containing propionate carrier molecule would significantly increase PYY and 
GLP-1 and subsequently suppress appetite and energy intake. 
 
 
5.4.1 Materials 
 
5.4.1.1 Dietary Treatments 
In addition to PCM, inulin was used as a positive control in this study. Inulin, Beneo HP, 
Raftiline batch HPHPD7BPD was acquired from Sudzucker AG Mannheim, Ocshenfurt, 
Germany. In order to increase palatability, sourdough bread with added sugar was used in this 
study. In contrast to the previous study, the amount of PCM was reduced from 10 g to 5 g in 
each roll (table 5.3). Therefore, volunteers were required to take two rolls per day in order to 
have 10 g supplementation. In addition, the amount of propionate supplemented in the PCM was 
increased from 10% to 20% (2 g of propionate and 8 g of inulin was provided).  
 
Table 5.3 Ingredient of the control (inulin) and PCM containing bread rolls (g) 
Ingredient Weight / bread roll (g) %  
   
Flour - goldcrest 95.2 86.5 
Raftiline HP inulin / PCM 6.7 6.1 
Sugar 2.9 2.6 
Block yeast 2.9 2.6 
Salt 1.5 1.4 
Zippy plus 1.0 0.9 
Total 110 100 
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5.4.1.2 Sample Size Calculations 
The sample population was calculated using the Russ Lenth power calculator (Lenth, 2009). The 
primary outcome was plasma PYY release with subsequent reduction in appetite feelings and energy 
intake. A difference of 20 pmol/l with standard deviation of 18 pmol/l in each group was considered 
as a significant impact on appetite. Based on a power of 90% with p value of 0.05, it was estimated 
that 20 volunteers were needed to reach the significant. To allow for a drop-out, 26 volunteers were 
recruited. 
 
5.4.1.3 Volunteers 
Healthy overweight volunteers aged between 21 to 65 years old and BMI of 25 to 35 by advertising 
in Hammersmith, St. Mary’s, Charing Cross hospital and Imperial South Kensington’s campus. 26 
volunteers were involved in which each of them giving their written informed consent prior the start 
of the study. Volunteers were comprised of local population, Imperial College of London students 
and six of them were the volunteers from the previous PCM pilot study. Before the study began, 
approval was sought from Hammersmith, Queen Charlotte’s and Chelsea Research Ethic Committee 
(08/H0707/99) (Registration No: NCT00750438) and the study was performed in accordance with 
principles of the Declaration of Helsinki. Volunteers’ details are described in section 5.4.3.1.  
 
5.4.2 Methods 
 
5.4.2.1 Study Design 
 
5.4.2.1.1 Randomisation 
Volunteers were randomly assigned to PCM or inulin group by a colleague who was not 
involved in this study using a sealed envelope system. 
 
5.4.2.1.2 Assessment Day 
Volunteers arrived at Clinical Unit, Sir John McMichael Centre, Hammersmith Hospital at 0830 
in the morning after 10-12 hours overnight fast on the same day every week for five weeks. 
Upon arrival, a cannula was placed in an antecubital vein for the duration of the study. In each 
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visit, the study day started at 0900 and finished around 1500 (360 minutes). Similar with 
previous study, hydrogen breath tests, VAS and blood were collected at -10, 0, 30, 60, 90, 120, 
180, 210, 240, 270, 300 and 360 minutes (figure 5.8). In visit one, volunteers went through an 
acclimatization study day in order for them to familiarise with the study protocol. Visit two was 
the control feeding study with no supplement. After completion of the control study day, 
volunteers were randomised to receive either 10 g/day of inulin or 10 g/day PCM contained in 
bread rolls, to be taken at home for six days before having the next study day the following 
week. During the home supplementation, they were asked to take two rolls a day.  In visit three, 
volunteers had an appetite study day supplemented with inulin / PCM during breakfast and lunch 
based on what they received in the randomization process. After the study day three, they had a 
washout period for seven days. Visit four was a second control feeding study day, hence no 
treatment was provided. Next, the volunteers were swapped their supplementation to the other 
treatment group; so those who had taken PCM previously now took inulin and vice versa. At 
visit five, the final study day, volunteers had either inulin or PCM during the breakfast and lunch 
according to what they received in the previous six days (Figure 5.7). 
 
5.4.2.1.2.1 Study Meals 
The same meals as the previous study were given to volunteers (refer to Section 5.3.2.1.3.1). 
 
5.4.2.1.2.2 Breath Hydrogen Assessment 
The same method has been used with the pilot study (Refer to Section 2.3.2.2.3). 
 
5.4.2.1.2.3 Gut Hormones Analysis 
Blood sampling for gut hormones PYY and GLP-1 were drawn at -10, 0, 30, 60, 90, 120, 180, 
210, 240, 270, 300 and 360 minutes and collected into lithium heparin tubes containing aprotinin 
(200 µl/7.5 ml blood). Each sample was then spun at 4000g at 4
o
C for 10 minutes and the plasma 
separated and divided into aliquots before immediate storage at -80
o
C. Gut hormones, PYY and 
GLP-1 were analysed using RIA. Please refer to Section 2.3.2.2.5 for the methodology.   
 
5.4.2.1.2.4 Subjective Appetite Scores 
The same method has been used with the study 1. Please refer to Section 2.3.2.2.2. 
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Propionate Carrier Molecule 
10 g /d for 6 days 
Inulin  
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Home supplementation Study day Home supplementation  Study 
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Control  
treatment 1 
Control  
treatment 2 
Week 2 Week 3 Week 4 Week 5 Week 1 
 Figure 5.7 The study design. This randomised, double-blind and crossover study consists of 5 study visits; the acclimatization study day (visit 1), control study 
day (visit 2), Supplementation study day 1 (visit 3), control study day (visit 4) and supplementation study day 2 (visit 5). Volunteers were randomised to the 
treatment arrangement after they attended visit 2. The randomisation was performed using envelope system by a colleague of our department who was not 
involved in the study. After the randomisation process, volunteers were given the supplementation to take it at home for 6 days before attended their test 
supplementation study day on visit 3. A week after volunteers had their washout period, they continued the study by having the second supplementation on day 
17 to day 23. Volunteers who had PCM on first supplementation would have inulin on second supplementation, and vice versa.        
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5.4.2.1.3 Statistical Analysis 
Data are presented as mean ± SEM. Prior the analyses, data were checked for Gaussian 
distribution using the D'Agostino & Pearson omnibus normality test. When compared the 
treatment between all groups, tAUC was calculated using the trapezium rule for breath hydrogen, 
postprandial GLP-1 and PYY and VAS result and compared to each group using repeated 
measures one way ANOVA. Postprandial time course for hydrogen breath test was compared 
using one-way repeated measures ANOVA with Bonferroni post hoc test as the data is 
significant. Differences between post-supplementation and baseline of energy intake were 
assessed using a student two-tailed paired t-test. A P value of 0.05 or less was considered 
significant. Statistical analysis was performed on Graph Prism 5 (GraphPad Software, Inc., La 
Jolla, USA). 
 
 
                       = Fasting 
     = Blood sampling, VAS and breath test 
 
0900 
Breakfast ± 
supplement 
 
Standardised 
evening meal 
 
1200 
Lunch ± 
supplement 
 
Study day 
 
Day -1 
 
 
0830 
Cannula 
inserted 
 
1500 
Ad libitum 
meal 
 Figure 5.8 Protocol of the study day. Volunteers were attended the test study days after had their 10 – 12 
hours fasting. Prior to fasting, they were asked to eat a standardised evening meal and finished eating before 
2100 but water was exceptionally allowed until the next morning. Upon arrival, cannula was inserted and 
followed with baseline blood sampling, VAS and breath hydrogen test measured. After they had their 
breakfast, the blood sampling, VAS and breath hydrogen test were continuously accessed every 30 minutes 
throughout the study period. Lunch was provided at 180 minutes (1200) and ad libitum energy intake 
assessment was performed at 360 minutes (1500). Supplementation of either inulin or PCM was included in 
the breakfast and lunch on visit 3 and visit 5 according to the randomization group.  
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5.4.3 Results 
 
5.4.3.1 Volunteers characteristics 
Twenty six volunteers were recruited in this study but only twenty volunteers (male=5 and 
female=15) completed this study. The mean ages were 41.0 ± 2.9 years (21 – 66 years) and BMI 
were 30.3 ± 0.6 kg/m
2
. Two volunteers withdrew from the study due to personal reasons and four 
volunteers who had energy intake more than two standard deviations away from the population 
mean were also excluded.  
 
 
5.4.3.2 Energy Intake 
Including PCM into volunteers’ diets significantly reduced energy intake (P<0.05) by 18.8% 
compared to the baseline visit (392.2 ± 59.4 kcal [control PCM] and 318.3 ± 57.5 kcal[PCM]) 
whilst a reduction of 18.1% was also demonstrated in the inulin group when compared to the 
baseline visit (270.4 ± 43.9 kcal [inulin] and 330.1 ± 47.5 kcal [control inulin]) (Figure 5.9).  
 
 
 
Figure 5.9 Ad libitum energy intake assessment (kcal) following intake of 10 g PCM and inulin 
supplementations. Bread rolls-containing 5 g of either PCM or inulin was served during standardised 
breakfast and lunch at 0 min and 180 mins whilst ad libitum meal was provided at 360 mins. Control inulin and 
control PCM are the study days without any supplementation and performed prior the treatments study days. 
Data is expressed as mean ± SEM, (n = 20).*P<0.05 inulin and PCM vs. control 
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5.4.3.3 Evening Meal Assessment 
This analysis was performed in order to investigate potential variations that might influence 
energy intake on the appetite study day. The result showed that volunteers in both groups 
increased their energy intake during post-supplementation evening meals. In addition, volunteers 
in the inulin group significantly increased energy intake (P=0.046) (Mean ± SEM; 874.3 ± 79.9 
kcal [control inulin], 1038.2 ± 80.7 kcal [inulin], 845.2 ± 94.6 kcal [control PCM] and 1028.8 ± 
87.8 kcal [PCM]) (Figure 5.10). 
 
 
 
Figure 5.10 Evening meal energy intake assessment (kcal) following intake of 10 g PCM and inulin 
supplementations. Bread rolls-containing 5 g of either PCM or inulin was served during standardised 
breakfast and lunch at 0 min and 180 mins whilst ad libitum meal was provided at 360 mins. Control inulin and 
control PCM are the study days without any supplementation. Data is expressed as mean ± SEM, (n = 
20).*P<0.05 inulin vs. control. 
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5.4.3.4 Subjective Appetite Scores 
Supplementing PCM in the volunteers’ diet had no significant effect for tAUC360mins fullness 
(P=0.109), tAUC360mins hunger (P=0.086), tAUC360mins prospective food intake (P=0.076) and 
tAUC360mins desire to eat (P=0.105) compared to other treatments (Figure 5.11 i) – iv)) 
 
 
i)                                                                                     ii) 
 
 
 
 
 
 
 
 
 
 
iii)                                                                            iv) 
 
 
 
 
 
 
 
 
 
Figure 5.11 Subjective appetite scores accessed by VAS following intake of 10 g PCM and inulin 
supplementations i) tAUC360min fullness scores ii) tAUC360min hunger scores iii) tAUC360min prospective food 
intake scores iv) tAUC360min desire to eat scores. Bread rolls-containing 5 g of either PCM or inulin was served 
during standardised breakfast and lunch at 0 min and 180 mins whilst ad libitum meal was provided at 360 
mins. Control inulin and control PCM are the study days without any supplementation. Data is expressed as 
mean ± SEM, (n = 20). 
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5.4.3.5 Gut Hormones Analysis  
 
5.4.3.5.1 GLP-1 Analysis 
Postprandial plasma GLP-1 levels peaked at 210 minutes after ingestion of all treatments (figure 
5.12). No significant effect was demonstrated in tAUC360mins (P=0.389) with mean ± SEM 
tAUC360mins scores of (72140.2 ± 5043.0 pmol/L*min [control inulin], 71826.6 ± 4001.5 
pmol/L*min [inulin], 72107.1 ± 3870.9 pmol/L*min [control PCM] and 67746.6 ± 3892.2 
pmol/L*min [PCM]) (Figure 5.12 [inset]). 
 
 
Figure 5.12 Postprandial plasma GLP-1 levels (pmol/L) and tAUC360min (inset) following 10 g PCM and 
inulin supplementations. Bread rolls-containing 5 g of either PCM or inulin was served during standardised 
breakfast (0 min) and lunch (180 mins) whilst ad libitum meal was provided at 360 mins. Control inulin and 
control PCM were the study days without any supplementation. Data is expressed as mean ± SEM, (n = 20). 
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5.4.3.5.2 PYY Analysis 
Administration of PCM in volunteers’ diet had no significant effect on tAUC360mins plasma PYY 
compared to other treatments (P=0.739) (Figure 5.13). tAUC360mins scores of the treatments are 
7068.6 ± 613.7 pmol/L*min [control inulin], 7098.6 ± 557.9 pmol/L*min [inulin], 7396.7 ± 
484.7 pmol/L*min [control PCM] and 6754.0 ± 607.8 pmol/L*min [PCM] (Figure 5.13 [inset]). 
 
 
Figure 5.13 Postprandial plasma PYY levels (pmol/L) and tAUC360min (inset) following intake of 10 g 
PCM and inulin supplementations. Bread rolls-containing 5 g of either PCM or inulin was served during 
standardised breakfast (0 min) and lunch (180 mins) whilst ad libitum meal was provided at 360 mins. Control 
inulin and control PCM were the study days without any supplementation and performed prior the treatments 
study days.Data is expressed as mean ± SEM, (n = 20). 
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5.4.3.6 Breath Hydrogen Analysis 
Inulin significantly increased (P<0.0001) breath hydrogen excretion compared with other 
treatments. Inulin also increased tAUC360min compared to other treatments but no significant 
difference (P=0.259) was demonstrated (Figure 5.14) (mean ± SEM; 3291.8 ± 589.2 ppm*min 
[control inulin], 5514.8 ± 1042.8 ppm*min [inulin], 4045.7 ± 833.2 ppm*min [control PCM] and 
4389.8 ± 1007.0 ppm*min [PCM]. 
 
 
 
Figure 5.14 Breath hydrogen test (ppm) and tAUC360min (inset) following intake of 10 g PCM and inulin 
supplementations. Bread rolls-containing 5 g of either PCM or inulin was served during standardised 
breakfast (0 min) and lunch (180 mins) whilst ad libitum meal was provided at 360 mins. Control inulin and 
control PCM were the study days without any supplementation. Data is expressed as mean ± SEM, (n = 20). 
*P<0.05 PCM vs. control inulin, **P<0.01 inulin vs. PCM, ***P<0.001 inulin vs. control inulin and control PCM. 
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5.4.4 Discussion 
From Study 1, it is now known that PCM was safely delivered to the colon and subsequently 
involved in the colonic fermentation activities. Furthermore, PCM also increased postprandial 
plasma PYY levels compared to the control treatment. The current study showed that adding 
20% PCM into volunteers’ diet reduced ad libitum energy intake compared to baseline, but had 
no significant difference in breath hydrogen release, plasma PYY and GLP-1 levels and appetite 
sensations when compared to the inulin group. 
 
In contrast to Study 1, inclusion of 20% PCM in this study did not significantly alter breath 
hydrogen levels when compared to baseline study day, but the inulin group did significantly 
increase breath hydrogen levels within the group. However, there was no significant difference 
between the treatments. Adding inulin-type fructans in the diet have consistently been shown to 
increase colonic fermentation in other studies (Cani et al., 2009; Fernandes et al., 2011; Piche et 
al., 2003). In this study, it is suggested that lack of effect of PCM to significantly increase breath 
hydrogen levels is because the amount of inulin in the PCM group was less than the amount 
provided in the inulin group. In PCM group, only 8 g of inulin was provided as the remaining 2 g 
was propionate. In contrast, inulin group provided 10 g inulin for the colonic fermentation. 
Therefore, this might explain the non-significant effect of PCM on breath hydrogen levels.  
 
Moreover, it is also possible that splitting the 10 g dose into 5 g during breakfast and lunch has 
influenced colonic fermentation activities. It was hypothesized that splitting the dose would 
prolong the fermentation activities thus subsequently elevated plasma GLP-1 and PYY released. 
However, the hypothesis was not proven as no significant effect on breath hydrogen released was 
showed. In the pilot study, 10 g PCM supplemented during breakfast took 270 mins to reach the 
colon and subsequently ferment by the gut bacteria. Therefore, it might be possible that splitting 
the dose has diluted PCM levels and consequently minimised the effect of PCM. Therefore the 
twice daily dose used in this study may not be the most effective method to increase 
fermentation activities. However, there is currently insufficient evidence available in the 
literature to elucidate an optimal dosing regimen for fermentable carbohydrate. Peters et al. 
reported that no effects on satiety and energy intake when administered three types of equicaloric 
test bars containing either 0.9 g β-glucan, 8 g fructooligosaccharides or combination of both 
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fibres in two study days (Peters et al., 2009). In contrast, Cani et al. showed that supplementation 
of 8 g of oligofructose twice daily enhance satiety and decreased hunger at meal and dinner for 
two weeks (Cani et al., 2006a). This raises the question as to whether the dose supplied was 
insufficient to increase colonic propionate and modulate gut hormones release. 
 
An increase in colonic fermentation is suggested to correlate with elevation of gut hormones 
release (Piche et al., 2003). In this study, the lack of effect of PCM on increasing colonic 
fermentation mirrored the non significant effect on postprandial plasma PYY and GLP-1 levels. 
Surprisingly, adding inulin in the diet also had no significant effect on plasma GLP-1 and PYY 
levels. The result of this study was opposite to a study on overweight volunteers which showed 
that PYY, but not GLP-1 was significantly increased after 12 weeks intake of 21 g/day 
oligofructose supplementation (Parnell and Reimer, 2009), whilst Cani et al. showed that 
supplementing 16 g/day significantly increased PYY and GLP-1 released in healthy subjects 
(Cani et al., 2009). These studies showed that perhaps there is still no consensus on the effect of 
fermentable supplementation on GLP-1 and PYY in the literature. Furthermore, this discrepancy 
may be related to different methodologies and supplementation periods applied when comparing 
the studies. In addition, PCM is a novel supplement, therefore the effect possibly would not be 
the same with other dietary fibres.     
 
In this study, assessment of appetite rating and energy intake were the main endpoints. Intake of 
inulin and PCM showed to have a similar trend in increasing fullness, reducing hunger, 
prospective food intake and desire to eat sensations within each group, but no significant 
difference was found between the treatments. Meanwhile, energy intake assessment consumed at 
ad libitum meal was significantly decreased in both groups, but no significant difference when 
compared between the groups. However, the reduction of energy intake demonstrated in inulin 
group might have been confounded by a significant increase of evening meal intake prior 
attending the study day. Indeed, the effect of evening meals on baseline hunger as well as plasma 
PYY and GLP-1 have been discussed in details in Chandarana et al. (Chandarana et al., 2009). In 
future, standardised ready meals will be provided in the future studies in order to control for this 
confounding issue. However, the finding of this study seems to have a similarity with the 
observation demonstrated in rodent studies in our lab. In this rodent study, Wistar rats were fed 
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5%, 10% and 20% of their total diet with PCM for 10 days and were compared to cellulose and 
inulin treatment. The result exhibited that whilst 5% PCM showed no effect on food intake and 
body weight, 10% PCM was able to reduce food intake compared to cellulose, but the effect was 
not different when compared to inulin (Peters, 2010). This result suggested that 10% PCM 
possibly has similar effect with inulin in modulating energy homeostasis. A lack of PCM effect 
on appetite may be because of several methodological reasons. The dose used in the present 
study was different from Study 1. In Study 1, 10% PCM was used whilst in this study, 20% PCM 
was supplemented. The dose was increased from 10% to 20% in assuming that this will 
increased propionate delivery to the colon, increased the fermentation activities to secrete gut 
hormones secretion and ultimately altered appetite and energy intake. However, it seems that the 
hypothesis was not proven as there was no clear evidence of change in appetite rating, plasma 
PYY and plasma GLP-1 levels.  
 
Splitting the PCM dose from 10 g per roll taken once at breakfast to five grams per bread roll 
taken at breakfast and lunch might also contribute to the lack of effect of PCM on appetite. The 
dose was split to five grams per bread roll in order to improve palatability as it was reported that 
intake of 10 g per roll in study 1 was associated with bitter taste. In addition, as the control, 
inulin is a natural plant product with a slight sweet taste (Niness, 1999), imbalance taste between 
PCM and inulin was improved by adding 2.85 g sugar in each bread roll. Although this step has 
improved the bread palatability, adding sugars in the bread rolls has resulted in increased caloric 
content compared to the normal bread roll supplemented on the baseline visit (352 kcal in the 
inulin or PCM supplemented bread rolls compared to 240 kcal in the normal brown bread rolls). 
Therefore, it is possible that the discrepancies of the bread rolls caloric content might have 
affected energy intake assessed during the ad libitum meal and increased the caloric intake 
during evening meal.   
 
Following the potential effect of PCM on reducing energy intake demonstrated in this study, 
further investigation on the effect of supplementing different DE of PCM on modulating appetite 
and energy intake will be performed. In the next study (Study 3), the methodological issues that 
were experienced in this study such as the dose levels and method of delivering PCM will be 
investigated.  
  
229 
 
5.5 STUDY 3: The Effects of Propionate Carrier Molecule on Colonic 
Fermentation, Gut Hormones Release and Appetite: A Dose Optimization 
Study 
 
 
Aim: To investigate the degree of esterification of propionate carrier molecule needed to have 
the effective effect on stimulating plasma PYY and GLP-1 release, reduce subjective appetite 
and energy intake. 
 
Hypothesis: Increase degree of esterification of propionate carrier molecule significantly 
increase gut hormones, PYY and GLP-1 and subsequently suppresses appetite and energy intake. 
 
 
 
5.5.1 Materials 
 
5.5.1.1 Dietary Treatments 
In this study, PCM was provided to volunteers in three different DE; 0.25, 0.5 and 0.8. This is to 
provide different amount of propionate in each substance; 0.25 contains 10% propionate per 
PCM, 0.5 has 20% propionate per PCM and 0.8 provided 30% propionate per PCM. PCM and 
inulin were provided to volunteers in white, powdered form and has a similar appearance.  
 
 
5.5.1.2 Volunteers 
Nine healthy volunteers (8 males and 1 female) aged between 21 to 65 years old and BMI of 25 to 35 
were recruited in this study. They were recruited through advertising in Hammersmith Imperial 
College London and Hammersmith Hospital. Volunteers were given their written informed consent 
prior the start of the study. The study was approved from Hammersmith, Queen Charlotte’s and 
Chelsea Research Ethic Committee (08/H0707/99) (Registration No: NCT00750438) and performed 
in accordance with principles of the Declaration of Helsinki. Volunteers’ details are described in table 
5.7. The inclusion and exclusion of this study were the same as Study 1 and Study 2. 
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5.5.2 Methods  
 
5.5.2.1 Study Design 
In this single-blinded, randomised study, volunteers were received 10 g inulin and 10 g PCM 
with 10%, 20% and 30% propionate daily for three days and followed with four days washout 
period every week for four weeks.The first two days were the run-in period in which they needed 
to take 5 g PCM twice on day 1 and 10 g PCM once on day 2. During this period, volunteers 
were given a choice whether to mix it into a drink or with their foods as long as the 
supplementation was not cooked or heated in high temperature. Appetite assessment study day 
was performed on day three. All the study visits were performed in Clinical Unit, Sir John 
McMichael Centre, Hammersmith Hospital (Figure 5.15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 days run-in period 
Study day 
Washout days 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
5 g 5 g 10 g 
Screening 
visit 
10 g inulin 
10 g PCM, DE 0.25 
10 g PCM, DE 0.5 
10 g PCM, DE 0.8 
Figure 5.15 Dose optimization study design. Volunteers were asked to attend 4 study visits; 10 g inulin, 
10 g PCM with DE 0.25, 10 g PCM with DE 0.5 and PCM with DE 0.8. 2 days before attending study visits, 
volunteers take 5 g PCM on the morning and the evening on day 1 and 10 g PCM on the morning of day 2. 
Study day was held on day 3. After the study day, volunteers were had their washout study days for 4 days 
before continued the following supplementation period.   
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5.5.2.1.1 Free-Living Supplementation Period 
 
 
5.5.2.1.2 Appetite Assessment Study Day 
On each study visit, a cannula was inserted in the forearm for blood sampling throughout the 
day. The investigations started at 0900 to 1700 and took approximately 420 minutes to complete. 
Similar with study 1 and study 2, breath hydrogen test, VAS, energy intake assessment and 
blood withdrawal were performed. A day before the study day, volunteers were instructed to 
complete 24 hours food diary to check whether the standardised foods are taken in every visit. 
 
 
5.5.2.1.2.1 Study Meals 
After baseline measurements, volunteers were provided with standardised meals consists of 
breakfast, lunch and an ad libitum meal. The preference of these meals was made by volunteers 
during screening session and their choices were applied for all of the study visits. Breakfast was 
provided at 0 minute with an addition of 10 g of inulin and 10%, 20% and 30% PCM on 4 
consecutive weeks. A lunch was served at 180 minutes. At 420 minutes, an ad libitum spaghetti 
bolognaise was provided for energy intake assessment. Volunteers were instructed to eat until 
comfortably full and the meal was weighed before and after administration (please refers to 
Table 5.4 for macronutrient and energy composition). 
 
Table 5.4 Macronutrient composition and energy content of standardised breakfast, lunch and ad 
libitum meal provided during the study days. 
 CHO Protein Fat Energy (kcal) 
Breakfast      
130 ml semi-skimmed milk 6.50 4.42 2.21 63.70 
300 ml whole milk 14.10 9.60 10.80 192.00 
40 g Chocolate nesquik 31.84 1.68 1.28 150.40 
30 g Rice crispies 26.10 1.80 0.30 114.90 
     
10 g supplement (PCM or Inulin)    320 
     
Lunch     
400 g Sainsburys Chicken and  Mushroom Pie  13.20 28.10 11.90 356.00 
     
Ad libitum meal (g)     
Spaghetti Bolognaise 12.30 7.90 7.00 - 
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5.5.2.1.2.2 Breath Hydrogen Assessment 
Breath hydrogen was assessed in the same method applied in the pilot study (Section 2.3.2.2.3). 
However, in this study, breath hydrogen was accessed at every hour at -10, 0, 60, 120, 180, 240, 
300, 360 and 420 minutes.   
  
 
 
5.5.2.1.2.3 Gut Hormones Analysis 
Blood sampling for PYY and GLP-1 were drawn at -10, 0, 15, 30, 60, 90, 120, 180, 210, 240, 
300, 360 and 420 minutes, which were then analysed using radioimmunoassay. Please refer to 
Section 2.3.2.2.5. 
 
 
5.5.2.1.2.4 Glucose assay 
Glucose samples were analysed in the Department of Clinical Biochemistry, Hammersmith 
Hospital. Analyses of the glucose were performed using an Abbott Architect ci8200 analyser 
(Abbott Diagnostics, Maidenhead, UK). Glucose assay sensitivity was 0.3 mmol/L with an intra-
assay coefficients of variation of 1.0% . 
 
 
 
5.5.2.1.2.5 Insulin Assay 
Blood sampling for insulin were drawn at -10, 0, 15, 30, 60, 90, 120, 180, 210, 240, 300, 360 and 
420 minutes and were determined by using iodine-125 RIA kits (Millipore, Missouri, USA). The 
methods are described in the Section 2.3.2.2.6. 
 
 
5.5.2.1.2.6 Subjective Appetite Scores 
Subjective appetite scores used the same method described in the section 2.3.2.2.2 but in 
different timepoints which were -10, 0, 30, 60, 90, 120, 180, 240, 300, 360, 420 minutes.    
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5.5.2.1.3 Statistical Analysis 
Data are presented as the mean ± SEM. Before the analyses were performed, data were checked 
for Gaussian distribution using the Kolmogorov-Smirnov test. Postprandial time course for 
hydrogen breath test, postrandial GLP-1 and PYY and VAS were compared using one-way 
repeated measures ANOVA with Bonferroni post hoc test if the data is significant. When 
compared the treatment between all groups, AUC was calculated using the trapezium rule for 
breath hydrogen, postprandial GLP-1 and PYY and VAS result and compared to each group 
using repeated measures one way ANOVA. Total mean energy intake in each group as well as 
change from baseline (with inulin as baseline) was also determined by using one way ANOVA. 
A P value of 0.05 or less was considered significant. Statistical analysis was performed on Graph 
Prism 5 (GraphPad Software, Inc., La Jolla, USA). 
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5.5.3 Results 
 
5.5.3.1 Volunteers characteristics 
Table 5.5 characterises the demographic data for the volunteers that participated in this study. 
This is the first time dose optimization study using PCM was performed in humans, therefore 
power calculation based on the previous PCM studies could not be done. All of the volunteers 
were involved in the appetite study day and home supplementation.  
 
 
 
Table 5.5 Baseline characteristics of the study volunteers 
Characteristics Numbers 
Completed (n) 9 
Withdrawn (n) 0 
  
Sex (n)  
 Male 8 
 female 1 
  
Age  26.3 ± 2.0 
Age range  21 – 39 
BMI (kg/m
2
)        23.9 ± 0.7 
                                             Values are expressed as mean ± SEM 
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5.5.3.2 Energy intake 
Supplementing PCM into volunteers’ diet showed to have a dose response effect to reduce 
energy intake with 30% PCM showed as the highest reduction compared to inulin [Figure 5.16 i) 
and ii)]. In addition, change from baseline showed a reduction of 4.3% for 10% PCM, 7.5% for 
20% PCM and 15.9% for 30% PCM. However, there was no significant differences between the 
treatments (P=0.208). The mean energy intake of the treatments was 1120.0 ± 131.7 kcal 
[inulin], 1061.0 ± 135.6 kcal [10% PCM], 1034.0 ± 124.2 kcal [20% PCM] and 930.4 ± 124.2 
kcal [30% PCM]).  
i) 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii) –  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16 Ad libitum energy intake assessment (kcal) (i) and change from baseline (kcal) (ii) 
following intake of 10g inulin, 10% PCM, 20% PCM and 30% PCM. PCM was supplemented in volunteers’ 
meal at breakfast (0 min). Standardised breakfast, lunch and ad libitum meal were provided at 0, 180 and 420 
minutes respectively. Data is expressed as mean ± SEM, (n = 9). 
  
236 
 
5.5.3.3 Subjective Appetite Scores 
Including 10%, 20% and 30% PCM in the diet tended to have dose-response effect on increasing 
iAUC420mins fullness scores, reducing hunger and prospective food intake but these were not 
statistically significant when compared to inulin (P=0.398, P=0.757 and P=0.826 respectively) 
[Figure 5.17 i) - vi)]. No significant difference was also found in iAUC420mins pleasant to eat scores 
(P=0.991),  
 
i)                                                                                    ii) 
 
 
 
 
 
 
 
 
iii)                                                                            iiii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17 Subjective appetite ratings following intake of inulin, 10% PCM, 20% PCM and 30% PCM. i) 
fullness scores ii) iAUC420min for fullness scores iii) hunger scores iiii) iAUC420min for hunger scores v) 
prospective food intake scores vi) iAUC420min for the prospective to eat scores vii) pleasant to eat scores viii) 
iAUC420min for pleasant to eat scores. PCM was supplemented in volunteers’ meal at breakfast (0 min). 
Standardised breakfast, lunch and ad libitum meal were provided at 0, 180 and 420 minutes respectively. Data 
is expressed as mean ± SEM, (n = 9). 
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5.5.3.4 Breath Hydrogen Analysis 
Supplementing different dose of PCM increased breath hydrogen excretion starting from 180 
minutes ingestion with 10% PCM showed the highest released of breath hydrogen. However, this 
was not significant when compared to inulin (Figure 5.18). Inulin significantly increased breath 
hydrogen analysis (P=0.006) and tAUC420mins excretion levels compared to all treatment 
(P=0.015). Mean tAUC/time of breath hydrogen excretion for inulin 10% PCM, 20% PCM and 
30% PCM are 28.4 ± 3.0 ppm/mins, 22.7 ± 3.2 ppm/mins, 17.1 ± 1.5 ppm/mins and 20.7 ± 2.1 
ppm/mins. 
 
 
 
Figure 5.18 Hydrogen breath test (ppm) and tAUC420mins (inset) following 7 hours intake of inulin, 10% 
PCM, 20% PCM and 30% PCM. PCM was supplemented in volunteers’ meal during breakfast. Standardised 
breakfast, lunch and ad libitum meal were provided at 0, 180 and 420 minutes respectively. Data is expressed 
as mean ± SEM, (n = 9). *P=0.015, *P<0.05 inulin vs. 20% PCM, ***P<0.001 inulin vs. 30% PCM. 
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5.5.3.5 Plasma Metabolites 
 
 
5.5.3.5.1 PYY Analysis 
In this analysis, only dose PCM 30% was selected as this dose has been shown to reduce energy 
intake at optimum levels compared to other dose. Inclusion of 30% PCM in the diet showed to 
increase plasma PYY levels and peaked at 300 minutes after ingestion of the supplement (Figure 
5.19). iAUC420mins for plasma PYY secretion after intake of 30% PCM was significantly increased 
compared to inulin supplementation (P=0.047) (mean ± SEM; 358.6 ± 490.3 pmol/L*min [inulin] 
and 1818.0 ± 397.8 pmol/L*min [30% PCM] (Figure 5.19 [inset]). 
 
 
 
Figure 5.19 Postprandial PYY levels (pmol/L) and iAUC420mins (inset) following intake of inulin, 10% 
PCM, 20% PCM and 30% PCM. PCM was supplemented in volunteers’ meal during breakfast. Standardised 
breakfast, lunch and ad libitum meal were provided at 0, 180 and 420 minutes respectively.  Data is expressed 
as mean ± SEM, (n = 9).*P<0.05 30% PCM vs. inulin. 
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5.5.3.5.2 GLP-1 Analysis 
Similar with PYY analysis, only 30% PCM dose was selected for this analysis. Addition of 30% 
PCM showed no significant effect on increasing GLP-1 levels compared to inulin treatment 
(P=0.338) (Figure 5.20). iAUC420mins for plasma GLP-1 secretion after PCM supplementation was 
not significant when compared to inulin (P=0.109) (mean ± SEM; 4244.0 ± 683.8 pmol/L*min 
[Inulin] and 2130.0 ± 875.3 pmol/L*min [30% PCM] (Figure 5.20 [inset]). 
 
 
 
Figure 5.20 Postprandial GLP-1 levels (pmol/L) and iAUC420min (inset) following intake of inulin, 10% 
PCM, 20% PCM and 30% PCM. PCM was supplemented in volunteers’ meal during breakfast. Standardised 
breakfast, lunch and ad libitum meal were provided at 0, 180 and 420 minutes respectively.  Data is expressed 
as mean ± SEM, (n = 9). 
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5.5.3.5.3 Plasma glucose 
Inclusion of different dose of PCM showed no significant effect on reducing postprandial glucose 
levels compared to inulin group (P=0.972) (Figure 5.21). tAUC/Time for the plasma glucose 
response between 0 and 420 minutes after addition of PCM was not significantly different between 
the treatments (P=0.506) (mean ± SEM; 5.5 ± 0.2 mmol/L*min [inulin], 5.4 ± 0.2 mmol/L*min 
[10% PCM], 5.5 ± 0.1 mmol/L*min [20% PCM] and 5.4 ± 0.3 mmol/L*min [30% PCM]) (Figure 
5.20 [inset]). 
 
  
 
Figure 5.21 Postprandial glucose levels (mmol/L) and tAUC420min (inset) following intake of inulin, 10% 
PCM, 20% PCM and 30% PCM. PCM was supplemented in volunteers’ meal during breakfast. Standardised 
breakfast, lunch and ad libitum meal were provided at 0, 180 and 420 minutes respectively. Data is expressed 
as mean ± SEM, (n = 9). 
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5.5.3.5.4 Insulin Analysis 
Supplementing PCM into volunteers’ diet showed a trend towards reduction insulin levels (P=0.060) 
when dose levels were increased. 30% PCM showed to reduce insulin levels 30 minutes and 240 
minutes after ingestion compared to other treatment (Figure 5.22). tAUC/Time (mean ± SEM; 63.3 ± 
8.6 uU/ml*min [inulin], 59.0 ± 5.9 uU/ml*min [10% PCM], 52.8 ± 5.2 uU/ml*min [20% PCM] and 
48.8 ± 5.7 uU/ml*min [30% PCM] (Figure 5.22 [inset]). 
 
 
 
Figure 5.22 Postprandial insulin levels (uU/ml) and tAUC420min (inset) following intake of inulin, 10% 
PCM, 20% PCM and 30% PCM. PCM was supplemented in volunteers’ meal during breakfast. Standardised 
breakfast, lunch and ad libitum meal were provided at 0, 180 and 420 minutes respectively. Data is expressed 
as mean ± SEM, (n = 9). 
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5.5.4 Discussion 
The aim of the present study was to investigate the optimum dose of propionate needed to affect 
appetite and energy intake. In this study, propionate was added as 10% (1 g), 20% (2 g) and 30% 
(3 g) of total weight of PCM. The result of this study supported the hypothesis that the higher the 
amount of propionate supplemented in the PCM, the greater effects it has on energy intake. 30% 
propionate/PCM showed the most pronounce effect on reducing energy intake and significantly 
increased plasma PYY secretion when compared to inulin, but the supplement had no significant 
effect on plasma GLP-1 secretion. The beneficial effect of 30% PCM on plasma PYY possibly 
due to the additional concentration of propionate (3 g) to trigger plasma PYY released compared 
to inulin alone in inulin group. A trend towards dose response effect can also be seen on 
reducing insulinemia, appetite ratings and energy intake. However, increasing DE of PCM has 
no effect on breath hydrogen secretion and plasma glucose levels.  
 
Theoretically, supplementing inulin and propionate to the colon would increase the release of 
GLP-1 secretion. However, this observation was not found in this study. From these three 
studies, it seems that there was no relationship between PCM and plasma GLP-1 secretion. In 
contrast to PCM, inulin has been consistently shown to increase plasma GLP-1 secretion in 
rodents and humans (Cani et al., 2004; Cani et al., 2005a; Cani et al., 2005b; Cani et al., 2006b; 
Cani et al., 2007b; Delzenne et al., 2005; Delzenne et al., 2007; Verhoef et al., 2011). It might be 
possible that there is unknown interaction/mechanism that might have limited PCM to increase 
GLP-1 levels. However, this warrants further investigation. Evidence from the literature shows 
that peripheral GLP-1 infusion reduces postprandial blood glucose in healthy subjects, non-
insulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus (Gutniak et al., 
1992; Nathan et al., 1992). It is suggested that GLP-1 reduced postprandial glycaemia via several 
mechanisms, including suppressing the release of glucagon and insulin secretion (Gutniak et al., 
1992; Komatsu et al., 1989; Ritzel et al., 1995), delay gastric emptying (Wettergren et al., 1993) 
and also enhancing glucose delivery or disposal in peripheral tissues (D'Alessio et al., 1994; 
D'Alessio et al., 1995; Morales et al., 1997). Based on these findings, it might be possible that 
the lack of PCM effect on postprandial GLP-1 levels resulted in no significant effect on reducing 
postprandial glycemia in this study. Moreover, propionate is a gluconeogenic substrate 
(Bergman, 1990) and it has been demonstrated to increase blood glucose levels in both humans 
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and animals studies (Kley et al., 2009; Verbrugghe et al., 2011; Wolever et al., 1991; Remesy et 
al., 2004). Therefore, this might be the reason why there was no significant effect on lowering 
blood glucose levels. In contrast to these studies, some studies able to show the hypoglycaemic 
effect of propionate (Berggren et al., 1996; Darwiche et al., 2001; Liljeberg et al., 1995; 
Liljeberg and Bjorck, 1996; Lin et al., 2012; Todesco et al., 1991).  
 
Interestingly, including PCM into the volunteers’ diet has been shown to reduce plasma insulin 
levels and that the largest reduction was demonstrated with 30% propionate/PCM dose when 
compared to inulin as a baseline. Similar observations have been reported in other human  
(Darwiche et al., 2001; Liljeberg et al., 1995; Liljeberg and Bjorck, 1996) and mice (Lin et al., 
2012) studies. Darwiche et al. suggested that addition of oral propionate on reducing insulin 
levels could possibly be related to its physiological role in reducing gastric emptying rate 
(Darwiche et al., 2001). Furthermore, it is also suggested that the effect of propionate on 
stimulating adipogenesis and suppressing lipolysis might also contribute to improved insulin 
sensitivity (Allen et al., 2009; Al-Lahham et al., 2010a; Ge et al., 2008; Hong et al., 2005). 
However, although 30% propionate/PCM significantly increased plasma PYY levels compared 
to inulin, this dose does not associated with increase fermentation activity as shown in study 1. 
The lack of effect of PCM on stimulating colonic fermentation was possibly related to the 
increased amount of propionate in the PCM molecule that reduced the amount of inulin available 
for colonic fermentation, For example, 10% PCM provided 9 g inulin and 1 g propionate whilst 
30% propionate provided 7 g inulin and 3 g propionate, thus the increased amount of bound 
propionate has reduced the amount of inulin in the PCM molecule to be fermented by the gut 
microbiota. 
 
In conclusion, the results of this study suggest that PCM has potential effects on suppressing 
appetite, energy intake and reduced insulin levels. The highest dose tested in this study, 30% 
propionate/PCM, has shown the highest effect on modulating energy intake, possibly through 
increasing plasma PYY. However, the next question that needs to be answered is whether 10 g 
PCM is the optimum and effective dose to suppress appetite and energy intake. Therefore, in the 
next study, the effect of 5 g, 10 g and 15 g PCM doses will be investigated in single-blinded, 
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controlled and five weeks using 30% propionate/PCM that has been characterised from this 
study.  
 
 
5.6 STUDY 4: The Effects of Propionate Carrier Molecule on Colonic 
Fermentation, Gut Hormones Release and Appetite: A Dose Escalating study 
 
Aim: To determine the optimal dose of propionate carrier molecule to increase plasma PYY 
secretion, reduce subjective appetite and energy intake.   
 
Hypothesis: Increase doses of propionate carrier molecule would have a dose-response effect on 
appetite regulation and that the highest dose of propionate carrier molecule will have the most 
significant effect on postprandial plasma PYY levels and subsequently suppresses appetite and 
energy intake. 
 
 
5.6.1 Material  
 
5.6.1.1 Dietary Treatments 
30% propionate/PCM supplementation used in this study was prepared in the similar method 
with PCM doses in the study 3 (Section 5.5.1.1). The supplement was provided by Dr. Douglas 
Morrison, SUERC, Scotland, UK). 
 
5.6.1.2 Volunteers 
Nine healthy volunteers (8 males and 1 female) aged between 21 to 61 years old and BMI of 25 to 35 
were recruited in this study. They were recruited through advertising in various sites of Imperial 
College London. Volunteers were given their written informed consent prior the start of the study. 
Before the study began, approval was sought from Hammersmith, Queen Charlotte’s and Chelsea 
Research Ethic Committee (08/H0707/99) (Registration No: NCT00750438) and the study was 
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performed in accordance with principles of the Declaration of Helsinki. Volunteers’ details are 
described in Table 5.6.  
 
5.6.2 Methods 
5.6.2.1 Assessment Day 
Volunteers were asked to attend four study visits.The first visit is a baseline study day, therefore 
no supplementation was administered. On the second visit, five grams of PCM was provided and 
the dose was increased by five grams in every visit until they received 15 g on visit 4. Each study 
visit took 420 minutes to complete. In each visit, breath hydrogen test, VAS, energy intake 
assessment and blood withdrawal were performed (Figure 5.23). Home supplementation was 
started a day after baseline study day. During this period, they were asked to take PCM 
supplementation for six days in order to allow for gut adaptation before the effect of PCM dose 
was evaluated at the end of supplementation which was on day 7 (Figure 5.24). 
 
5.6.2.1.1 Study Meals 
Meals were provided in the similar protocol with study 3 (Section 5.5.2.1.2.1) 
 
5.6.2.1.2 Breath Hydrogen Assessment 
Breath hydrogen was assessed in the same method applied in the oligofructose study (Section 
2.3.2.2.3). However, in this study, breath hydrogen was accessed at every hour began at -10, 0, 
60, 120, 180, 240, 300, 360 and 420 minutes.   
 
5.6.2.1.3 Gut Hormones Analysis 
Blood sampling for insulin, glucose and gut hormones PYY were drawn at -10, 0, 15, 30, 60, 90, 
120, 180, 210, 240, 300, 360 and 420 minutes and the levels were determined using 
radioimmunoassay.  Methods are discussed in details in Section 2.3.2.2.5. 
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5.6.2.1.4 Glucose assay 
Glucose assay were analysed in the Department of Clinical Biochemistry, Hammersmith 
Hospital using an Abbott Architect ci8200 analyser (Abbott Diagnostics, Maidenhead, UK). 
Glucose assay sensitivity was 0.3 mmol/L with an intra-assay coefficient of variation of 1.0%. 
 
 
5.6.2.1.5 Insulin Assay 
Insulin assay was performed by using iodine-125 RIA kits (Millipore, Missouri, USA). Please 
refer to Section 2.3.2.2.6 for more detail. 
 
 
5.6.2.1.6 Subjective Appetite Scores 
Subjective appetite scores used the same method described in the section 2.3.2.2.2 but in 
different timepoints which were -10, 0, 30, 60, 90, 120, 180, 240, 300, 360, 420 minutes and last 
assessment was performed after meal.    
 
 
5.6.2.2 Statistical Analysis 
Data are presented as the mean ± SEM. Prior the analysis, Gaussian distribution was used to 
check for data normality using the Kolmogorov-Smirnov test. Time course for breath hydrogen 
test, VAS and postprandial plasma metabolites; glucose, GLP-1 and PYY were compared using 
two-way repeated measures ANOVA with treatment and time as within-subjects factors. tAUC 
was measured using the trapezium rule for breath hydrogen test, plasma glucose, GLP-1 and 
PYY, VAS before divided with the overall timepoints (tAUC/Time) and compared using one 
way ANOVA. Comparison between treatments were assessed using repeated measures ANOVA 
if normally distributed and Friedman test if the data is not normally distributed. A P value of 
0.05 or less was considered significant. Statistical analysis was performed using graph prism 5 
(GraphPad Software, Inc., La Jolla, USA). 
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Figure 5.24 The schematic diagram of study day protocol. Volunteers were expected to attend their study days at 0900 after 10 – 12 hours fasting. Upon 
arrival, they were cannulated and followed with baseline VAS, H2 breath test and blood pressure measurements. Standardised breakfast containing PCM dose of 0 
g, 5 g, 10 g and 15 g were served at 0 minute every week respectively. Postprandial measurements were started at 15 minutes postprandially and continuously 
performed every 30 minutes until the end of the study day. At 180 minutes, standardised lunch was provided and they were given 15 minutes to finish eating their 
meals. An Ad libitum was served at 420 minutes for energy intake assessment.       
15 g PCM 
supplementation 
10 g PCM 
supplementation 
5 g PCM 
supplementation 
Study visit 4   
(15 g PCM) 
Study visit 3   
(10 g PCM) 
Study visit 2   
(5 g PCM) 
Baseline 
study day 
Day 1 – day 6 Day 7 Day 8 – day 13 Day 14 Day 21 Day 15 – day 20 
Figure 5.23 The schematic diagram of dose escalating study day. In 4 continuous weeks, volunteers were asked to take 0 g, 5 g, 10 g 
and 15 g of PCM in increasing order. Each dose has to be taken in 7 days which was divided into 6 days self-supplementation at home before 
they were asked to attend the appetite study day on day 7.  
 
Blood, VAS, H2 test and BP 
Blood 
Blood and VAS 
VAS 
Standardised 
breakfast 
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Ad libitum 
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5.6.3 Results 
 
 
5.6.3.1 Volunteers characteristics 
Table 5.6 characterises the demographic data for volunteers that participated in this study. This is 
the first time dose escalating study using PCM was performed in human, therefore power 
calculation based on the previous PCM studies could not be done. All of the volunteers were 
involved with 0 g, 5 g, 10 g and 15 g PCM study day and home supplementation 
 
Table 5.6 Baseline characteristics of the study volunteers 
Characteristics Numbers 
Completed (n) 9 
Withdrawn (n) 0 
  
Sex (n)  
 Male 8 
 Female 1 
  
Age  32.4 ± 5.2 
Age range  21 – 61 
BMI (kg/m
2
)        25.6 ± 1.6 
                                             Values are expressed as mean ± SEM 
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5.6.3.2 Energy intake 
PCM doses of 10 g and 15 g showed to reduce energy intake assessed at 420 minutes compared 
to other treatments [Figure 5.25 i) and ii)]. However, there was no significant different (P=0.340) 
demonstrated between the treatments (mean ± SEM; 1179.7 ± 156.9 kcal [0 g], 1199.1 ± 174.2 
kcal [5 g], 1080.5 ± 163.8 kcal [10 g],1056.7 ± 168.9 kcal [15 g]). 
 
 i) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25 Ad libitum energy intake assessment (kcal) (i) and change from baseline ii) following 
intake of 0 g, 5 g, 10 g and 15 g  PCM. PCM was supplemented in volunteers’ meal during breakfast. 
Standardised breakfast, lunch and ad libitum meal were provided at 0, 180 and 420 minutes respectively. Data 
is expressed as mean ± SEM, (n = 9). 
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5.6.3.3 Subjective Appetite Scores 
 
5.6.3.3.1 Appetite assessment 
Administration of PCM with 0, 5, 10 and 15 g showed to increase fullness, reduced hunger, 
pleasantness and prospective food intake scores but there were no significant different between these 
treatments (P=0.271, P=0.176, P=0.768 and P=0.222) [Figure 5.26 i), iii), v), and vii)]. However, 
tAUC/mins prospective food intake scores were significantly decreased (P=0.030) with 10 g PCM 
(mean ± SEM; -3.6 ± 3.8 mm/mins [0 g], -10.7 ± 4.8 mm/mins [5 g], -16.3 ± 4.6 mm/mins [10 g] and 
-15.0 ± 5.4 mm/mins [15 g]) when compared to the baseline. In addition, dose of 10 g PCM also 
reduced tAUC/mins hunger and pleasantness scores compared to other doses, but no significant 
difference was showed, hunger (mean ± SEM; -11.2 ± 6.0 mm/mins [0 g], -12.1 ± 5.7 mm/mins [5 
g], -22.7 ± 5.3 mm/mins [10 g] and -12.1 ± 4.2 mm/mins [15 g]), pleasant to eat food (mean ± SEM; 
-15.1 ± 4.1 mm/mins [0 g], -14.2 ± 4.8 mm/mins [5 g], -19.1 ± 5.6 mm/mins [10 g] and -14.8 ± 5.5 
mm/mins [15 g]) whilst dose of 15 g was found to increase tAUC/mins fullness scores but no 
significant difference was found (mean ± SEM; 15.7 ± 5.1 mm/mins [0 g], 21.0 ± 5.5 mm/mins [5 g], 
21.6 ± 5.0 mm/mins [10 g], and 27.1 ± 6.0 mm/mins [15 g]) [Figure 5.26 ii), iiii), vi), and viii)]). 
 
i)                                                                                    ii) 
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iii)                                                                            iiii) 
 
 
 
 
 
 
 
 
v)                                                                             vi) 
 
 
 
 
 
 
 
 
 
vii)                                                                           viii) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.26 Subjective appetite ratings assessed by VAS following intake of 0 g, 5 g, 10 g and 15 g 
PCM i) fullness scores ii) tAUC/mins for fullness scores iii) hunger scores iiii) tAUC/mins for the hunger scores 
v) pleasant to eat scores vi) tAUC/mins for pleasant to eat scores vii) prospective food intake scores viii) 
tAUC/min for prospective to eat scores. PCM was supplemented in volunteers’ meal during breakfast. 
Standardised breakfast, lunch and ad libitum meal were provided at 0, 180 and 420 minutes respectively. Data 
is expressed as mean ± SEM, (n = 9).*P<0.05 0g vs. 10g PCM. 
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5.6.3.3.2 Side effects assessment 
In analysing potential side effect scores following PCM consumption, we asked volunteers to 
mark 1 = mild effect, 2 = medium and 3 = severe effect. PCM supplementations were well-
tolerated with low cases on GI side effects were reported and showed no dose response effect. 
However, the most reported cases upon PCM supplementations were bloating and flatulence 
(Figure 5.27). Surprisingly, the highest reported cases on these side effects was after intake of 10 
g dose (n=5) compared to higher dose of 15 g (n=3 and 2 respectively) and 20 g (n=2) 
supplementation. Nevertheless, these side effects were reported as mild effect.   
 
 
 
Figure 5.27 Assessment of GI side effects; stomach discomfort, nausea, bloating, flatulence, 
heartburn, belching, diarrhoea and bowel habits following intake of 0 g, 5 g, 10 g and 15 g PCM. PCM 
was supplemented in volunteers’ meal during breakfast. Standardised breakfast, lunch and ad libitum meal 
were provided at 0, 180 and 420 minutes respectively.  Data is expressed as mean ± SEM, (n = 9). 
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5.6.3.3.3 Supplementation assessment 
Assessment of supplementation administered at 0 minute after the breakfast meal showed no 
significant difference in pleasant (P=0.971), bitter (p=0.504), tasty (P=0.569), sweet (P=0.814), 
sick (P=0.2781) and salty (P=0.227) scores between these doses (Figure 5.32). However, 
volunteers scored reduce pleasantness, tasty, sweet and increase bitterness and saltiness as the 
doses were increased. However, these scores were not significant.     
 
 
 
Figure 5.28 Supplement assessment following intake of 0 g, 5 g, 10 gand 15 g PCM. PCM was 
supplemented in volunteers’ meal during breakfast. Standardised breakfast, lunch and ad libitummeal were 
provided at 0, 180 and 420 minutes respectively. Data is expressed as mean ± SEM, (n = 9). 
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5.6.3.4 Plasma Metabolites 
 
 
5.6.3.4.1 PYY Analysis 
Addition of PCM supplementations showed no significant effect on increasing plasma PYY levels. 
In this analysis, we were interested to investigate the effect of high doses of PCM on PYY secretion, 
therefore, plasma samples of 5 g study day was not performed (Figure 5.29). tAUC/Time for plasma 
PYY secretion after PCM supplementation was not significantly different between each others 
(P=0.732) (Mean ± SEM; 22.4 ± 2.0 pmol/L*min [0 g], 24.2 ± 3.4 pmol/L*min [10 g] and 22.7 ± 3.1 
pmol/L*min [15 g]  (Figure 5.29 [inset]). 
 
 
 
Figure 5.29 Postprandial PYY levels (pmol/L) and tAUC420min (inset) following intake of 0 g, 5 g, 10 g 
and 15 g PCM. PCM was supplemented in volunteers’ meal during breakfast. Standardised breakfast, lunch 
and ad libitum meal were provided at 0, 180 and 420 minutes respectively. Data is expressed as mean ± SEM, 
(n = 9). 
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5.6.3.4.2 Glucose Assay 
Postprandial plasma glucose peaked at 30 minutes after breakfast and again increased for 60 minutes 
after lunch (Figure 5.30). tAUC/Time for the plasma glucose response between 0 and 420 minutes 
after addition of PCM were not significantly different between the treatments (P=0.158) (mean ± 
SEM; 4.8 ± 0.3 mmol/L*min [0 g], 5.0 ± 0.2 mmol/L*min [5 g], 4.9 ± 0.2 mmol/L*min [10 g] and 
5.0 ± 0.2 mmol/L*min [15 g] (Figure 5.30 [inset]). 
 
 
Figure 5.30 Postprandial glucose levels (mmol/L) andtAUC420min (inset) following intake of 0 g, 5 g, 10 g 
and 15 g PCM. PCM was supplemented in volunteers’ meal during breakfast. Standardised breakfast, lunch 
and ad libitum meal were provided at 0, 180 and 420 minutes respectively. Data is expressed as mean ± SEM, 
(n = 9). 
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5.6.3.4.3 Insulin Assay 
Postprandial insulin levels peaked at 30 minutes after breakfast with the highest levels showed by 15 
g PCM dose and 30 minutes after lunch with 5 g released the highest insulin levels but this was not 
significantly different compared to other treatments (P=0.051) (Figure 5.31). tAUC/Time (mean ± 
SEM; 40.5±5.3 uU/ml*min [0 g], 46.7 ± 5.9 uU/ml*min [5 g], 38.8 ± 5.0 uU/ml*min [10 g] and 38.2 
± 5.7 uU/ml*min [15 g]) (Figure 5.31[inset]). 
 
 
 
Figure 5.31 Postprandial insulin levels (uU/ml) and tAUC420min (inset) following intake of 0 g, 5 g, 10 g 
and 15 g PCM. PCM was supplemented in volunteers’ meal during breakfast. Standardised breakfast, lunch 
and ad libitummeal were provided at 0, 180 and 420 minutes respectively. Data is expressed as mean ± SEM, 
(n = 9). 
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5.6.3.5 Breath Hydrogen Analysis 
Breath hydrogen excretion has been used as a marker for bacterial fermentation activities in the 
gut. Including different doses of PCM significantly increased (P=0.011) the breath hydrogen 
excretion compared to control study day (Figure 5.32). In the first 3 hours, 15 g PCM was 
pronouncedly increased the breath hydrogen excretion compared to other treatments with two of 
the volunteers in this group showed an early rise in the first of two hours PCM ingestion, but the 
levels seem to maintain after 180 minutes until the end of the study day.The excretion of 
hydrogen was found to be peaked at 240 minutes with 15 g PCM showed the highest effect, but 
there was no significant difference between the treatments (P=0.438). However, when compared 
to control treatment, 15 g of PCM showed a trend towards higher breath hydrogen excretion 
(p=0.007). Mean tAUC/time of breath hydrogen excretion for 0 g, 5 g, 10 g and 15 g are 15.9 ± 
1.5 ppm*min, 21.9 ± 1.3 ppm*min, 19.5 ± 1.1 ppm*min, and 21.6 ± 1.8 ppm*min respectively. 
 
Figure 5.32 Breath hydrogen test (ppm) and tAUC420min (inset) following intake of 0 g, 5 g, 10 gand 15 g 
PCM. PCM was supplemented in volunteers’ meal during breakfast. Standardised meals for breakfast, lunch 
and ad libitum meal were provided at 0, 180 and 420 minutes respectively. Data is expressed as mean ± SEM, 
(n = 9).*P<0.05 0 g vs 5g PCM, *P<0.05 0g vs 15 g PCM.   
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5.6.4 Discussion 
In this dose escalation study, the effect of increasing 30% propionate/PCM doses on plasma 
PYY released, subjective appetite and energy intake were investigated. The results revealed 
that10 g PCM significantly reduced prospective food intake whilst 15 g PCM was pronouncedly 
increased fullness score. Moreover, the result also showed a dose response effect on reducing 
energy intake with 15 g PCM was showed the highest effect on reducing energy intake compared 
to inulin, but no significant difference in group analysis. However, it is a challenge to elucidate 
the optimal dose of fibre on appetite, without causing adverse gastrointestinal symptoms or 
unpalatable taste. Although high intake of fibres were commonly related to gastrointestinal side 
effects, intake of 15 g PCM in this study seemed to be well tolerated with only mild effects being 
reported. However, the main concern with 15 g PCM was the palatability in which high ratings 
on salty and bitter taste were scored. The salty and bitter tastes of PCM were derived from free, 
unbound propionate which was released during the conjugation process of propionate to inulin. 
Therefore, it might be possible that unpleasant tastes experienced by volunteers could influence 
volunteers’ appetite and subsequently reduced energy intake.  
 
A study suggested that the unpalatable taste due to high dose of oral propionate is a potential 
confounder in appetite studies as it could induce the released of gut hormones such as GLP-1 
(Frost et al., 2003) and delay gastric emptying (Darzi et al., 2012; Frost et al., 2003) which 
subsequently reduced food intake and hunger. Furthermore, it is also has been shown to increase 
nausea (Frost et al., 2003). Unfortunately, plasma GLP-1 was not measured in this study 
therefore it is not known whether 15 g PCM can influence GLP-1 secretion. Plasma GLP-1 was 
not measured in this study because results from the three previous studies showed no significant 
effect on plasma GLP-1, therefore plasma PYY secretion was the main focus in this study. 
Interestingly, it seems that plasma PYY released was not confounded by the unpleasant taste of 
15 g PCM as 10 g of 30% propionate/PCM has been shown to increase plasma PYY levels 
compared to other doses. 
 
Studies showed that increased release of PYY is related to increase satiety. However, this 
relationship was mostly exhibited after administration of intravenous infusion (Batterham et al., 
2002; Batterham et al., 2003; Degen et al., 2005; Sloth et al., 2007) whilst the satiety effect after 
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oral feeding of dietary fibre is still unclear (Juvonen et al., 2011; Weickert et al., 2006). 
Nevertheless, the present study revealed that there is a potential association between plasma 
PYY released and satiety after oral feeding, but because this study involved a small number of 
volunteers, this observation remained to be further investigated.   
 
Similar to Study 3, PCM supplementation had no significant effect on reducing glucose as 
compared to other oral propionate studies (Darwiche et al., 2001; Liljeberg et al., 1995; Liljeberg 
and Bjorck, 1996; Todesco et al., 1991). However, Darzi et al. suggested that the effect of oral 
propionate on reducing glucose and insulin levels in these studies (Darwiche et al., 2001; 
Liljeberg et al., 1995; Liljeberg and Bjorck, 1996; Todesco et al., 1991) were confounded by the 
unpalatable taste of propionate and not due to the metabolic effect (Darzi et al., 2012). On the 
other hands, 10 g of 30% propionate/PCM showed a similar trend on reducing tAUC/time insulin 
levels as demonstrated in study 3 with average levels of 40-50 µU/ml*min. However, there was 
no significant effect when compared to 5 g and 15 g PCM. In agreement to our study, Darzi et al. 
also found no significant effect in reducing postprandial glucose and insulin levels after intake of 
propionate-rich bread (Darzi et al., 2012). Furthermore, Wolever et al. showed that rectal 
infusion of propionate in six healthy volunteers significantly increased peripheral glycaemia 
compared to acetate and saline infusion (Wolever et al., 1989) which highlighted the role of 
propionate as a gluconeogenic precursor in ruminants (Yost et al., 1977) and cats (Kley et al., 
2009; Verbrugghe et al., 2011). It seems that the role of propionate on postprandial glycaemia 
and insulinemia in humans are still unclear and need further exploration.  
 
Although this study showed that PCM supplementation led to increase colonic fermentation, this 
observation was only estimated using breath hydrogen test as a surrogate marker. To date, breath 
hydrogen test is the only practical method to access colonic fermentation activities. This is 
because currently no method available to directly access colonic SCFAs measurement. 
Therefore, measuring colonic SCFAs in humans remains a challenge as not many evidence 
available to show how these molecules are released, absorbed and metabolised in the literature. 
The closest available methods to estimate the production of SCFAs are via blood and faecal 
sample, but the result might not reflect the actual colonic SCFAs production (Topping and 
Clifton, 2001). In investigating the role of fermentable carbohydrates on appetite and energy 
  
260 
 
intake, it is one of the focuses to estimate the production of propionate from the fermentation and 
whether the external supplementation would actually help in triggering the endogenous SCFAs 
to stimulate gut hormone release. In the context of PCM supplementation, it is important to 
investigate whether or not the molecule was delivered or reached the colon. This perhaps can be 
investigated using stable isotope technique as suggested by Topping and Clifton (Topping and 
Clifton, 2001). To date, there are currently limited SCFAs studies using this method to 
investigate the endogenous SCFAs production possibly due to difficulties in developing the 
method. In this technique, a carbohydrate is radiolabelled,  supplemented in a diet and that the 
excretion is observed via peripheral venous plasma or excreted air from breath hydrogen test 
(Topping and Clifton, 2001). Therefore, this will be one of the aspects that will be investigated in 
the future study.    
 
In conclusion, this study suggested that PCM has a potential to be developed as anti-obesity 
treatment. The main challenge in supplementing PCM particularly in high doses is the presence 
of unpleasant pungent taste as demonstrated in the dose of 15 g which can be a potential 
confounding factor in reducing energy intake. 10 g of 30% propionate/PCM seems to be the 
most suitable and effective dose in reducing energy intake with minimal adverse effects. It is 
postulated that PCM potentially suppressed energy intake via PYY stimulation although this was 
not significant when compared to other treatments. It is possibly that the short duration of study 
and underpowered sample size that actually influenced the lack effect of PCM on anorectic gut 
hormones. Alternative methods of supplementing SCFAs, the intravenous and rectal infusion, 
although has been shown to elevate plasma PYY and GLP-1 (Freeland and Wolever, 2010), is 
not a practical method to apply as it requires certain equipment and medical training. Most 
importantly, the fact that propionate able to stimulate the release of PYY showed that it is not 
impossible to increase gut hormones production via external stimulation/supplementation. 
However, this warrants further investigations. If successful, oral supplementation of SCFAs can 
be developed as a future treatment for obesity. 
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Chapter 6 
 
 
 
 
 
General Discussion 
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This thesis describes studies that were designed to investigate the role of fermentable 
carbohydrates in stimulating gut hormone release and its effect on appetite and energy balance. It 
is hypothesised that the fermentable carbohydrate, oligofructose and a novel propionate carrier 
molecule (PCM) could increase circulating plasma PYY and GLP-1, decrease subjective appetite 
and energy intake, thus leading to a reduction of body fat and body weight. The investigations in 
Chapter 2 – Chapter 5 have suggested that oligofructose increased plasma PYY, reduced appetite 
and energy intake in healthy overweight volunteers. However, effects on postprandial plasma 
PYY and energy intake were not significant when compared to cellulose supplementation. There 
was also no suppression on energy intake or body weight following eight weeks supplementation 
at home. Following the lack of effect of fermentable carbohydrate on modulating appetite and 
body weight, a SCFA, propionate (an end product of fermentable carbohydrate) was 
supplemented directly to the colon, by attaching the molecule to a carrier, an inulin. The result 
showed that addition of PCM in the diet led to increased plasma PYY and reduced energy intake. 
This interesting finding highlighted the potential role of this novel molecule as a new target for 
anti-obesity treatment.     
 
Unlike the current study, other research groups have shown that oligofructose play a significant 
role in regulating appetite and body weight in both animals and human studies (Cani et al., 
2005a; Cani et al., 2006a; Cani et al., 2009; Parnell and Reimer, 2009; Zhou et al., 2009). 
Fermentable carbohydrates are postulated to modulate energy homeostasis by stimulating the 
release of gut hormones, PYY and GLP-1. Investigation in rodents showed that including 
oligofructose in the diet increased proximal and medial colonic GLP-17-36 and portal PYY, GLP-
17-36 amide and GLP-2 levels (Cani et al., 2007b; Delzenne et al., 2005).  Interestingly, increased 
GLP-1 secretion also has been linked with increased GLP-1 expressing cells following 
differentiation of the L-cells in the proximal colon (Cani et al., 2007b). The significant 
modulation of gut hormones following oligofructose intake has led to suppressed food intake, 
attenuated body fat and body weight gain (Cani et al., 2005b; Cani et al., 2007b). In this study, it 
is hypothesised that intake of 30 g/day oligofructose would increase circulating PYY and GLP-1 
levels, thus this would decrease appetite, energy intake, body weight and adiposity following a 
six week supplementation period (following 2 weeks run-in period). In this study, dose 
supplementation was determined based on preliminary results from an oligofructose dose-finding 
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study (Pedersen, 2010). This dose-finding study suggests that oligofructose has a dose-dependent 
effect in increasing plasma PYY and reducing energy intake with doses of 35 g and 55 g/day 
having the most pronounced effect. However, as doses of more than 30 g/day related to 
gastrointestinal side effects, a dose of 30 g/day was selected as a supplementation dose in this 
study.  
 
The findings of Chapter 2 and 3 show that intake of oligofructose significantly increased plasma 
PYY in the oligofructose group but not in the cellulose group. However, the rise following 
oligofructose supplementation was not significant when compared to the cellulose group. In 
addition, although oligofructose significantly reduced subjective hunger, no significant effect on 
energy intake was demonstrated when compared to cellulose. A similar observation was seen in 
the assessment of appetite following an eight week free-living supplementation period. No 
significant change on energy intake was found, although there was a tendency for oligofructose 
to reduce subjective hunger. These results suggest that the increased plasma PYY levels 
following oligofructose intake are able to suppress appetite, but were insufficient to alter energy 
intake. The lack of effect of oligofructose to reduce energy intake (assessed by food diaries) 
during the free-living supplementation period also mirrored the non-significant effect of 
oligofructose on body weight, total, regional and ectopic body adiposity. The result of this study 
is in contrast with earlier oligofructose human studies which showed that increased PYY (Cani et 
al., 2009; Parnell and Reimer, 2009; Verhoef et al., 2011), GLP-1 (Cani et al., 2009; Verhoef et 
al., 2011) as well as reduced ghrelin plasma levels (Parnell and Reimer, 2009) have resulted in 
significant suppression of energy intake in healthy lean volunteers (Cani et al., 2009; Verhoef et 
al., 2011) and reduced body weight in overweight adults (Parnell and Reimer, 2009). The 
discrepancy between the current result and these studies could be due to several methodological 
differences.  
 
Firstly, an eight week supplementation period in this study possibly is not long enough for the 
gut to adapt with oligofructose supplementation to stimulate L-cells to increase production of 
PYY and GLP-1 levels. Other oligofructose studies were performed for a duration of 12 weeks 
(Antal et al., 2008; Parnell and Reimer, 2009) and one year (Abrams et al., 2007). Secondly, it 
might be possible that the sample population of this study (22 volunteers) had low statistical 
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power to detect small differences between the dietary treatments. The sample size of this study 
was determined based on power calculation that used AUC postprandial PYY levels from an 
oligofructose dose response study as a main outcome (Pedersen, 2010). In contrast, other 
oligofructose studies (Abrams et al., 2007; Antal et al., 2008; Parnell and Reimer, 2009) have 
investigated the effect of oligofructose on body weight maintenance in larger scale sample sizes, 
33 volunteers (Antal et al., 2008), 48 volunteer (Parnell and Reimer, 2009) and 97 volunteers 
(Abrams et al., 2007). Fourthly, whilst the earlier oligofructose studies (Antal et al., 2008; Cani 
et al., 2006a; Cani et al., 2009; Parnell and Reimer, 2009; Verhoef et al., 2011) compared the 
effect of oligofructose with a digestible carbohydrate, maltodextrin, the effect of oligofructose in 
this study was compared with a non-fermentable carbohydrate, cellulose. However, 13g of 
maltodextrin was also added to cellulose in order to match the caloric content with oligofructose. 
The main challenge in comparing the effect of two types of fibre in appetite studies is that fibres 
have their own physico-chemical properties that promote satiety at different parts of the gut 
(Howarth et al., 2001). In the case of cellulose, it mainly acts as a bulking agent in the gut and 
also in shortening transit time, whilst oligofructose exerts it effect in the colon through bacterial 
fermentation. Therefore, it is postulated that this results in non-significant effect on appetite-
related outcome measures. Currently there is lack of evidence comparing the effect of 
fermentable carbohydrates with non-fermentable carbohydrates on appetite and energy balance. 
Howarth et al. showed that three weeks supplementation with fermentable carbohydrates, β-
glucan and pectin had no significant effect on appetite, body weight or fat loss (Howarth et al., 
2003) when compared with the non-fermentable carbohydrate, methylcellulose. However, three 
weeks fibre intake in this study might be too short to evaluate the effectiveness of fermentable 
carbohydrate on regulating appetite and body weight loss. 
 
Interestingly, recent evidence suggested that the effect of resistant starch on reducing energy 
intake and body fat maybe related with activation in the brain. In animals, rats that reduced 
weight following intake of resistant starch also have been shown to increase activation in 
hypothalamic VMH and PVN in MEMRI-imaging study (So et al., 2007). In mice, adding 
oligofructose-enriched inulin in the diet led to significant increased activation in the ARC and 
reduced energy intake and body weight compared to a control group (Anastasovska et al., 2012). 
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The SCFAs, the end products of colonic fermentation of fibres have also been shown to cross the 
BBB (Conn et al., 1983; Song et al., 2009; Anastasovska et al., 2012).  
 
Based on these studies, fermentable carbohydrates and their products, SCFAs, potentially have a 
significant role in central neuronal processing and higher CNS. However, to date, the effect can 
only be found in rodents as no investigation of SCFAs or fermentable carbohydrates have been 
performed in humans. In this study, the effect of supplementing oligofructose on brain activation 
was investigated following task-responsive signal changes in non-homeostatic regions. In 
humans, task-responsive signal changes are mostly studied in non-homeostatic regions as it is 
impossible to study this type of investigation in hypothalamus and brainstem due to its 
susceptibility to signal drop out due to the air sinuses during the image acquisition.  
 
It is hypothesised that intake of oligofructose reduces brain activation in the NAc, amygdala, 
OFC, hippocampus, insula and vACC following food image stimulation. However, the result of 
this study did not support the hypothesis as no significant change in BOLD activation in the 
aforementioned ROIs was demonstrated following high calorie foods vs. objects stimulation in 
the oligofructose group. Surprisingly, activation in these regions was reduced after intake of 
cellulose and a significant effect was demonstrated in the OFC. Interestingly, a significant 
reduction of BOLD signal in the OFC following cellulose intake was similarly demonstrated 
when PYY3-36 or combination of PYY3-36 and GLP-17-36 were infused in healthy lean volunteers 
following stimulation with high calorie foods vs. objects and during resting experiment 
(Batterham et al., 2007; De Silva et al., 2011). Infusion of PYY and GLP-1 has previously been 
shown to reduce hunger and appetite (Batterham et al., 2003; Flint et al., 1998; Gutzwiller et al., 
1999). Hence, this suggests that reduced BOLD activation in pre-selected ROIs following 
cellulose supplementation is related with a satiation effect. However, as energy intake was not 
measured in this study, this effect cannot be confirmed. Nevertheless, there was a significant 
reduction in VAS volume food intake and a trend toward a reduced hunger score in cellulose 
group. No significant effect on subjective appetite was shown in the oligofructose group. This 
finding conflict with the results observed on the appetite assessment study day as oligofructose, 
but not cellulose was shown to significantly suppress subjective appetite. 
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Despite the encouraging finding of the effect cellulose on brain reward activation, this result 
cannot be used to conclude its role in modulating neuronal signals as a small number of 
volunteers (oligofructose=4, cellulose=6) were involved in this study. Nevertheless, as this is the 
first time the role of fermentable carbohydrate has been investigated on human neuronal brain 
activation, therefore it can be used as a preliminary observation and for powering sample size for 
future investigation. Therefore, in the future, It would be interesting to reinvestigate this study in 
a longer supplementation period (>12 weeks) using a larger cohort. 
 
As fermentable carbohydrates were unable to affect appetite and energy balance, the role of 
fermentable carbohydrates main product, the SCFAs, was investigated in this study. SCFAs have 
been proposed to play a significant role in energy homeostasis. This is because SCFAs may be 
able to induce the enteroendocrine L-cells to stimulate the production of gut hormones, PYY and 
GLP-1. It is postulated that SCFAs induce the effect by binding to its receptor, FFAR2 and 
FFAR3 (Brown et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003) which has been found in 
various tissues including the intestines (Karaki et al., 2008; Tazoe et al., 2008) and adipocytes 
(Al-Lahham et al., 2010b; Brown et al., 2003; Ge et al., 2008). In the intestine, FFAR2 and 
FFAR3 can be found in L-cells where it has been found to be co-localised with cell expressing 
PYY and GLP-1. Therefore, it is possible that the L-cells sense SCFAs through the receptors, 
thus subsequently release PYY and GLP-1.     
 
Based on the potential role of SCFAs in increasing gut hormones secretion, many studies have 
attempted to use SCFAs as dietary supplements and investigated their role in reducing appetite and 
energy intake. However, not all studies have been able to show an effect. Darzi et al. suggested that 
propionate had no significant effect in reducing appetite or energy intake (Darzi et al., 2012). SCFAs 
are volatile fatty acids. Therefore, it might be possible that they have been absorbed into the 
circulation before it reached the gut. Moreover, intake of SCFAs has also been related with nausea 
and poor palatability (Darzi et al., 2011; Frost et al., 2003). In contrast to earlier SCFA studies which 
directly included SCFA in volunteers’ diet (Darzi et al., 2012; Frost et al., 2003; Liljeberg et al., 1995; 
Liljeberg and Bjorck, 1996; Todesco et al., 1991), propionate in this study was chemically attached to 
a carrier, inulin (a long molecular weight of oligofructose) via a conjugated linkage. This linkage can 
only be cleaved by enzymatic process in the gut, thus ensuring that propionate will only be released 
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in the colon whilst inulin will subsequently be fermented by the gut bacteria. It is postulated that this 
system would increase colonic SCFAs to increase PYY and GLP-1. It is hypothesised that intake of 
PCM will deliver propionate directly to the gut, increase colonic SCFAs and stimulate plasma PYY 
and GLP-1 release, thus leading to a reduction of  hunger and energy intake in healthy normal and 
overweight volunteers. 
 
The development of PCM for appetite regulation was investigated in four small pilot studies in 
Chapter four of this thesis. In study 1, as this is the first time PCM was investigated in humans, 
the tolerability of 10 g PCM with a low degree of esterification (a degree of propionate dose is 
added into the complex molecule), 0.25 or 10% propionate/PCM (or 1 g of propionate and 9 g of 
inulin) was investigated in six healthy overweight volunteers. The result supports the hypothesis 
that PCM with DE 0.25 was safely delivered to the colon (monitored by increase breath 
hydrogen test as a fermentation marker) with a tendency to increase plasma PYY levels. In 
addition, the dose was also well-tolerated by the volunteers. 
 
To understand the effects of PCM on increasing plasma PYY levels, a randomised, double-
blinded, crossover study was performed to investigate the role of PCM with DE 0.5 has on 
appetite and energy intake. The study design was strengthened by an increased sample size of 20 
volunteers and DE was increased from 0.25 (10% propionate/PCM) to 0.5 (20% 
propionate/PCM) or 2 g propionate and 8 g inulin. It is hypothesised that this will stimulate 
higher production of PYY and GLP-1.  However, the result was inconsistent with my hypothesis 
as 10g PCM with DE 0.5 had no significant effect on increasing plasma PYY and GLP-1 levels. 
However, it significantly reduced ad libitum energy intake when compared to inulin. 
Surprisingly, energy intake in the inulin group was also reduced by a similar magnitude with 
PCM but no significant difference was demonstrated between the groups. It can be postulated 
that the supplemented propionate was insufficient to trigger higher release of gut hormones to 
affect energy intake when compared to inulin. Based on the discrepancy between PCM 0.25 and 
PCM 0.5 on circulating PYY and GLP-1 and energy intake, a dose finding study was performed 
in study 3 to determine optimum levels of PCM to influence appetite regulation.  
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In study 3, the effect of 10g PCM with DE 0.25 (10% propionate/PCM), 0.5 (20% 
propionate/PCM) and 0.8 (30% propionate/PCM) on gut hormone release and energy intake was 
investigated in nine healthy lean volunteers and the effect was compared to inulin. It is 
hypothesised that PCM would have dose response effects on increased PYY and GLP-1 levels, 
suppressing appetite and energy intake. PCM with DE 0.8 (30% propionate/PCM) would have 
the most pronounced effect in reducing energy intake compared to other doses. These findings 
were consistent with the study hypothesis. PCM with different different DE have dose response 
effects on reducing energy intake with the highest effect being demonstrated by 0.8 PCM. The 
dose response effect of PCM has also been demonstrated in subjective fullness and prospective 
food intake VAS scores. Based on the promising effect of PCM with DE of 0.8 (30% 
propionate/PCM), this dose was selected to be used in the next dose-finding study.  
 
This dose-escalation study aimed to investigate the effect of 5 g, 10 g and 15 g PCM with DE on 
plasma PYY levels, subjective appetite and energy intake. It is hypothesised that the higher the 
dose supplemented in diet, the greater effect can be seen on appetite, plasma PYY and energy 
intake. The result of this study is consistent with this hypothesis. PCM doses were demonstrated 
to have a dose dependant effect on energy intake. Both 10 g and 15 g doses reduced energy 
intake, but this was not significant. However, the main challenge with supplementing high dose 
of SCFAs in the diet is potentially related with pungent and bitter taste. In the context of PCM, 
15 g was related to a high salty taste derived from unbound propionate that was released during 
conjugation propionate to inulin. Based on the result from this study, 10 g PCM with DE of 0.8 
was selected as the optimum dose and this dose will be used in the future, double-blinded study 
in healthy overweight subjects. In the future, it would also be interesting to determine the levels 
of SCFAs in human system (blood, faeces and urine) produced from PCM supplementation 
using gas chromatography.  
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Conclusion 
In conclusion, results from the oligofructose study showed that oligofructose has acute impact on 
human appetite but no role in modulating energy intake, body weight, adiposity and BOLD 
fMRI signal change following food cues stimulation over eight-week supplementation period. 
The exploration of new methods of delivering SCFAs directly to the colon may give an exciting 
opportunity to increase colonic SCFA and stimulate the production of PYY and GLP-1. Hence 
this highlights its potential to be developed as an appetite suppressant and long-term body weight 
treatment. This finding warrants further investigation in overweight/obese subjects to elucidate 
the interaction of increase plasma PYY levels on energy intake and body weight maintenance.  
 
 
Future Work 
In Chapter 2, it is suggested that intake of oligofructose has lead to increase plasma PYY 
concentration. Indeed, similar observation also has been demonstrated in other studies (Cani et 
al., 2009; Parnell and Reimer, 2009; Piche et al., 2003). However, the levels were not different 
when compared to cellulose supplementation. As previously discussed, PYY is one of the 
anorectic gut hormones which is released following stimulation by SCFAs’ receptor, FFA2 and 
FFA3 in L-cells (Kaji et al., 2011; Karaki et al., 2006; Karaki et al., 2008) after bacterial 
fermentation of fermentable carbohydrates. Although many studies have shown that 
oligofructose supplementation leads to increase PYY and GLP-1 concentration, not many studies 
have related the released of PYY and GLP-1 concentration with SCFAs profile and colonial 
bacterial fermentation. Therefore, it would be interesting to investigate the link between changes 
in gut hormone levels, SCFA profile and colonic bacterial composition. This particularly 
important as inter-individual differences in colonic SCFA profile might be the contributor of lack 
of effect of oligofructose on inducing anorectic gut hormone release in this study. SCFA profile 
can be determined by gas chromatoghraphy as previously described (Fernandes et al., 2011; 
Vogt et al., 2004b). On the other hand, gut microflora composition has been shown to be differ 
between lean and overweight mice and humans (Ley et al., 2005; Ley et al., 2006; Turnbaugh et 
al., 2006). In addition, the ‘obese gut microbiota’ also has been suggested to have high efficient 
to harvest energy compared to lean microflora. Therefore, it is also interesting to investigate 
whether the obese/overweight volunteers in this study also have similar ‘obese microbiota 
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pattern’ and whether oligofructose supplementation able to change the gut microbiota 
composition in the obese volunteers following 8 weeks supplementation. To date, no known 
human study has investigated the effect of oligofructose on gut microbiota composition, SCFA 
profile and gut hormone release concurrently. 
 
Based on the promising findings in Chapter 5, a randomised, controlled, parallel study was 
designed to investigate the effect of supplementing PCM with DE 0.8 (30% propionate/PCM) on 
appetite, body fat and body weight in healthy overweight/obese volunteers in the department of 
Investigative Medicine (protocol reference number:08/H0707/99) (ClinicalTrial.gov 
identification no: NCT00750438). In this study, the effect of 10 g/day PCM with DE 0.8 (30% 
propionate/PCM) on appetite regulation will be investigated by measuring circulating gut 
hormones levels, subjective appetite, energy intake, glucose tolerance, insulin sensitivity, body 
weight and body adiposity in volunteers with BMI of 25 to 40 kg/m
2
 and aged between 30 to 65 
years old) in the duration of 26 weeks. The effect of PCM will be compared with inulin. It is 
estimated that 60 volunteers (PCM=30 and inulin=30) are needed to detect significant effect 
between these treatment. This investigation will be performed in 13 visits which include an 
acclimatization appetite assessment visit prior the start of the study. Baseline visits were 
performed between visit 2-5 before volunteers are undergo self-living supplementation period for 
24 weeks. During the supplementation period, they will be asked to attend five short study visits 
for body weight, waist and hip measurements as well as bioelectrical impedance for body fat 
quantification. Post-supplementation measurement will be performed similarly with baseline 
visit at weeks 11 – 13. Body adiposity will be determined using whole body MRI scanning. In 
addition, questionnaires of physical activity and energy intake (using food diaries) will also be 
monitored during this period.    
 
Although SCFAs have been studied in energy homeostasis and appetite regulation, no work has 
yet been done to understand the exact mechanisms of how SCFAs distribute in the body. This is 
particularly interesting as SCFAs can possibly cross the BBB (Conn et al., 1983) and influence 
appetite directly via CNS. To date, specific methods for a direct assessment of bio-distribution 
and bio-kinetics of these SCFAs in vivo is still lacking. Therefore, it would be interesting to 
further elucidate the mechanisms and bio-distribution of PCM in the body. It is suggested that 
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this can be performed using the advanced imaging technique, positron emission tomography 
using radioisotope carbon-11 [
11
C] to trace the distribution of SCFAs in the body. Based on the 
evidence of the physiological effect of propionate on energy homeostasis, it can be speculated 
that the highest levels of propionate can be located in the large intestine as it the centre for 
fermentation activities, followed by liver, brain, portal vein and to a lesser extent in the 
periphery. Therefore, it is hoped that the result of this study would lead to a clearer 
understanding of the effect of SCFA, particularly PCM on appetite regulation and body weight, 
thus raising its potential to be developed as an anti-obesity treatment.    
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Participant information sheet 
 
Project title:  
 
Effect of oligofructose on appetite, body composition, 
and gut hormones in healthy overweight subjects 
 
Investigators: Ms Norlida Mat Daud (PhD student), Mrs Nurhafzan Ismail (PhD student), 
Professor Jimmy Bell, Dr. Tony Goldstone, and Professor Gary Frost (Principle Investigator) 
Institution: Imperial College London, Department of Investigative Medicine, Hammersmith 
Hospital Campus 
 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take the 
time to read the following information carefully and discuss it with others if you wish. Ask us 
if there is something that is not clear or if you would like more information. 
 
If you do decide to take part in the study, please let us know beforehand if you have been 
involved in any other study during the last year. You are free to withdraw at any time without 
explanation. Thank you for taking the time to read this information sheet. 
 
 
What is the study about? 
The nutrients under investigation in this study are natural, harmless dietary fibres called 
oligofructose and cellulose. Oligofructose is a natural storage compound found in garlic, 
onion, Jerusalem artichoke, and chicory root. The most common source of oligofructose is 
chicory. Oligofructose is already used in many food products today. It provides 30-50% of 
the sweetness of table sugar and is often used as a low-calorie alternative to sugar and fat 
in dairy products and baked goods. Cellulose is a structural component of plant material and 
hence a part of a normal diet containing grains, fruit and vegetables. All bran is an example 
of a food item that is high in cellulose.   
 
Like other dietary fibres, oligofructose and cellulose cannot be digested in the small 
intestine; hence almost all oligofructose and cellulose reach the large intestine. In the large 
intestine cellulose and oligofructose behave differently. Oligofructose is broken down by the 
gut flora producing several bio-active compounds which may improve the health of the host. 
Cellulose on the other hand acts mainly as a bulking agent. Regular intake of dietary fibres 
may also improve appetite regulation and thus may be useful in bodyweight management.  
 
You will only receive one of the two dietary fibres mentioned above. The study is blinded 
which mean that you will not know which one of the fibres you will receive. Once you have 
completed the study you may ask the investigators which kind of dietary fibre you were 
provided with.  
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This study is looking into the effect of a daily intake of 30g dietary fibre on appetite, food 
intake, body weight, appetite regulating hormones and sugar in the blood in healthy, 
overweight people. We will ask you to ingest 3 daily doses of a dietary fibre supplement with 
your normal diet for a total of 8 weeks and record your daily food intake and appetite feeling 
for a total of two weeks over a 9 week period. The daily dose of dietary fibre will be 
increased gradually over two weeks which should minimize any potential discomfort related 
to an increase in dietary fibre intake.  
 
We will also be looking at the acute response to the dietary fibre supplements. For that 
reason we are going to ask you to come in for three appetite study session in our Clinical 
Investigation Unit. The total duration of the study will be approximately 10 weeks. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part you will be 
given this information sheet to keep and asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason.  
 
Who can take part in the study? 
To take in the study there are some inclusion criteria you need to fulfil; these are listed 
below. Please check this list carefully. 
 
Inclusion criteria 
 Healthy males and females aged 20-50 
 BMI 25-35 kg/m2 
 Weight stable for three months prior to enrolment in study (weight change < 3 
kg over a period of three months)  
 Non-smokers 
 No current or history of endocrine disease, gastrointestinal disease, kidney or 
liver diseases, cardiovascular disease, pancreatitis, or cancer  
 Habitual dietary fibre ≤ 25g/day (as assessed by 3-day dietary record 
following screening) 
 Hydrogen producers (will be tested at screening) 
 
There are also a number of reasons why you may not be able to take part; these are 
the listed below: 
 
Exclusion criteria 
 Use of antibiotics less than three months prior to participation in the study 
 Participation in other research studies in the previous three months 
 Blood donation less than three months before participation in study 
 Anaemia 
 High blood pressure 
 Pregnancy or breastfeeding 
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 Substance abuse 
 Vegan or vegetarian diet 
 Food intolerance or food allergies 
 Regular use of prebiotic, probiotic or synbiotic food items/ supplements 
 Intense exercise undertaken for more than 5h per week 
 Metallic or electronic implants e.g. pacemaker, cochlear ear implants, fixed 
dental braces 
 Claustrophobia 
 Depression  
 
 
What do I need to do? 
Overview 
Before consuming the dietary fibre supplement you need to attend the clinical investigation 
unit and Robert Steiner Unit on four occasions. On the two first visits you will have MRI 
scans, for further details on these please turn to page 8. The following two visits are 
appetite study sessions (visit 3 and 4). Between visit 3 and 4 you will be asked to record 
everything you eat and drink for seven days. You will also be asked to complete some 
simple questionnaires on your appetite sensations and general wellbeing for those same 
seven days.  
 
During or after the dietary fibre supplementation further MRI scans will be conducted at visit 
5 and 7. Visit 6 will be another appetite study session (same as visit 3 and 4). Please  
see page 5 for an overview of the visits. 
 
Screening procedure 
 
Before you are enrolled in the study you need to come in for a screening interview. As part 
of the screening process, you will be asked to complete a screening questionnaire to 
determine your general health status and eating habits. 
 
 A small blood sample will be taken to check for anaemia. Furthermore you will be asked to 
blow into a handheld breath hydrogen monitor (hydrogen is produced when dietary fibres 
are broken down in the gut). Only those who produce hydrogen will included in the study.  
Your body weight, height, body composition and blood pressure will be measured. Body 
composition will be assessed by bio-electrical impedance. This is a painless procedure and 
only takes a few minutes. The impedance machine resembles a normal set of weighing 
scales.   
 
To ensure that you are comfortable eating the food items served during the study you will be 
asked to taste some of the food items that will be used on the study sessions and rate how 
much you like these items. After the screening you will be asked to complete a three day 
dietary record and return this as soon as possible. This is to assess your normal dietary 
habits and usual dietary fibre intake. 
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Visit 1 – Assessment of Body Composition 
 Magnetic Resonance Imaging – baseline scan  
 Blood sample (30 ml) 
 
Visit 2 – Exploration of Neural Activation in the Brain 
 Functional Magnetic Resonance Imaging – baseline scan 
 Blood samples (80 ml) and questionnaires 
Visit 3 – Appetite study day  
 Blood sampling (30 ml) 
 Visual Analogue Scales questionnaires (assessment of appetite and side-effect ) 
 Breath hydrogen monitoring 
 Test meals 
Baseline dietary record and appetite and side-effect assessment  
(Day -7 to -1) 
Visit 4 – Appetite study day (DAY 0)  
Same procedure as on visit 3, total amount of blood withdrawn: 160 ml  
Supplementation Run-in: DAY 1-14 
 Gradual increase in daily intake of supplement to 30g per day 
6 weeks of Supplementation: DAY 15-56 
 30g of supplement to be consumed daily with main meals (3 x 10g) 
 Contact by phone and/or email four times over the six weeks 
Visit 5 - Exploration of Neural Activation in the Brain 
Same procedure as on visit 2 
Visit takes place some time during week 4 of the supplement period (Day 36-42) 
Dietary record and appetite and side-effect assessment  
(Day 49-55) 
Visit 6– Appetite study day – Post-intervention visit (DAY 56) 
Same procedure as on visit 4 
Visit 7 – Assessment of Body Composition 
 Magnetic Resonance Imaging – post-intervention scan  - same procedure as on visit 1 
 
Screening Visit 
 Interview and explanation of study 
 Blood test (30 ml = 3 tablespoons) and breath hydrogen test 
 Screening questionnaires: Personal details, Dutch Eating Behaviour Questionnaire, SCOFF, MRI 
safety check form 
 Consent form 
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Dietary fibre supplementation  
 
The supplement will be provided in sachets (containing 10g portions). During the two first 
weeks following the second appetite study session (visit 4) in the hospital your daily intake 
should gradually be increased to 30g per day. On day 15 the actual supplementation period 
begins and this will last six weeks. From day 15 to 55 you will be asked to consume 3 x 10g 
of the provided supplement every day. The supplement is to be consumed with the main 
meals and can be mixed into most drinks, sprinkled on or mixed into food. The supplement 
must not be cooked and exposed to high temperatures (for example by adding it to freshly 
boiled water). Unused sachets must be returned to the investigators. 
 
During the 6 week supplementation period the investigators will contact you by phone and 
email to ensure that the fibre supplementation has no untoward side-effects and ensure that 
instructions are followed and answer any questions you may have about the study.  
 
 
Dietary records and questionnaires  
A 7 day dietary record is to be completed prior to the visit 4 and at the end of the fibre 
supplementation period (day 49-55). In this record you write down everything you eat and 
drink, including snacks between meals.  
 
On the same days appetite sensation and side-effects will be recorded using visual 
analogue scales. At the end of the day you will be asked questions like “How full did you 
feel after eating meals today?” and “How hungry did you feel between meals today?”. You 
will answer them by making a vertical mark on a ten centimetre line anchored with the terms 
“not at all” and “extremely”. Similarly, side-effects such as nausea, sickness, flatulence, 
bloating, diarrhoea, and general wellbeing will be assessed. The questionnaires are very 
simple and take no more than 5 minutes to complete. 
 
 
Appetite study session in the research ward (day -8, 0, and 56) 
24h before coming in for a study session you will be asked to abstain from strenuous 
exercise, alcohol and caffeine containing drinks. The evening before every study session 
you need to consume a standard meal (of your choice).  
 
On the morning of the study sessions you will be asked to arrive fasted overnight (10 hour 
fast). You can drink as much water as you like during the fast. After explanation of the 
procedures and confirmation that you are happy to proceed, your body weight will be 
recorded. Blood pressure will be measured after 5 minutes rest in a seated position. A 
catheter will be inserted in a forearm vein facilitating blood sampling throughout the day. 
Two baseline blood samples will be withdrawn and then breakfast will be served; you will 
have 20 minutes to consume the meal. Blood sampling will continue regularly after 
breakfast and appetite questionnaires - Visual analogue scales (VAS) - are completed every 
time a blood sample is drawn. Breath hydrogen will be measured using handheld breath 
hydrogen monitors at selected time points throughout the session. About 4 hours after 
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breakfast you will be served lunch. Breakfast and lunch will consist of the same food items 
on every study session. Seven hours after breakfast a large meal will be served. You can 
choose between chicken tikka masala, macaroni cheese and bolognaise bake. Please be 
aware that your choice applies to all three appetite study sessions.  The meal is served in 
excess and you are asked to eat until comfortably full. You will be given a maximum of 30 
minutes to consume the meal, and should eat alone and undisturbed. Reading material and 
TV, mobile phones, other electronic devices etc. should not be within reach during the meal. 
During the study session you will be asked to minimise physical activity. You can watch 
films or TV, bring a laptop, books, magazines and the like to keep you occupied during your 
stay in the ward. Water is allowed ad libitum though you will be requested not to drink less 
than 10 minutes prior to a blood sample and VAS completion.  
 
During the study session you will be asked to minimise physical activity. You can watch 
films or TV, bring a laptop, books, magazines and the like to keep you occupied during your 
stay in the ward. Water is allowed freely though you will be requested not to drink less than 
10 minutes prior to a blood sample and VAS completion.  
 
 
Whole body MRI scans before and after taking the fibre 
supplement (visit 1 and 7) 
You will attend the Robert Steiner MRI unit at Hammersmith Hospital after a 10h overnight fast. 
The study visit will last between 2-3 hours. You are asked to refrain from strenuous exercise and 
drinking alcohol the day before each visit. You will be asked to change into hospital clothes and 
complete a metal check form. 
 
You will have your height and weight, waist and hips measured and a scanning technique 
which measures your amount of body fat and where it is stored i.e. around your waist or 
around your hips, called bio-electrical impedance analysis. This painless method involves 
lying still under a semi-tube base unit while a wireless belt is placed on your abdomen for 
around 30 seconds or measuring the electrical current from your body for 10 seconds. You 
will also be given a short questionnaire to complete about how physically active you are, 
your general health and family history of any illnesses. 
 
You will have a measurement of the volumes of your body parts and the body fat 
percentages of each body section. This safe body volume imaging technique involves 
standing in an enclosed cubicle in front of a 3D scanner which uses white light. The 
measurement process takes no more than 10 seconds and does not use radiation. You will 
have a small plastic cannula tube inserted into a vein in one arm to take a blood sample to 
measure your blood sugar, fat and hormones. With your permission, we will also take a 
sample of DNA and RNA from blood or saliva to look for changes in your genes that may be 
involved in the how the body controls appetite and body weight. 
 
You will then lie on the trolley in the scanner. During the scan you will lie supine or prone in 
the scanner and are automatically moved through the scanner. While in the scanner you will 
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have access to a buzzer to sound an alarm, and will be able to hear and respond to 
instructions from the scanning console. You will be in the MR scanner for up to 1 hour.  
 
Scanning will be performed on either the Philips 3.0 Tesla or Philips 1.5 Tesla MR scanners in the 
Robert Steiner MR Unit at the Hammersmith Hospital. None of the magnetic resonance imaging 
techniques to be used employs ionising radiation or intravenous contrast agents. Whole body 
anatomical MR scanning will be performed to determine total and regional fat volumes. 
 
 
Functional MRI scans before and whilst taking the fibre supplement (visit 
2 and 5) 
You are asked to refrain from strenuous exercise and drinking alcohol the day before each 
visit. The evening prior to the scan you will be asked to have a standard evening meal. We 
will also ask you to keep a record of all food and drink consumed for one day before the 
visit, the day of the visit and for one day afterwards. If female, you may be asked to have 
the study visit at a particular time in your menstrual cycle since this can alter your appetite. 
 
Similar to the whole body MRI scan you will attend the Clinical Investigation Ward and 
Robert Steiner MRI unit at Hammersmith Hospital after a 10h overnight fast. The study visit 
will last between 2 - 3 hours. After explanation of the procedure a doctor or a nurse will 
insert a small plastic tube into a vein in the arm to take a blood sample. With your 
permission, we will also take on one occasion a sample of DNA and RNA from blood or 
saliva to look for changes in your genes that may be involved in the how the body controls 
appetite and body weight. 
 
You will also have your height, weight and body fat content measured again using a ‘bio-
electrical impedance’ machine. This is a painless safe method which involves measuring the 
electrical current from your body and takes only about 5 minutes. You will also complete 
questionnaires about your eating habits, personality and mood on each study visit. These 
questionnaires should take about 30 minutes to complete on the first visit and 5 minutes to 
complete on the second visit.  
 
After having completed the MRI safety check form and an appetite questionnaire (VAS) you 
will be asked to lie on a trolley and then be moved into the scanner. The scanner is made 
up of a large magnet with a central bore or tunnel; you will lie on the scanning couch inside 
the bore during the scan. The scanner uses changes in magnetic fields to obtain a precise 
picture of your brain. Your head will be placed in a padded head coil for support. The 
scanner makes a loud knocking noise when it is running, and therefore you will be asked to 
wear earplugs during the scan.  
 
You will be asked to perform simple computer tasks whilst lying inside the MRI scanner. 
Food pictures and other pictures will be shown on a computer screen and with a hand-held 
response pad you can respond to the visual information. During the scan you will have an 
alarm bell to sound if you have any concerns. If you do not like being in the magnet for any 
reason, the scan can be immediately stopped at any time. The scan will take no longer than 
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1 hour. After the scan further blood samples will be taken and you will be asked to complete 
another appetite questionnaire. The total volume of blood taken at this visit will be up to 
80mL (5 tablespoons). At one of the visits you will also be asked to score how often and 
how much you usually like to eat the foods shown in the pictures using a visual analogue 
scale. 
 
Expected duration of the study 
The study will last about 10 weeks. You will be asked to attend the research ward on 
maximum 7 non-consecutive days. Some visits will only last about 1-3 hours, whereas the 
three appetite study sessions last from about 08.30 am to about 17.00.   
 
Number of participants in this study 
You will be one of approximately 20 volunteers who will participate in this study. 
 
Are there any risks of participating in the study? 
The risks for this study are low, as you will be checked that you meet the criteria for 
inclusion in the study prior to starting, and those with existing health problems will be unable 
to participate. 
 
There maybe slight discomfort and possible bruising due to the insertion of the catheter   for 
blood sampling. An experienced member of staff will insert the catheter and we will do our 
best to avoid these problems. The volume of blood collected in total during one study day is 
30-160 ml which is considerably less than a typical blood donation. During the entire study 
(about 10 weeks) a total of 600 ml of blood will be withdrawn. This includes the blood 
sample taken at the screening visit. 600 ml is just over one pint (568 ml). For a normal, 
healthy person the blood sampling should pose no risk. The maximum amount of blood 
taken in one day will be 160 ml (=10.6 tablespoons) and this amount will be taken over the 
course of 8 hours.  
 
When consuming high amounts of dietary fibre some people will experience increased wind, 
increases in bowel movements and/or bloating; these side-effects are expected to be 
temporary and mainly occur at the beginning of the study. The purpose of the 
supplementation run-in (day 1-14) is to minimise the occurrence of these side-effects. If you 
should experience any of these side-effects, they will not have any adverse effects on your 
health. 
 
At the MRI visits anatomical scans of your brain and whole body will be collected. It should 
be noted that these scans cannot be viewed as a comprehensive health screening 
procedure. However, very rarely, unexpected information can be detected during MRI scans 
or from blood tests which may warrant further investigation. In this event, a report will be 
sent to your GP, who will arrange further tests and coordinate further care. Significant 
abnormalities may also preclude you from further participation in the study. Such detection 
has the benefit of starting treatment early but in a small number of cases this may have 
implications for your future employment and insurance schemes.  
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What are the possible benefits of participating in the study? 
You will not directly benefit from taking part, however the information we get from this study 
may help identify how different dietary fibres affect appetite. Full expenses will be paid to 
cover travel incurred during the participation in this study upon provision of valid receipts. 
You will also receive £300 for your inconvenience on completion of the study. The 
honorarium will be less, and at the discretion of the Principal Investigator, if you withdraw 
before completion of the study or if the study is terminated prematurely. 
 
What if something goes wrong? 
If you suffer an adverse event or deterioration in health as a result of your participation in 
this study, appropriate compensation will be paid to you through the Imperial College School 
of Medicine’s “No Fault” Compensation Scheme. 
 
Will my taking part in this study be kept confidential? 
If you consent to take part in the study we may need access to your medical records. All 
information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you that leaves the hospital will have your name 
and address removed so that you cannot be recognised from it. We will inform your GP of 
your participation in this study. We will also inform all other doctors treating you (for 
example, hospital specialists), unless you have any objection to us doing so. 
 
General 
The handling of blood will be carried out in accordance with the University policy on the 
donation and use of human specimens in teaching and research (March 1998-SP/03/98). 
You will be free to withdraw from the study at any time and do not need to give any reason 
for your withdrawal. You can file complaints or queries about the study and their 
participation at any time to the principal investigator Professor Gary Frost by phone, phone 
0208383 8037 or by email: g.frost@imperial.ac.uk, Ms Norlida Mat Daud, e-mail: n.mat-
daud08@imperial.ac.uk or Mrs Nurhafzan Ismail, email: 
Nurhafzan.ismail08@imperial.ac.uk. 
 
Should you want to know the results of the study you can ask the investigators and they will 
send out the results written in lay terms. All information and data obtained from the study 
will be restricted to the investigators only and will be kept strictly confidential as required by 
the Data Protection Act (1998). All participant information will be coded. The Hounslow and 
Hillingdon Research Ethics Committee has given a favourable opinion on this study. 
 
Thank you for taking the time to read this information sheet. 
If you decide to take part in the study a copy of the information sheet and a copy of the 
signed consent form will be given to you. 
 
THIS INFORMATION SHEET IS VALID FOR USE UNTIL 31/12/2011.  
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CONSENT FORM 
 
Title of Project:  Effect of oligofructose on appetite, body composition and gut 
hormones in healthy overweight subjects 
 
Name of Researcher:   
 
 
 Please initial box 
 
1. I confirm that I have read and understand the information sheet version 3, date 1/09/09 
for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that my images and sections of any of my medical notes may be looked at 
by responsible individuals from Imperial College London or from regulatory authorities 
where it is relevant to my taking part in research.  I give permission for these individuals 
to have access to my records and scans. 
 
4. I agree to the investigators contacting my general practitioner about my participation in 
the study and the results of any medical tests from my visits and scans.  
 
5. I give permission for my images to be used for research by responsible individuals from 
Imperial College London and Imperial College Healthcare NHS Trust so long as they do 
not contain identifying personal information. 
 
6. I agree for a DNA sample to be taken and stored to look for changes that may be involved 
in obesity and the control of blood sugar and appetite (this is optional - you do not have to 
consent to this if you do not want to). 
 
7. I agree to take part in the above study. 
 
8. I agree to be contacted again by the Investigators to participate in future research (this is 
optional - you do not have to consent to this if you do not want to). 
 
                                               
________________________ ________________ ____________________ 
Name of Patient Date Signature 
 
 
_________________________ ________________ ____________________ 
 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher Date  Signature 
 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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Appendix 3. Food Preference Sheet 
 
Food Preference 
You will be given a serving of food to eat and you are asked to say how much you like or dislike 
it. Use the scale to indicate your attitude by checking at the point which best describes your 
feeling about the food. Keep in mind that you are the judge. You are the only one who can tell 
what you like. An honest expression of your personal feeling is important to the study. 
 
 
 
 
Comments: 
 
 
 
 
 
 
 
 
 
 
Like 
Extremely 
Like 
moderately 
Like 
slightly 
Neither like 
nor dislike  
Dislike 
slightly 
Dislike 
moderately 
Dislike 
very much 
Dislike 
Extremely 
Like very 
much 
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Appendix 4. SCOFF questionnaires 
 
 
Initials: 
ID: 
Date: 
 
1. Do you make yourself sick because you feel uncomfortably full? 
YES / NO 
____________________________________________________ 
 
2. Do you worry you have lost control over how much you eat? 
YES / NO 
____________________________________________________ 
 
3. Have you recently lost more than one stone in a 3 month period? 
YES / NO 
____________________________________________________ 
 
4. Do you believe yourself to be fat when others say you are too thin? 
YES / NO 
____________________________________________________ 
 
5. Would you say that food dominates your life? 
YES / NO 
____________________________________________________ 
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Appendix 5. Dutch Eating Behaviour  Questionnaires  
Participant code_____________________                                     Date___/___/___ 
 
Please answer the following questions as carefully and honestly as possible. 
Read each question and simply fill in the column which best applies to you. 
 
N
ev
er
 
Se
ld
o
m
 
So
m
et
im
es
 
O
ft
en
 
V
er
y 
o
ft
en
 
N
o
t 
re
le
va
n
t 
1. If you have put on weight, do you eat less than you usually do?        
2. Do you have a desire to eat when you are irritated?        
3. If food tastes good to you, do you eat more than you usually do?        
4. Do you try to eat less at meal times than you would like to eat?        
5. Do you have a desire to eat when you have nothing to do?        
6. Do you have a desire to eat when you are depressed or discouraged?        
7. If food smells and looks good, do you eat more than you usually eat?        
8. How often do you refuse food or drink offered because you are concerned about 
your weight?  
      
9. Do you have a desire to eat when you are feeling lonely?        
10. If you see or smell something delicious, do you have a desire to eat it?        
11. Do you watch exactly what you eat?        
12. Do you have a desire to eat when somebody lets you down?        
13. If you have something delicious to eat, do you eat it straight away?        
14. Do you deliberately eat foods that are slimming?        
15. Do you have a desire to eat when you are cross?        
16. Do you have a desire to eat when you are approaching something unpleasant to happen?        
17. If you walk past the baker do you have a desire to buy something delicious?        
18. When you have eaten too much, do you eat less than usual the following days?        
19. Do you get a desire to eat when you are anxious, worried or tense?        
20. If you walk past a snack bar or café, do you have a desire to buy something delicious?        
21. Do you deliberately eat less in order not to become heavier?        
22. Do you have a desire to eat when things are going against you, or things have gone wrong?        
23. If you see others eating, do you have also the desire to eat?        
24. How often do you try not to eat between meals because you are watching your weight?        
25. Do you have a desire to eat when you are frightened?        
26. Can you resist eating delicious food?        
27. How often in the evening do you try not to eat because you are watching your weight?        
28. Do you have a desire to eat when you are disappointed?        
29. Do you eat more than usual when you see other eating?        
30. Do you take your weight into account when you eat?        
31. Do you have a desire to eat when you are emotionally upset?        
32. When preparing a meal are you inclined to eat something?        
33. Do you have a desire to eat when you are bored or restless?        
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Appendix 6 – Three-Factor Eating Questionnaires 
Please circle the response that you feel best describes you 
 
ID#: Initials: Date: 
 
Part I 
 
True 
 
False 
1. When I smell a sizzling steak or see a juicy piece of meat, I find it very difficult to 
keep from eating, even if I have just finished a meal. 
T F 
2. I usually eat too much at social occasions, like parties and picnics. T F 
3. I am usually so hungry that I eat more than three times a day. T F 
4. When I have eaten my quota of calories, I am usually good about not eating any 
more. 
T F 
5. Dieting is so hard from me because I just get too hungry. T F 
6. I deliberately take small helpings as a means of controlling my weight. T F 
7. Sometimes things just taste so good that I keep on eating even when I am no longer 
hungry. 
T F 
8. Since I am often hungry, I sometimes wish that while I am eating, an expert would 
tell me that I have had enough or that I can have something more to eat. 
T F 
9. When I feel anxious, I find myself eating. T F 
10. Life is too short to worry about dieting. T F 
11. Since my weight goes up and down, I have gone on reducing diets more than once. T F 
12. I often feel so hungry that I just have to eat something. T F 
13. When I am with someone who is overeating, I usually overeat too. T F 
14. I have a pretty good idea of the number of calories in common food. T F 
15. Sometimes when I start eating, I just can’t seem to stop. T F 
16. It is not difficult for me to leave something on my plate. T F 
17. At certain times of the day, I get hungry because I have gotten used to eating then. T F 
18. While on a diet, if I eat food that is not allowed, I consciously eat less for a period 
of time to make up for it. 
T F 
19. Being with someone who is eating often makes me hungry enough to eat also. T F 
20. When I feel blue, I often overeat. T F 
21. I enjoy eating too much to spoil it by counting calories or watching my weight. T F 
22. When I see a real delicacy, I often get so hungry that I have to eat right away. T F 
23. I often stop eating when I am not really full as a conscious means of limiting the 
amount that I eat. 
T F 
24. I get so hungry that my stomach often seems like a bottomless pit. T F 
25. My weight has hardly changed at all in the last ten years. T F 
26. I am always hungry so it is hard for me to stop eating before I finish that food on 
my plate. 
T F 
27. When I feel lonely, I console myself by eating. T F 
28. I consciously hold back at meals in order not to gain weight. T F 
29. I sometimes get very hungry late in the evening or at night. T F 
30. I eat anything I want, any time I want. T F 
31. Without even thinking about it, I take a long time to eat. T F 
32. I count calories as a means of controlling my weight. T F 
33. I do not eat some foods because they make me fat. T F 
34. I am always hungry enough to eat at any time. T F 
35. I pay a great deal of attention to changes in my figure. T F 
36. While on a diet, if I eat a food that is not allowed, I often then splurge and eat other 
high calorie foods. 
T F 
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ID#: Initials: Date: 
 
Part II 
    
37. How often are you dieting in a conscious 
effort to control your weight? 
 
rarely 
 
sometimes 
 
usually 
 
always 
38. Would a weight fluctuation of 5 lbs  
affect the way you live your life? 
 
not at all 
 
slightly 
 
moderately 
 
very much 
39. How often do you feel hungry?  
only at 
mealtimes 
sometimes 
between 
meals 
often 
between 
meals 
 
almost 
always 
40. Do your feelings of guild about overeating 
help you to control your food intake? 
 
never 
 
rarely 
 
often 
 
always 
41. How difficult would it be for you to stop 
eating halfway through dinner and not eat 
for the next four hours? 
 
easy 
 
slightly 
difficult 
 
moderately 
difficult 
 
very 
difficult 
42. How conscious are you of what you are 
eating? 
 
not at all 
 
slightly 
 
moderately 
 
extremely 
43. How frequently do you avoid ‘stocking up’ 
on tempting foods? 
almost 
never 
 
seldom 
 
usually 
almost 
always 
44. How likely are you to shop for low calorie 
foods? 
 
unlikely 
slightly 
unlikely 
moderately 
unlikely 
 
very likely 
45. Do you eat sensibly in front of others and 
splurge alone? 
 
never 
 
rarely 
 
often 
 
always 
46. How likely are you to consciously eat 
slowly in order to cut down on how much 
you eat? 
 
unlikely 
 
slightly 
unlikely 
 
moderately 
unlikely 
 
very likely 
47. How frequently do you skip dessert because 
you are no longer hungry? 
 
almost 
never 
 
seldom 
at least 
once a 
week 
 
almost 
every day 
48. How likely are you to consciously eat less 
than you want? 
 
unlikely 
slightly 
likely 
moderately 
likely 
 
very likely 
49. Do you go on eating binges though you are 
not hungry? 
 
never 
 
rarely 
 
sometimes 
at least 
once a 
week 
50. On a scale of 0 to 5, where 0 means no 
restraint (eating whatever you want, 
whenever you want it) and 5 means total 
restraint (constantly limiting food intake 
and never ‘giving in’), what number would 
you give yourself? 
0 
 
eat 
whatever 
you want, 
whenever 
you want it 
1 
 
usually eat 
whatever 
you want, 
whenever 
you want it 
2 
 
often eat 
whatever 
you want, 
whenever 
you want it 
3 
 
often limit 
food 
intake, but 
often ‘give 
in’ 
4 
 
usually 
limit food 
intake, 
rarely 
‘give in’ 
5 
 
constantly 
limiting 
food 
intake, 
never 
‘giving 
in’ 
51. To what extent does this statement describe 
your eating behaviour? ‘I start dieting in the 
morning, but because of any number of 
things that happen during the day, by 
evening I have given up and eat what I 
want, promising myself to start dieting 
again tomorrow’ 
 
 
 
 
not like me 
 
 
 
little like 
me 
 
 
 
pretty good 
description 
of me 
 
 
 
describes 
me 
perfectly 
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Appendix 7 – Visual Analogue Scales 
 
Participant code___________                                              Date___/___/___             
Answer the following questions by placing a vertical mark through the line for each question. 
Mark the line according to how you feel right now 
 
How full do you feel? 
 
Not at all                                                                                                                     Extremely                                                                                                              
 
 
How hungry do you feel? 
 
 Not at all                                                                            Extremely 
 
 
How much food do you think you could eat? 
 
Not at all                                                                                                                Extremely                                                                                                                  
 
 
How strong is your desire to eat? 
 
Not at all                                                                                                             Extremely                                                                                                                 
        
 
Did you feel nauseous? 
 
Not at all                                                                                                            Extremely  
 
 
Does your stomach hurt? 
 
  Not at all                                                                                                                Extremely  
 
 
Do you feel bloated? 
 
Not at all                                                                                               Extremely  
 
 
 
Did you experience problems with flatulence in the past half an hour? 
 
Not at all                                                                                                          Extremely  
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Appendix 8 – 3-day Food Diaries 
 
FOOD RECORD 
 
Read through these instructions and the example carefully once or twice before you start. 
 
Please record ALL food and drink consumed at the time of eating and NOT from memory at 
the end of the day.  Keep this record sheet with you throughout the day. You should include 
all meals and snacks, plus sweets, drinks etc.  When recording food eaten at meals, please 
include any sauces, dressing or extras eg: gravy, salad dressing, pickles, as well as the main 
food. 
 
If you do not eat a particular meal or snack simply draw a line across the page at this point. 
 
 
Guidelines for describing food & drink: 
 
1. Please give details of method of cooking eg: grilled, boiled, roasted. 
 
2. Give as many details as possible about the type of food you eat: 
 
a) State brand name where applicable 
eg: 'Princes' sardines in tomato sauce OR 
'Sainsburys' half-fat Edam cheese. 
 
b) Name the type of biscuit, cake or cereal 
eg: Rich Tea, Madeira, Branflakes. 
 
c) Name the type of cheese, fish or meat 
eg: Cheshire cheese, haddock fillet, pork chop. 
 
3. Suggestions for recording quantity of food and drink: 
 
a) For many foods such as vegetables, cereals and some fruit a household  
measure is adequate, state the number of teaspoons (tsp) or tablespoons (tbsp) or cups, 
and whether level, rounded or heaped. 
 
 
Level  
 
Rounded  
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Heaped  
 
b) All convenience foods have their weight on the packaging and this can  
be quoted 
eg: 150g carton Ski raspberry yoghurt OR 
½ 15 oz can baked beans. 
 
c) Bread, fruit loaves etc.  Indicate the size of the loaf and the thickness of the  
     slice  
eg: 1 thick slice granary bread, small loaf. 
 
d) Cheese, fish, meat.  When possible, please weigh your portions of these  
foods.  Otherwise describe as well as you can. 
 
eg: 2 large thin slices ham OR 
2 small lamb chops (no fat eaten) OR 
Medium fillet of cod grilled with 1 tsp flora OR 
Cube of cheddar cheese the size of a matchbox. 
 
Remember to include everything you eat and drink including snacks and nibbles. 
Please do not change what you normally eat just because you are filling in this record - Be 
Honest! 
 
Look at the example of how to fill in you record - you may find this helpful. 
 
THANK YOU VERY MUCH FOR YOUR HELP 
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DIETARY RECORD SHEET - EXAMPLE 
 
Record ALL food and drink consumed during the day including snacks, nibbles, sauces and 
dressings. 
 
Record method of cooking, type and quantity of food 
eg: 6 tbsp boiled wholemeal spaghetti 
2 egg sized roast potatoes. 
 
DAY:  Example  DATE: 1st June 1994 
 
MEAL/ 
SNACK 
QUANTITY 
 EATEN 
DETAILS OF FOOD & DRINK Leave 
Blank 
Early 
Morning: 
1 cup 
1 tbsp 
Tea with  
Skimmed milk 
 
Breakfast: 3 heaped tbsp 
¼ pint 
1 medium slice 
1 tsp 
2 mugs 
Branflakes (Kellogg's) 
Skimmed milk for cereal & drinks 
Wholemeal bread (large loaf) 
Flora extra light margarine 
Coffee 
 
During 
Morning: 
1 mug 
1 tbsp 
1 medium 
Coffee with 
skimmed milk 
Apple (eaten with skin) 
 
Midday:  
4 medium slices 
 
4 level tsp 
2 thin slices 
1 large 
1 1 can (330ml) 
Sandwiches: 
wholemeal bread (Allinsons) large loaf, sliced 
Flora extra light margarine 
Ham (no fat) 
Tomato 
Banana 
Diet Tango 
 
During 
Afternoon: 
1 glass 
25g pkt 
Low Calorie squash made with concentrated squash 
KP roasted salted peanuts 
 
Evening 
Meal: 
4 heaped tbsp 
 
1 apple sized 
3 tbsp 
1 x 150g tub 
1 glass 
1 cup 
1 tbsp 
Chicken & mushroom casserole (home-made with skimmed 
milk in the sauce) 
Jacket potato 
Broccoli, boiled 
Shape raspberry yoghurt 
Half mineral water/half natural orange juice 
Tea with  
skimmed milk 
 
During 
Evening: 
   
Bedtime 
Snack: 
1 mug 
1 tsp 
½ mug 
2 
Ovaltine made with: 
Ovaltine 
ordinary silver top milk, the rest water 
Rich Tea biscuits (Sainsburys). 
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 Appendix 9 – 8 Weeks Supplementation Record 
 
 
SUPPLEMENTATION RECORD 
 
Read through these instructions and the example carefully once or twice 
before you start. 
 
 
You have been given ______ of sachets for the 8 weeks of supplementation. 
 
 
You are advice to take: 
 
1 sachet a day for the 1
st
 week starting from _____________ to _____________ 
 
2 sachets a day for the 2
nd
 week starting from ______________ to ____________ 
 
3 sachets a day for the 3
rd
 week starting from ______________ to _____________ 
 
Please remember that:   
 
1- The supplement has to be consumed either with the main meals, 
mixed into drinks, sprinkled on or mixed into food. 
2- The supplement must not be cooked and exposed to high 
temperatures (for example by adding it to freshly boiled water).  
3- Unused sachets must be returned to the investigators. 
 
We would like you to record, what you eat or drink with the supplementation 
for 8 consecutive weeks. You should start on the morning of that day and 
continue for the six following days. Please be alert to the date you need to 
increase your supplementation above.   
 
Record at the time of eating and NOT from memory at the end of the day.  
Keep this record sheet with you throughout the day. 
 
Please do not change what you normally eat just because you are filling in this 
record - Be Honest! 
 
Look at the example of how to fill in you record - you may find this helpful. 
 
 
THANK YOU VERY MUCH FOR YOUR HELP 
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SUPPLEMENT RECORD SHEET 
Record time and details of supplementation. E.g as below:  
Time taken Quantity taken Details of food & drink (with what you take the supplement) Leave blank 
8.30 am ½ sachet  Sprinkle in 250 ml porridge  
 
WEEK 1 – WEEK 8 
Balance sachets:       
 Time taken Quantity 
 taken 
Details of food & drink (with what you take the 
supplement) 
Leave blank 
Breakfast Lunch Dinner 
Day 1       
Day 2       
Day 3       
Day 4       
Day 5       
Day 6       
Day 7       
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Appendix 10 –fMRI study sheet 
Date of scan:   Initials:  ID #:   Hospital #: 
Group:  A B Visit no:   1  2   
Food picture runs: AB CD  EF  GH (start at 11.30 +90)  
MR personnel: Norlida Mat Daud/Nurhafzan Ismail/Tony Goldstone/Giuliana Durighel/Christina 
Prechtl/Sam Scholtz/Navpreet Chinna/Other:  
Check buttons work in WordPad  
3T MRI #:    IFIS hood / Data logging PC / (IFIS PC Folder#:             
Attach: Respiratory belt (under arms) Pulse oximeter (L ring, red on pulp) Check audio cable 
Time into Philips 3T scanner:     Time out scanner: 
Scans: Test* Rest* Food x 2  Field AMV* T1      DTI    
Time (mins): 2 9 10 x 2  4 6 6  10          
No. of vols:  192 192 x 2  114 (* = hunger rating included) 
Prep phase  Full Auto  Auto Auto (ensure CLEAR ON)        
Time of scan:             /   
T1/T2/T2W_FLAIR Anatomical scan:  Parallel to AC-PC Line  
fMRI scans: gradient epi BOLD, TR 3000, TE 30, FOV 280x220x143, 2x2x3.25 mm, FA 90, 44 slices 
ascending contiguous, SENSE 2. Slice pos: 30o to AC-PC Line, CLEAR ON 
      Add    + 0.0926 to 
Initial RL tilt   degrees Initial *r[0] =  -   (parallel AC-PC) 
-30o RL tilt   degrees  Adjusted *r[0] = -    (30o to AC-PC) 
Rest: 192 vols. Eyes shut, awake. Initial 6 vols discarded. At end: Awake   or   Asleep 
Field map: spin echo TR 800, TE 20, flip 90, 3.25 x 2 x 2 mm, δTE 0 & 2.5 
Food: 2 x 192 vols. Stimulus duration 2.5 sec; ISI 3.0 sec. ITI 0.5 sec; 3 conditions x 5 blocks x 6 
pictures x 2 runs (high calorie, low calorie, household object) +  16 inter-condition blurred blocks per 
run. Block length 18 sec. Initial 6 vols to be discarded.  
AMV: 114 vols. Auditory (story), visual (4Hz colour checkboard), motor (tap R index finger 1Hz) 
DTI: 32 dir, b factor 1000, TR 13951, TE 59, 73 slices, SENSE 2.5, 224x224, 1.75x1.75x2mm, AC-PC 
line, no z-gradient correction, full prep, PB-volume shim 
Hunger VAS button: Problems: 
Test                                   Rest                                             AMV 
 Download edat files x5 to memory stick  Save edat files to Appetite folder 
 Save LabChart Pro data to laptop             Download LabChart Pro data to Appetite 
 Upload MR scans to MRIdb                       Save MR scans to disc DVD #: 
 Upload T1 T2 MR scans to PACS            Export fieldmap raw data to Export/Appetite 
 GP letter sent - 1st visit only                      Photocopy x2 (case folder, hospital notes) 
 MRI T1 anatomical report                        Pcopy x3 (case folder, master file, hosp notes) 
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Appendix 11 – Example of Probiotic, Prebiotic and Synbiotic Products to Avoid During the 
Supplementation Period 
 
Dairy: 
 Muller Vitality drinks and yogurts 
 Activia (drinks and yogurts) 
 Benecol 
 Flora proactive 
 Actimel 
 Yakult 
 Ski yogurts 
 Alpro soya yofu products 
 Irish Creamy Probiotic yogurts 
 Tesco natural defences yogurt 
 Tesco probiotic dairy drinks 
 
 + all other products containing bifidobacteria and/or added inulin/fructo-oligosaccharides   
 
 
Cereals  
 Weetabix Oatibix bitesize (Apple & Sultana and Original) 
 Weetabix Oaty bars (White chocolate, Milk chocolate, Strawberry) 
 Ryvita Goodness bars 
 Sainsbury’s cereal bars, Be Good to Yourself (Maple, Peach & Apricot) 
 Alpen light cereal bars 
 
 + all other products containing added inulin/fructo-oligosaccharides 
 
 
Dietary Supplements containing bacteria cultures and/or high amounts of inulin/fructo-
oligosaccharides 
 
Beware of all “light”, “low fat”, reduced sugar” or “reduced calories” products where fat or 
sugar may be replaced by inulin or oligofructose 
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